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 II 
Abstract  
 
My main thesis is that Saudi culture, in the context of the field of Molecular Genetics 
Epidemiology (MGE) research, poses many challenges to the currently used biomedical 
research regulations developed by the Saudi National Committee of Bioethics (NCBE). 
The NCBE regulations are informed by selected international research ethics guidelines, 
and they are influenced by a set of assumptions about how we ought to think about ethics. 
The overall focus is on a version of liberalism, where there is a strong commitment to 
autonomy, there is a significant focus on informed consent, the harm principle guides the 
justification of action, and paternalism is seen as something that is to be avoided. There are 
no specific guidelines that regulate MGE research in Saudi Arabia. Therefore, it was 
important as a first step in the thesis to analyse the relevant regulations (both the Saudi and 
the selected international ones) and explore the related normative issues. One of the main 
empirical findings of this project was an observed and reported lack of adherence to the 
requirements of the NCBE regulations. There are a number of different ways to interpret 
this finding. One way, and this was suggested by some members of the focus groups, is 
that this research demonstrates a clear failure of researchers to abide by the appropriate 
guidance, and that the relevant response is to act aggressively to correct such research 
practice in the hospitals where the data was collected. This would ensure compliance with 
the guidelines. An alternative view is that the problem emerges from a mismatch between 
the liberal international guidelines and the nature of the Saudi context. One possible way to 
address this tension is to formulate a set of guidelines and research practices that build 
upon the nature of Saudi social relations and norms. This may result in a focus on what we 
can call trust-based, rather than the currently promoted autonomy-based, bioethics.   
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 1 
1 Chapter One: General introduction 
My main thesis is that Saudi culture, in the context of the field of Molecular Genetics 
Epidemiology (MGE) research, could pose challenges to the currently used biomedical 
research regulations developed by the Saudi National Committee of Bioethics (NCBE). 
The NCBE regulations are informed by selected international research ethics guidelines, 
and they are influenced by a set of assumptions about how we ought to think about ethics. 
The overall focus is on a version of liberalism, where there is a strong commitment to 
autonomy, there is a significant focus on informed consent, the harm principle guides the 
justification of action, and paternalism is seen as something that is to be avoided. There are 
no specific guidelines that regulate MGE research in Saudi Arabia. Therefore, it was 
important as a first step in the thesis to analyse the relevant regulations (the Saudi and the 
selected international ones) and explore the related normative issues. One of the main 
empirical findings of this project was an observed and reported lack of adherence to the 
requirements of the NCBE regulations. There are a number of different ways to interpret 
this finding. One way, and this was suggested by some members of the focus groups, is 
that this research demonstrates a clear failure of researchers to abide by the appropriate 
guidance, and that the appropriate response is to act aggressively to correct such research 
practice in the hospitals where the data was collected. This would ensure compliance with 
the guidelines. An alternative view could, however, be taken that suggests that the problem 
emerges from a mismatch between the liberal international guidelines and the nature of the 
Saudi context. One possible way to address this tension is to formulate a set of guidelines 
and research practice that builds upon the nature of Saudi social relations and norms. This 
may result in a focus on what we can call trust-based, rather than prioritising the currently 
promoted autonomy-based, bioethics.  
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One of the original contributions to knowledge of this thesis is an empirical study of 
recruitment practice for MGE research in Saudi Arabia. The method used in the study is 
outlined and justified in Chapter Five. Data was collected in three phases. Phase One 
involved observation of the taking of informed consent within the context of recruitment to 
MGE research. Phase Two involved semi-structured interviews with individuals who had 
donated blood for MGE research, the aim of which was to obtain an idea about how the 
interviewees understood and perceived their experience as a donor for MGE research. 
Phase Three of the data collection included convening two focus groups to discuss the 
results of phases one and two, and more broadly discuss the norms that do and should 
govern MGE research in Saudi Arabia. The results are reported in Chapter Six.  
The final section of this thesis discusses its philosophical and empirical findings, as 
reported in its first two sections. It sets them in context, extending and deepening the issues 
that were raised (Chapter Seven). Based on the tensions and problems that have been 
observed, reported and discussed, the thesis concludes by recommending that those 
responsible for Saudi medical research and generating MGE research ethics guidelines 
need to reflect carefully on the appropriateness of prioritising the autonomy-based model 
of Western guidelines and the problems that emerge when applied in a Saudi context. 
1.1 Setting the scene 
In this section, I will set the scene by defining two important concepts used in this 
thesis (i.e. informed consent, and molecular and genetics research) and how they are to be 
understood. The thesis’s main focus is on molecular and genetic epidemiology (MGE) 
research, which uses blood samples taken with the patient’s consent for this purpose during 
routine clinical visits to tertiary care centres in Saudi Arabia. 
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1.1.1 Informed consent 
As the focus of this work is on donating blood for research, where research 
participants have consented to a specific piece of MGE research, it is essential to outline 
what is meant by informed consent. According to the Saudi guidelines: ‘A person gives his 
consent with his free will, without exploitation or coercion and upon full understanding of 
what is required from him and of the research objectives and potential risks as well as of 
rights and obligations arising out of his participation therein.’ (NCBE, 2010 p3). This 
understanding, as I will explain in Chapter Three (Section 3.1.1.4 Informed Consent), 
accords with all the international research ethics guidelines.  
In order for an informed consent to withstand legal and ethical scrutiny it must have 
three major components, starting from the threshold elements which require competence 
and voluntariness, and then an information element, which includes disclosure, 
recommendation and an understanding of both and, lastly, the consent element, which 
consists of decision and authorisation (Meisel and Roth, 1981). Accordingly, threats to the 
process of attaining an informed consent can come from more than one direction. 
The main role of informed consent is to legitimise an action that will impact on the 
consenting party. According to Manson (2007), consent ‘is a way to waive certain rights, 
and thus it allows actions to be performed that would otherwise be impermissible’ 
(Manson, 2007, p299). Manson argues that, in a broad sense, every successful act of 
consent is in fact an act of informed consent, because a level of communication (i.e. most 
likely communicating information) is required. However, the term ‘informed consent’ 
gained its standing in medical and research ethics because it is more specific than the 
general understanding of consent. It is more specific insofar as it requires explicit 
disclosure of information about a number of factors (i.e. risks, benefits, obligations, side 
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effects and alternatives options, if any). This disclosure is required as the basis for 
obtaining permission for a proposed action or set of actions from a person (O’Neill, 2002; 
Manson and O'Neill, 2007; Manson, 2007). 
1.1.2 General introduction to DNA (the genetics material)  
Deoxyribo Nucleic Acid (DNA) is the biological unit that stores the essential 
information (genes) required for the cell to function properly (GHR, 2015). The main 
building unit of DNA is the nucleotide, which comprises a deoxyribose sugar, a phosphate 
and nitrogenous bases (adenine, thiamine, cytosine or guanine) (GHR, 2014). Two strands 
of the nucleotides are linked by the nitrogenous bases (adenine with guanine and cytosine 
with thiamine) in the form of a double helix, which is the essential form of DNA (GHR, 
2015). Every three nucleotides form a codon, which is a sequence of three nitrogenous 
bases that code for an amino acid (the protein-building unit), a starting point, and a 
terminating point. Sequences of codons that generate a specific protein (a sequence of 
nitrogenous bases) are called a gene (GHR, 2015). 
Every gene is responsible for creating a specific protein, which has a specific task, at 
a specific time, in the life cycle of a cell (GHR, 2015). The cell depends on thousands of 
proteins (GHR, 2015). However, the sequence of the nitrogenous bases of these genes can 
be disturbed (mutated) by factors such as exposure to radiation or certain chemicals (GHR, 
2015). In view of that possibility, the cell is equipped with another copy of the same gene, 
called an allele. Of the two alleles that code for the same protein, one comes from each of 
the parents (GHR, 2015). If only one gene is mutated in a recessive disorder, then the other 
healthy allele takes over the process of protein synthesis; however, if the disorder is 
dominant even with the presence of a healthy allele, one defective gene is enough to 
express the disorder (GHR, 2015).  
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In some cases, the cell is equipped with mechanisms to correct an incidence of 
mutation. However, in many cases those mechanisms fail to correct the mutation and the 
gene is then passed on to the next generation. Based on the role of the coded protein in the 
cell life cycle, mutations could be life-limiting (e.g. cancer), serious (e.g. sickle cell 
anaemia), chronic (e.g. glaucoma) or benign (e.g. some forms of myopia) (Al Husain and 
Al Bunyan, 1997). Any diagnosed disease caused by one or more mutant genes is called a 
genetic disorder (Al Husain and Al Bunyan, 1997). 
As the mutation is passed down to the offspring, siblings share similar DNA 
characteristics (Tallbear, 2013; Boddington, 2012). Therefore, every DNA molecule can 
possess a set of mutations, which can identify individuals, and sometimes families, with 
extremely high precision (Tallbear, 2013; Boddington, 2012). This high level of 
identifying ability is called the DNA fingerprint (Tallbear, 2013; Boddington, 2012).  
1.1.2.1 Genetic Epidemiology 
The term epidemiology derives from the Greek ‘Epi’ (meaning upon or over) and 
‘Demos’ (meaning population or people). Thus, epidemiology, in general, is concerned 
with population health. The Oxford Dictionary defines epidemiology as: ‘the branch of 
medicine which deals with the incidence, distribution, and possible control of diseases and 
other factors relating to health’ (Oxford, 2014). The Oxford Dictionary definition does not 
explicitly link epidemiology with public health per se, but it is assumed that the incidence 
and distribution are statistically calculated values dependent upon a well-defined 
population. There are also other definitions specific to the kind of epidemiology being 
defined. For example, molecular epidemiology can be characterised by two main factors:  
1. the use of molecular biology techniques in order to determine the characteristics 
of genes and/or proteins in specific population; and 
 6 
2. the study of the incidence and distribution of disease among human populations. 
(Foxman and Riley, 2001). Foxman and Riley (2001) provide a summary of eight different 
definitions of molecular epidemiology (see Table 1-1). 
Among these eight, the most relevant definition is the one by McMichael (1994), 
because it is sufficiently general to describe the different molecular epidemiology activities 
currently occurring in Saudi Arabia. The recurring concept in these diverse definitions is 
that epidemiology is connected with understanding the ‘aetiology’ (the study of causation) 
of ‘disease’, that is to say, how and why disease is distributed among specific groups. But 
despite this emphasis on ‘disease’ or ‘aetiology’, epidemiology is not always about the 
people who are affected by disease. It is also concerned with healthy people, and how to 
prevent or control disease and its elements (so it could, for example, include studies of 
healthy people who are carriers of an affected gene, those who have been vaccinated, or 
those in a high risk group). As the Oxford Dictionary’s definition is comprehensive enough 
to capture the most important concepts surrounding epidemiology, it will be accepted for 
the purposes of this work. 
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TABLE 1-1: VARIOUS DEFINITIONS OF MOLECULAR EPIDEMIOLOGY (FOXMAN AND RILEY, 
2001)  
AUTHOR Reference  Definition  
Higginson J Am J Pathol 
1977;86:460–84 
 “the application of sophisticated 
techniques to the epidemiologic 
study of biological material” (p. 463) 
Schulte PA In: Schulte PA, Perera FP, 
eds. San Diego, CA: 
Academic Press,1993:3–
44 
“molecular epidemiology is the use 
of biologic markers or biologic 
measurements in epidemiologic 
research” (p. 13) 
Tompkins LS 
 
In: Miller VL, Kaper JB, 
Portnoy DA,et al, 
eds.Washington, 
DC:American Society for 
Microbiology,1994:63–73 
“the application of molecular biology 
to the study of infectious disease 
epidemiology” (p. 65) 
McMichael 
AJ 
Am J Epidemiol 
1994;140:1–11 
“using molecular biomarkers in 
epidemiology” (p. 5) 
Groopman 
JD, Kensler 
TW, Links 
JM 
Toxicol Lett 1995;82-
83:763–9 
 
“molecular epidemiologic research 
involves the identification of 
relations between previous exposure 
to some putative causative agent and 
subsequent biological effects in a 
cluster of individuals in populations” 
(p. 763) 
Hall A Trop Med Int Health 
1996;1:407–8 
 
“the analysis of nucleic acids and 
proteins in the study of health and 
disease determinants in human 
populations” (p. 407) 
Shpilberg O, 
Dorman JS, 
Ferrell RE, et 
al 
J Clin Epidemiol 
1997;50:633–8 
 
“molecular epidemiology uses 
molecular techniques to define 
disease and its pre-clinical states, to 
quantify exposure and its early 
biological effect, and to identify the 
presence of susceptibility genes” (p. 
633) 
Levin BR, 
Lipsitch M, 
Bonhoeffer S 
Science 1999;283:806–9 
 
“the practical goals of molecular 
epidemiology are to identify the 
microparasites responsible for 
infectious diseases and determine 
their physical sources, their 
biological relationships, and their 
route of transmission and those of the 
genes responsible for their virulence, 
vaccine relevant antigens and drug 
resistance” (p. 806) 
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1.1.2.2 Genetic Exceptionalism  
‘Genetic exceptionalism’, according to Murray (1997), means that ‘genetic 
information is sufficiently different from other kinds of health-related information that it 
needs special protection’ (Murray, 1997). What supports this claim is that DNA has three 
major characteristics: 
 it can provide information about genetic mutations (i.e. disease vulnerability 
and mutation carriage rate); 
 it can identify individuals; and 
 genetic test results are more reliable than most other serology tests. 
Advocates of exceptionalism claim that the prominent problem with genetic testing 
is that in some circumstances genetic testing provides definitive information about future 
(Spinello, 2004).  
The notion of genetic exceptionalism has not gone uncontested. Some commentators 
suggest that genetic testing does not differ in any relevant way from any other clinical 
testing. Green and Botkin (2003), for example, argue that the notion of such 
exceptionalism should be rejected, since, despite the fact that genetic tests can reveal 
sensitive information like paternity, the same sensitive information can be inferred from 
the common clinical blood test the ABO1 typing system, as well as by HLA2 typing. The 
same can be said for many other serious medical indicators if not treated as confidential 
(for example, lack of exercise, hypercholesterolemia, and family history of heart disease 
are strong indicators of a risk of heart disease, which itself is sensitive information, for 
                                                        
1 Blood type testing A, B, AB, and O; if the parents are O blood types, offspring should be O. 
2 Human Leucocyte Antigen, a serology test used to determine organ transplant suitability. 
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instance if medical insurance is being sought). This position has been strongly embraced 
by many other researchers (Gostin and Hodge Jr, 1999; Hellman, 2003; Lazzarini, 2001; 
Suter, 2011). 
1.1.2.3 Molecular and Genetic Epidemiology (MGE) 
‘Molecular epidemiology’ and ‘genetic epidemiology’ are used interchangeably in 
the medical and ethical literature (Boddington, 2012). There is no consensus as to what 
constitutes the difference between them, which makes precise definition difficult 
(Boddington, 2012). Despite the lack of agreement on their definition, they share some of 
the same ethical concerns. Therefore, in this work I will refer to them jointly as Molecular 
and Genetic Epidemiology (MGE). I will also use the definition that is most pertinent to 
the overall aim of this project, which looks at them as the branch of medicine that is 
concerned with the distribution, prevention and control of genetic diseases and genetic 
carriage rates (see section 1.1.2.1 Genetics Epidemiology). MGE aims to characterise the 
sequences of amino acids in proteins, and nucleic acids in genes. It uses advanced 
biomedical techniques in genetics to study how these changes affect the distribution and 
determination of disease occurrence, prevention or control in human populations. There are 
myriad other definitions (see section 1.1.2.1 Genetics Epidemiology), but, for the purposes 
of this research, I will only consider the aforementioned definition because it captures the 
most important points.  
1.2 The Saudi Arabian Context 
Advances in technology have spurred the evolution of molecular and genetic 
epidemiology (MGE) research to unprecedented levels. With such advancements come the 
responsibility of protecting research participants from foreseen, unnecessary risks and 
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balancing risks in general against benefits. In the history of Western biomedical ethics, 
several organisations and bodies have assembled ethical guidelines for medical research 
that involves the use of human participants (e.g., the Nuremberg Code, the Helsinki 
Declaration, the Council for International Organizations of Medical Sciences (CIOMS), 
and the International Council for Harmonisation - Good Clinical Practice (ICH-GCP)). In 
the context of MGE research in Saudi Arabia, there are at least two major challenges to on-
going efforts to achieve comprehensive consensus guidelines: (i) It might be argued that 
most of these guidelines are written more for clinical trials than for MGE because they use 
vocabulary specific to clinical research that does not translate in a meaningful way in other 
types of research (e.g. terminology such as ‘minimum risk’, ‘side effects’, ‘adverse events’ 
and ‘monitor’ in the ICH-GCP). (ii) It is usually the case that guidelines developed in the 
West are later adopted by the less-developed world. The main challenge is that the 
inherited normative assumptions that are built into the guidelines might not be applicable 
to contexts other than Western ones.  
Saudi Arabia is a particularly suitable place to test the Western normative 
assumptions embedded in Western bioethical guidelines, and their suitability for MGE 
research in general. This is because Saudi Arabia provides an environment with a different 
heritage, culture and norms to the West. An initial set of problems that looked potentially 
challenging to Western norms, such as the nature of the blood purity value among Saudi 
tribes, what blood means in the Saudi context, how consent is practiced and understood in 
Saudi hospitals, the nature of the health care system in Saudi Arabia, and the nature of 
Saudi doctor-patient relationships, were quickly identified during this research for further 
exploration. Another is stigma in tribal culture. One way of looking at MGE research in the 
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context of those challenges is that it could be a useful case study for conceptualising 
research in the Saudi context more generally. 
1.2.1 The social context in Saudi Arabia 
Saudi Arabia is in the south-Western corner of Asia. It is a geographical link 
between Asia and Africa. It is the second largest Arabic country, with an area of 2.25 
million square kilometres and a population of more than 20 million Saudi (CDSI, 2014). 
Its capital is Riyadh, and it is a monarchy. The Saudi king, currently King Salman Bin 
Abdualziz Al Saud3, is the Custodian of the Two Holy Mosques. He is the sixth direct 
successor of the Al Saud monarch, who founded the Kingdom of Saudi Arabia. He is also 
the prime minister. Saudi Arabia is a Sunni Muslim country, where the monarchy rules by 
Sharei’ Law. 
1.2.2 The Saudi cultural and political climate 
Being at the heart of the Islamic world, literally and metaphorically, Saudi Arabia is 
highly significant in terms of religious leadership for Sunni Muslims internationally. It is 
home to two highly influential international Islamic jurisprudence councils, whose dicta 
and injunctions have an impact on Muslims across the Muslim world, as well Muslims in 
Saudi Arabia. Ethical principles used in the Kingdom are influenced by Islamic principles. 
Many of Saudi Arabia’s Islamic norms have spread to other countries. These Islamic 
norms are blended with other social norms stemming from the tribal nature of Saudi 
society, with all the pros and cons that convictions of tribal conformity dictate. In general, 
these factors help to promote the culture of trust and respect over that of agency (i.e. the 
                                                        
3 This was not the case when I handed in the original thesis but a change brought about by the death in 
January 2015of the King Abdullah Bin Abdulaziz, the elder brother of our new king.  
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personal capacity to act intentionally) and liberty (i.e. the ability to take decisions free 
from other influences).  
1.2.3 Health-related research in Saudi Arabia 
The Ministry of Health provides free health care in Saudi Arabia to all Saudis. 
However, there are many health care organisations in Saudi Arabia in addition to the Saudi 
Ministry of Health and its primary healthcare centres such as university hospitals, tertiary 
care hospitals, military hospitals, and private centres and hospitals. The primary healthcare 
centres are fairly distributed, reaching even the small, remote areas.  They handle basic 
healthcare needs, such as treatment for flu, colds and headaches.  If a patient needs tertiary 
care, he/she will be transferred to one of the Ministry of Health central hospitals or 
university hospitals, where specialist healthcare services are available. The main problem 
is that there are very long waiting lists for non-emergency care, which forces Saudis to 
seek and fund alternatives, which will often be provided by specialist hospitals.  
These specialist hospitals are usually fee-charging or provide services to a specific 
group of people. For example, National Guard Health Affairs (NGHA) provides services to 
the National Guard’s soldiers and their families; they also extend their services to very 
specialised serious cases, such as cancer, liver transplants, and heart transplants.   
Although Saudi Arabia is a young country, health-related research is very well 
established in a few Saudi organisations, in the form of dedicated – and often competing – 
Saudi research centres, notably the King Faisal Specialist Hospital and Research Centre 
(KFSH&RC), the King Abdullah International Medical Research Centre (KAIMRC), and 
the King Khalid Eye Specialist Hospital (KKESH), all located in Riyadh. These are the 
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three largest Saudi research centres, but they compete for research funds and official 
recognition.  
1.2.4 The emergence of bioethical debate in Saudi Arabia 
In Saudi Arabia, there is a history of putting the latest technologies into practice long 
before any guidelines are established to govern their use. This was the case for organ 
transplantation, where the regulations were inaugurated a decade after transplantation was 
first practised (Adlan, 2013). Similarly, guidelines for in vitro fertilisation (IVF) were 
announced in Saudi Arabia in 2004, 20 years after the first IVF procedure (Abduljabbar 
and Amin, 2009). Molecular biology is no exception. MGE research has been flourishing 
in Saudi Arabia for at least two decades. Indicative here is the growing number of 
biobanks, prompted by the surge in molecular biology research in recent years, which has 
been mainly clinical and oriented towards population genetics. However, this increase in 
biobanking has taken place with an underdeveloped consideration of the associated ethical 
dilemmas. Thus, paradoxically, there has been very little effort invested in studying the 
bioethical, legal and social challenges of such practices. 
Bioethics debate was introduced into Saudi Arabia as a result of an incident in 2000. 
A twenty-nine-year-old woman was planning to have another child of her own but she 
could not. Her gynaecologist consultant suggested a uterus implant, which had never been 
done before. The patient found a forty-six-year-old non-Saudi donor. Dr Al Fageeh 
(Fageeh et al., 2002) confirmed that the donor formally consented after a hysterectomy, 
due to multiloculated ovarian cysts. Major Saudi newspapers, such as Al-Riyadh and Al-
Sharq Al-Awsat, argued for months that the donor had ‘sufficient’ children and that money 
was most likely involved. After the uterus transplantation, the recipient had two menstrual 
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cycles, which was a scientific and medical breakthrough. However, due to the significant 
anti-rejection medications that were required, it transpired that she could not bear children 
(Fageeh et al., 2002). Following several newspaper articles, there was an unprecedented, 
cultural and ethical outcry in the Kingdom of Saudi Arabia (Fageeh, 2001). The main 
concern was that the procedure went against Saudi culture, and was unethical, because 
some Islamic scholars pronounced it forbidden (Fageeh, 2001).  Some concern centred on 
the assumption that the ovaries had been transferred as well as the uterus. In Islam, having 
a child is sacred. It is contrary to religion - and therefore in Saudi Arabia also contrary to 
law – for people to have children unless they are married. Bearing a child out of wedlock is 
punishable by law and is stigmatized by the culture. The use of donated gametes in fertility 
research is accordingly forbidden, so only married people are allowed to have children 
using IVF, and then only using the egg of the wife and the sperm of the husband. In the 
transplanted uterus case, the assumption that the ovaries were transplanted with the uterus 
gave rise to the belief that donated gametes had therefore also been involved (Serour, 
2008).  
There was also another public debate when the donor’s relatives filed a lawsuit 
against the surgeon, claiming that the patient had not been informed about the transplant: 
they claimed that she had been told that there was a tumour in her uterus requiring a 
hysterectomy, and only later did she learn that her uterus had been involved in a transplant 
procedure. In newspaper interviews the surgeon clarified that Saudi officials had 
investigated the claim and found that the patient had signed the proper informed consent 
form (Fageeh, 2001) – although, of course, signing a consent form does not necessarily 
mean that consent had been voluntarily given, nor that the information was understood 
(AlSharq, 2004). 
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The fact that the procedure was a medical ‘first’, with no proper training of the 
surgery team, was at the centre of another heated debate about the lack of regulations 
concerning what can effectively be considered an impermissible experimental procedure 
on a human participant (Catsanoz et al., 2011).  
The debate between Islamic scholars and researchers became so heated that the then 
King Fahad Bin Abdul Aziz interjected and stopped it. He deemed that it had become more 
philosophical than practical (Fageeh, 2001). The king also clearly instructed all health care 
providers that no more unethical practices or research would be allowed. To this end, he 
established the National Committee of Bioethics on 7th Aug 2001 to oversee research in 
the Kingdom and to provide practitioners with the principles of permissible practice. This 
committee also has to approve any research activity conducted in the Kingdom, but can 
delegate this responsibility to institutional review boards within hospitals. Research can 
only commence after such an institutional review board approves it (Fageeh, 2001).  
The National Committee of Bioethics issued its national guidelines on bioethics on 
19 August 2010. These were intended to guide medical research ethics in the country. The 
guidelines are adapted from internationally accepted good practice, blended with Islamic 
Sharei’ jurisprudence. The international guidelines that inspired the new legal document 
were, prior to this, the only source of guidance at the disposal of policy- and decision-
makers in Saudi hospitals and research organisations. The development process took about 
ten years from the time the committee started until it announced its findings. There is now 
royal approval of the new law, making the document legally binding for all research 
undertaken in the Kingdom.   
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1.3 Challenges of MGE in Saudi Arabia 
One of the aims of this study is to answer the question of what is the ethical impact 
of genetic knowledge on Saudi Arabian culture, and whether the Saudi guidelines that are 
in force are capable of dealing with this. In order to answer this question, it is necessary to 
understand the challenges that could impact on practice. 
1.3.1 Consanguinity 
In most Saudi tribes, first cousin marriage is not a random practice; it is a matter of 
honour that is diligently encouraged. The Saudi tribes themselves have different rankings, 
based on blood purity, history, wealth (in terms of controlling water sources and number of 
cattle), and stories about their generosity toward strangers, visitors and allies. The social 
ranking within the tribe is based on blood purity, which means that a person is linked to the 
tribe by the blood-line of his parents. To start with he is connected to a tribe only by his 
paternal lineage, while his maternal lineage determines his social class within his tribe. In 
the event that his mother is not from the same tribe or not from a stronger tribe, the person 
will be assigned an inferior ranking. Since marriage between strong tribes is very 
expensive and is usually used as tool for inter-political harmony between tribe leaders, the 
majority of tribal marriages are usually between first cousins. A person who rejects that 
unwritten agreement risks the future of his offspring’s social position in the tribe. 
In Saudi Arabia, consanguinity has been a very frequent phenomenon over past 
centuries. During the period between 2004 and 2005, El Mouzan (2008) reported a 
consanguinity rate of 56% (n=11,554) in comparison to Jordan 51.3%, United Arab 
Emirates 50.5%, Tunisia 49%, Egypt 40%, Yemen 40%, and Kuwait 36% (Bittles, 2001; 
El-Ashry et al., 2007; Jurdi and Saxena, 2003; Khoury and Massad, 1992). All of these 
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countries share the same Eastern and/or Arabic tribal values. Global patterns of 
consanguinity can be seen in Figure 1. 
 
FIGURE 1-1: GLOBAL DISTRIBUTION OF MARRIAGES BETWEEN 1ST AND 2ND COUSINS 
(BITTLES AND BLACK, 2010). 
 
 The high rate of consanguinity in Saudi Arabia was found to be significantly 
associated with major congenital diseases (El Mouzan et al., 2008), the incidences of 
which are relatively higher than that reported elsewhere (Al Husain and Al Bunyan, 1997; 
Elhadd et al., 2007; Panter-Brick, 1991).  
Often, MGE research is used in Saudi Arabia to link the detected mutations with 
demographic and environmental factors in order to control, or even prevent, their outcome. 
Genome-wide association studies (GWAS) perform a similar task in terms of trying to 
associate the DNA single-nucleotide polymorphism (SNP) that is usually present in the 
non-coding area of mutations with diseases. In order to do this, a group of compromised 
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people with genetic conditions and a group of healthy people (control) are selected, so that 
the differences might be compared and contrasted, and a better idea developed as to which 
genetic mutations are responsible. For more accurate results, GWAS usually seeks a 
control group from the same family as the compromised participants. One of the most 
challenging results of MGE in Saudi Arabia is the suggestion that a premarital genetic test 
should – as a matter of law – be conducted to identify carriers of the more common Saudi 
genetic diseases, including sickle cell anaemia, glucose-6 phosphate deficiency and 
thalassaemia.  
The main ethical challenge in such a context is that consanguinity has been 
associated with various harmful genetic conditions in the published results of MGE 
research on blood from Saudi patients and their relatives.  It is not the intention of this 
thesis to discuss whether or not consanguinity is good, nor whether it is accurate to hold it 
responsible for the relatively higher prevalence of genetic diseases among Saudis. The 
ethical challenge, however, is using MGE research as an epistemic authority (Al Husain 
and Al Bunyan, 1997; Elhadd et al., 2007; Panter-Brick, 1991; Hamamy, 2012) to 
undermine what could be seen as an important cultural value (i.e., consanguinity).  Even if 
the cultural value is to be addressed and reflected upon, MGE research, as pure laboratory-
oriented science, should not be used as the only tool to readdress the questioned value as it 
usually lacks consideration of the necessary social, ethical and cultural dimensions. MGE 
research should only be used as an indicator to start a serious ethical and social study to 
address the issue fairly, which does not seem to be the case in Saudi Arabia. Also it is 
unclear whether or not Saudis would participate in a research study if they were aware that 
the results would be used to undermine one of their cultural values. Even if an individual 
consents to participate in MGE research, is it right for him/her to do so given that his/her 
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participation may provide information about a whole family or even a tribe (if enough 
individuals chose to participate)? This challenge will be further explored below. 
1.3.2 Premarital genetic testing in Saudi Arabia 
The Saudi Royal Cabinet issued the Saudi Royal Decree No. 3 dated 11-7-1424H (7 
Sept 2003), mandating that all Saudi couples have to undertake a pre-marriage test to be 
declared genetically suitable for each other, as well as being free from sexually transmitted 
diseases (El-Hazmi, 2004). 
The test itself is a legal requirement for issuing a marriage certificate, but there are 
no legal restrictions to marriage implied by the results, and the couple can elect to go ahead 
with the marriage plan without legal sanction, even if either or both of them test positive. 
However, some Saudi legislators have proposed that marriages should be legally prevented 
if both persons are carriers of the same recessive gene. Leading Islamic scholars have 
rejected this suggestion because Sharei’ laws does not accept adding conditions to what 
already exists; but this issue is still the subject of public debate in academic circles and on 
television, radio, and news print media (Al-Aama, 2010; Al-Mendalawi, 2011; El-Hazmi, 
2006; Ibrahim et al., 2011; Memish and Saeedi, 2011).  
A similar debate took place in Cyprus during the1970s when trying to control the 
high rate (15% of the population) of patients with autosomal recessive β Thalassaemia. 
Three arguments were used to campaign against marriage between two β Thalassaemia 
mutated gene carriers: 
 the first argument concerned the burden of the disease for society: the aim 
was mainly to draw attention to the idea that Cyprus’s small society could not 
 20 
bear the financial cost of treating the disease. Even if it could, the relative 
costs would jeopardise other health services, 
 the second argument was the burden of the disease for the family: this 
argument highlighted the emotional distress that parents, family and friends 
have to deal with; 
 the third argument was the burden of the disease for the patient: in this 
argument, an appeal was made to the norms of good parenting and parents’ 
electing to have children that would live in pain and die prematurely, when 
they could take early preventive measures. (Hoedemaekers, 1998) 
Hoedemaekers (1998) argues that this programme, and others that followed, were 
purely motivated by the desire to reduce costs. It was underpinned by the presence of 
budget stress, which could be seen as a conflict of interests (e.g. health professionals 
asserted that they were planning to stop receiving new cases in order to reduce health care 
costs, on the grounds that “it is imperative to be successful [in reducing disease 
incidences])” (Hadjiminas, 1994 as cited in Hoedemaekers, 1998).  
In Saudi Arabia a similar approach was pursued, which opens up the same objection 
as that considered by Hoedemaekers (1998). It prioritised reducing the number of affected 
children over giving care and support to compromised families. The public campaign in 
Saudi Arabia promised to eradicate ‘genetic diseases’ for the better health of future 
children, which is misleading on a number of counts: (a) the test being promoted is only 
for Thalassemia, Sickle Cell anaemia and G-6-P; and these are not all the ‘genetic 
diseases’; (b) to ‘eradicate’ genetic diseases is a process that would take massive public 
education to change established cultural practice. It is unfortunate that there has been no 
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in-depth study of the impact of the premarital test on Saudi culture, as this would enable a 
valuable assessment of how Saudis are dealing with the clash between the burden of 
genetic incompatibility and the value of consanguinity. 
The ethical challenges could be summarised in the following three points:  
A- In the Saudi cultural context, premarital tests could be seen as a proxy to 
limit consanguinity due to the established assumption that it is responsible 
for the relatively higher prevalence of genetic diseases in countries that 
value consanguinity in the same way (see the previous sub-section 1.3.1 
Consanguinity.) Premarital tests should not be used as an epistemic 
authority to prevent or control consanguinity, for the same reasons that 
MGE research results should not be used alone either (see an example in Al 
Odaib et al., 2003; and Alenizi, 2014). It does not seem right to use what is 
claimed to be a generalizable laboratory result to label consanguinity as 
wrong and then take further laboratory tests to prevent consanguinity on a 
personal level (i.e., just before marriage). 
B- Another ethical challenge is the way in which premarital tests were 
introduced to the public. As explored earlier in this subsection, these tests 
were introduced with what look like overpromises, such as contributing to 
eradicating all genetic and sexually-transmitted diseases by the taking the 
test and then adhering to its results (such as by cancelling the marriage). To 
the best of my knowledge, there is no social support service for those who 
will bear the burden of such knowledge when they culturally cannot cancel 
the marriage or those who cancel the marriage and then must live with the 
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stigma (e.g., refusing to marry a cousin and/or being labelled as genetically 
unfit).  
C- In addition to all of the above points, the notion of premarital tests seems to 
be motivated by prioritising the reduction of the cost of having children 
who could have one of the three diseases, rather than by caring for and 
supporting the compromised families.  
1.3.3 Stigmatisation 
Furthermore, as a result of decades of consanguinity, Saudi tribes are genetically 
homogenous, which means testing may result in tribal stigma, as well as the stigmatisation 
of individuals. As consanguinity has been practised for hundreds of years in the Arabian 
Peninsula, there is a concentration of genetic lineages amongst persons of the same tribe 
and a tribe can share very high rates of the same inherited genetic diseases. This is so 
common that Saudi geneticists can often identify an individual’s tribe or the region where 
their tribe is traditionally based solely by knowing the genetic disorders they have. It is 
very well known, for example, that the Saudi Eastern Provence has more carrier rates of β-
Thalassaemia and Glucose-6-phosphate dehydrogenase than the rest of the Kingdom. 
Although medical cover is now free for all Saudi citizens, the government is in the process 
of legislating (Decision No. 71, Council of Ministers) for the provision of private insurance 
for Saudis, where the premium may vary, based on individual risk factors. This could mean 
that people from the Eastern region (i.e. already characterised by higher rates of β-
Thalassaemia) will have higher premiums than people from the rest of the Kingdom. 
In Saudi Arabia, if a family were to become known as being carriers of a genetic 
disease, their daughters’ chances of getting married would be very slim. The main reason 
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for this is the process of arranged marriage, in which the mother of the groom looks for a 
suitable bride for her son. It has become common for mothers to ask whether the proposed 
bride has been previously engaged and then had the engagement broken due to the 
premarital test, or whether she is from a branch of the family that is known to have a 
particular disorder. If the answers to such questions raised doubts over the proposed bride, 
the mother would move on to other families to find someone more genetically suitable (Al 
Sulaiman et al., 2010). It is unfortunate that the cultural paradigm of this practice has not 
yet been studied; however, a study from Israel reported a similar case, where the father of a 
Arab Bedouin tribe refused to test his daughter, as it would decrease her marriage chances 
(Raz and Atar, 2004). Although the result would stigmatise both the male and female in the 
engagement should they turn out to be carriers, women are more stigmatised than men in 
tribal cultures (Raz and Atar, 2004). 
To summarize the challenges for MGE research in the Saudi Arabian cultural 
context, stigma is ethically problematic in three ways: 
A- Blood donated by an individual, even with that person’s explicit consent, 
may provide information about the whole tribe, which might open the door 
to the stigmatization of far more people than the individual who originally 
consented. 
B- Women in Saudi Arabia are likely to be the most stigmatized because of the 
arranged marriage practice, in which the mother of the groom looks for the 
most ‘suitable’ bride. 
C- Stigma in general creates and perpetuates an unfair disadvantage. 
 24 
1.3.4 Blood purity 
As explained earlier, blood purity determines the rank of a person in his own tribe. If 
the person’s genetic lineage is connected to the tribe from both of his parents’ sides, or 
from his father’s side, while his mother is from a stronger or similarly ranked tribe, he 
would be in the highest rank among his peers.  
The notion of blood purity has been used by the government to determine the 
veracity of non-Saudi individuals’ claims to belong to one of the strong tribes in the border 
regions, either on the northern border (for example, the tribe of Onaizi) or on the southern 
(the tribe of Nahdi). This was an attempt by the Saudi government to stop illegal 
immigrants from getting permits for citizenship through tribal leaders.  
It is noticeable that participants in the Arabic online forums have started to gain an 
interest in online analysis services for identifying DNA genealogy, for example, 
www.familytreedna.com (Arab-DNA, 2012; Howitat, 2012). There are heated debates on 
these Arabic forums about tribal belonging. This is a new form of genetic identity that has 
gone unaddressed by the Saudi government.  
It appears that the MGE technology, in some reported cases, has started to infringe 
on the main fabric of the tribe’s identity. For example, there was a highly publicised case 
recently when two brothers won a verdict to divorce their sister from her husband and the 
father of her two children against the couple’s will because the brothers claimed that the 
husband was not as ‘pure blooded’ as their sister. The couple appealed the decision to a 
higher court, where they were able to reverse the divorce and authenticate their marriage 
after a three year court battle (Arabian Business, 2012). This is not an isolated case: Al 
Sharq Alawsat, a Saudi news website, claimed in September 2013 to have found at least 
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sixteen divorce cases based on blood purity incompatibility between Saudis, including nine 
cases in Riyadh, six cases in the Eastern province, one case in Medina and one case in 
Jeddah (Al Sharq, 2013). The Al Madinah newspaper reported that during the first two 
months of 2014, there were 13 cases of blood purity incompatibilities (2014). Another case 
concerned a woman who tried to kill herself after her family received a court ruling that 
her future husband was not from an equivalent pure bloodline (Alwatan, 2013).  
To summarise the challenges in this context, MGE consumer-oriented services are 
introducing what could be regarded by some Saudis as a more reliable epistemological tool 
to verify lineage than the traditional way (looking towards shared culture, language, 
religion, history and interests) as a way to promote or demote families among specific 
tribes. This could be problematic in situations such as when couples are divorced against 
their will just because the tribe’s elders regard one of the spouses as not genetically pure. 
Thus, utilising of such technologies, in this specific way, has the potential to infringe on 
established-families’ stability. Also, consumer-oriented services appear to introduce a 
whole new paradigm of genetic identity that will be discussed below (section 7.2.3 Blood 
as identity tool). 
1.3.5 Patient vulnerability 
Saudis generally like to be regarded by each other as conservative, generous, kind, 
supportive and religious. According to some Western physicians who have worked in 
Saudi hospitals, those claims are not completely wrong. Western physicians affirm that 
Saudi patients trust the physician who treats them (Lacey, 2011), and confer on the 
physician an authoritative status (Abolfotouh and Adlan, 2011). In some cases, Saudi 
patients even try to personalise the relationship by attempting to engage on a social level. 
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Saudis also like to be perceived as believers (Halligan, 2006). If misfortunes occur they are 
attributed to God’s will as it is part of the Islamic creed that God sometimes tests people’s 
beliefs through either doubt or hardship (Al-Shahri, 2002, Rassool, 2000). Good Muslims 
should be patient, accepting and tolerant, and surrender to God’s will, basing their every 
action on Islamic rules. Therefore, if they were convinced that donating blood is a good 
deed rewarded by God in the hereafter, it is difficult for them to say no, given perceptions 
about what it is to be a good Muslim.  
In the past, in the Western context, it was normal to expect a level of paternalism to 
be practiced in medical decision-making. Physicians thought that they were the most 
qualified to take difficult decisions. In contemporary medical practice, the doctrine of 
informed consent is believed to counter such paternalism and promote autonomy (Manson, 
2007). Some of the factors explained in this section may suggest that Saudi physicians are 
still leaning towards some level of paternalism, even though paternalism is largely 
dismissed in contemporary medical ethics (Manson and O'Neill, 2007; Manson, 2007; 
Adlan, 2013)  
Saudi patients usually look up to the doctor who treats them. They rate him/her as a 
healer or, more precisely, as an authoritative figure (Mobeireek et al., 1996). It could be 
argued that such authority makes the physician feel paternally responsible for his patients’ 
care. Despite the debate over the appropriateness of paternalistic behaviour, when it comes 
to inviting patients to participate in health-related research, the matter takes a more critical 
turn, as is unlikely that any patient would say ‘no’ to a physician in Saudi culture just 
because of their professional role (Mobeireek et al., 1996). Even though informed consent 
is mandatory, in Saudi Arabia informed consent is rated as mere paperwork (Jamjoom et 
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al., 2011). It appears that among Saudi patients and their doctors, verbal commitments that 
everything will be fine are more powerful than any signed documents (Abolfotouh and 
Adlan, 2011). This would suggest that paternalism is not the choice of the physician; it 
could be the result of prioritising other values, such as trust between the caregiver and the 
research subject. This claim will be further discussed later in this thesis.  
The ethical challenge in this specific context is considering Saudis as vulnerable to 
not providing what is held to be an appropriate level of consent. For example, they could 
be seen as not being good Muslims if they refuse to perform a good deed that would cost 
them only a few blood drops. If they said no to the treating doctor, they would fear they 
would lose some of the treatment privileges, and some physicians choose not to provide 
full information to patients.   
1.3.6 Conclusion of the Saudi Context 
In conclusion, the aforementioned challenges are not unique to the Saudi Arabian 
context, but, I argue, they are particularly important due to the complex nature of the Saudi 
culture. I have argued that due to the nature of the tribal hierarchy, religion, and the stress 
on healthcare in Saudi Arabia, values such as trust and respect are much more applauded 
than commitment to individualism and free choice, this claim will be discussed in detail in 
this thesis. MGE research has the potential to be harmful, insofar as it can intertwine with 
challenges such as stigmatisation, and patient vulnerability and produce negative effects. 
This claim will be discussed in detail in Chapter Four.  
1.4 The need for empirical data 
This thesis investigates whether the research ethics guidelines for MGE research, 
constructed from Western regulations, are appropriate within the Saudi context. Therefore, 
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I will argue in this section that empirical bioethics and more specifically the normative 
policy- or practice-oriented bioethics (NPOB) approach, that uses both normative analysis 
and empirical data to inform the analysis of each other (Ives and Draper, 2009), is the most 
suitable approach to achieve the aim and objectives of this thesis.  
The importance of normative analysis in this thesis stems from the complex nature of 
the normative challenges surrounding MGE research and the specific Saudi Arabian 
context. However, different disciplines have different ways of identifying these challenges. 
Some might argue that applying ethical theory and moral reasoning are enough to answer 
the question in hand. There are two reasons why this is not the case and why there is a 
need for empirical research as well as normative reflection. Firstly, my overall research 
question starts with posing a normative question about how MGE research ought to be 
regarded in the Saudi-specific context. Such a question calls for studying the context 
empirically to understand Saudi culture and attitudes to donating blood for MGE research 
as a first step to reflecting upon the policies and investigating those policies’ 
appropriateness. Secondly, philosophical reasoning and intuition are among the most 
important tools in moral philosophy; for decades these tools have led moral philosophers to 
come up with highly respected moral theories. However, relying on these tools alone 
would not be enough to resolve conflicts between two or more principles if those 
principles are equally justified in the philosophy literature, but contradict each other. In 
such situations, disagreements between theories would enrich further debate and reasoning 
but would be of limited applicability and value for someone trying to identify which one is 
more suitable within a specific context (Hoffmaster, (1992). For example, some writers 
support genetic exceptionalism, arguing that genetics ought to be treated differently to 
other research disciplines because it generates unique medical data that may be a greater 
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risk to participants than other kinds of health information (Green and Botkin, 2003). 
Genetic exceptionalism is, then, used to justify exceptional measures for the regulation of 
genetics research. Others argue that genetic information is not exceptional and that the 
same risks can be associated with any personal information and, therefore, require no 
exceptional treatment. Using only a philosophical analysis approach would add to the body 
of knowledge and might contribute to one or both of these positions on genetic 
information. Philosophical analysis could be rated as a necessary contribution to the field 
of applied ethics but of little benefit to the discussion of the policies in question, as the 
outcome should be more inspired by the culture (Moorlock, 2013).  
Concentrating exclusively on the philosophical debate would be problematic because 
philosophy as a discipline is not a part of any Saudi education curriculum, including the 
higher education systems (Goucha, 2007). It is, therefore, extremely rare to find a 
normative analysis or rigorous philosophical debate about values in Saudi Arabia. Most 
bioethics papers are either practice-oriented or propose an Islamic version of bioethics, 
where authors try to find a connection between medical/research practice and Islamic law. 
Therefore, philosophical analyses alone would be of limited value because it risks being 
alien and might not be acceptable. Knowing how Saudi stakeholders in the context of 
MGE argue for their normative values and what seems important to them, one can provide 
potentially less resistible advice that is more likely to be followed which cannot be 
identified by looking at philosophical literature, and so must be done empirically. 
For centuries, normative analyses, through moral reasoning and reflection, were 
among the most important tools that enabled moral philosophers to produce their moral 
theories. In the same vein, but with a twist towards empirical bioethics, Hedgecoe (2004) 
suggests the importance of introducing a ‘[r]igorous normative analysis to the lived moral 
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experience in addition to critical empirical work which is usually the best way to assess the 
lived moral experience’ (Hedgecoe, 2004, p120-122). In this same paper, Hedgecoe (2004) 
argues for the need for empirical work to inform philosophical reasoning and intuition. The 
social science critique describes traditional applied ethics as: a) abstract, b) rooted mainly 
in rational and formal argument, c) being based on the assumption that moral norms are 
prescriptive and binding through rationality, d) believing that solving problems relies on 
the application of moral theory, and e) overlooking cultural differences (Hedgecoe, 2004). 
Those criticisms have influenced my aims to provide a contextual understanding of MGE 
research in Saudi Arabia as an essential step to conducting a culturally sensitive normative 
analysis. Based on Hedgecoe’s (2004) work, I considered that, if any work attempts 
normative analysis with appropriate cultural understanding in the way that this work 
promises, it cannot afford to neglect the need for empirical data that shed light on the 
intuitions and experiences of stakeholders in the analysed context. To the best of my 
knowledge, no work has yet investigated the intuitions of stakeholders in health research in 
Saudi Arabia. This means that such important intuitions can be easily overlooked if this 
work based its methodology only on traditional ways of reasoning in moral philosophy. 
The social science critics believe that morality would not make sense if the solution to an 
ethical problem did not consider empirical understanding the nature of the problem to 
which the solution was offered. To be effective, any solution to an ethical problem must 
pay close attention to the potential problem that this solution might address. For example, 
one might suggest that Saudi MGE research ought to be regarded in a specific way that 
empowers full autonomy through informed consent documentation; this suggestion would 
be of limited value if in Saudi Arabia it would be regarded as an example of undermining 
tribal cultural systems. Those imposed suggestions potentially could, at the least, create 
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adherence issues that could be circumvented if the context were considered for the 
suggested solution.  
Over the last twenty years, there has been a significant increase in the use of 
empirical data and its analysis in bioethics, as well as numerous references being made to 
data collected and published by others (Sugarman et al., 2007; Borry et al., 2006; Leget et 
al., 2009). Despite that, there is no consistency on what is meant by empirical bioethics 
either theoretically or practically (Molewijk & Frith, 2009). Therefore it is important to 
outline in the beginning what I mean by empirical bioethics which is in general terms 
conducting both ethical analysis and empirical analysis and allowing each analysis to 
inform the other 
In the previous paragraphs, I illustrated the importance of the empirical bioethics for 
this thesis and stated how Molewijk & Frith (2009) criticised a lack of consistency in how 
empirical bioethics is approached in the literature.  To detail this claim Molewijk (2004) 
suggests three different ways in which authors use empirical bioethics: a) Prescriptive 
applied ethics - the data collected by the empirical investigation are only used as a premise 
in an argument or to measure how people are behaving. In prescriptive applied ethics 
priority is given to the theory over any data collected empirically.  b) Theory building - the 
main aim of a theorist is to produce a theory, thus they need the data to refine the theory in 
a one-way relationship, from theory to empirical finding but not the other way around. c) 
Critical applied ethics - this mainly uses both the empirical analysis and the philosophical 
analysis in two-ways relationship and neither is prioritised. This means allowing the data 
to inform the theory and vice versa (Leget et al., 2009). There are many different and 
equally valid methodological approaches and the important thing is to employ that one that 
best addresses one’s aims. In the context of this thesis, the main promise is to provide an 
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understanding of what is going on in the field of Saudi MGE research ethics as a necessary 
step to providing answers to more important normative questions like how Saudi MGE 
research ought to be regulated. In order to do that, it is important to follow the 
methodology that would allow the context to inform the theoretical analysis and visa versa 
in a critical way.  
Hedgecoe (2004) outlines a concept of ‘critical bioethics’ which uses social science 
techniques as tools to better inform normative analysis. This approach to bioethics can be 
regarded as critical of common bioethics practice (i.e., not using empirical data) from a 
social scientist point of view. It calls for the development of a methodology that would 
have stronger potential to bring the empirical data into ethical analysis and theorising. 
Such a call has paved the way for the suggestion of a different methodological empirical 
approach which ‘is important in two significant ways: to achieve a contextual 
understanding, and to understand meaning’ (p251); this methodological approach is called 
empirical bioethics (Ives and Draper, 2009).  
1.4.1 Normative policy- or practice-oriented bioethics 
As Ives and Draper (2009) see it, a policy must be in harmony with the community 
that will be expected to follow it. Empirical work is a means of uncovering what the 
stakeholders think about, and how they react to, those policies. Stakeholders’ input cannot, 
however, be taken as the sole authority for the regulation of MGE research in Saudi 
Arabia. Giving such authority to such views could lead to the ‘defence of the indefensible’, 
or at least face the difficulty of justifying conflicting points of view (Moorlock, 2013, p4). 
Instead, stakeholder views will be combined with philosophical reasoning so as to come up 
with a better understanding of the MGE research practice in Saudi Arabia. It is essential to 
provide the needed ‘encounter with experience’ (Ives, 2008) which has yet to be assessed 
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in the MGE research in Saudi Arabia. This, Ives describes as ‘[b]ringing philosophical 
ethical analysis to the ground, and rooting it in real people and in real problems’ (Ives, 
2008, p3). Thus, for the sake of providing a better critique of policies in Saudi Arabia, it is 
important to employ empirical analysis in addition to philosophical analysis. Accordingly, 
the most appropriate research approach is the NPOB approach, as this will help to 
understand the normative assumptions of the Saudi MGE-regulating policies, as well as to 
determine what value is attached to MGE research in Saudi Arabia (i.e. whether people 
think it a valuable thing to do and why) by combining both normative analysis and 
empirical analysis. Another important reason for why NPOB seems the most suitable 
approach for this thesis is the importance of both intuitions in moral philosophy and the 
empirical data in gaining a more accurate understanding of the Saudi MGE research 
context. NPOB’s main promise is ‘to integrate empirical data and philosophical bioethics 
is to utilize empirically gathered lay intuition as the foundation for ethical reasoning in 
NPOB...[this]... involves a modification of a long-established tradition on non-intervention 
in qualitative data gathering, combined with a form of reflective equilibrium where the 
demands of theory and data are given equal weight and a pragmatic compromise reached’ 
(Ives & Draper, 2009 p 249). Thus it was the best approach that would fulfil this thesis 
aims.  
1.4.2 The is/ought fallacy 
Some might argue that such a work, if undertaken lightly or uncritically, would fall 
foul of the is/ought fallacy. The is/ought fallacy refers to accepting the descriptive value 
(what is usually practiced by people) to be a prescriptive value (a statement of what they 
therefore ought to do or value). According to David Hume you cannot derive an ‘ought’ 
from an ‘is’ because the ‘is’ statement is descriptive while the ‘ought’ statement is 
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prescriptive. In other words we cannot have a moral conclusion based on premises that do 
not have at least one moral claim among them. Consider, for example, society X prefers 
doing Y, therefore doing Y should be regarded as morally acceptable. The fallacy here is 
accepting a moral claim Y based solely on what society X prefers, without seeing that we 
need at least one premise that ‘bridges’ the descriptive and the normative, such as: ‘where 
a society prefers an action it is what we ought to do’. To avoid the is/ought fallacy, I will 
not use the empirical data in the embedded study to make moral claims, but rather they will 
be used to inform my moral reasoning. Thus, using data will help provide better analysis 
insofar as data are used in the same way that intuition uses example and scenarios; it is 
mainly by informing the reasoning for moral theories and by respecting the idea that facts 
and values are not distinct in practice  (Ives & Dunn, 2010). In the context of the empirical 
project in this thesis, to ensure that it will not fall foul of the is/ought fallacy, it is essential 
not to advocate any moral conclusion based on the data analysis alone without critical 
moral reasoning. The plan is to use the data as well as personal reflexivity to ensure an 
“encounter with the experience” (Ives & Draper, 2009) of the stakeholders and use the 
understanding gained to help develop a more encompassing normative analysis without 
claiming that because in the Saudi context, X action is happening therefor X should be an 
accepted moral practice.  
In conclusion, the empirical part of this research aims to explore the current practice 
of MGE research in Saudi Arabia, not in order to provide a sociological understanding of 
how social actors react with each other, but to provide an overview of the normative 
assumptions that tacitly guide donors, researchers, and policy-makers with regard to MGE 
research. The Saudi stakeholders’ normative assumptions will be compared with the 
normative assumptions explored in the Chapters regarding the guidelines that are supposed 
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to guide MGE research practice in Saudi Arabia. Accordingly, this work can be understood 
as an empirical study in bioethics, specifically normative policy-oriented bioethics 
(NPOB), as described by Ives and Draper (2009). NPOB refers to the blending of 
normative bioethics analysis and empirical data analysis in the examination of normative 
principles underlying policies (Ives and Draper, 2009). This approach will better serve the 
overarching aim of this research, which is to contextualise ethical theories related to the 
ethical issues of relevance to thinking about genetics for policy-makers in Saudi Arabia. 
1.5 Thesis Aims and Objectives 
The aim of this thesis is to explore the ethics of collecting and using donated blood 
for MGE research in the context of Saudi Arabia, as a preliminary step to enabling 
policymakers to generate specifically Saudi oriented guidelines for MGE research in the 
Kingdom. Accordingly, I have studied the current regulations governing the collection and 
use of blood for MGE research in Saudi Arabia against the background of the international 
policies that informed the development of the Saudi general bioethics guidance (NCBE 
2010). This enabled me to determine whether the reviewed international policies’ 
embedded norms that anticipate ethical issues in MGE research. Accordingly, the thesis 
objectives were:  
1) To outline the international ethics guidelines for the collection and storage of 
blood samples from adults for the purposes of MGE research. This was achieved through 
desk-based research, reviewing the literature and applying critical analysis to the selected 
international guidelines to determine their appropriateness in this context. 
2) To explore how the current Saudi guidelines regulate the collection and storage 
of blood for MGE research and reflect the principles and norms distilled from the 
international guidelines. The Saudi guidelines were distilled and compared to those driving 
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the international guidelines. In order to determine how appropriate they are for the 
regulation and collection of blood for MGE research in Saudi Arabia, the Saudi context in 
terms of culture, religion and politics was explored to gain insight into how a blend of 
these factors interacts with complying with the selected international bioethics regulations 
regarding the donation of blood for MGE.   
3) To illustrate how the official Saudi guidelines and ethical norms are 
implemented in current practice in relation to the collection and storing of blood, with 
reference to samples taken from adults who have given prior consent to a particular type of 
MGE. This was achieved by field observations (i.e. recruitment of blood donors for MGE 
research sessions in one of Saudi Arabia’s tertiary care hospitals) and interviews with 
people who had been invited to participate in MGE research in Saudi Arabia. 
4) To explore, using focus groups, how the results might be perceived by those 
charged with generating and applying the Saudi guidelines and norms for research.  
 
1.6 Research questions 
1. What are the influential international guidelines for the collection and storage of 
blood, with reference to samples taken from adults for MGE research purposes? 
2. What are the Saudi guidelines for the collection and storage of blood for pre-
approved MGE research, and to what extent do they reflect the international guidelines 
already identified? 
3. To what extent are the Saudi or the international guidelines followed in practice in 
the Kingdom? 
4. What, if any, are the challenges of collecting blood from Saudi donors for MGE 
research, as perceived by the stakeholders? 
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5. What is the feedback of those charged with generating the Saudi guidelines and 
norms for research to the results of the investigation into current practice in relation to 
blood collected for genetics research? 
6. What recommendations would help to promote better and more culturally sensitive 
guidelines with respect to the donation of blood for MGE in Saudi Arabia? 
1.7 Summary 
In this chapter, I introduced the overarching aim of this thesis and its objectives. The 
primary aim is to explore the ethics of using donated blood for MGE research in the 
context of Saudi Arabia, as a preliminary step to enabling policymakers to generate 
specifically Saudi-oriented bioethics guidelines for collecting and using blood for MGE 
research in the Kingdom. Accordingly it was essential to start by introducing the Saudi 
context, which puts the MGE research in its Saudi context, to cast a light on what could be 
the challenges that ought to be considered when writing specific regulations for MGE 
research in Saudi Arabia.  
This chapter also introduced some of the Saudis’ values and provided the context in 
anticipation of tensions that will emerge in Chapter Four between cultural norms in SA and 
the international guidelines. This introduction outlines how the thesis has explored the 
ways in which MGE research in the Saudi context, by contrasting what the policymakers 
expect with what is going in the field.  Based on this, I have also argued for the use of 
empirical bioethics, by showing that a combination of empirical data and philosophical 
analyses are the best way to answer the overarching aim of this study.   
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Section One: The normative analysis of the selected guidelines 
This section will be dedicated to the normative analysis of the selected international 
guidelines (Chapter Two), the Saudi NCBE guidelines (Chapter Three) and how the Saudi 
context would pose challenges to MGE research regulated by those guidelines (Chapter 
Four).  
In the first two chapters of this section (i.e. Chapters Two & Three) the policies are 
analysed in three main steps. The first stage involved in-depth reading and familiarisation, 
looking at the selected policies in the historical and regulatory context. This helped to 
understand the motivations behind these policies and paved the way to the second stage. 
Secondly, I familiarised myself with the policies and tried to look past the words to the 
normative assumptions at work, to gain the necessary richness and depth (Bowen, 2009). 
Thirdly, after I familiarised myself with the data, I used a mixture of content analysis 
(arranging the text’s content in a way that answers the research questions) and thematic 
analysis (in the sense of pattern recognition in the text) (Bowen, 2009).  I then engaged in 
philosophical analysis of the relevant themes in the light of the issues uncovered in the 
literature.  
The final chapter in this section (Chapter Four) will be dedicated to normatively 
analysing and describing how the Saudi culture and its contexts outlined in Subsection 1.5 
above poses challenges to how MGE research is currently regulated in Saudi Arabia.  
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2 Chapter Two: The international Guidelines 
This chapter will be mainly dedicated to answering the first research question of this 
thesis, namely identifying the international guidelines governing the collection and storage 
of blood samples taken from adults for the purpose of MGE research. In order to do so, I 
will justify the selection of the guidelines that will be interrogated, to determine how they 
can be used to regulate the collection of blood for MGE research in general.  The main 
points that can be applied to MGE are summarised in Tables 2-2 to 2-5. I will also argue 
that there are three key points here. The first is that the current selected and analysed 
guidelines were written largely with Randomised Controlled Trials (RCTs) in mind. 
Secondly, the lack of guidelines specifically intended to regulate MGE research resulted in 
the adoption of some elements of the ones analysed in this chapter, which is problematic 
because of the different nature of MGE research, and results in gaps that lead to strange 
conclusions, such as the way that risks and harm are understood. Thirdly, looking at MGE 
as an area of research also allows us to see that the international guidelines might well be 
problematic, because they fail to take local culture and context sufficiently into account. 
Although the guidelines explored in this section are not legally binding unless adopted into 
national law, they are nevertheless important because they set out internationally 
recognised norms. The extent to which they have been cited, which will be demonstrated 
in this chapter, has reinforced their role in the ethical regulation of research.  
2.1 International guidelines on bioethics: inclusion and exclusion criteria 
There are myriad international bioethics guidelines; selection for inclusion in this 
thesis was based on the international regulations that are used specifically as references for 
the Saudi national bioethics guidelines. Those selected guidelines are the Nuremberg Code, 
the Declaration of Helsinki, the International Conference of Harmonisation – Good 
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Clinical Practice (ICH-GCP), the Council for International Organisations of Medical 
Sciences (CIOMS), and UNESCO’s Universal Declaration of Bioethics and Human 
Rights. The Saudi NCBE guidelines mention in a very general way that the references are 
based on Islamic Sharei’ laws and the international guidelines (NCBE, 2010). Further 
consultation with experts from the committee confirmed that the above selected guidelines 
were agreed by NCBE members to be the most influential and that they were often 
appealed to in the most respected Specialists Saudi hospitals (KFSH&RC, 2013; NGHA, 
2013).  
2.2 The context of the selected international guidelines 
In the following subsection, I will briefly summarise these guidelines and identify to 
whom they apply. This step is important for three reasons: 
 It helps to place these guidelines within their historical context. 
  It helps to understand who is expected to read and comply with them. 
 It gives an insight into many Western ethical perspectives and priorities. 
All of these points, I argue, are essential for assessing the suitability of the guidelines 
for regulating GME research in Saudi Arabia, which will be more fully discussed later in 
this study.  
2.2.1 Nuremberg Code 
The Nuremberg Code is the oldest set of guidelines for acceptable research involving 
human participants.  Conceived in Nuremberg, Germany in August 1947, it consists of ten 
principles, presented by mainly American judges at the trial of Nazi doctors charged with 
conducting murderous and torturous human experiments on those detained in 
concentration camps (Utley, 1992). Although it was not originally intended to provide 
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guidelines for clinical trials, this code is considered to be the cornerstone of international 
research ethics (Utley, 1992). In its development, judges considered specific cases of 
unethical and inhuman research perpetrated by the defendants. The Nazi doctors’ main line 
of defence was that there were no laws to distinguish legal from non-legal research 
activities at the time, and that similar research had been conducted elsewhere (Manson and 
O'Neill, 2007). The Nazi doctors’ lawyer specifically mentioned the malaria trial 
conducted by the United States upon prisoners of war. Some commentators think that the 
Nuremberg Code’s main contribution was merging the Hippocratic Oath (in which the 
physician is responsible for protecting the best interests of his or her patient) with the 
contemporary notion of protecting human rights (Shuster, 1997). 
2.2.2 Declaration of Helsinki  
In 1947, the World Medical Association (Bowman and Hui, 2000) was established. It 
continues to grow and gain increasing respect; to date, it represents more than eight million 
physicians worldwide (Carlson et al., 2004). In 1964, the WMA published the Declaration 
of Helsinki (DoH) (Carlson et al., 2004; Puri et al., 2009). They incorporated the ten 
principles of the Nuremberg Code with the 1947 Declaration of Geneva, which was also 
authored by the WMA as a statement of physicians’ ethical duties. During the last 46 
years, the DoH has been revised six times; the last revision was in October 2013. Among 
these revisions was one in the year 2000 that did not support the idea of testing drug 
efficacy by using placebo control in clinical trials when an alternative treatment is 
available, which was the main reason that many countries, such as the USA, stopped using 
it as reference for its research ethics bylaws.  
As the Saudi bioethics bylaws were announced in 2008 as binding law articles, a 
subcommittee was formed in 2009 to publish the guidelines that explained the bylaws. In 
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those guidelines the version used as reference was the 2008 version of the DoH. Therefore, 
in the context of this thesis I will use the 2008 version, not the 2013 version.       
This declaration consists of three parts. The first is made up of points introducing the 
general concept and the statement of the declaration. The second part is made up of twenty 
points concerning general principles of all medical research. The third part consists of five 
points concerning the combining of medical research with medical care. According to 
Williams (2008), the Declaration of Helsinki is primarily concerned with public health 
research, as it differentiates between individual and public health; this idea can be refuted 
by the fact that the DoH does not mention any non-clinical research in its guidelines, 
which suggests it is more focused on clinical trials, particularly RCTs, than public health 
research.  
This declaration clearly defines its audience: ‘Although the Declaration is addressed 
primarily to physicians, the WMA encourages other participants in medical research 
involving human subjects to adopt these principles’ (DoH, 2008, p1). This might give the 
impression that these guidelines are more applicable than the Nuremberg code to scientists 
(who are the most likely to do laboratory work in MGE research). However, elsewhere the 
Helsinki Declaration also states that scientists should be under the supervision of a 
clinically competent medical person when they are conducting research that involves 
human participants (DoH, 2008, p3). Thus, it can be argued that the document considers 
physicians as its main audience, which Millum et al. (2013) and Emanuel (2013) consider 
to be a mistake because ‘a statement of ethical principles does not require a mandate from 
the people who ought to follow those principles’ (Millum et al., 2013, p2143). Similarly, it 
could be argued that scientists adhering to the code may regard themselves as both obliged 
to work with a clinician and themselves be bound by the precepts. However, it can be 
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understood that if anything went wrong, it is the physician who is held responsible (DoH, 
2008). This suggests that although it is written for physicians, it also applies to scientists, 
but all the liabilities fall to the physicians.  
The fact that the document does not define what it means by the involvement of 
human participants, as different types of involvement might call for different measures, 
may have contributed to ambiguity surrounding to whom this document is addressed. For 
example, the nature of the involvement of a patient who is asked to fill out a questionnaire 
is wholly different from that of a patient who is asked to join a Phase One clinical trial (i.e. 
asking a healthy person to take an investigational drug in order to assess its safety profile). 
This can be justified in clinical trials or RCTs but mandating the physician to assume 
major responsibility is to protect participant’s interests.  It fails, however, to acknowledge 
that not all research is as risky as clinical trials (Williams, 2008). The point of having a 
physician assuming responsibility for a questionnaire could be sometimes unjustified. 
2.2.3  International Conference of Harmonisation – Good Clinical Practice (ICH-
GCP) 
The original mission statement of the International Conference of Harmonisation 
(ICH) was to regulate clinical trials in America, Europe, and Japan (Dixon, 1999). Now, 
Canada, Australia, European Union and the World Health Organisation (WHO), as well as 
many other countries (including Saudi Arabia), have adopted these guidelines (Alahmad et 
al., 2012). Their main goal is to achieve a consensus on the guidelines that dictate how 
clinical trials should be performed, investigated, sponsored, and audited for the final step 
of approving a pharmaceutical product or a new medical intervention (e.g. a medicine, 
device, or new operational manoeuvre). With harmonisation it is possible to conduct 
clinical trials across national borders.  
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Since its announcement in 1996, the GCP system has provided a unified system for 
exchanging clinical research data between the countries that have accepted it. This means 
that drug companies can target populations outside their geographical area as long as the 
GCP guidelines are accepted and enforced in the targeted country. In other words, a single 
set of guidelines governs clinical trials internationally, rather than different guidelines for 
different countries. The main audience for the GCP is principal investigators. The GCP 
guidelines define the principal investigator as ‘[The] person responsible for the conduct of 
the clinical trial at a trial site. If a trial is conducted by a team of individuals at a trial site, 
the investigator is the responsible leader of the team and may be called the principal 
investigator’ (GCP, 1996, p5). Given that the GCP is meant to regulate clinical trials, the 
clinical site in question is usually a hospital or other health centre. In a hospital, it is less 
likely that a non-physician would be allowed to lead a clinical trial, as the safety of patients 
is the responsibility of the attending physician. This is especially true in research-
orientated Saudi hospitals, because of the lack of research training amongst non-
physicians. Based on this, Saudi policy makers inferred that the GCP policy did not 
specifically address physicians, but that the context of clinical research dictates that the 
person addressed in the guidelines should be the one responsible for patient safety (i.e. the 
physician). Conversely, this could mean that all researchers have to take responsibility for 
the safety of participants: the PI takes overall responsibility for the site’s conduct and the 
coordinating investigator takes overall responsibility for running the trial across sites. The 
latter, an EU designation, could very well not be a physician but an epidemiologist or 
genetic scientist, for example, but the site PI should be a clinician. 
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2.2.4 Council for International Organizations of Medical Sciences (CIOMS) 
The WHO and the United Nations Educational, Scientific and Cultural Organisation 
(UNESCO) together established the CIOMS as a non-profit and non-governmental 
organisation in 1949. By 1991 CIOMS issued a set of guidelines oriented to regulate 
epidemiology research. In 1993, CIOMS disseminated a set of 15 principles regulating the 
involvement of human participants in health-related research. Later, in 2002, the CIOMS 
guidelines were updated to regulate clinical research. CIOMS started the revision of these 
Guidelines by forming a multidisciplinary group, which resulted in the 2008 CIOMS 
principles that will be used in this thesis which is know as the International Ethical 
Guidelines for Epidemiological Studies as well as clinical research (CIOMS, 2008). 
CIOMS originally targeted the assessment of the suitability of the 1964 Helsinki 
Declaration (Emanuel et al., 2008). In the 1980s, there were many clinical trials occurring 
in the developing world that were responding, not to the most urgent problems of the 
developing world, but to the sponsors’ needs. Problems such as malaria, HIV, respiratory 
infections, tropical diseases, and many others were neglected despite the need for 
solutions. The vulnerability of less developed nations posed many ethical challenges to 
multinational research, such as the recruiting of participants from low income populations 
and the protection of their particular interests (Emanuel et al., 2008). Some might say that 
such contexts and debates enlivened the CIOMS and gave it a more sensitive grounding 
with the developing world through its understanding of cultural diversity. Nevertheless, it 
was still far from being sufficiently specific address all research activities in the less-
developed world (e.g. MGE).  
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2.2.5 Universal Declaration of Bioethics and Human Rights of UNESCO 
UNESCO is trying to move from mere recommendations and guidelines to 
internationally agreed declarations at the state level. In 2005, UNESCO announced its 
Universal Declaration of Bioethics and Human Rights. This was a result of two years of 
deliberation by 36 members of the International Bioethics Committee (IBC), which served 
as a transparent, independent committee of bioethics experts. The declaration was then 
discussed by member states as a non-binding agreement, in the hope that it would be 
incorporated within the member states’ legislation. The IBC includes bioethics experts 
from different backgrounds, including scientists, lawyers, philosophers, and medics 
(UNESCO, 2005). Efforts were made to include spiritual and religious groups as well, but 
despite this, some academic groups, specific branches of scientists, and some interested 
politicians still claim that their voices were not properly represented or consulted during 
the drawing up of the declaration (Langlois, 2011). In addition, many countries, including 
the UK, did not ratify the declaration. However, it has been introduced and accepted in 
Saudi Arabia, and the chairman of the ICB is the chairman of the Saudi National Bioethics 
Committee.  
Its initial aim involved clinical research. Some say it is essential as a step towards 
unified international bioethical guidelines (ten Have and Jean, 2009), while sceptics 
believe it lacks strength because some articles are vague and lack clarity (Levitt and Zwart, 
2009).  
Having summarised the context of the selected guidelines, in the next subsection I 
will analyse how MGE research could be regulated using these selected international 
guidelines. This step is important because MGE research is not mentioned per se in these 
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particular regulations, but some general guidelines can be used in the MGE research 
regulations context.   
2.3 How Molecular & Genetics Epidemiology could be regulated: 
Of the different areas covered in the guidelines, only five items were relevant to the 
regulation of the collection of blood for MGE. These are: 
 The importance of ethical committee review: The committee main tasks would be: 
- Accepting only properly constituted and justified research, and rejecting 
research where the methods cannot achieve the aims, where the aims cannot be 
justified, and where there is an absence of equipoise in defining the aims. 
- Rejecting any research that does not respect the local cultural norms. 
- Rejecting any research that intends to exploit local research participants. 
 The need for participant consent. 
 Minimising risk for the human research participants. 
 Protecting participants’ privacy and confidentiality. 
 Declaring conflicts of interest to the research committees. 
The justification for isolating each of these items and their applicability to MGE 
follows. 
2.3.1 Review by local ethics committees 
Review by an independent committee is thought to ensure that research has scientific 
validity and investigators are providing maximum protection to participants. With the 
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exception of the Nuremberg Code, all the included guidelines mention the importance of a 
local independent committee looking at a research proposal and deciding its scientific and 
ethical merit. However, if a hospital has only one committee that studies research 
proposals for all the hospitals subspecialties, it risks a lack of fair representation of the 
hospital service subspecialty. In an ideal situation, the committee is expected, according to 
the analysed guidelines, to reject or accept the research proposal after weighing all of its 
elements in a reflective process. Assuming that the research committee members are local 
experts, this is a way to protect local populations from exploitation in the service of 
internationally funded research (see Subsection 2.3.1.3 Avoid local research subject 
exploitation).  
2.3.1.1 Accepting only properly constituted and justified research 
One of the charges levelled during the Nuremberg trial was that the Nazi’s trials 
were methodologically flawed. Accordingly, the suffering imposed could not be justified – 
even if at that time it was defensible to use such a justification - with reference to the 
potentially good ends. The problem was that the ends could not be achieved by the 
methods used. Moreover, the defendants, as scientists, must have realised this (Utley, 
1992).  This charge is reflected in the Nuremberg Code, which dictates that research 
should be properly constituted, and be for the ‘good of society’ (See Table 2-3) (N.Code, 
1949). In MGE research as well as any other health related research the suitability of the 
method for achieving the good for society aim could be taken as a measure of research 
fruitfulness. Of course MGE researchers could use those regulations if it is more 
specifically addressed how it can be good for society. It is important, therefore, to know 
where the line between the MGE research fruitfulness (in the above mentioned way) and 
its burden (see Subsection 2.3.3 Risk).  
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Although the Nuremberg code is one of the most influenced international 
instruments, it fails to recognise that different countries may have different laws and 
guidelines articulating what is locally accepted as ‘for the good of society’ is used to 
determine what it is properly constituted and justified. Such a distinction is very important 
to reflect the peculiarity of MGE research in a culture like the Saudi one. This distinction 
was addressed in later guidelines. The Declaration of Helsinki, for instance, states ‘It 
[Research] must take into consideration the laws and regulations of the country or 
countries in which the research is to be performed as well as applicable international norms 
and standards, but these must not be allowed to reduce or eliminate any of the protections 
for research subjects set forth in this Declaration’ (Table 2-3) (DoH, 2008, p2). However, 
in the context of MGE research in Saudi Arabia, there are two challenges contained in this 
guideline: a) it assumes the presence of specific laws that regulate MGE research 
specifically. b) It can be seen that prioritising the interests of individuals over societal good 
is essential for the research to be justified, which might not be true in many societies such 
as, for example, in Saudi Arabia in the context of the health service, as I will discuss in 
Chapter Four. 
2.3.1.2 Respecting other cultural norms 
It can be claimed that the local research ethics committee protects the local 
community by applying local cultural norms. Of the included guidelines, only the CIOMS 
noted the importance of respecting cultural norms ‘that are morally acceptable within the 
communities in which the research is carried out…’ (CIOMS, 2008, p6). Whilst Article 12 
of the UNESCO Declaration of Bioethics appears to promote respect for cultural diversity, 
it includes the proviso: ‘However, such considerations are not to be invoked to infringe 
upon human dignity, human rights and fundamental freedoms nor upon principles set out 
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in this Declaration, nor to limit their scope’ (UNESCO, 2005, p1). This suggests that local 
norms and values are to be respected only insofar as they are compatible with human 
rights, which protect the interests of individuals. Jing-Bao (2005) claims that the wording 
embodies a cultural assumption about non-Western values that is likely to conflict with 
other Western values, such as respect for human dignity, human rights, and fundamental 
freedoms (Jing-Bao, 2005). A discussion of moral relativism will be included in Chapter 
Four. The main challenge in MGE research is that the Saudi context, as explained earlier 
and as will be further discussed in Chapter Four, could be regarded as presenting a 
different context to the one in which the guidelines were written. This difference could 
cause some tension between the Western inherited norms in the analysed guidelines and 
Saudi norms. Respecting Saudi norms as simply being ‘different’ might not be enough if 
those norms are regarded as challenging the interest of individuals.   
2.3.1.3 Avoid exploitation of the local research subject  
‘Exploitation’ is a complex concept variously interpreted; therefore, it is important to 
introduce what I mean by exploitation and how I use my understanding of exploitation in 
the context of this thesis. 
People have different ideas about what exploitations means (see Table 2-1). In the 
context of this thesis, Wertheimer (2007) seems to offer the best approach to understanding 
exploitation, for two reasons. Firstly, his is, perhaps, the leading account in the literature of 
exploitation (Wertheimer, 2007), and secondly, despite the negative connotation of the 
word, he unpacked the actual moral problem. According to Wertheimer (2007), not all acts 
of exploitation are morally wrong. For example, it could be argued that any form of 
contract of employment is a form of exploitation because.in this case it could be related to 
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the claim of instrumentalisation, but such contracts need not be seen as morally 
problematic in themselves, especially if the concerned parties provide valid consent. 
However, if an employment contract contained coercion, deception or slavery, then we 
would deem the contract morally problematic, not just by appealing to the negative 
connotation of the word ‘exploitation’, but also by identifying the morally problematic 
action. 
Based on this account, the charge exploitation is not a straightforward claim to 
establish, especially in the MGE research context. For example, if a patient had consented 
to donate a few drops of blood for research purposes in exchange for receiving a medical 
examination, it might seem inaccurate to describe such a transaction as unfair exploitation, 
because no actual harm was induced to the consenting body (Wertheimer, 2007). To accept 
the claim that someone is exploited in an ethically problematic way, it is important to 
distinguish between two different concepts: harmful exploitation that is when the exploiter 
gains benefit from harming the exploited, and when the exploitation results in a mutual 
benefit (Wertheimer, 2007). The first form of exploitation is easily condemned. The latter, 
however, needs closer examination to understand what actually goes on in such 
interactions, which is likely to be the case in donating blood for MGE research in Saudi 
Arabia  
Based on this way of understanding of exploitation, two aspects of potential 
exploitation in the context of MGE research in Saudi Arabia could be discussed. The first 
aspect is the unfair exploitation of the research subject by the researcher. In some places in 
the world, research studies offer the only opportunity for individuals to be seen by health 
care providers, leaving patients with little choice but to agree to participate. In this context 
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the exploitation arises because someone is taking advantage of the lack of choice of 
someone else to do anything other than agree. Such a choice, or lack of it, is more relevant 
to the exploitation claim when compared to the level of harm in cases such as RCTs (See 
2.3.3 Risk). In the analysed documents, such kinds of exploitation were mainly discussed 
in the context of stressing the importance of informed consent, as I will discuss in 2.3.2 
Consent. 
The second aspect of potential exploitation in the context of MGE research in Saudi 
Arabia is the exploitation of international funding agencies of less-developed countries. 
This seems to be covered in the way CIOMS dictates that ‘investigators should submit the 
research protocol for ethical and scientific review in the country of the sponsoring 
organisation, and the ethical standards applied should be no less stringent than they would 
be for research carried out in that country’ (see Table 2-4) (CIOMS, 2008 p14). In addition 
to the previously explained demand for well-written research, it appears that this statement 
was expected to deal with what could be regarded as the ethically problematic exploitation 
of the less-developed world. The history of clinical trials is full of such exploitation, for 
example, the maternal-foetal HIV transmission trials, which were approved and funded by 
the American NIH to perform RCTs that would not have had approval to take place in the 
United States (De Zulueta, 2001). It might be easier to spot ethically problematic 
exploitation in RCTs than in MGE research because the risks, vulnerability issues and 
fairness seem more obvious in the former. In RCTs the risk can be clinically assessed with 
a diagnosis and prognosis, but in MGE research the risk could be more general than any 
clinical assessment (e.g. stigmatisation).  The CIOMS requirement cited above can be used 
to protect RCTs participants, but it is not enough to protect MGE research participants. 
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The challenge here is that there are no clear boundaries between research and diagnostics 
in molecular genetics (Nelson et al., 2001).  
In summary, in this subsection I have demonstrated that normative assumptions may 
be made when applying the analysed guidelines to regulate MGE research in general. The 
most central guideline was the call for local committee review. This committee’s main 
duty is to protect human research participants by a) ensuring that research proposals have 
clear reasons for justifying the enrolment of human subjects as a necessary requirement; b) 
accepting only properly constituted well justified research, and c) ensuring that ethics 
committees are representative of their communities and that they protect the interests of the 
research subjects within those communities. Despite the call for accepting cultural 
diversity, it can be sensed that the other values appear to be given a superior moral 
standing over the values that reflect the perspectives of other cultures. This seems to stem 
from a paternalistic notion of protecting research participants from potential ethically 
problematic exploitation, that may result from a practice or value that might contradict 
some of the principles supported by those internationally influential guidelines.  
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TABLE 2-1: HOW EXPLOITATION IS DEFINED IN THE LITRETURE ACCORDING TO WERTHEIMER 
(2007, P248) 
Author  Definition 
BUCHANAN 1985 “[T]O EXPLOIT A PERSON INVOLVES THE HARMFUL, MERELY 
INSTRUMENTAL UTILIZATION OF HIM OR HIS CAPACITIES, FOR ONE'S 
OWN ADVANTAGE OR FOR THE SAKE OF ONE'S OWN ENDS.” 
BENN 1988  “EXPLOITATION [IN EXCHANGE] DEMANDS…THAT THERE IS NO 
REASONABLY ELIGIBLE ALTERNATIVE [FOR THE EXPLOITEE] AND 
THAT THE CONSIDERATION OR ADVANTAGE RECEIVED IS 
INCOMMENSURATE WITH THE PRICE PAID. ONE IS NOT EXPLOITED IF 
ONE IS OFFERED WHAT ONE DESPERATELY NEEDS AT A FAIR AND 
REASONABLE PRICE.” 
GOODIN 1988 
 
“EXPLOITATION OF PERSONS CONSISTS IN … WRONGFUL BEHAVIOR 
[THAT VIOLATES] THE MORAL NORM OF PROTECTING THE 
VULNERABLE.” 
FEINBERG 1988 
 
“COMMON TO ALL EXPLOITATION OF ONE PERSON (B) BY ANOTHER 
(A)…IS THAT A MAKES A PROFIT OR GAIN BY TURNING SOME 
CHARACTERISTIC OF B TO HIS OWN ADVANTAGE…EXPLOITATION … 
CAN OCCUR IN MORALLY UNSAVORY FORMS WITHOUT HARMING THE 
EXPLOITEE'S INTERESTS AND … DESPITE THE EXPLOITEE'S FULLY 
VOLUNTARY CONSENT TO THE EXPLOITATIVE BEHAVIOR…” 
MUNZER 1990 “PERSONS ARE EXPLOITED IF (ARABIC-FORUM1) OTHERS SECURE A 
BENEFIT BY (2) USING THEM AS A TOOL OR RESOURCE SO AS 
(NELSON ET AL.) TO CAUSE THEM SERIOUS HARM.” 
LEVINE 1988 “AN EXPLOITATIVE EXCHANGE IS… AN EXCHANGE IN WHICH THE 
EXPLOITED PARTY GETS LESS THAN THE EXPLOITING PARTY, WHO 
DOES BETTER AT THE EXPLOITED PARTY'S EXPENSE… [T]HE 
EXCHANGE MUST RESULT FROM SOCIAL RELATIONS OF UNEQUAL 
POWER … EXPLOITATION CAN BE ENTERED INTO VOLUNTARILY; 
AND CAN EVEN, IN SOME SENSE, BE ADVANTAGEOUS TO THE 
EXPLOITED PARTY.” 
MOORE 1973, 53 “[E]XPLOITATION FORMS PART OF AN EXCHANGE OF GOODS AND 
SERVICES WHEN 1) THE GOODS AND SERVICES EXCHANGED ARE 
QUITE OBVIOUSLY NOT OF EQUIVALENT VALUE, AND 2) ONE PARTY 
TO THE EXCHANGE USES A SUBSTANTIAL DEGREE OF COERCION.” 
HILL 1994 “[E]XPLOITATION IS A PSYCHOLOGICAL, RATHER THAN A SOCIAL OR 
AN ECONOMIC, CONCEPT. FOR AN OFFER TO BE EXPLOITATIVE, IT 
MUST SERVE TO CREATE OR TO TAKE ADVANTAGE OF SOME 
RECOGNIZED PSYCHOLOGICAL VULNERABILITY WHICH, IN TURN, 
DISTURBS THE OFFEREE'S ABILITY TO REASON EFFECTIVELY.” 
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2.3.2 Consent 
Consent seems to be the most prominent value in all of the included international 
guidelines (Table 2-2). During the last 50 years, the Nuremberg Code has been applauded 
for introducing the notion of informed consent (Manson and O'Neill, 2007; Beauchamp 
and Childress, 2001). This is despite the fact that the term ‘informed consent’ is not 
mentioned in the document and emerged later. What was mentioned is the term, ‘voluntary 
consent’: ‘The voluntary consent of the human subject is absolutely essential’ (Table 2-2). 
Amongst the analysed guidelines, the phrase ‘informed consent’ did not appear in the 
Nuremberg Codes or the Declaration of Helsinki. With the emergence of the term 
‘informed consent’ in the CIOMS, the word ‘voluntary’ did not disappear from the other 
guidelines, but it did become part of the definition of informed consent. For example, in 
the Declaration of Helsinki, the notion of consent was introduced as a ‘voluntary’ notion in 
relation to competent individuals: ‘Participation by competent individuals as subjects in 
medical research must be voluntary’ (Table 2-3) (DoH, 2008, p3). This was also true in the 
case of CIOMS and ICH definitions.  
UNESCO’s claim about when consent ought to be invoked reads as ‘Any preventive, 
diagnostic and therapeutic medical intervention is only to be carried out with the prior, free 
and informed consent of the person concerned, based on adequate information’ (Table 2-4) 
(UNESCO, 2005, p6). In this context, ‘free’ can be taken to mean a voluntary condition, 
even though the word ‘voluntary’ is itself absent.  
As these codes developed, the notion of ‘consent’ appeared to grow gradually, from 
its emphasis as a voluntary condition, to a more central concept, symbolised as ‘informed 
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consent’ in research ethics. In the Declaration of Helsinki (DoH, 2008), the requirements 
to meet the consent condition are as follows: ‘In medical research involving competent 
human subjects, each potential subject must be adequately informed of the aims, methods, 
sources of funding, any possible conflicts of interest, institutional affiliations of the 
researcher, the anticipated benefits and potential risks of the study and the discomfort it 
may entail, and any other relevant aspects of the study’ (DoH, 2008, p3). However, neither 
the Nuremberg Code nor the Declaration of Helsinki offer an account of how consent 
should be documented, in the way that CIOMS and ICH-GCP do. Both CIOMS and the 
ICH-GCP explicitly explain the informed consent element which constitutes the patient 
information sheet (Haven and Jean, 2009; GCP, 1996). The ICH-GCP is mainly oriented 
towards clinical trials and, therefore, it is expected that the elements of informed consent 
covered in it is mainly for the use of clinical trials. It can, of course, be used for different 
kinds of research, but it has gaps, leading to inadequate conclusions. For example, one of 
the elements of the ICH-GCP guidelines for informed consent mandates that the 
participant should be informed if there is an alternative treatment. If an MGE researcher 
wants to use such a guideline, the researcher would either disregard it completely or need 
to explain to the patient why such a statement was in the patient information sheet, even 
though it is not relevant.  
Almost all these guidelines stress the importance of giving the participant the right to 
withdraw. This idea was mentioned briefly in the Nuremberg Code: ‘the human subject 
should be at liberty to bring the experiment to an end’ (N.Code, 1949), which is an odd 
way to put it, as it only ends the experiment as far as that individual is concerned; it does 
not stop the whole study. Later, within the Declaration of Helsinki, the right to withdraw is 
supplemented with the reassurance to the participant that withdrawing will not invite 
 57 
reprisals: ‘The potential subject must be informed of the right to refuse to participate in the 
study or to withdraw consent to participate at any time without reprisal’ (DoH, 2008 p3). 
The rest of the guidelines, for example ICH-GCP, went further in explaining what could be 
meant by ‘reprisal’ by clarifying that withdrawal should be permitted without penalty or 
loss of benefits. It also mentioned the right to withdrawal but with greater detail about 
protecting withdrawing participants and assuring them that their specific rights would not 
be compromised as a result of the withdrawal.  
It is important, however, to see how the freedom to withdraw (as part and parcel of 
the process of continued consent) is put into practice in the case of MGE. The challenges 
of clinical trial withdrawal are different from those relating to blood donation for MGE 
research. In a clinical trial, it is desirable that the participant remains in the trial until the 
last scheduled visit. Failing to do so means that the individual’s participation is incomplete 
and can probably not be used in the final analysis. On the other hand, it only takes one visit 
to extract blood, assess someone’s lineage, and take his or her medical history. Therefore, 
if an MGE research participant decides to withdraw, a more transparent procedure is 
needed—a procedure in which the patient knows exactly what stage the investigation is at 
the time of withdrawal, combined with a stronger commitment from the research team to 
abstain from using the data.  At the very least, one must be honest with the participant, by 
letting him/her know when the point of no return is reached, if there is such a point (for 
example, once data has been published or analysed in a specific way). This requirement 
can be frustrating to the researcher as, in some cases, genetic research is undertaken with a 
whole family, where every person is important in order to study a mutation. Here, a 
conflict of interest may arise in two ways: (i) researchers may wish to respect the 
participant’s right to withdraw, but it conflicts with the researcher’s desire to continue, and 
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thereby not lose funding and prematurely terminate the research; (ii) a single member of a 
studied family may not be able to withdraw him/herself without affecting the participation 
of the remaining family members. The participant might ask that the donated material be 
destroyed, but it is not possible to destroy the generated data because it is shared with other 
family members. 
Data collection is a very important part of MGE research. The Declaration of 
Helsinki mandates informed consent only in cases where identifiable data is used: ‘For 
medical research using identifiable human material [this includes tissues as well as blood] 
or data, physicians must normally seek consent for the collection, analysis, storage and/or 
reuse’ (DoH, 2008). CIOMS is more specific than the Declaration of Helsinki, in that it 
includes guidelines for excerpting data rather than just extracting it. ‘Extract’ specifically 
refers to texts (e.g. medical records and laboratory reports) while ‘excerpt’ covers a wider 
domain of capturing (e.g. photography, recordings, and different forms of graphs). CIOMS 
also goes into detail regarding the mandating of informed consent, even in the case of a 
reviewing a patient’s medical records, although it does give the ethics review committee 
the right to waive some, or even all, of the informed consent elements in some 
circumstances, such as when the required data can be totally non-identifiable (CIOMS, 
2008). The ICH-GCP specifically mandates that all stakeholders (committee members, 
sponsors, monitoring agencies, clinical trials organisation, and authorities who need access 
for verifications) reveal who would need access to the data that has been taken with 
consent.  
Consent in relation to MGE is problematic as it is not immediately obvious what data 
it covers given that data from one person is applicable to some or all family/tribe members, 
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and also because the status of tissue as property is contentious. In the UK, in the case of 
biobanking, for instance, according to empirical investigation, most people who donate 
blood for research describe it as a gift (Barbour, 2003). The gift terminology was used 
quite explicitly by Titmuss (1974) to distinguish blood donation in the UK - as gifting to 
the healthcare system for clinical uses - from the American system, where blood is 
purchased from one person and sold on to another individual or organisation. However, 
one can only gift, or sell, something one owns in the first place (De Witte and Have, 1997; 
Busby, 2004). The ownership debate of the blood or tissue material as tangible property 
takes a different context in MGE research because the data taken from the genetic material 
is not as physical or tangible as the blood or tissue sample from which it is derived. The 
notion of ownership is one of the shortcomings of medical research ethics guidelines in 
general (Godard et al., 2003), as they fail to clearly demarcate data ownership. This is a 
major issue in MGE because many people of the same family, or even tribe, share the same 
genetic makeup and, therefore, the data. If we accept the premise that this data is property 
owned by someone, it arguably belongs to the whole tribe, not just the individuals who 
participate in the research. This will be discussed further in Chapter Four. 
The Declaration of Helsinki and CIOMS are the only guidelines that offer the 
possibility of waiving the requirement to gain consent. The Declaration of Helsinki 
suggests: ‘There may be situations where consent would be impossible or impractical to 
obtain for such research or would pose a threat to the validity of the research. In such 
situations the research may be done only after consideration and approval of a research 
ethics committee’ (DoH, 2008, p4). CIOMS suggests: ‘Waiver of individual informed 
consent is to be regarded as exceptional, and must in all cases be approved by an ethical 
review committee…’ (CIOMS, 2008, p16). Further, it offers an account of what those 
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exceptional situations might be: for example, if there is no more than the minimal risks, 
‘that is, risk that is no more likely and not greater than that attached to routine medical or 
psychological examination’ expected of the research, and if the nature of the procedure 
does not require an informed consent such as taking patients’ temperature (CIOMS, 2008, 
p18). The importance of this point is that some researchers may know that it will be a 
challenge or considerable expense to gain consent, for example, to reuse surplus blood 
given for clinical tests. If researchers can convince the review committee that the research 
is minimally risky, as per CIOMS, and that it is impractical to recall patients to consent to 
using material that is going to be thrown away, they may receive the approval of the 
committee to use surplus blood for their research. The problem with such an outcome is 
that it reduces the concept of harm to a very narrow understanding, i.e. the one that can be 
clinically diagnosed. It does not take into account that harm is a wider concept than direct 
physical risk, for example, the harm resulting from stigmatisation. In MGE research in 
general, policy makers cannot afford not to look at the potential stigma experienced as a 
possible risk that could be, in some cases, worse than the kind of harms incurred in a 
routine physical or psychological examination. Thus, it is important to see how the 
analysed guidelines look at the concept of harm and risk in the context of MGE research.  
2.3.3 Risk 
The risk here is taken to be the chance of harm being done. All the analysed 
guidelines stipulate that no major risks to human participants are acceptable. The only 
exception, introduced by the Nuremberg Code, is when the physician himself serves as a 
research participant: ‘No experiment should be conducted where there is a prior reason to 
believe that death or disabling injury will occur; except, perhaps, in those experiments 
where the experimental physicians also serve as subjects’ (N.Code, 1949). This also serves 
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as an indication of what a major risk is, namely something that may result in ‘death or 
disabling injury’, with no indication of other harms, such as stigmatisation, which is a key 
risk in MGE research. The regulation assumes that no amount of benefit can outweigh a 
certain level of harm. It appears that the Nuremberg Code expressed those levels of harm 
in points 4, 5, 6 and 7 (N.Code), which are mainly describing physical or mental harm (i.e., 
a harm that can be diagnosed medically), such as injury, disability or death. Of course, 
there are serious risks that ought to be mentioned considering the historical context. 
However, MGE research harbours other kinds of risks, such as stigma, violation of 
privacy, loss of confidentiality and exposure to information about susceptibility to diseases 
like cancer, Alzheimer’s and Huntington’s for which there is currently little available by 
way of remedy or prevention.    
The notion of minimal risk is introduced by the CIOMS and UNESCO. This is a 
notion of potential significance to MGE. Bathe & McGuire (Bathe and McGuire, 2009), 
for example, suggest that using stored tissue does not exceed the minimum risk, and thus 
argue that committees ought to look at it with less scrutiny than other types of research if 
the samples are anonymised (i.e. no personal identifying information included). The main 
challenge, however, is how to define minimal risk.  It is described by the CIOMS in the 
following way ‘In this [minimal risk] expression “risk” is taken in its common meaning of 
a possible but not certain adverse effect (on health)’ (see Table 2-4) (CIOMS, 2008, p89). 
In the context of MGE research it is not clear how minimum risk is supposed to be 
assessed. There is a need, when identifying risks and determining the associated levels of 
harm to distinguish between those arising when pre-collected data/tissue are used, those 
arising from obtaining the tissue and those arising as a result of using the data/tissue.   
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If a research risk assessment suggests only minimal risk, the researcher is in a 
position to ask for a waiver of informed consent such as may occur then ‘surplus’ tissue is 
used. The real risk, however, may be concerned with the wealth of information that the 
extracted data could provide.  
The risk/benefit analysis is mentioned in most of the documents as a way to judge 
whether a research proposal is acceptable. The rule of thumb suggested by UNESCO is 
that ‘direct and indirect benefits to patients, research participants and other affected 
individuals should be maximized and any possible harm to such individuals should be 
minimized’ (UNESCO, 2005, p6). The main challenge for MGE research is that research 
participants will probably not directly benefit from the research because the indirect 
benefit is very vague.  In contrast, indirect benefit to the participants from the research 
outcome could be claimed if the research contributes to a larger general purpose to provide 
a therapeutic benefit, from which they may benefit at some future point. Even if we accept 
that MGE research contributes to general knowledge, the question that ought to be asked 
is, at what price are we gaining this knowledge? In Subsection 1.3, Challenges of MGE 
research in Saudi Arabia, I outlined some risks that are specific to MGE research in the 
Saudi context (e.g., the genetically homogenous Saudi tribes, the use of the MGE research 
results as an epistemic authority to undermine local cultural values, stigmatisation and 
Saudi patient vulnerability). Thus, the risk/benefit ratio in the context of MGE research in 
Saudi Arabia might not be as straightforward as in RCTs. In current situations, it is 
difficult to determine who is in authority to evaluate the risk of MGE research among the 
stakeholders. One might argue that this is specific to the case of MGE research because of 
how the data in genetically homogenous populations such as the Saudi population can put 
more people at risk than those who originally participated. Thus, the risk assessment 
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should consider a wider circle than that of the people who individually decide to 
participate. Moreover, according to Manson and O’Neill (2007), the assumption that all the 
risks will be comprehended after an informed consent meeting is not realistic. 
Accordingly, the individualistic account of informed consent (where someone is expected 
to be fully informed and then make a decision) might be impossible. 
On the other hand, translational research in the field of genetics is in its infancy, so 
any risk, however minimal, will have no tangible direct immediate benefit to outweigh it 
(Rosoff, 2012). This might dictate a shift in thinking from the notion of risk assessment as 
mentioned earlier to the idea of ‘the common good’, which would not be a familiar concept 
in the field of MGE research. Some researchers found out that some donors mentioned that 
they were just glad to help (Michie et al., 2011), which may be engaging with the notion of 
common good, albeit they used donors’ recall of what is common good as a proxy for their 
understanding (Michie et al., 2011). Thus, even though patients stated that they just wanted 
to help, the statement could be a result of what they were told in the recruitment process, or 
that it was how they remembered the reason. Those who insist on using the idea of the 
common good to ignore the risks of MGE, may be promising more than MGE can 
currently deliver (Rosoff, 2012).  
2.3.4 Identifiable material 
In the context of MGE research material there are many ways of isolating the 
identifiers that can reveal participant identity such as: a) coding or masking: this is when 
the material or data is separated from, but still can be traced to, its origin (i.e. the research 
participant). Every sample or set of data is given unique codes that refer to the identifiers 
in other and usually separated databases. The access to this separated database is usually 
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limited, and needs a key to break the code. b) semi-anonymised: when the identifiers are 
totally isolated, but some demographic data is still attached.  c) completely anonymised: 
when the material can never be traced back to its origin (i.e. the participant) (Boddington, 
2012). 
With the exception of the Nuremberg Code and UNESCO, the guidelines represent 
the concept of identifiable material differently. For example, the Declaration of Helsinki 
simply mentions the importance of regulating research that uses identifiable material. On 
the other hand, CIOMS goes a step further, trying to differentiate between the identifiable 
and non-identifiable and calling for more restricted measures in dealing with identifiable 
material. The main challenge in MGE research is that molecular material is always 
identifiable in the sense that comparing results could lead to an educated guess about who 
the data represents (Boddington, 2012). The ability to guess from where the sample has 
been taken translates into two factors: the issue of confidentiality and the ability to 
stigmatise a huge number of people (sometimes hundreds of thousands) due to the nature 
of autosomal genetic disorders, as explained earlier. 
2.4 Summary  
This chapter has outlined the selected international regulations that were used as 
references for the Saudi ones. I have analysed them to determine how they might be 
interpreted as governing MGE research. This was mainly to answer the first research 
question of this thesis, which is a necessary step towards the overall arching aim of this 
work (Subsection 1.4 Aims and Objectives).  
All the included guidelines point towards accepting only properly constituted and 
justified research, in the sense that research proposals should be rejected where the 
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methods cannot achieve the aims, where the aims cannot be justified, and where there is an 
absence of equipoise in defining the aims. However, not all of them have mention of clear 
guidance about who should take that decision (analysing research proposals and approve or 
disapprove them). Some of the studied guidelines require an independent research 
committee to make the judgment over whether or not a study should be allowed. The 
research committee review has evolved from being recommended, to being mandatory. 
Some of the guidelines explicitly describe how a research committee’s membership should 
be constituted, but less is said about how it should function, what to do in cases of conflict 
of interest, who is responsible for ensuring that they have sufficient funding to undertake 
the reviews, and how to committees should make decisions.   
Consent is a requirement in all the included guidelines in one way or another. All of 
the guidelines stress the importance of its being voluntary and the participant’s right to 
withdraw without adverse consequences. However, the regulations are oriented towards 
the individual rather than families or groups. Informed consent in epidemiology research, 
including MGE, is not only meant to address individuals. I will argue that, for MGE, a 
different notion of informed consent is necessary. It is a notion that covers all the 
stakeholders, such as families and/or groups sharing the same genetic lineage. I will 
explore this argument at length and justify it at a later stage of this thesis (Subsection 7.5 
Ethics committees and protecting tribal interests.) 
Both MGE and clinical trials are health-related research with the potential to cause 
harm and ought to be regulated to protect human participants. However, each operates in a 
different risk paradigm. Clinical trials are more likely to result in physical or medicine-
related harm, whereas MGE research, while potentially resulting in some form of harm that 
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can be medically assessed (e.g. psychological harm), could also harbour other community-
based harms, such as stigma.  
Genetic material can be identifiable if compared with other data, but this does not 
necessarily mean that MGE research should be regulated using clinical trials guidelines. 
Rather, it means that additional measures should be adopted to protect donors’ identities.  
The overall conclusion is that the guidelines often apparently endorse a version of 
liberalism: where there is a strong commitment to autonomy, there is significant focus on 
informed consent. This could be attributed to the historical context. However, the lack of 
specific guidelines to regulate MGE research in Saudi Arabia have lead to use some 
elements from the selected guidelines to regarded all health-related research including 
MGE research. However, applying them in their current state to MGE research in Saudi 
Arabia is problematic because they have gaps and may produce strange conclusions.  
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TABLE 2-2: SUMMARY DISCUSSED CONSENT IN THE ANALYSED REGULATIONS: 
 
Nuremberg Code Declaration of Helsinki  CIOMS ICH-GCP UNESCO 
Voluntariness  
"The voluntary 
consent of the 
human subject is 
absolutely 
essential." 
"Participation by competent 
individuals as subjects in medical 
research must be voluntary." 
"must obtain the voluntary 
informed consent of the 
prospective subject" 
"That the subject's participation 
in the trial is voluntary and that 
the subject may refuse to 
participate" 
Not mentioned 
Informed 
consent 
Not mentioned  
"In medical research involving 
competent human subjects, each 
potential subject must be 
adequately informed of the aims, 
methods, sources of funding, any 
possible conflicts of interest, 
institutional affiliations of the 
researcher, the anticipated benefits 
and potential risks of the study and 
the discomfort it may entail, and 
any other relevant aspects of the 
study. " 
Informed consent can be 
demanded by the ethics 
committee  
"Both the informed consent 
discussion and the written 
informed consent form and any 
other written information to be 
provided to subjects" 
Any preventive, diagnostic 
and therapeutic medical 
intervention is only to be 
carried out with the prior, 
free and informed consent 
of the person concerned, 
based on adequate 
information.  
Right to 
withdraw  
"the human subject 
should be at liberty 
to bring the 
experiment to an 
end" 
"The potential subject must be 
informed of the right to refuse to 
participate in the study or to 
withdraw consent to participate at 
any time without reprisal."  
"that the individual is free to 
refuse to participate and will be 
free to withdraw from the 
research at any time without 
penalty or loss of benefits to 
which he or she would 
otherwise be entitled"  
"or withdraw from the trial, at 
any time, without penalty or 
loss of benefits to which the 
subject is otherwise entitled." 
The consent should, where 
appropriate, be express and 
may be withdrawn by the 
person concerned at any 
time and for any reason 
without disadvantage or 
prejudice. 
IC for data  Not mentioned  
"For medical research using 
identifiable human material or data, 
physicians must normally seek 
consent for the collection, analysis, 
storage and/or reuse. "  
"…should not submit any 
identifiable data about a patient 
to an investigator or to a 
database unless the patient 
permits such submission of data 
or it is authorized or mandated 
by law."   
"The sponsor should verify that 
each subject has consented, in 
writing, to direct access to 
his/her original medical records 
for trial-related monitoring, 
audit, IRB/IEC review, and 
regulatory inspection." 
Not mentioned  
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TABLE 2-2: SUMMARY OF THE CONSENT THEMES IN THE ANALYSED REGULATIONS (CONTINUE):  
 
Nuremberg Code Declaration of Helsinki  CIOMS ICH-GCP UNESCO 
IC for 
collecting 
sample  
Not mentioned  
"For medical research using 
identifiable human material or 
data, physicians must normally 
seek consent for the collection, 
analysis, storage and/or reuse."  
"When collecting and storing human 
biological samples … for future 
epidemiological research, the investigator 
must obtain the voluntary informed consent of 
the individual donor" 
Not mentioned  Not mentioned  
IC for 
using 
stored 
sample  
Not mentioned  Not mentioned   
"The protocol of every study using stored 
human biological samples (and related data) 
must be submitted to an ethical review 
committee, which should satisfy itself that the 
proposed use of the samples comes within the 
scope specifically agreed to by the subjects."  
Not mentioned  Not mentioned 
Explicit 
elements of 
IC 
Not mentioned  Not Mentioned  
"Before requesting an individual's consent to 
participate in research, the 1069 investigator 
must provide the following information, in 
language or another 1070 form of 
communication that the individual can 
understand..."  
"be provided to 
subjects should 
include 
explanations of the 
following:..." 
Not mentioned  
Wave IC Not mentioned  
"There may be situations where 
consent would be impossible or 
impractical to obtain for such 
research or would pose a threat 
to the validity of the research. 
In such situations the research 
may be done only after 
consideration and approval of a 
research ethics committee."  
"Waiver of individual informed consent is to 
be regarded as exceptional"  
Not mentioned    
Re-new 
consent - 
taking new 
IC 
Not mentioned  Not Mentioned  
"renew the informed consent of each subject if 
there are significant changes in the conditions 
or procedures of the research or if new 
information becomes available that could 
affect the willingness of subjects to continue to 
participate"  
Not mentioned    
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TABLE 2-2: SUMMARY OF “ACCEPTING ONLY WELL SUPPORTED RESEARCH” IN THE ANALYSED REGULATIONS:  
 Nuremberg Code Declaration of Helsinki  CIOMS ICH-GCP UNESCO 
Scientifically sound 
research  
"to yield fruitful results 
for the good of society, 
unprocurable by other 
methods or means of 
study, and not random 
and unnecessary in 
nature." 
"Medical research involving 
human subjects must conform 
to generally accepted 
scientific principles, be based 
on a thorough knowledge of 
the scientific literature,"  
"must be submitted 
for review of their 
scientific merit and 
ethical acceptability 
to one or more 
scientific review and 
ethical review 
committees." 
"reviewing and 
approving / providing 
favourable opinion 
on, the trial protocol, 
the suitability of the 
investigator(s), 
facilities, and the 
methods and material 
to be used in 
obtaining and 
documenting 
informed consent of 
the trial subjects." 
Not Mentioned  
Comply with local 
guidelines as well as 
international ones  
Not mentioned  
"It must take into 
consideration the laws and 
regulations of the country or 
countries in which the 
research is to be performed as 
well as applicable 
international norms and 
standards but these must not 
be allowed to reduce or 
eliminate any of the 
protections for research 
subjects set forth in this 
Declaration. "  
"investigators should  
submit the research 
protocol for ethical 
and scientific review 
in the country of the 
sponsoring 
organization, and the 
ethical standards 
applied should be no 
less stringent than 
they would be for 
research carried out 
in that country."  
Not mentioned  
Transnational 
health research 
should be 
responsive to the 
needs of host 
countries, and the 
importance of 
research 
contributing to the 
alleviation of urgent 
global health 
problems should be 
recognized 
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TABLE 2-3: SUMMARY OF “ACCEPTING ONLY WELL SUPPORTED RESEARCH” IN THE ANALYSED REGULATIONS (CONTINUE):  
 Nuremberg Code Declaration of Helsinki  CIOMS ICH-GCP UNESCO 
Local research committee 
approval  
Not mentioned  
"The research protocol must 
be submitted for 
consideration, comment, 
guidance and approval to a 
research ethics committee 
before the study begins" 
"submitted for review 
of their scientific 
merit and ethical 
acceptability to one 
or more scientific 
review and ethical 
review committees"  
"reviewing and 
approving / 
providing 
favourable opinion 
on, the trial 
protocol, the 
suitability of the 
investigator(s), 
facilities, and the 
methods and 
material to be used 
in obtaining and 
documenting 
informed consent of 
the trial subjects." 
"When research is 
undertaken or otherwise 
pursued in one or more 
States (the host State(s)) 
and funded by a source in 
another State, such 
research should be the 
object of an appropriate 
level of ethical review in 
the host State(s) and the 
State in which the funder is 
located. This review 
should be based on ethical 
and legal standards that are 
consistent with the 
principles set out in this 
Declaration" 
Respect of different 
cultural norms  
Not mentioned  Not mentioned  
"...and that are 
morally acceptable 
within the 
communities in 
which the research  is 
carried out.."  
Not mentioned  Mentioned  
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TABLE 2-4: SUMMARY OF THE “RISK” THEMES IN THE ANALYSED REGULATIONS:  
 
Nuremberg Code Declaration of Helsinki  CIOMS ICH-GCP UNESCO 
No extreme risk  
"to avoid all unnecessary 
physical and mental 
suffering and injury"  
"Physicians must 
immediately stop a study 
when the risks are found to 
outweigh the potential 
benefits "  
"the investigator must 
ensure that potential 
benefits and harms are 
reasonably balanced 
and risks are 
minimized."  
Not mentioned  
"Appropriate assessment 
and adequate management 
of risk related to medicine, 
life sciences and associated 
technologies should be 
promoted." 
Risk/benefit ratio  
"No experiment should be 
conducted where there is a 
prior reason to believe that 
death or disabling injury will 
occur; except, perhaps, in 
those experiments where the 
experimental physicians also 
serve as subjects."  
Not mentioned  
"the investigator must 
ensure that potential 
benefits and harms are 
reasonably balanced 
and  risks are 
minimized."  
"… risks and 
inconveniences 
should be 
weighed against 
the anticipated 
benefit for the 
individual trial 
subject and 
society.." 
“direct and indirect … 
should be maximized and 
any possible harm to such 
individuals should be 
minimized. 
 Risk   Not mentioned  
"The benefits, risks, 
burdens and effectiveness 
of a new intervention must 
be tested against those of 
the best current proven 
intervention" 
"Minimal risk. In this 
expression “risk” is 
taken in its common 
meaning of a possible 
but not certain adverse 
effect (on health)."  
Not mentioned  
"Research which does not 
have potential direct health 
benefit should only be 
undertaken by way of 
exception,...exposing the 
person only to a minimal 
risk and minimal burden 
and if the research is 
expected …" 
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TABLE2-5: SUMMARY OF SOME OTHER ETHICAL THEMES IN THE ANALYSED REGULATIONS:  
 
Nuremberg 
Code 
Declaration of 
Helsinki  
CIOMS ICH-GCP UNESCO 
Identifiable human 
material and data  
Not mentioned  
yes: it is mentioned 
that the guidelines 
is oriented to 
regulate human 
research that use 
those material   
Yes: It differentiated 
between deniable and 
non-identifiable 
material  
"The sponsor is responsible 
for securing agreement from 
all involved parties to ensure 
direct access (see 1.21) to all 
trial related sites, source 
data/documents , and reports 
for the purpose of 
monitoring and auditing by 
the sponsor, and inspection 
by domestic and foreign 
regulatory authorities" 
Not mentioned  
Results available to 
participants  
Not mentioned  
"At the conclusion 
of the study, 
patients entered into 
the study are 
entitled to be 
informed about the 
outcome of the 
study and to share 
any benefits that 
result from it,"  
"policy with regard to 
the use of results of 
genetic tests and 
familial genetic 
information, and the 
precautions in place 
to prevent disclosure 
of the results of a 
subject's genetic tests 
to immediate family 
relatives or to others 
(e.g., insurance 
companies or 
employers) without 
the consent of the 
subject"  
Not mentioned  Not mentioned 
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TABLE 2-5: SUMMARY OF SOME OTHER ETHICAL THEMES IN THE ANALYSED REGULATIONS (CONTINUE):  
 
Nuremberg 
Code 
Declaration of 
Helsinki  
CIOMS ICH-GCP UNESCO 
The conflict of 
interest  
Not mentioned  Not mentioned  
"Disclosure and 
review of potential 
conflicts of interest"  
Not mentioned  
"Professionalism, honesty, 
integrity and transparency 
in decision-making should 
be promoted, in particular 
declarations of all conflicts 
of interest and appropriate 
sharing of knowledge." 
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3 Chapter Three: The Saudi Research Guidelines 
This chapter addresses the second research question of this thesis. It discusses 
the Saudi guidelines, making three main points. The first is that, as they are based on 
selected influential international guidelines, they kept those documents’ normative 
assumptions. The second is that the Saudi guidelines have captured some of the 
MGE research issues, but suffer the same level of problematic assumptions as the 
Western ones, which makes them difficult to apply to MGE research in its Saudi 
context. Firstly, I will analyse the Saudi research ethics guidelines and the extent to 
which it is a suitable regulatory framework for MGE in Saudi Arabia, in the light of 
the Saudi social, culture, and political context, The second subsection of this chapter 
will analyse the Saudi guidelines, using the same method employed in the previous 
chapter in relation to the international guidelines, to see how they can be used to 
regulate MGE research in the context of Saudi Arabia.  
Also in this chapter I will build upon the information about Saudi culture 
introduced in Chapter One, to provide further context to the regulations.  
3.1 The National Committee of Bioethics (NCBE): 
The NCBE was initiated with a Royal Decree on 18/5/1422H (24/7/2001G). It 
consists of 16 members from different official stakeholders including: 
 The King Abdulaziz City for Science and Technology (as the most generous 
Saudi Research funding governmental agency),  
 The National Guard (as one of the largest health and research organisation),  
 The Ministry of Defence  (for their military hospitals),  
 The Ministry of Interior,  
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 The council of Islamic Research and Ifta’ (the official side of Fatwa or 
Islamic verdict),  
 The Ministry of Higher education,  
 The Ministry of Health,  
 The Ministry of Education,  
 The Ministry of Agriculture,  
 The Saudi Wild life authority,  
 The Saudi Food and Drug Agency,  
 The Saudi Human Rights Agency,  
 The Office of Research Monitoring,  
 A selected representative from the Saudi private sector,  
 An official legislative consultant.    
In the early days of the national committee, there was a question of who should 
be the chairman. According to His Highness Prof. Abdulaziz Al Swailem, the NCBE 
chairman in one of his presentations, the consensus was that the chairperson should 
be chosen based on the idea that the committee members wanted an impartial 
representative. The best representative was the King Abdulaziz Medical City for 
Science and Technology (KACST) for reasons such as its generous funding history, 
which afforded KACST much respected amongst all Saudi researchers, the 
availability of resources in KACST, and its infrastructure, which could house and 
support the committee financially and logistically.  
The NCBE consists of four subcommittees: the legal sub-committee, the 
human research sub-committee, the flora & animal sub-committee, and the education 
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& media sub-committee. The NCBE hopes to transform the research ethics practice 
to become more rigorous and better documented through the following steps (NCBE, 
2010):  
- The first stage is to engage with local organisations interested in research in 
order to encourage them to establish a local committee that reviews and oversees the 
ethical conduct of their research. This was supported by Ministerial Resolution 
number 180 dated 9/6/1425H (26/7/2006), mandating that every organisation 
carrying out research activity should have its own local review committee.   
- The second stage is to register those Local committees: Every local review 
committee should be registered with the national committee, giving full information 
of who the chairperson and committee members are, with their credentials and 
positions. 
- The third stage is registration of active researchers: Every researcher is 
expected to engage in online training about the Saudi regulations, successful 
completion of which licences him/her to participate in research that recruits human 
participants.  
- The fourth step involves education programmes organised by the NCBE to 
educate the local committees, which is a necessary step before the last stage,  
- The fifth stage is enforcement through monitoring, auditing and activating a 
punishment system for those who do not comply with the regulations.  
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The NCBE 2010 guidelines now govern every researcher recruiting donors of 
biological material in Saudi Arabia, including MGE. However, the overall progress 
of the NCBE stages is still far from complete, according to a personal 
correspondence with one of the policymakers involved in preparing a translated 
version of the NCBE regulations.  
3.2 The Saudi NCBE guidelines: 
The NCBE has published its regulations for research involving biological 
material from human and/or animal donors in a booklet with 15 chapters. The most 
relevant chapters to this research are: Chapter 7: Informed Consent, Chapter 8: 
Research Using Human material, and Chapter 11: Genetic material and DNA 
biobanking. For consistency with the previous chapter, the Saudi guidelines will not 
be described in full but, rather, I will outline the main items pertinent to MGE 
research.   
The NCBE national guidelines address scientists as well as physicians: 
‘Researcher: A person academically qualified in a subject related to the research and 
has completed a course on research ethics’ (NCBE, 2010, p2).  
3.2.1 Terminology defined by the NCBME 
Like every Saudi legal document, this one commences with definitions of the 
terminology subsequently used to ensure clarity and unified understanding, and to 
avoid misunderstanding. The approach, in most of the cases, seems to be to provide 
pragmatic definitions rather than to engage with conceptual issues. For example, 
‘informed consent’ is introduced as ‘A person giving his consent with his free will, 
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without exploitation or coercion and upon full understanding of what is required 
from him and of the research objectives and potential risks as well as of rights and 
obligations arising out of his participation therein.’ (NCBE, 2010, p3). It is a very 
broad pragmatic understanding in the sense that it is action oriented. It refrains from 
engagement with the bigger debate as to what informed consent is, as I will discuss 
in a later stage of this chapter.  
Genetics material was defined as ‘Chain of nitrogenous bases that exist within 
the cells or are extracted therefrom and are responsible for carrying traits and 
characteristics from the mother cell to the sub-cell and from one living creature to its 
offspring’ (NCBE, 2010, p2).  
Ahliah: It is also noticeable that the official English translation of the word 
‘autonomy’ was not chosen. ’Autonomy’ can normally be back-translated as ‘self 
governing’ (Al Hokkm Al Thatti). Rather, the Arabic word ‘Ahliah’ was chosen, 
which is usually translated as ‘capacity’. Ahliah has a specific meaning in Islamic 
literature. Historically, in the Islamic literature a person is described as having full 
Ahliah by the following specific criteria, when s/he:  
 is not mentally impaired or mentally ill;  
 is not a child (childhood ends with puberty), Sharei’ laws do not give a 
specific age as it varies from person to person because it is determined by reaching 
puberty;  however, in Saudi Arabia a person is legally an adult, if he/she is or older 
than 18 years; 
- is not a slave (slavery was abolished in the early 1960s in Saudi Arabia); and,  
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- has enough mental ability to reflect on what can be rated as a right action versus 
a wrongdoing.  
It appears that the NCBE used the term Ahliah to reinforce the use of the 
above-mentioned criteria focused on capacity. They did not add any further 
definition of Ahliah.  
Definition of research designs: the document differentiates between clinical 
research, non-clinical research, and clinical trials. Clinical research appears to be 
defined as any health related research that aims to recruit human participants directly 
as volunteers to collect data or research materials. Non-clinical research is defined as 
that which collects data that is not related directly to specific persons and then 
analyses it to ‘produce general knowledge or facts’ (NCBE, 2010, p5). The only 
noticeable difference between the non-clinical and clinical research seems to be the 
source of data. Clinical research seems to require the linkage of the data with its 
human sources, while non-clinical research collects data that is ‘not directly related 
to people’ (NCBE, 2010, p5). This could mean that dealing with anonymised data 
could be rated as non-clinical research, but the data anonymity is not mentioned 
directly. Based on this understanding, MGE research, if the data is anonymised, falls 
under the definition of non-clinical research.      
3.2.2 Sending Biological specimens out of the country:  
In 2003, a royal decree based on NCBE guidance was issued to regulate the 
export of any biological research material taken from Saudis (Adlan, 2013). This was 
in response to Saudi researchers seeking international collaborations that included 
sharing biological material with collaborators in the absence of specific Saudi 
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guidance for how this should be done. Prior to this, it appears that the sharing of 
samples was regarded as acceptable practice, given the volume of international 
collaboration that yielded publications in international journals. It appears that the 
NCBE gives genetic material a high level of attention as regulating its export was the 
first official guideline. In 2010, when the full version of the NCBE guidelines was 
officially announced, they re-used the 2003 royal decree and included it in the final 
version (NCBE, 2010). Among the export guidelines were the following: 
- Collaborations are only acceptable with internationally respected 
organisations, and where no local research centre has the capacity to perform the 
research.  
- A written legal agreement between the collaborating institutions should be 
seen and accepted by the local review research committee.  
- If there is no other way to perform the research except by exporting the Saudi 
samples, the biological material should be totally anonymous to the international 
collaborator, and patients’ identity should never be revealed to any third party 
including, but not limited to, the international collaborator.  
- The NCBE committee should be informed and approve the collaboration and 
the contract, its approval should be received in writing and it should be sent to the 
collaborator for their acknowledgement.  
Anecdotally, researchers in Saudi Arabia have expressed discontent with 
having to gain the approval of the local committee as well as the NCBE committee, 
regarding this as an unnecessary waste of valuable time (Adlan, 2013).  
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The fact that regulating the export of Saudi genetic material was the first and 
earliest introduced set of bylaws is an indication of a set of assumptions regarding 
Saudi genetic material, as follows: 
a) NCBE appears to regard Saudi genetic material as a strategic resource 
that ought to be protected. It is not clear from the guidelines how it was seen as 
strategic, but I will discuss that claim in detail in Chapter Four. Unfortunately, there 
is no academic evidence as to the practice before these guidelines were introduced. 
Nevertheless, at an official conference held by the NCBE, one of the national 
committee members said in a public meeting that he still remembers the days when 
some researchers used to transfer blood in their personal luggage when visiting their 
international collaborators. The motivation for the speedy announcement of the by-
laws on the export of genetic material is not known, but it could be due to one or 
more of the following: 
 The NCBE believed in some form of genetic exceptionalism. Genetic 
exceptionalism, as explained earlier, is thinking that DNA material can reveal more 
sensitive information than any other biological material. It therefore ought to be 
given an exceptional status and treated differently (Manson and O'Neill, 2007). 
 The NCBE may have been responding to a specific (but undisclosed) 
occasion where Saudi DNA was exploited and/or misused by an international 
collaborator (or there was a perception of such a risk occurring).  
 The NCBE may have assumed that Saudi DNA has commercial potential. 
The significant rate of first-cousin consanguinity in Saudi Arabia is associated with 
major congenital diseases (El Mouzan et al., 2008). This high incidence of congenital 
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disease may have given rise to the idea that the Saudi population could be targeted 
for research aimed at patenting specific DNA diagnostic tests. The NCBE committee 
may have sought to protect such a strategic financial resource from being exploited 
by other countries that may have ensured that donors, through the Saudi collaborator, 
waived their rights to any future commercial gain. If a patient waives his right over 
his genetic material, legally his state cannot regain any financial interest in the 
material. That, however, does not mean that the guidelines gave patients property 
rights over their own genetic material; to the contrary, it announced that the Saudi 
genetic material is a national property and belongs to the state.    
 The NCBE could have feared biological threats to Saudi Arabia from 
biological warfare specifically targeting the Saudi or the Arabic genetic population. 
This interpretation could be supported by an outrage that started in October 2002 
when American researchers, working in one of the highly respected Saudi research 
centres, published a paper in collaboration with a research centre in Israel (i.e. under 
the Saudi boycott laws to Israel, such a collaboration is impermissible). The views of 
the non-scientific commentators, fuelled by paranoid rumours, were given greater 
weight than the scientific evidence supported; some articles condemning that 
collaboration can still be found on the internet (Arabic-forum1, 2012). 
b) The Saudi NCBE committee work under on the assumption that there 
are respectable international research centres, which could imply that there are also 
disreputable ones. Such a distinction is problematic, unless accompanied by the 
means of distinguishing between the two by using objective criteria. The problem 
with the word ‘respected’ lies in its vagueness. Criteria that could have helped clarify 
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the guidelines include peer review publication, similar processes for recruitment of 
donors, and the standing of the scientists it employs. The Saudi Ministry of Higher 
Education (MHE) faced a similar dilemma. There was a time when the MHE tried to 
authenticate the degrees Saudi students acquired from non-Saudi universities. To do 
so they announced lists of acceptable and unacceptable universities. They called it 
the list of authenticated universities (ةحئلا تاعماجلا فرتعملا اهب يف جراخ ةيدوعسلا). It 
appears that the MHE was advised to change the name of the list for a more 
politically correct one. The word ‘authenticated’ suggested a superiority that is 
neither accurate nor polite. The list has since been renamed ‘recommended 
universities’. The new term, ‘recommended’, could be misleading, as students, 
especially those who are self-funded, are constrained to choose only from those 
universities that are recommended. Thus it is not recommended, it is mandated if the 
student wants his degree to be authenticated through the Saudi education system. A 
similar situation pertains to the notion of ‘respected’ international collaborators, 
except that there is no list to guide the researcher’s choice of collaborators from 
outside Saudi.  
c) As explained in Saudi health services context (Subsection 1.2.3: 
Health-related research in Saudi Arabia), Saudi research centres are in competition 
with each other. This could be the rationale behind the decision to force researchers 
to seek local collaborations in the first instance. International collaboration is only 
permissible if there is no Saudi centre that is equipped with the logistics to perform 
the targeted research. The assumption of aggressive competition is supported by the 
fact that three of the largest Saudi research centres are in Riyadh, two of them have a 
noticeable competition over resources, personnel, national projects, and research 
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funds. Further evidence of competition is that in Riyadh alone there are two 
competing liver transplant centres, two separate non-commercial cord blood banking 
facilities, and two separate bone marrow donor registries. Both sets of competing 
centres claim superiority over the other.       
3.2.3 Accepting only properly constituted and justified research 
According to the Saudi guidelines, research project can be categorised as 
poorly constituted or poorly justified and then rejected for many reasons, including:  
 where the methods cannot achieve the aims: this usually occurs when the 
researcher lacks understanding of different research methodologies and their 
limitations (e.g. someone aims to achieve generalisable data but fails to propose a 
randomly selected or representative sample); 
 where the aims cannot be justified: this usually occurs when a researcher fails 
to support their aims with an equipoise. In other words only scientific aims are 
acceptable not political ones even if it is ideological or conceptual research; 
Like the international guidelines previously analysed, the Saudi Guidelines 
share a zero tolerance for unjustified research. According to the national NCBE, 
protocols should be very well reasoned and articulated, and contain scientific aims 
and objectives.  Local research committees, which are mandatory in every 
organisation recruiting human for research projects, should approve both the 
scientific and ethical merits of all research undertaken in that organisation.  
Most of the previously analysed international regulations have mandated an 
independent committee to review the merits of research based on the research 
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proposal. This process is the mechanism by which potentially poor research is 
excluded as a step to protect human participants. In the same manner, the Saudi 
regulation mandated two measures for protecting human participants in research. The 
first is the local human ethics committee, its main duty being to protect human 
research participants and reject research that is not worthy of approval for any 
scientific, ethical, or legal reasons. The second is the research monitoring office, 
which is expected to monitor both the research in progress and the institutional 
committees’ adherence to the NCBE regulations. The research monitoring office is 
the enforcement arm of the NCBE. Its main duty is to ensure that the local research 
ethics committees are complying with the NCBM guidelines. 
Previously, in Chapter Two, I concluded that the selected analysed guidelines 
were written with RCTs in mind, and this seems to be the case also with the Saudi 
regulations. Despite a clear distinction in the early definition stage between clinical 
research, non-clinical research and clinical trial, the following quote appears to use 
the term ‘research’ in its general form, while specifically meaning clinical trial  
‘Research conducted on humans shall be for clear scientific objectives, and shall be 
preceded by sufficient laboratory experiments on animals if the nature of the research 
so requires.’ (NCBE, 2010, p59). 
The NCBE guidelines do, however, have a section dedicated to genetic 
material and biobanking, Section Eleven:  Dealing with Genetic Material and its 
Banking, which consists of seven articles. In this section it is clear that the national 
committee is very determined to prohibit any unjustified research, by using review 
processes (i.e. the mandatory approval of a local ethics committee). Approving any 
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research, including MGE research, means that the local committee is legally 
responsible for the proper conduct of the research.  
The process of local review conforms to the international guidelines e.g. those 
found in CIOMS, ICH-GCP, the Declaration of Helsinki, and the UNESCO 
documents. The Saudi guidelines offer very detailed regulation, covering 22 pages, 
for how these committees should work (NCBE, 2010). Such concentrated effort to 
regulate the local ethics committees could be seen in the context of the original call 
for ethics guidelines in the country. The story of the Saudi uterus transplant (see 
Subsection 1.2.4: The Emergence of Bioethics Debate in Saudi Arabia) seems to 
have had a dramatic effect on many levels. The Saudi bioethics guidelines at the time 
were insufficient to determine decisively whether the researcher really deceived the 
donor, as was claimed, mainly because a signed consent document could be 
produced. The signature was authenticated by officials (i.e. the donor did sign the 
document) but how this signature was obtained was unclear (Adlan, 2013). Opinion 
was, therefore, divided about whether the research was ethical or not (see Subsection 
1.2.4: The Emergence of Bioethics Debate in Saudi Arabia). Had the NCBE 
guidelines existed, the researcher would have needed to apply for, and receive, 
approval before undertaking the procedure. A local committee would have been 
responsible for ensuring that neither the patient nor the donor was exploited and the 
researcher/physician would have been legally and ethically protected by their 
favourable opinion, assuming the protocol was followed.  
The bioethics regulations require committees to have a mechanism for auditing 
the activities of favourably reviewed research. The office of research monitoring, 
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which is part of the national committee, is the body that ensures compliance with the 
guidelines and holds a committee liable for any lack of adherence to the guidelines 
(NCBE, 2010). The NCBE regulation was not very explicit, however, in the case of 
uncovered wrongdoing, and how the blame would be shared between the researcher 
and the local committee. It appears that it was left entirely to the office of research 
monitoring to decide. It could be argued that it is not fair that the local committee 
holds responsibility for researchers’ actions. Alternatively, someone might read 
through the guidelines and conclude that the committee would be responsible in the 
following cases: 
- If the research proposal was not reviewed according to the detailed advisory 
regulations. 
- If the local committee gave a favourable opinion to a research proposal that 
should have not been approved  
-  If the committee failed to spot researcher wrongdoing during the mandated 
audit rounds that they should have carried out during the research execution.  
Thus, the local committee is not punished for the researcher wrongdoing, it is 
punished for not following the regulations that would have helped to uncover the 
wrongdoing.  
The researcher will be liable alone in the following cases:  
- If the committee reported his wrongdoing to the office of research monitoring  
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- If the local committee had done everything as instructed, but the researcher 
was successful in covering -up his wrongdoing. 
This understanding of how the liability might be distributed may work only in 
the case if the researcher was fraudulent. In the case of a genuine mistake, the office 
of research monitoring has the responsibility to assess how the liability should be 
distributed. As far as genetics research is concerned, responsibility for approving 
research concerning MGE or biobanking also rests with the local committee (NCBE, 
2010).  
In conclusion Figure 3-1 describes the institutional hierarchy to protect human 
participation in research put in place by the NCBE: the local research committees 
oversee the researchers and the office of research monitoring oversees the work of 
the local committees. I have also argued that the regulations were written with RTCs 
in mind, similar to the selected international guidelines. The monitoring regulation 
could be seen as taken from the monitoring discipline decried in the ICH-GCP.   
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FIGURE 3-1: THE INSTITUTIONAL HIERARCHY OF RESPONSIBILITY FOR RESEARCH 
GOVERNANCE IN SAUDI ARABIA 
3.2.4 Informed Consent: 
The Saudi NCBE regulations appear to use ‘informed consent’ in two different, 
but related, ways. The first is the ‘informed consent’ document that patients sign 
prior to participating in any research e.g. NCBE article 11 reads ‘No investigator 
may conduct research on any human subject prior to obtaining an informed consent 
from him or from his guardian in accordance with procedures specified by the 
Regulations.’ (NCBE, 2010, p53). The second way is the notion of ‘consent’ itself  
‘A person giving his consent with his free will, without exploitation or coercion and 
upon full understanding of what is required from him and of the research objectives 
and potential risks as well as of rights and obligations arising out of his participation 
therein’ (NCBE, 2010, p6). The definition does not mandate the paperwork and 
signature to record the consent; it simply assumed it. The challenge is that the same 
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definition could be secured by other means of consenting (i.e. other than by signing a 
consent document) such as shaking one’s head, saying ok, a smile of approval, and 
many other forms of human communications. On the other hand, it is accepted that 
informed consent is a species of the concept of consent (Manson, 2007). 
This definition, however, is consistent with the international guidelines 
summarised in Chapter Two. It defines informed consent in terms of voluntary 
approval and sets out the criteria for voluntariness. In order to be voluntary the 
approval must be given without exploitation or coercion.  The informed part is 
covered by the requirement for ‘understanding’ and the scope of the information that 
must be understood is outlined:  the research objectives, the risks and consequences 
of participation, and the participant’s rights (such as the right to withdrawal, or the 
right not to participate) and responsibilities (such as giving blood, taking medication, 
engaging in, or abstaining from, activities). The fact that this definition agrees with 
the international informed consent definitions suggests that it adopts the norms of the 
international guidelines it cites (i.e. the individualistic notion of autonomy.)  
Similar concerns can be raised about this definition as those resulting from the 
international guidelines. One such concern is the presumption that the Saudi patient 
can be in a state where they could be free of coercion. This is open to challenge 
given the vulnerability generated by the patient’s need for medical attention. The 
recruiting research centres are part of highly esteemed, specialized hospitals, which - 
unlike the free, less reputable governmental hospitals - charge high fees. Saudi 
patients are likely to feel privileged to have a chance to be treated in those hospitals 
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(Adlan, 2013). This may render them vulnerable, as they are likely to have a strong 
desire not to lose that privilege.  
Saudi patients are reluctant to disagree with their doctors, including agreeing to 
invasive interventions that are more invasive than donating blood for any sort of 
research that the treating physician is involved in (Abolfotouh and Adlan, 2011). 
This could be due to either the fear of upsetting the doctor in a way that the patient 
thinks could lead to losing the treatment privilege, or it could be due to the culture of 
trust  (See 1.2.1: The Social Context of Saudi Arabia.)  
In Saudi culture, in common with much of the East, family influence plays a 
major part in a person’s decisions. The assumption that a person can decide without 
such influence is problematic because it does not take into account factors which 
influence the decision. Another serious point to consider is that the nature of MGE 
research is such that it involves a whole family, if not the entire tribe.   It is important 
to stress that these challenges are not specific to Saudi culture; they are also reported 
in different contexts, mostly recognised in non-Western academic writing such as in 
Arabic or far Eastern contexts (Dickenson, 1999; Tan-Alora and Lumitao, 2001; 
Widdows, 2009).  It is fair to claim that the dominant notion in Western medical 
ethics is the North American understanding of the value of autonomy, which could 
be challenging to other norms in Europe (Dickenson, 1999), and which will be 
discussed in detail in Chapter Four. 
The required consent documentation is fully described with a specific set of 
elements that must be included for the participant to read (NCBE, 2010). This 
specification appears to have been influenced by the informed consent section of the 
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ICH-GCP. ICH-GCP was originally designed specifically to regulate clinical trials; 
this means that the presumption throughout the Saudi informed consent regulations is 
that it is oriented towards clinical research. This can be noted in lines such as: ‘A 
description of alternative treatments available outside the scope of the research, if 
any’ (NCBE, 2010, p53); and ‘A description of all medical procedures and 
treatments related to the research or carried out only as a result of conducting the 
research, if any…’ (NCBE, 2010, p53).  
In the first Chapter, I introduced the Saudi health context and explained how 
Saudi patients could be seen as vulnerable when it comes to their relationship with 
the treating physician (see Subsection 1.2.5.5: Patient Vulnerability). At a regulatory 
level, the national committee seems to presume a level of Saudi patient vulnerability 
when it comes to the treating physician. This can be seen in the restrictions on 
physician-PIs recruiting their own patients to studies: ‘If the human subject is a 
patient, a person other than his attending physician shall obtain his "Informed 
Consent," provided said person is well-informed about the research and able to 
answer all the patient's questions’ (NCBE, 2010, p56).  
The national committee gave permission to the local committees to wave 
informed consent where biological samples cannot be traced back to the donor: 
‘…the Local Committee may agree for the research to be conducted without 
obtaining Informed Consent if it is not possible to link the information in the records 
or from the biological or pathological samples obtained by the investigator with the 
source person or if the outcomes related to individuals are available to the public’ 
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(NCBE, 2010, p58). This article is extremely vague and could be problematic when 
dealing with genetic research in Saudi Arabia for at least two reasons:  
 In the Saudi context, it is highly likely that an individual’s DNA could readily 
be used to identify his/her families for the reasons already outlined,  
 It is already public knowledge that some tribes are known to be affected by 
certain inherited disorders, so where these conditions are present in the sample this 
will give a strong indication as to the person’s tribe, which offers some level of 
identification, although not necessarily right down to the individual. The availability 
of the result, albeit not the identity of individuals, would create an argument that it 
should be acceptable to carry out MGE research on Saudis belonging to those tribes 
without their informed consent.   
Due to the nature of the Saudi genetics relatedness, one could argue that the 
local committee has to consider potential family/tribal stigma in the balance of harms 
and benefits before agreeing to the waiver. In addition to that, the promise of 
complete anonymity has been proven inaccurate in the case of genetics information 
(Boddington, 2012), which also needs to be considered by the committee before any 
wavier is granted.  
In conclusion, the Saudi National guidelines aim to make the regulations in 
relation to informed consent as thorough as possible. This can be seen in the amount 
of instruction in comparison to other topics it covers. This might reflect the notion of 
liberal individualism which has been inherited from the international regulations that 
were used as its reference point.  
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3.2.5 Biobanking in Saudi Arabia 
Donating blood for biobanks is covered by article number 31: ‘A central 
information bank shall be established at the City to store the information pertaining 
to the genetic material and to organize its usage according to the procedures 
determined by the policies. The bank will make the information available to 
scientific research groups that use the genetic material in the Kingdom.’ (NCBE, 
2010,  p77) 
The article is not clear in terms of where and how such a bank should be 
established. Moreover, the article does not provide information about how a national 
DNA bank should be regulated. There are a few vague statements about protecting 
confidentiality and preventing linkage of the data to its donors (i.e. anonymisation). 
The guideline seems to suggest that the committee regards genetic material as 
potentially harmful to the person, such when they suggest: ‘Scientific results shall 
not be leaked to the media if this could lead to promoting discrimination on the basis 
of race or family or tribal affiliation.’ (NCBE, 2010, p94). Thus, protection seems to 
be provided in two ways, the first is through avoiding linking the data to the source 
(anonymity), while the second is respecting the confidentiality of the donor where 
anonymity is not achieved.  
The National Committee guidelines regarding biobanking can seem laconic 
when compared to the energy spent on regulating the work of local committees and 
on informed consent. It does not address data ownership nor answer the question of 
how the research centres should deal with the wide-ranging data that can potentially 
be derived from donated genetic material. The only limitation occurs where the local 
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committee believes that the results could provoke a stigmatization or lead to racial 
consequences. This might be seen as contradicting the wording of other NCBE 
regulations about waving informed consent (see the previous Subsection). By this 
addition MGE research is in a better position and stigma is one of the points that 
ought to be investigated by the local committee.  
Another difficulty concerning biobanks is access to the donor’s medical 
records and history was not anticipated in the guidance. In some hospitals these 
records may contain the full medical history of the donor and his parents from birth.  
The National Committee also did not regulate the utilization of this data, nor how 
anonymity can be achieved when the researchers aim to extract longitudinal data 
from the donor’s medical history. Ignoring such challenges is to overlook a major 
biomedical research ethics debate that started with closing the deDECOD company, 
which started the Icelandic Biobank in 1998. They used two informed consent 
models, the opt-in for the donated material and the opt-out for the stored clinical data 
(Palsson, 2008). A few years later in 2003, the whole biobank was closed down after 
being criticized nationally and internationally (Palsson, 2008). These criticisms were 
centred on various challenges, namely: 
  Commodification: deCODE Genetics is a company (i.e., profit-oriented) 
which raised concerns about selling the Icelandic heritage data for material 
gain (Berger, 1999). Moreover, deCODE Genetics signed a contract with 
another giant Swiss pharmaceutical company to finance research on twelve 
genes specifically (e.g. those thought to be linked to congenital heart disease 
and Alzheimer’s disease) (Palsson and Thorgelnsson 1999).  
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 Privacy: In January 2000, deCODE Genetics announced that they were in 
the process of completing the ‘Book of Iceland’ and were going to publish it 
on the internet. This announcement raised the level of attention and started 
to attract an increasing number of activists who were against the exclusive 
rights given to deCODE Genetics (Annas, 2000).  Among the strongest 
opponents of deCODE Genetics was the Icelandic Medical Association 
(IMA). The IMA’s opposition was based on ‘concern about inadequate 
measures to protect privacy, the lack of access to data among academic 
researchers, and the belief that individual consent should be required before 
inclusion of medical records in the data base’ (Annas, 2000, p1830).  
The main idea of biobanks challenges the individualistic notion of a moral 
agent (i.e. an independent individual who can decide on his/her own best interests) 
insofar as it sees the person as part of a larger genetics picture and not as isolated 
genetically from his family or tribe. The Saudi biobanking regulations appear to 
confuse biobanking with collecting genetic materials for preapproved research. This 
claim can be supported by looking at the following article: ‘A central data bank shall 
be established within KACST for the purpose of maintaining information related to 
genetic material and regulating use thereof in accordance with procedures specified 
by the Regulations. Said bank shall provide information for research, using genetic 
material in the Kingdom’ (NCBE, 2010, p87). However, in the following article the 
regulations appear to suggest a model of individual informed consent where the 
participant needs to be approached and agree to any usage of his material, as article 
32.1 tried to illustrate (NCBE, 2010). The challenge with such confusion is that, with 
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a large number of stored samples, it is very labour consuming to keep contacting 
individuals about their material every time someone wants to use it. 
In conclusion, the biobank regulations in the National Committee guidelines 
are not sufficient for regulating biobank in Saudi Arabia and they ignore the major 
international debate about the regulation of biobanks and its challenges, for example, 
informed consent, data access and ownership, and the lack of any opportunity for 
donors to withdraw from the banking system.  
3.3 Summary 
This chapter has demonstrated two things. The first is that the Saudi NCBE 
regulations appear to have inherited the main normative assumptions of how Western 
researchers think about ethics. For example, the overall focus of the individualistic 
informed consent, where there is strong commitment to autonomy. The second 
argument is that the Saudi NCBE regulations can be used to regulate MGE research 
but, because of the previous two points there are still some gaps which need to be 
addressed. We are now in a position to further illustrate the Saudi context in terms of 
culture, religion and politics to set out how a blend of those factors may pose a 
challenge to complying with the selected international bioethics guidelines and the 
Saudi NCBE regulations regarding the donation of blood for MGE.   
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4   Chapter Four: The Saudi and International Guidelines Versus the Saudi 
Cultural Challenge 
4.1 Introduction 
In this chapter, I address the following research question: To what extent do 
the Saudi and the international guidelines meet the Saudi cultural challenges? I 
answer this research question by providing a normative analysis of the extent to 
which the current Saudi guidelines, sources and reference points (i.e. the selected 
international guidelines) meet the cultural challenges that are associated with specific 
Saudi Arabian norms and values by examining and discussing potential tensions 
between them. For this purpose, I critically review the related literature, as well as 
draw on personal reflections. To the best of my knowledge, very few papers in the 
literature discuss Saudi Arabian bioethics context and provide an account of the 
cultural challenges to the implementation of the international guidelines in the field 
of medical research in Saudi Arabia.  
4.2 Autonomy-Based Bioethics 
As I argued in the first two chapters, the principal overarching assumption of 
the analysed international guidelines is the individualistic notion of informed 
consent. The broad overview suggests that this concept originates from the liberal 
political and moral philosophy that flourished after World War II in North America 
and Europe. The idea that an action could be ethical only if the concerned person was 
informed and agreed to conducting it freely and without coercion or inappropriate 
influence. Gillon  (2003) for example rated autonomy as the most critical of the four 
principles or what he termed ‘the first among equals’. On the other hand Manson & 
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O’Neill (2007) argued that autonomy is an extremely vague concept and that it is 
used inconsistently in the literature to promote highly contested views. 
The term ‘autonomy-based bioethics’ reflects notions of respect for personal 
autonomy and respect of the person in the clinical and research contexts by 
accentuating freedom of choice and self-determination (Azétsop and Rennie, 2010). 
Despite the differences among them, the numerous definitions of autonomy tend to 
include an emphasis on agency (i.e. the personal capacity to act intentionally) and 
liberty (i.e. the ability to take decision free from influences) (Gillon, 2003; Manson 
and O'Neill, 2007; Beauchamp and Childress, 2001; Azétsop and Rennie, 2010). The 
Nuremberg Code, which is among the most highly regarded international biomedical 
ethics guidelines and one of the principal references that have crystallised the new 
Saudi bioethics guidelines, is one of those documents leaning towards autonomy-
based bioethics based on the criteria agency and liberty (see Subsection 2.2.2: 
Consent).  
Individualism is pivotal to the autonomy-based model of bioethics as it is 
mainly orienting its attention to obtaining the informed consent of ‘individual 
research participants’ with less attention given to what is best for the community 
where the research will be conducted (Azétsop and Rennie, 2010). 
To summarise the agreement on the autonomy-based bioethics model, it seems 
that it is built on two principal assumptions: 1) the liberal commitment to decision-
making: in the Western societal context, this makes sense because liberal values are 
prized within that society. They even constitute the principal theory of international 
relations, which assumes that the election of leaders is an individualistic act that is 
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independent from the state’s direct influence and based on free choice through the 
operation of democracy; 2) Agency: the ability of an agent to make decisions free 
from external influence.  
In Chapters Two and Three, I argued that the Saudi regulations and the 
international selected research ethics guidelines were oriented toward promoting 
individualistic notions such as promoting informed consent. Accordingly, and based 
on autonomy based bioethics, the Saudi guidelines and the international ones are 
mainly autonomy oriented guidelines. I will further, in this section, assess the 
suitability of such an approach to the Saudi context.  
Autonomy-based bioethics would not be the best framework to regulate MGE 
research in general because the participant is not an individual in the sense that 
his/her genetic material is shared with his/her kin, (Widdows, 2009) nor considering 
the genetically homogenous nature  of the Saudi population specifically (See 
Subsection 1.2.5.3 Stigmatisation). The Saudi NCBE regulations made it clear that 
the national committee’s main job is to insure that informed consent was properly 
given. Informed consent is pivotal to the autonomy-based bioethics model, and is 
problematic because the individualistic decision of the research participant has 
ramifications for the information of other individuals who chose not to participate or 
do not want to know the results of MGE ‘tests’. 
Another challenge that ought not to be neglected is the level of education of the 
average Saudi. The autonomy-based bioethics model seems to shift the responsibility 
for decisions to the patient in the clinical setting and to participants in the research 
setting. Such responsibility requires a full awareness of the ramifications of any 
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decisions. One of the requirements of informed consent is to provide full information 
to the consenting person to enable an informed decision to be made by them based 
upon what they want to do. The Saudi guidelines devote many articles and sub-
articles to describing the content of the consent document as a means of educating 
the patient. There are many challenges in this approach (i.e. expecting the form to be 
the ultimate tool of disclosure) like the assumption that patient will read carefully, a 
document that is neutrally written, with a level of disclosure that does not omit any 
information, and contains all the facts s/he needs to have, and most importantly do all 
of this in a small window of time. To start with, Manson and O’Neill (2007) argued 
that it is impossible to provide such a document (i.e. neutral, explicatively disclosing 
and with no omissions). However for the sake of argument I will assume that 
someone could provide such a document or process. Even so it requires a certain 
level of education to absorb that information, weigh it against his/her own interests, 
family interests, and tribe’s interests in the case of MGE research in Saudi Arabia, 
and then decide. The nature of the Saudi political cultural climate does not support 
such assumption. As I explained in Chapter One, Saudis tend to accept the 
physician’s decisions with no objections (Al-Jumah and Abolfotouh, 2011; Jamjoom 
et al., 2011; Adlan, 2013).   
Saudi patient vulnerability (see Subsection 1.2.5.5 Patient Vulnerability), 
suggests that they will not decide free of a physician’s influence which was 
discussed earlier. The autonomy–based bioethics model gives more weight to the 
informed consent practice, therefore any challenge to the informed consent would 
also challenge the autonomy-based model, and this is certainly the case in Saudi 
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Arabia. The hospitals that have the capacity to recruit for MGE research are the 
highly specialist hospitals (See Subsection 1.2.3 Health-related Services in Saudi 
Arabia). Those hospital are not part of the free Saudi MOH services, they are usually 
the most expensive services in Saudi Arabia. However, Saudis can ask for the 
support of a Royal Prince Order to wave the health cost charges according to strict 
eligibility criteria; this means that the bills will be transferred to the Crown Prince to 
pay (Adlan, 2013). Giving the impression that a very expensive service is going to be 
given for free would create a sense of gratitude that might impinge on the patients’ 
ability to say no.  The long waiting lists even inside these specialist hospitals places 
patients under stress because they are on waiting lists for months or, in some cases 
years, before their follow-up visits.  
In addition to all of those features, Saudis, like most people in the Eastern 
world, are oriented to thinking about decision-making within the context of and 
benefit to the extended family, not just what is wanted by or is best for any one 
individual (Tan-Alora and Lumitao, 2001; Barr, 2002). This is a point taken up by 
some Western commentators who argue that health ought to be perceived in a more 
general way than just as the right of several individuals to decide (Ter Meulen et al., 
2007). In Western ethics, on the other hand, there is nothing to stop an individual 
regarding his/her interests as being inseparable from those of his/her family or 
community. But individuals are not presumed to be subjugated to the interests of the 
family as a whole. However, according to Dunstan (1994) individualistic autonomy 
presupposes the right to decide what to do based on one’s own preferences about 
what matters in one’s life without interference by others. This view is dominant in 
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Western liberal bioethics literature (Stirrat and Gill, 2005). Dunstan (1994) contrasts 
this with non-Western cultures, where ethical norms do not require having the right 
to choose as individuals. Most decisions are not made with a sole focus on the 
individual themselves; rather, they concern how decisions would affect not only 
one’s spouse and children but also one’s parents, siblings, and, in some cases, one’s 
wider family. The core difference, I therefore argue, is in how the policymakers see 
the patient, not the grounds on which the individual’s decision is taken. The 
policymaker regards the patient/participant as an individual who has the right to 
decide individually according to his own beliefs even if the decision would infringe 
on others’ interests. Alternatively, someone might say that the policy-maker ought to 
look at the participant as part of a community, tribe, or family that could be harmed 
by that individual’s decision. MGE research in Saudi Arabia is regulated based on 
the autonomy-based bioethics where an informed consent document records the 
consent of participants as individuals rather than as part of bigger families, or even 
tribes.   
In the Saudi context individualism might not be the most appreciated value; 
family however is considered to be extremely valuable for Saudis, and it lies between 
the levels of individuals and governments. The marriage between two people, for 
example is about family decision-making, it is the union between two families or, in 
some cases, two tribes, not just two individuals. Thus, the approval for the marriage 
should originate from a circle of people that is larger than the two persons who wish 
to get married. Such practices provide a cultural safety net, if something goes wrong. 
For example, if someone has children, the whole extended family is morally 
 
 
 
 
 
104 
responsible for taking care of them in the event that their parents are unable to do so. 
In the extreme case, people take the value of family to mean that when a father dies, 
it would be the duty of his brother to marry his widow and raise his children. In such 
a culturally rich environment (i.e. where even marriage decisions are taken by the 
entire family and brothers feel obliged to raise their nephews and nieces) promoting 
an individualistic autonomy-based can be regarded as untenable (Alsuwaigh, 1989).   
Despite these complex cultural forces, the current Saudi guidelines suggest that 
consent should be gained from individuals. The concern is that in Saudi Arabia, 
MGE research is still in its early stages (Adlan, 2013; Abolfotouh & Adlan, 2011), 
although because of massive investments, MGE research is advancing rapidly. The 
common practice, however, seems to be international collaborations, which help 
researchers to advance their knowledge and publish in higher impact journals. That 
in turn depends on research with global impact thereby encouraging further 
international collaborations (Alwattan, 2015).  
Notwithstanding the cultural norms of family decision-making there is the 
additional issue that MGE research may have an impact on whole families rather 
than individuals. For instance, according to Saudi policies, collecting blood from a 
few members of a family who have individually consented is sufficient to conduct 
family-based genetic research. Depending on the type of investigation, a research 
team can obtain information about a whole family, including those family members 
who did not consent. This is a general issue raised in genetic research, not only MGE 
research in Saudi Arabia (Hallowell et al., 2003; Forrest et al 2003). However, what 
makes such texts in Saudi Arabia more controversial is that the genetic information 
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from one family can give substantially reliable information about the whole tribe 
because of the genetically homogenous tribes in Saudi Arabia that was described 
earlier (See Subsection 1.3 Challenges of MGE research in Saudi Arabia).  
One of the principal objections to the current Saudi guidelines is that 
individualism seems to undermine the value of groups, family and/or community. 
This encourages the idea that when a critical medical decision must be made, health 
providers look for people to decide what is best for them individually, which, in 
some cases, comes into conflicts with the potential good of families or communities 
(Wolpe, 1998, Lindemann, 1995, Bowman and Hui, 2000, Glass and Rud, 2012, 
Etzioni, 2011). Despite all the challenges described in this subsection, autonomy-
based bioethics is a main characteristic of the Saudi NCBE regulations. It seems to 
adopt the idea that signing the individual informed consent form is the main tool to 
protecting a participant’s interests. 
4.3 Informed consent in Saudi Arabia 
As explained previously (see Subsection 1.1.1 Informed Consent) the 
consensus among research bioethics commentators is that voluntariness (assuming 
competence), disclosure (assuming full understanding) and decision (accepting or 
refusing) characterise informed consent (Meisel and Roth, 1981; Beauchamp and 
Childress, 2002). Disclosure, for example, was argued to be an unrealistic 
expectation; and the paradox is that if it is not fulfilled a question would be raised 
about the legitimacy of informed consent (Manson and O'Neill, 2007). The main 
disclosure assumption is that an explicit amount of information should be disclosed 
to participants, which includes all the relative information about the research, the 
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choice, the alternatives, the risks with their likelihood and any information that might 
affect the final decision in a way that is comprehensible to the participant. The list of 
details is growing to the extent it would be impossible to comprehend the whole 
amount (e.g. a 30 page consent document and/or information sheet) (Manson and 
O'Neill, 2007). Due to the complex nature of MGE research where information is 
very sophisticated the disclosure would be even more difficult.  
4.3.1 Informed consent and the assumption of vulnerability  
The other challenge to the way in which informed consent is gained, is the 
assumption of voluntariness. I will take voluntariness in the same way intended by 
the Saudi NCBE regulation as being free to act without exploitation or coercion 
(NCBE, 2010). Beauchamp & Childress (2009) argued that coercion requires a 
genuine actual threat of force to ‘displace a person’s self-directed course of action’ 
(Beauchamp and Childress, 2009, p133). The problem is that both physician and 
patient/participant come to the consent interview with a set of norms and values that 
drive specific assumptions about the relationship between them (Corrigan, 2003).  
Therefore, it is problematic if a person genuinely thought that upsetting her physician 
by saying ‘no’ would threaten her treatment privileges or might cost her access to 
that physician.  
An informed consent is intended to prevent overt coercion (Corrigan, 2003), 
but covert coercion also needs to be taken into account. For example, in the Saudi 
context as I explained (see Subsection 1.2.4 Patient Vulnerability) patients are under 
the influence of two strong forces. The first is their feeling towards their physicians 
as their healer who should be trusted without question.  Second, the fact that MGE 
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research is running in most sophisticated hospitals where only those who have the 
support of a Crown Prince can be treated (see Subsection 4.1.1 Autonomy-Based 
Bioethics). One can argue that this is especially the case because there were no clear 
unified Saudi research ethics guidelines before 2010 to address the risk of coercion 
among Saudi patients. This means that physicians were acting according to the 
environment of trust rather than a dictated specific imported ways of understanding 
coercion.  
4.3.2 Informed consent and the value of trust  
This environment of trust is not alien to the Saudi cultural context explained in 
subsection 1.2 The Saudi Arabian Context. The reality of the tribal culture is built on 
trust. The tribe members come to trust a specific person in the tribe, either one of 
their elders or the most religious tribal member. This person is trusted to protect the 
interests of his people under the tribal cultural laws. This culture is even reflected in 
the Saudi political system. The Saudi monarchy is mainly a tribal monarchy.  In this 
system the king represents the family wise person, the elder who make decisions on 
behalf of the tribes that agreed to obey him. Based on this, it can be said that the 
value of trust is deeply rooted in the Saudi culture. Therefore, it is not strange for 
Saudis to try and find an authoritative figure in health-related services to trust and 
obey.  
This, however, should not mean that Saudis must trust their physicians to the 
extent that they will donate blood for MGE research even when this is something 
they do not want to do. Consent must be crucial; the problem is that a signed 
document is all that is needed to extract patient blood for MGE research. 
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4.3.3 Informed consent in Saudi hospitals 
Saudi hospitals used to use their own local hospitals’ regulations to regulate 
research and, specifically, informed consent long before the Saudi National 
Committee announced its new regulations in 2010. One of the central goals of the 
national committee was to provide unified regulations for all the hospitals and 
research centres that legally bind every researcher who uses human participants. In 
numerous cases, informed consent in Saudi Arabia is no different than many other 
places that reduced the informed consent process to the technicality of a signed 
informed consent document on official paper (Abolfotouh and Adlan, 2011; Adlan, 
2013).  
Another point that might affect the consent process, as understood by Western 
policy-makers, is that there is a clash between the regulations (i.e. expecting Saudi 
patient to choose based on explicit informed consent) and the Saudi culture (where a 
patient trusts his physician to uphold his best interests I have already published the 
results of a quantitative cross section survey that suggests that patients are dependent 
on their physicians and fear upsetting them (Abolfotouh and Adlan, 2011). It was a 
survey of 162 patients designed to assess the quality of informed consent for invasive 
procedures at a tertiary hospital in Riyadh, Saudi Arabia. The majority of the patients 
(87.7%) who agreed to sign the informed consent form thought that they were fairly 
well informed, despite 66.5% reporting that they were told that signing the form was 
simply routine paperwork. We doubted the claim that patients were informed, they 
might think that they were informed because they were told that the signature on the 
informed consent form is just paperwork (Abolfotouh and Adlan, 2011). In addition, 
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approximately 35% of them thought that the information given as part of the process 
of gaining consent was insufficiently explained to them. Another interesting finding 
was that the mean score of the overall experience and satisfaction is almost 54 ± 
17.88, which reflects lack of satisfaction. Sixty-six percent of the surveyed sample 
reported that they were told that the informed consent is just paperwork. This could 
mean either that the Saudi doctors are breaking the law or it could support my 
overarching argument that autonomy-based bioethics framework need to be reviewed 
to regulate bioethics in Saudi Arabia. Among these survey participants it seems that 
patient-physician relationship was more regarded than the right of patient to decide 
individually because the overall quality of informed consent is better when the doctor 
is the one who is taking consent as oppose to any other member of the research team 
(Abolfotouh and Adlan, 2011) which reflects the importance of patient-physician 
relations.     
Another cross-sectional survey of 528 persons attending Saudi outpatient 
clinics at a tertiary care hospital investigated patients' attitudes towards the idea of 
using their medical files in retrospective research without their consent and using 
their surplus tissue in research (Al-Qadire et al., 2010). They reported that patients 
are more likely to accept researchers using data from their medical records (MR) 
than non-patient (companions) who attended the same hospital. Most importantly, 
they found that Saudis perceived MR differently to surplus tissue-based research, 
which is strong indication, that blood, even surplus blood, ought to be treated 
differently than MR.  
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It is also important to note that Al-Qadire’s (2010) findings  in term of people 
who wish to be consented contradicts the work I published in 2011. They reported 
that only 38% and 37% of their sample would accept use of MR and Tissue-based 
Research (TR) respectively without consent. It is important to bear in mind that the 
sample population is different but more important than the population difference is 
that both are cross sectional studies using surveys. The main limitation of cross 
sectional studies is that they only provides specific information about a specific time 
in a specific context described by the researchers which means it is not generalizable 
(Sugarman et al., 2001). Another way of looking at it is that in our 2011 published 
work we found a positive correlation between the overall satisfaction and quality of 
the informed consent when physicians are the ones who gain consent. The 2010 
study did not specify the consenting context (for example who asked the patients to 
consent).   
4.4 Stigma in the tribal context  
As I explained earlier (see Subsection 1.2.2 The Saudi Cultural Context & 
Subsection 1.3.3. Stigmatisation), in the Saudi tribal context, stigma is one of the 
most substantial risks in MGE research. This is because of the genetically 
homogenous composition of most of the tribes in Saudi Arabia. In the international 
guidelines, I could not find any specific regulations that could be used to protect 
people from stigma in this context (when information derived from family has the 
potential to stigmatise their tribe.) 
However, Article 36.2 reads ‘Scientific results shall not be leaked to the media 
if this could lead to promoting discrimination on the basis of race or family or tribal 
  
 
 
 
111 
affiliation’ (NCBE, 2010, p94). This can be seen as a strong indication that Saudi 
policymakers understand the risks of MGE research in the genetically homogenous 
Saudi context.  
Another article in the NCBE puts a clear restriction on any research that is 
intended or can be perceived to be intended to promote discrimination: ‘Research 
with negative impacts on society may not be conducted, especially research 
reinforcing racial discrimination’ (NCBE, 2010, p94).  
The main challenge in the two articles is that they did not mention stigma, in 
fact the NCBE did not regulate to avoid stigma specifically in its regulation. These 
two articles are the closest it gets to discuss stigma in the NCBE regulations. Genetic 
discrimination could be seen as the unfair deprivation of the rights of a person, 
family, ethnic group, or tribe solely based on information derived from their genes, 
that indicates an apparent or perceived variation from what is deemed to be the 
normal or healthy human gene (Kenen and Schmidt, 1978; Billings et al., 1992). In 
other words, it could be taken as treating people unfairly. On the other hand, stigma 
has been the centre of many definitions and debates because mainly it is perceived 
differently based on the complexity of what is alleged to be stigmatising or 
discriminating (Parker and Aggleton, 2003). Space does not permit me to enter into a 
lengthy debate about what stigma is. Rather I will adopt a simple and pragmatic 
definition offered by Boddington (2012): ‘An individual who suffers stigma is 
disqualified from full social acceptance.’  (p.99). The word originates from the Greek 
practise of marking the body of slaves or criminals in a way that makes it visible to 
everyone else that those marked people are of an inferior status (Boddington, (2012). 
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Stigma has mainly been discussed as a sociological practice. Therefore, one can 
conclude that what can be regarded as stigma is based on system of beliefs, values, 
and behaviour.  
For a long time, people who were most stigmatised in Saudi Arabia were those 
who had contracted sexually transmitted diseases—the assumption was that they 
became infected from engaging in forbidden sexual activities (Badahdah, 2010) — 
and those with psychiatric disorders (Shahrour and Rehmani, 2009). In the case of 
genetic information, stigma can be assigned to a person even if he or she is perfectly 
healthy, but is known to be a carrier. Some researchers suggests that people have 
refused to undergo genetic testing, even for diagnoses (i.e. not research) where 
physicians wanted to test for genetic susceptibility to epilepsy (Obeid, 2008; Koura 
et al., 2012) or to autism in Saudi Arabia (Alqahtani, 2012) because in both cases 
society treats carrier families for such mutations as defective. Genetic research 
presents a new challenge, where the results of genetic testing could be used to deem 
a person as “defective.”  
It is fair to say that not every molecular abnormality is regarded as 
stigmatising. For genetic information to be stigmatising, it must first be placed in the 
public domain and then perceived by people as demeaning. For example the claim 
that a majority of people from the X tribe are carriers of G6PD disorder (See 
Subsection 1.3.3 Stigmatisation) could be a fair description of an epidemiological 
finding. It can be described as stigma only if people from tribe Y starts to rate tribe X 
as inferior to them. It could be argued that such stigma could then lead to 
discrimination either in cultural domain (i.e. social ranking) or at a personal, 
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economic level (i.e. medical insurance). In the Saudi context the consequences of 
stigma have reached the level of discrimination in the cultural domain (See 
Subsection 1.3.3 Stigmatisation) and soon, with the introduction of health insurance, 
will extend to the personal economical level. 
The important question is whether, if we had the NCBE regulations 30 years 
ago, the current level of stigmatisation would be less than it is now? It could be 
argued that the NCBE guidelines’ lack of mentioning stigma, suggests the answer is 
‘No’. it is impossible to stop MGE research results reaching the public domain. This 
is because as soon as advances are published, even in the purely academic domain, 
the chances are that it would reach the public eventually, and some tribe members 
could find out and then use that information to stigmatise others (see the way MGE 
research has been utilised for proof or disproof blood purity Subsection 1.3.4 Blood 
Purity).    
MGE research is advancing rapidly the world over and not just in Saudi 
Arabia. Therefore, it is important to address potential stigmatisation as a problem 
with two dimensions: a) to deal with existing stigma and remedy its consequences; b) 
to prevent further stigmatisation which is more general than its consequences.  
It could be the case that the Saudi policymakers wanted to be pragmatic in 
responding to stigmatisation and discrimination by bolstering the importance of 
participant confidentiality, defined, for instance, as ‘Non-disclosure or passing of any 
data, information or results related to the research or the human subject, to any third 
party not connected with the research.’ (NCBE, 2010, p8). ‘Set ethical controls and 
monitor implementation thereof to safeguard rights of human subjects during 
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research and ensure confidentiality and security of research information’ (NCBE, 
2010, p19). The challenge, however, as I argued earlier (see Subsection 2.2.4 
Identifiable material) is that genetic material, even if fully anonymised still harbours 
the risk of providing the basis for guessing family names by simply marrying data in 
different databases (Gitschier, 2009). Gitschier (2009) demonstrated the possibility 
of making an educated guess about the family names of participants in the HapMap 
project, which began in 2002 and included numerous countries with the aim of 
identifying human genetic variations. The HapMap project included a large Mormon 
population. By using data triangulation (i.e. by correlating information from different 
available sources), Gitschier could make educated guesses about the family names. 
Because of her work, the HapMap project re-consented all the participants to ensure 
that they understood that such identification might be possible (Boddington, 2012). 
Accordingly, in Saudi Arabia, you can know the region where a person comes from 
and his family name due to the genetically homogenous nature. The NCBE 
guidelines seemed to aspire to further protection from stigma by announcing that the 
state owns the National Saudi genetic material and its data.  
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4.5 Ownership4 of Genetic Material 
Because Article 31.4 did not elaborate on the Saudi policymakers’ reasons for 
protecting the Saudi genetic material as a national property, I will offer three 
potential explanations: 1) genetics essentialism, 2) monitory interest, and 3) national 
security, and discuss each in turn. 
The first possible reason is that Saudi policymakers might entertain a level of 
genetic essentialism, which is the reduction of human beings to DNA (Boddington, 
2012). It could be the case that Saudi policymakers think that the core of Saudi 
identity is incorporated in the Saudis’ DNA. The fact that Saudis are culturally tribal 
could support this assumption, because every tribe has preserved its blood purity. 
Therefore Saudi genetic material assumed the status of national heritage to be 
protected and not to be commodified. However, the genetic data that MGE research 
has generated presents a similar problem. Such guidelines raise a more critical 
question of what can become a commodity, whether it is the DNA material itself or 
the data that was generated by it. The guidelines tried to avoid distinguishing 
between the genetic material and the data that is generated from it by declaring that 
the material itself is owned by the state to prevent the causal sequence of having 
                                                        
4 The term ‘ownership’ has several different, precise meanings and connotations 
within philosophy and again in law. As it was used in the NCBM guidelines’ 
(translated English version), however, the term ‘ownership’ was not meant in either 
of these senses. Rather, it means something more akin to ‘control’ or ‘authority’ and 
was simply intended to prevent sending genetics material outside the country in 
international collaborations that do not respect the Saudi patient rights over any 
future patents. Therefore, it seems that NCBE did not attempt to look at ownership 
through commodification, or through contracting rights, or in any way that sees the 
body as mere property (De Witte & ten Have, 1997; Thomasma, 1997; Gillett & 
McKergow, 2007).  
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genetic data out of Saudi legislative control. The guidelines, however, did not draw a 
clear line between the individual’s right to his or her genetic material and the state’s 
right to Saudi genetic materials. For example, if someone wanted to contribute his 
own blood to an international organisation, the policy does not provide clear 
guidance as to whether the person can be prevented by the state or whether there 
would be sanctions if he could not be prevented but went ahead anyway. In another 
scenario, if the person does not want to donate his blood, does the state have the 
power to force him because the material that he refuses to give is not his, it is for the 
state? Between these two extreme scenarios there are many other problematic 
situations like hundreds of samples already sent to other international collaborators 
who received each one of those sample with individually signed informed consent 
gained by the Saudi collaborator.  
The second possible reason is that Saudi policymakers might consider 
protecting Saudi rights in any patents that could emerge from using Saudi genetic 
material because they believe that patenting it could be financial beneficial. It could 
be the case that the Saudi policy makers wanted to prevent what happened in the 
famous case of Moore versus Regents of the University of Los Angeles which was 
won by the defendants who used a tissue line that was successfully harvested from 
James Moore but they denied him any financial benefits (Lavoie, 1989). Due to the 
nature of the Saudi tribes’ genetic material and how it concentrates genetics 
variations from hundreds of generations as described in the first Chapter, the 
committee seem to think that the Saudi DNA attracts particular interest in relation to 
the study of rare diseases. Such interest could result in either cure or a patented test 
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where even the DNA donor organisation cannot use the test for its own patients 
without incurring inflated charges imposed by the patent-holder. 
A third possible reason could be that Saudi policymakers are very conscious of 
the possibility that its enemies could use the Saudi genetic material to manufacture 
specific biological weapons that target only Saudis.  
One, two or all of these three could be the reasons for the existence of Article 
31.4. The wording of the article does not suggest which one of the three possibilities 
is more likely, therefore it was important to ask stakeholders in the empirical arm for 
their opinion on this. To the best of my knowledge this is the first attempt to try to 
understand this article in its context. In the following Subsection I will explore 
whether the NCBE regulations are enough to protect Saudi genetic material. 
Regardless of what is the most likely explanation, the NCBE regulations seem to 
regard Saudi genetic material as in some way special. 
4.6 Sending Saudi genetic materials outside Saudi Arabia 
In this subsection I will try to contrast the claim of special rank bestowed upon 
Saudi genetic material with actual practice. I will demonstrate two avenues by which 
Saudi genetic material can reach an international research centre. These two avenues 
could be seen as a challenge to the regulations insofar as these unregulated practices 
challenge the NCBE regulation normative assumption regarding the duty to protect 
Saudi genetic materials.  
Someone might argue that under the assumption of special rank bestowed on 
Saudi genetic material, the NCBE regulations tried to minimise sending Saudi 
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genetic material abroad for research. However, it cannot prevent the export of Saudi 
genetic materials, as it does not address these two avenues. The first avenue is the 
sending of blood samples to international laboratories for clinical reasons. This will 
often happen when hospitals have a contract to carry out some laboratory tests in an 
internationally approved organisation or when the technology required to perform the 
tests is not available in Saudi Arabia. Usually, these organisations seek informed 
consent that either waives a right to ownership by the patient or gives permission to 
the organisation to do as it pleases with any surplus blood (Tutton, 2002; Godard et 
al., 2003). The more serious challenge is sending blood abroad for genetic 
diagnostics. In some cases, the physician is not sure what test to run as he is not sure 
of a diagnosis; thus the blood is sent for what can be regarded as full genomic 
analysis, such as microarray or even synopses analysis (i.e. both tests are from the 
most sophisticated genetic analysis used for both research and clinical reasons). It 
could be argued that some researchers from the private sector could exploit this 
avenue to facilitate research collaboration without seeking any prior approvals. The 
Saudi policies seem to control the export of genetic materials (see 3.2.2 Sending 
Saudi Genetics Material Outside Saudi Arabia), but to the best of my knowledge, 
they do not explore the divide between research and clinical investigation, which 
would, in theory, leave open a back door by which genetic material could leave the 
country.  
The second avenue is the sending of buckle cells (swabs from inside the mouth 
taken for DNA extractions) to websites by private individuals who wish to obtain 
information about paternal linage. This avenue could be problematic for two main 
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reasons. First, if the Saudi policymakers think that genetic material ought to be 
protected, this avenue leaks valuable material without any kind of control. This is a 
real test of the claim of the Saudi policymaker regarding the ownership of Saudi 
genetic material by the state. In this case, individuals or groups of people express 
their autonomy taking advantage of services that are beyond the reach of Saudi 
research governance. This raises the question of the relative weight to be attributed to 
personal autonomy versus the state claim of rights to genetic material which will be 
discussed under the light of the collected data. The second reason is the nature of the 
Saudi tribal culture, where the better proof of pure blood means greater respect and 
thus a higher rank in society. Some online services, those offering individual-
oriented genetics linage testing, seem to encourage a level of biological or genetic 
superiority claims among Saudis. 
In a tribal culture like the Saudi one, the quest to prove superiority by genetics 
testing could be seen as problematic, because genetic research has empowered 
individuals to claim a higher status in society as well as to stigmatise whole families 
for not being truly the descendants of those they have claimed all their life. For many 
reasons like those I argued earlier (see Subsection 1.2 The Saudi Arabian Context), 
such genetics testing empowers a whole new social ranking system among Saudis 
(Arab-DNA, 2012; Howitat, 2012) (see also Subsection 1.3.4 Blood Purity).  
Keeping in mind those two unregulated avenues of sending Saudi genetic 
material abroad and contrasting it with the NCBE regulations, NCBE regulations risk 
being inconsistent. 
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4.7 Summary  
This chapter has outlined three main normative challenges that pose a tension 
between the current NCBE regulations and Saudi culture. The first tension was 
between the autonomy-oriented ethos adopted by the NCBE regulations and the 
cultural nature of Saudis. I suggested that Saudis tend to be more trusting of the 
healthcare provider due to the nature of Saudi tribal and political culture, and thus 
providing a signed consent form may be regarded as just paperwork.  
Also, in regard to the concern of how stigma is treated in the NCBE 
regulations, I argued that it is not enough to regulate discrimination, which could be 
seen as one of the harms resulting from stigma, without addressing the source (i.e. 
the risk of potential power of the genetics research to stigmatise not only individuals 
but also tribes).  
I then discussed the assumption that the Saudi genetic material has been 
afforded a special position, and challenged the consistency of that assumption. The 
NCBE seems to think that it ought to protect Saudi genetic material but it does not 
explain why. In this chapter I suggested three different explanations, and then 
provided two examples where practice remains unregulated.  
In conclusion, at a normative level the NCBE’s regulations, despite its best 
effort to include some of the cultural concerns, can be seen to conflict with some 
Saudi cultural values. This could be due to the fact that most of the normative 
assumptions inherent in the Saudi NCBE regulations are inherited from the Western 
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normative assumptions found in the international policies used as reference points 
for the Saudi ones. 
Section One: Summary  
In this section I provided a normative analysis in three levels: the first was the 
international guidelines that were used to inform the Saudi ones, the second was 
Saudi NCBE regulations, and the third level was assessing tensions between the 
NCBE regulations and Saudi culture and values, drawing on descriptions provided in 
the introduction about the nature of Saudi culture and its social, political and 
religious values. I concluded that Saudi culture poses many challenges to the recently 
developed NCBE regulation.  
I concluded that the set of assumptions about how ethics should be considered 
was inherited from the international selected guidelines to the NCBE regulation. 
Such assumptions posed tensions in many domains when MGE research is 
considered. I argued that the Saudi NCBE is dominated by values derived from 
liberalism, or more precisely a vision of liberalism where there is a strong 
commitment to individual autonomy. As a result the concept of informed consent 
was empowered, the harm principle guides the justification of action, and 
paternalism is seen as something that is to be avoided.  
I contrasted those values to a normative analysis of the Saudi culture drawing 
on personal experience, and literature reviews. I am now in position to test these 
challenges and tensions using empirical data to explore how stakeholders in MGE 
research in Saudi Arabia operate around these issues.   
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Section Two: The Empirical project 
5 Chapter Five: Method 
5.1 Background 
This chapter will explain the empirical study’s design and justify the choice of 
method (the tools used to collect and analyse the empirical data), its methodology 
(the theory behind the selected method), and the challenges faced in the fieldwork.  
5.2 Design 
In the empirical study for this thesis, it was important to focus on the 
participants’ words and perceptions in order to uncover the tacit meanings and set of 
norms with regard to donating blood for MGE research in Saudi Arabia. Qualitative 
methods could best achieve this (Silverman, 2005; Denzin and Lincoln, 2011). Three 
different established methods of qualitative data collection were used and the choice 
of each is justified below. Quantitative methods were not appropriate as they are 
mainly concern with the measurement of variables in controlled settings (Denzin and 
Lincoln, 2011). Quantitative research facilitates the calculation of relationships 
between variables that are collected by pre-prepared instruments (Becker, 1996). 
Based on this understanding of the nature of quantitative research, it is a useful tool 
to measure proportions of individuals with specific beliefs or attitudes and 
statistically to calculate associations, significant differences, or predictions between 
them, their demographics, or their socio-demographics factors, aimed at 
generalizable findings (Hull et al., 2001). Therefore, quantitative research was not 
suitable for the purposes of this empirical study as, to meet its aims, it needed to 
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explore the meanings, values, concepts, experiences, and reasons used by Saudis in 
the context of MGE research. 
5.2.1 Data Collection 
5.2.1.1  Overview 
Phase One: data were collected through observation of patient recruitment for 
MGE research. The intention was to view individuals’ behaviours in their natural 
settings in order to determine the extent to which there was adherence to the current 
Saudi bioethics guidelines governing recruitment.  
Phase Two: data were collected through semi-structured interviews with 
individuals who had recently donated blood for MGE research. The aim of the 
interviews was to explore how the interviewees experienced donation and 
recruitment for MGE research and the extent to which they understood what they 
were agreeing to in their consent interview. 
Phase Three: data were collected using focus groups comprised of researchers 
(group 1) and bioethics policy-makers (group 2). The intention was to explore how 
the participants thought MGE research in SA was and should be governed, and to 
gain participants’ reactions to the practices and experiences encountered in phases 
one and two. 
Having provided an overview of the methods chosen for data collection I will 
now describe and justify each phase in detail.  
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5.2.2 Phase One – Observations 
A useful and pragmatic definition of observation as a research method is given 
by Marshall and Rossman (1989) as cited in Kawulich (2005): ‘the systematic 
description of events, behaviors, and artifacts in the social setting chosen for study’ 
(p79). Observation is associated with ethnography, as it enables ethnographers to 
observe phenomena in their natural context using their own five senses to provide 
what can be described as ‘written photograph[s]’ (Erlandson, 1993; Kawulich, 2005). 
However, ‘it is important note that the two [participant observation and ethnography] 
are not synonymous’ (Ives & Damery, 2014, p109). In other words, ethnography is 
not only participant observation and, most importantly, not every participant 
observation is ethnography (Ives & Damery, 2014).  
There are two main methods of observation: direct observation (Kawulich); 
(Bernard, 2011; Hull et al., 2001) and participant observation (when the researcher 
assumes an ‘insider’ role and becomes part of the observed setup) (Hull et al., 2001; 
Kawulich, 2005). The main goal of observation in this phase was to directly view 
both those who were giving consent and those who were receiving it in MGE 
research recruiting sessions. Observation was used according to Mays & Pope (1995) 
account namely as ‘it can help to overcome the discrepancy between what people say 
and what they actually do.’ (p3) Passive observation, or what Bernard (2011) and 
Hull et al. (2001) called direct observation was chosen because of the risk of going 
‘native’ which is described by Mays & Pope (1995) as ‘becoming so immersed in the 
group culture that the research agenda is lost, or that it becomes extremely difficult 
or emotionally draining to exit the field and conclude the data collection.’ (p3). 
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Observation enables non-verbal communication, including how the participants acted 
in the study situation, as well as how the recruiting process time was spent 
(Schmuck, 1997) to be recorded. Observation enables the uncovering the tacit 
aspects of values or culture that remain out of our awareness (DeWalt and DeWalt, 
2010). 
I was a passive observer and did not participate in the observed consenting 
procedure in any way (Robson, 2002). The observations were not video or audio 
recorded, but extensive field notes were taken. No identifying information was 
recorded in the field notes. Prior to the observations, I read the observed 
organisations specific clinical polices related to research consent interviews. This 
was to determine whether these conformed with the NCBE guidelines. This also 
enabled me to observe the extent to which the practices I observed conformed to the 
organisations own guidelines.  
I, as a researcher, was aware of the challenges around observation as a 
qualitative research methodology. The most important two challenges were the 
observer effect and the robustness of the data collection. Observer effect usually 
refers the potential for changes in people’s behaviours when they are under the 
impression that they are being observed. To overcome this challenge, or at least 
minimise its effect, it is usually advisable to spend the time in the natural setting (i.e. 
not to be perceived as a stranger by observed participants) (Hull et al., 2001).  
I planned to minimise the observer effect by trying to habituate myself as much 
as possible with the research sites and clinics. However, I did not dismiss the 
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possibility of the observer effect therefore I planned to look sceptically at the data as 
it could be the best practice that would echo the regulation in details.  
I resisted taking notes during the observed sessions in order not to disturb the 
normal flow of events in the recruitment. All the field notes were recorded 
immediately after the observed sessions ended. In order to ensure the robustness of 
the data, I planned to be as systemic as possible, i.e. by conducting each observation 
using the same routine and, immediately after each session, by writing up all the 
details that I could remember while they was still vivid in my memory (see Appendix 
1: example of the field notes). 
5.2.2.1 Recruitment and ethical considerations 
The original intention of this phase was to observe both prospective donors and 
researchers in recruiting sessions for potential blood donors for MGE research in 
three major hospitals in Saudi Arabia. Although these hospitals were all in Riyadh, 
they can be regarded as representative of the whole kingdom because they all receive 
patients and referrals from across the country.  
A poster (Appendix 2) was displayed in staff areas informing staff of my name, 
contact details, and the purpose of the study. When a consent interview was booked, 
relevant staff members were approached in person and in a private space, reminded 
about the study and asked if they were willing to be observed. All of the approached 
staff members verbally consented to participate. A similar poster (Appendix 3, 
translated into Arabic) was displayed in patient waiting areas. Patients were asked 
for permission for me to observe the researchers gaining their consent by the 
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researchers themselves, using a process of verbal consent as they entered the 
consultation room (Appendix 4) after checking that they had read the poster 
(Appendix 3), understood it, and had no objections to its content. I decided not gain 
the patients’ consent myself for the following reasons: 
 It was important to ensure that the observed researchers had the opportunity 
to veto an observation if the patients were unwilling to agree. My presence may have 
made this more difficult as it was socially more comfortable not to invite me into the 
room than it would have been to ask me to leave.  
 Although the patients were part of the observation, the researchers were the 
target participants as they were the ones responsible for adhering to the NCBE 
guidelines.  
 The poster that was displayed, before the observations, was designed to draw 
the attention of the research team (who were observed) to verbally consent the 
patient.  
 I wanted to observe the process passively with no interaction whatsoever with 
the patient during the recruiting process – gaining consent myself would have 
inserted me into the interaction and potentially influenced behaviour, which would 
be detrimental to the study. 
 Asking patients to provide written consent had the potential to confuse 
patients about what they were consenting to (i.e. to my study and blood donation for 
MGE research). Accordingly, it seemed more ethical to downplay my research so as 
not to distract their attention away from the more serious decision about participating 
in the MGE research. 
 
 
 
 
 
128 
The researcher-participant was given the opportunity to withdraw within 48 
hours of being observed. 
5.2.2.2 Inclusion and Exclusion criteria 
All consent interviews were planned to take place in the three-targeted 
hospitals that were recruiting adult blood donors for MGE research during the period 
from February 2013 to May 2013. As the age of consenting in Saudi Arabia is 18, 
being an adult was defined in this project as any person who is 18 years old or older. 
Mental capacity was assumed when a participant appeared able to rationalise his or 
her decision to participate. All researchers were assumed to have mental capacity by 
virtue of their job. Those who did not wish to have their interview observed 
(researcher or patient) were excluded.  
5.2.2.3 Sampling 
Convenience sampling technique was employed. Convenience sampling was 
deemed to be the most suitable technique as it helps facilitate recruitment in a 
manner that matches the overall timeframe of the project. Observations were planned 
at three different institutes, all of which have active, busy research departments and 
multiple genetics studies involving international collaborators.  
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TABLE 5-1: THE THREE RESEARCH SITES  
 
First hospital Second hospital Third Hospital 
Specialty Ophthalmic–specialised General-specialised General-specialised 
Reference Ministry of Health (MOH) Military hospital 5 The Royal Court  
Capacity 400 beds 600 beds 500 beds 
Branches in other 
cities 
Yes Yes Yes 
Researchers’ 
education 
Weekly grand rounds Many education 
programs 
Many education 
programs 
MGE specialised 
laboratory 
Yes Yes Yes 
MGE research 
international 
collaboration 
Yes 
 
Yes Yes 
 
Strict patient 
eligibility system 
Yes Yes Yes 
 
5.2.3 Phase Two – Interviews with patients who had been invited to donate 
blood for MGE research 
The main reason for using interviews was to gain an understanding of the 
potential subtext of the interviewees’ statements (Kvale, 2008). Follow-up questions 
can be used in interviews to reveal tacit meanings within interviewee comments. The 
interviews were used to explore participants’ understanding of values and norms 
around MGE, and their experience of being invited to participate in MGE research 
(Bryman 2004). Interviews have been described as ‘conversations with a purpose’ 
(Taylor, 2005). Interviews were chosen to enable me to explore the donors’ thoughts 
on the experience using their own words, beliefs, hopes, attitudes, fears, and agendas. 
This kind of in-depth understanding, guided by follow-up questions about what 
the donors really meant to say or how they understood their participation, would not 
                                                        
5 This hospital treats not only personnel and their families, but also other Saudi and 
non-Saudi people based on specific eligibility criteria. 
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be as effective if we used another approach, such as a survey. Other qualitative 
approaches, like focus groups, could have been used. However, the level of 
information sought was personal, asking donors to recall their own experiences, 
rather than a general discussion about donation, for which focus groups may have 
been better suited. I elected to use interviews for this phase, for several reasons: 
 Interviews have greater potential to tease out personal accounts that are not 
influenced by any collective debates or contaminated by others’ opinions. 
 Personal conversations are more acceptable in Saudi culture than, for 
instance, surveys. Human contact builds up trust and not all Saudi adults are literate. 
Interviews were therefore thought more likely to yield reliable data  
 Some informants might not understand or appreciate the safe environment 
that is promised by focus groups and, as a result, may not have been comfortable 
sharing their experiences with others. 
 The nature of interviews would provide a more flexible tool to be applied 
than the logistics of focused groups (i.e., coordinating times, places, and venues 
suitable to all participants) (Sugarman et al., 2001; Taylor, 2005; Sugarman et al., 
2007; Creswell, 2012).  
The observations in Phase One set the scene for Phase Two by providing more 
realistic field interview expectations. They also informed the topic guide that was 
used in the intended in-depth interviews during Phase Two.  
The first version of the topic guide was completely informed by the literature. 
It addressed MGE research challenges in general. As a result of the interim analysis 
of results from Phase One, questions were redesigned to be simpler and to ask about 
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participants’ general understanding, and whether or not this understanding was 
gained during the recruiting process. Another change was to include the themes of 
patient deception and patient vulnerability, in order to tease out patients’ reflections 
on those points in an indirect way. 
It was also important to know what the patients’ overall perceptions were and 
what they recalled from the recruiting interviews. The intention was to have in-depth, 
semi-structured interviews with patients within a few days of their donations while 
they were more likely remember as many details as possible thereby avoiding recall 
bias. People tend to forget crucial details of their experience over time (Hutson and 
Blaha, 1991). Recall bias refers to when a patient’s recollection of an experience 
might be different to what actually happened (Fortun et al., 2008; Shields et al., 
2010).  
5.2.3.1 Sampling 
The main sampling strategy was purposive sampling. Creswell (2012) 
suggested that purposive sample ‘means that the inquirer selects individuals and sites 
for study because they can purposefully inform an understanding of the research 
problem and central phenomena of the study’ (p.165). The intention was to recruit 
from the three institutes in which patients had recently been invited to donate blood 
for MGE research. Some might argue that this sampling strategy can also be 
categorised as stratified purposive sampling, as defined by Miles and Huberman 
(Creswell, 2012), to ‘[I]llustrate subgroups and facilitate comparison’ (p158). 
Although I tried to look for informants from different institutes, I did not aim to 
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compare the resulting data. Thus, the sample strategy best categorised as purposive 
sampling. 
The recruiting period was from March 2013 to May 2013 which was the best 
time before the summer vacation when usually all clinics and research activities slow 
down for the summer season. The target population was all patients who were asked 
to donate blood for MGE research in the three selected institutes during this time 
period. It was anticipated that 20 interviews would be needed to reach saturation, but 
due to time pressures it was foreseen that it would not be possible to conduct more 
than 20 interviews even if saturation was not reached. The plan was flexible and 
would have allowed me to make amendments if recruiting a purposive sample was 
proven to be impossible (e.g., moving from a purposive samples to convenience 
samples). Convenience sampling is a more flexible sampling strategy, mainly 
because it is opportunistic or non-systematic in its nature and is best used when time 
and funds are limited (Creswell, 2012). The main disadvantage of this strategy is that 
it is not as rigorous in the sense that it could be rated as less objective than other 
sampling techniques, which might impact the quality of the collected data. Such a 
shortcoming would not be accepted as the first choice in this phase, but it would be 
tolerated in a pragmatic alternative plan to the purposive sampling strategy. The 
purposive sampling, however, worked fine because I was able to maintain 
recruitment from the intended centres, as I will explain in the results chapter.  
5.2.3.2 Recruitment and consent process 
At the end of the consent interviews in Phase One, the patient was asked if they 
were willing to agree to be interviewed about the consent process for the study. 
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Those who were willing were given more information (which was translated into 
Arabic and read to those who were not literate) (see Appendix 6 English version and 
Appendix 7 Arabic translation) and asked for their contact details.  
I then contacted them the following day to arrange an interview if the patient 
was still willing to participate. In addition to that, the recruiting clinics were given 
my contact numbers in order to contact me when a recruitment session was 
scheduled, so that I could approach those patients about the study after their consent 
interview. This process was planned to be repeated until data saturation was reached 
or 20 interviews were recorded (whichever was soonest). 
5.2.3.3 Inclusion and Exclusion criteria 
 Included in the study were adult (aged 18+) patients with capacity who had 
recently invited to donate blood for MGE research. Excluded from the study were: 
 those unwilling to participate; 
 and those for whom it was not possible to organise an interview at a mutually 
convenient time specifically during the first week after the consent interview.  
 
5.2.3.4 Interviews, language and translations  
The interviews in this phase were carried out in Arabic. All interviews were 
audio-recorded, transcribed, and translated. Every participant was given a number as 
part of a general anonymisation of transcriptions. 
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The plan was to translate the Arabic interviews into English using two 
different, independent translators. The two translations would then be compared to 
assess their quality and accuracy. If any differences found were major, a third 
independent translator would be asked to provide a third translation. I was unable, 
however, to find someone with the right expertise in terms of qualitative research 
transcription and translation. I was able to identify someone who understood the 
importance of data accuracy through her activities in quantitative research data 
collection. She was given a quick tutorial of what was expected. I consulted a 
colleague, who is bilingual and had participated in qualitative research, to assess the 
accuracy of both the transcription and the translations. Based on my colleague’s and 
my own assessment, the transcriptions were revisited many times to make sure they 
were as accurate as possible. Also, my colleague and I were convinced that those 
who were given the chance to translate failed to capture the essence of what was said 
in the original Arabic language. Therefore, in order to progress, the study had two 
options: the first was to do analysis in Arabic and then translate quotations into 
English. This was considered a good solution, but it also meant that my supervisors 
would not have access to the raw interview data, which would make it impossible for 
them to verify my analysis. Another disadvantage of this potential solution was that 
the lack of Arabic software that can assist with qualitative data coding. The second 
potential solution was to provide a more trusted, accurate, verbatim English 
translation despite the major time and financial investment. To do that, a multi-phase 
plan was initiated: 
 Revising large portions of the English texts provided by the inaccurate 
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translations and transforming them in order to ensure that they matched the Arabic 
text. 
 I then asked a bilingual consultant with qualitative research expertise to 
comment on the accuracy of the final version of the translations. 
My supervisors and I agreed that this solution would be the most appropriate 
given the availability of resources and time permitted for this project. 
An interim analysis of this phase’s data was used to inform the topic guide for 
Phase Three (for details of how this was done, see Subsection 4.5.2 below).  
5.2.4 Phase Three – Focus Groups 
The purpose of this phase was to discuss what the norms of MGE research in 
Saudi Arabia should be in general, as well as reactions to the initial findings in 
phases one and two specifically. In general, the main aim of focus groups is to 
encourage the collection of data through discussion and debate and through 
discussing the participants’ perceptions. Focus groups are considered a particularly 
suitable tool for exploring people’s opinions, wishes and concerns (Kitzinger, 2005). 
Focus groups work best when they create the perception of being among people who 
are most likely to share the same way of thinking, which, in theory, would encourage 
the exchange ideas and the discussion of those ideas in an environment perceived to 
be safe (Jourard, 1964). One of the main reasons for collecting data using focus 
groups in this phase was to explore how the participants perceive, and feel about 
(Krueger & Casey 2000), MGE research in Saudi Arabia. Thus, focus groups would 
be more appropriate than interviews or survey questionnaire insofar as they create an 
environment where individuals would feel safe expressing ideas or responding to 
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other people’s perceptions. Also, part of my study was to learn more about the 
different opinions and experiences that the researchers had (Morgan & Krueger, 
1993) and the ways that they influence and are influenced by other researchers’ 
input. 
In this phase, the mixture of the data collected by the previous two phases 
would generate a mixture of opinions driven by different experiences, behaviours, 
and perceptions; a focus group would provide the best data collection tool to 
investigate those complex reactions and ranges of opinions (Morgan and Krueger, 
1993). In addition, focus groups provide access to different kinds of data than that 
obtained by interviews. They are more suitable for assessing the richly textured 
normative influences on our behaviours  (Bloor et al. 2001). It, also, enables data to 
be collected in such a way that people’s behaviours, beliefs, and attitudes can emerge 
(Kitzinger, 2005). In focus groups ideas are generated based on discussion where the 
ideas are filtered through the participant’s discussion. Morgan and Krueger (1993) 
believe that the level of interaction in focus groups provides the ability to study 
motivations and reasons tested through the group’s discussion. Above all, this phase 
was mainly intended to tease out complex levels and the rich textures of the 
normative values held by the group, which makes focus groups the most suitable 
method of data collection in this phase (Bloor, 2001).  
Two focus groups were organised. The first focus group targeted individuals 
employed to recruit and consent patients for MGE research (e.g., research nurses, 
research coordinators, and research assistants). The second focus group targeted 
bioethics policy-makers in Saudi Arabia. The intention was that this group would 
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include a human research ethics committee chairman, a research director, a legal 
advisor, and a religious expert. The main reason for separating the two groups was 
that the second group would contain high profile research leaders in Saudi Arabia 
who might unwittingly intimidate the less powerful individuals who carried out the 
consent interviews. A focus group typically gathers in a safe, stress-free environment 
in which participants can feel at ease among peers who share similar experiences 
(Jourard, 1964). The intention was to recruit six to nine participants in each group. 
A topic guide was used to focus the discussion (Finch and Lewis, 2003). It also 
provided some consistency between the two groups, potentially enabling the results 
to be compared.  It was used to steer topics and guide discussion rather than ask very 
specific questions (Finch and Lewis, 2003). The topic guide was based an interim 
analysis of the qualitative data from phases one and two, combined with the 
analysis/synthesis of the international guidelines. 
The meetings were divided into two parts. In the first half, I provided a few 
minutes of introduction in the form of PowerPoint presentation slides (see Appendix 
10). The main aim of this introduction was to set the context for the discussion by 
giving participants an idea of the research and its objectives. It was carefully 
structured so as to not give any information about the interim results nor my own 
views on what the issues were, so as not to bias or lead the discussion. The topic 
guide for this phase was structured to concentrate discussion on the Saudi 
regulations, and on how the participants thought MGE research should be governed 
in the light of the existing regulations. The main topics addressed were the 
participants’ perceptions of the challenges of MGE research in Saudi Arabia, how 
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the policy addressed those challenges, how the participants thought the donors for 
MGE research regarded their participation, and who they thought owns the collected 
genetic material. The second half of the meeting was designed to obtain the 
participants’ reactions to the interim findings of Phase One and two (see Appendix 
10). Discussion was preceded by a short presentation of the results and guided by a 
series of open questions and prompts (Appendix 11) 
Group 1: Twelve potential participants were approached in each of the three 
clinics by senior coordinators who set up meetings with the potential participants so 
they did not feel any pressure to express themselves. During these meetings, an 
invitation to participate in the study was extended, and information sheets with the 
researcher’s contact information were provided for the staff members who wished to 
take part (Appendix 12).   
Group 2: Twelve potential participants were approached. As the potential 
participants were all high-profile leaders, their contact information was already in the 
public domain. I initiated first contact via phone as per Saudi cultural tradition (a 
telephone conversation is much more valued than any other means of contact). After 
the initial contact, an email with an invitation letter and information sheet was sent 
(see Appendix 13 & 14). The invitee would then decide whether or not to participate 
in the study by replying to this invitation.  
5.2.5 Analysis  
The analysis plan in qualitative research should match the main research 
purpose (Krueger and Casey, 2000; Miller and Crabtree, 1992). My analysis strategy 
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was oriented towards informing the normative claims related to the research question 
(Maxwell, 2012; Caudle, 2004). 
During the early stages of the data collection process I started to develop 
certain thoughts about the study’s emerging themes and coding process. I considered 
this early stage of familiarisation as essential to keep a strict rigour and not to jump 
too quickly into the comprehensive analysis, as this might drive the data collection 
away from an acceptable level of objectivity. This was also a very essential step in 
developing early interim analysis. 
5.2.5.1 Interim analysis: 
In each phase, and after in-depth familiarisation, an interim analysis process 
was used to inform the subsequent phase by enhancing the topic guide and adjusting 
my expectations of the knowledge of MGE research among the research participants 
in each phase. Interim analysis was used in the early stages to gain an initial 
understanding of what could emerge as themes from the collected data after Phases 
One and Two. In general, Interim analysis provides qualitative research with the 
ability to generate preliminary hypotheses about collected data, the ability to go back 
and refine the questions and pursue inquiries in more depth. Interim analysis in the 
context of this thesis was used strictly to empower the empirical arm of this project 
by giving the ability to check and interpret the data to develop general, more realistic 
expectations for further data collection from phase to phase. (Pope et al., 2006). 
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5.2.5.2 Observation Data Analysis:   
It is important to acknowledge that in observation work the data have already 
been reflected upon through the process of writing up the field notes. Despite the 
best efforts to report only the concrete facts, ideas are generated and impressions are 
gained during the observation stage itself. These early interpretations of what is 
witnessed have been perceived by some commentators to complicate the relationship 
between data collection and analysis (Ives & Damery, 2014). To overcome that 
challenge, as I described in Subsection 5.2.2 Phase One- Observation, I remained 
focussed on the main aim of the observations, which was to witness the actual 
behaviour of the stakeholders in their natural environment in a rigorous way. This 
dictated writing the field notes using dispassionate description as much as possible, 
as described by Allen (2010), (as cited in Ives & Damery (2014)).  
The analysis approach was selected to answer specific research questions. The 
strategy was to use data coding, which enables normative claims to be assessed and 
analysed. Therefore, the approach, in general, was very pragmatic insofar as it was 
aimed at exposing the normative values from the interpretation of the observed 
practice. In this phase, I used Wolcott’s (1994) approach of describing, analysing and 
interpreting the collected data. Creswell (2012) recommended such an approach to 
analyse observations, field notes or ethnography reports, because this approach gives 
the researcher the ability to better understand the culture dynamics. Although my 
thesis is not based on pure ethnographic methodology, Phase One was designed to 
include passive observations, to understand how MGE research takes place within 
the Saudi culture.  
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The first step was describing the data to allow the reader to see the events 
through my eyes by way of narrating, in as much detail as possible, both the setting 
and the events (Wolcott, 1994). In this step, I produced the field notes from what I 
could remember after each observation session (see Appendix 1 for an example) with 
the limited help of very few but, as I thought during the observation, essential 
preliminary field notes. These limited preliminary field notes were written during the 
observation in Arabic language with only codes and abbreviations. They were only 
used to help drafting as detailed as possible field notes and were shredded after the 
final field notes were produced. The field notes formed the data that were analysed. 
It was important to be fact-oriented rather than interpretive at this early stage.  
The second step was analysing the data through a sorting procedure (Wolcott, 
1994; Creswell, 2012). This included highlighting patterns and events in the 
observed setting in a way that provided answers to the research question concerning 
the adherence of Saudi researchers to the Saudi research guidelines. The highlighted 
patterns were then coded in preparation for interpretation.  
The third step was interpretation, which was a means to going beyond the 
scope of the collected data in order to understand what the data were actually saying 
(Wolcott, 1994; Creswell, 2012). In this step I used Wolcott’s (1994) interpretation 
stage to make sense of the coded patterns and to suggest themes to explain those 
patterns.  
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5.2.5.3 Phase Two analysis: 
The final, more comprehensive analysis for Phase Two was a pragmatic 
reasoning through inductive-deductive logic (LeCompte and Schensul, 1999; Hatch, 
2002; Marshall and Rossman, 2010, Creswell, 2012). The inductive, or bottom-up, 
approach was used after each phase. It allowed the data to develop suggested themes 
without the influence of any theory-testing approaches in a way similar to that 
described by Notley, Green & Marsland (2014). Such an approach revealed the need 
to work extensively with the data to abstract the inherited normative assumptions in 
the forms of themes; this also meant that I had to go back and forth between the data 
and the emerging themes until a thorough and robust set of themes was developed. 
Deductive reasoning was mainly employed in Phases Two and Three. A top-down 
approach was used to test emerging themes against the collected data, in the sense 
that themes that emerged from the interim analysis of Phase One were used to 
explore data collected from Phase Two, and the interim themes that emerged from 
Phase Two were used to explore data collected from Phase Three(Creswell, 2012).  
In Phase Two, the most appropriate approach, given the nature of this phase, 
was to engage in data interpretation to allow a data-guided analysis or bottom-up 
approach, following the pragmatic approach of thematic analysis, as suggested by 
Notely, Green & Marsland’s (2014) approach. This was done as follows: 
 Familiarisation: Reading and rereading the data was the first step. During this 
extensive familiarisation process, I tried to gain an overview of the study that 
was broader than any interviews. I sought to understand what the participants 
were trying to say while considering the normative assumptions that may 
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guide their responses. Examining the data in this way gave me a sense of the 
richness, depth and diversity of the data and guided the process of 
conceptualising, which helped prepare for the coding step.  
 Coding: After this familiarisation step, I started to organise a coding system. 
The coding was done so as to reflect the meanings in parts of the data (Coffey 
and Atkinson, 1996). In certain cases, the same portion of text was coded in 
two different ways depending on what the participants stated and how I 
understood what was stated, which might give more weight to a statement 
than what was intended (Miles and Huberman, 1994). I started first with free 
coding - coding the data as I read through them. I then transferred the codes 
into NVIVO software version 10.  
 Theme development: The codes and concepts were allowed to emerge into 
themes by grouping codes and concepts in a way that provided explanations 
for the data segments.  
 Thematic networks: The themes at this stage were starting to take a more 
mature shape, by connecting them and trying to find similarities and 
differences for better understanding of what was said in the interviews. 
 Integration and interpretation: interpreter approach allows explanations of 
those themes through the ‘reflexive stage of thematic analysis’ (Notley, 
Green & Marsland, 2014, p333). 
During the analysis progressing stage, I managed to ‘shuttle back and forth 
between conceptual speculation, reflection, reading, data collection and analysis’ 
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(Williams, 2004, p77), especially in the steps of ‘thematic network’ and ‘integration 
and interpretations’ steps for a more thorough and reliable data analysis.  
5.2.5.4 Phase Three Analysis 
At this stage, it was very important that I looked at all the data from each phase 
as a complete set before beginning to sort through it for the analysis of Phase Three. 
At this point, I read and reread the field notes, listened to the interviews and focus 
group recordings several times, read the Arabic and the English versions of the 
interviews and read the focus group transcriptions. This process of in-depth 
familiarisation helped to remind me of the bigger picture as the starting point before 
the detailed analysis of Phase Three. 
It was important to analyse this phase of the data in a similar way to Phase 
Two to maintain consistency for better understanding of the themes from the 
previous stage and from the discussion in the focus groups. The only difference at 
this stage was the coding step. I used a two stream strategy similar to Ives (2007). In 
the first stream, the coding was done in an unstructured way, or free coding, as the 
data were taken at face value without any attachment to the previous phase’s data set. 
The qualitative software analysis NVIVO software version 10 was used for the 
second stream and ‘aimed at standardising the codes so that the groups could be 
compared and analysed using the same conceptual framework’ (Ives, 2007, p167-168). 
The first stream’s code numbers were not changed or altered, and during the 
second stream, the codes that were removed were those that had been replicated or that 
could be merged into an existing code. Although the two stream coding was labour-
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intensive, it was deemed to be the most advantageous approach for the following reasons 
(Ives, 2007): 
 It provided sufficient conceptual flexibility to ensure that the analysis was not 
developed in a way that was conceptually committed to the previous phase’s 
outcomes. Nevertheless, it was rigorous enough as a pragmatic framework to 
ensure consistency. 
 It helped to decrease the chance of bias by maintaining a level of objectivity by 
thinking, rethinking and considering other, more objective coding.  
 Coding in this way reduces the temptation of forcing data into codes that did not 
actually fit.  
 It provided a chance to evaluate and re-evaluate my codes by starting with a free 
list of codes and then looking at them thoroughly to keep, merge or discard them 
during the second stream.  
NVIVO software was used as a tool to manage and organize the data, but it did 
not do the analysis. The researcher in qualitative research is the one who is fully 
responsible for asking the right questions and for extracting the answers that the data 
best provides through interpreting and choosing the segment of data that is to be coded 
(Bringer, Johnston, & Brackenridge, 2006). 
5.2.6 Validation and trustworthiness  
As qualitative data analysis is interpretative in nature (i.e., it depends on my 
own interpretation and understanding of what the participants said) at every stage, I 
made sure to challenge the findings of the study’s earlier stages whenever possible. 
The study was designed to allow each phase to inform the phase that follows it in 
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order to challenge the data’s validity. Therefore, the three phases themselves were a 
form of validation in the sense that I observed one group, interviewed another group, 
and then ran focus groups. These are three different ways of gathering information in 
the practice, which can be seen as a form of triangulation in the sense that I used 
multiple sources of data (Richards and Morse, 2012). 
Peer review was also employed in two stages, the first during the translation 
process by a bilingual qualitative research expert and again after the data analysis by 
my project supervisors, who independently coded the interviews and checked the 
analysis of the focus groups. The main goal of the peer reviewers was to ‘[keep] the 
researcher honest; [ask] hard questions about methods, meanings, and 
interpretations; and [provide] the researcher with the opportunity for catharsis by 
sympathetically listening to the researcher feelings’ (Creswell, 2012).  
5.2.7 Ethical approvals and permissions 
This project was approved by the following research committees: 
- The Science, Technology, Engineering and Mathematics Ethical Review 
Committee, University of Birmingham, Reference Number: ERN_12-1394, Date of 
Approval: 06/02/2013, 
- Human Ethics Committee/Institutional Review Board, King Khaled Eye 
Specialist Hospital, Reference Number: RP 1319-P, Date of Approval: 10/03/2013 
- Institutional Review Board, King Abdullah International Medical Research 
Centre, Reference Number: RC12/090/R, Date of Approval:  26/03/2013.  
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6 Chapter Six: Results 
6.1 Introduction 
This chapter will present the findings from the three phases of empirical work. 
The first subsection presents my interpretation of what was observed in Phase One. 
In the second subsection, I present the results of the Phase Two interviews. The third 
and fourth subsections of this chapter were built on the same coding, quoting and 
correction techniques used with Phases One and Two. These subsections show the 
results of the first and second focus groups. 
6.2 Phase One: Passive observation of informed consent processes 
The original intention during this phase was to observe the interviews during 
which potential blood donors for MGE research were interviewed, in the three major 
hospitals that do the majority of the recruiting for Saudi MGE research. Although 
these hospitals are all in Riyadh, they can be regarded as representative of the whole 
kingdom because they receive patients and referrals from across the country.  Two of 
the three hospitals’ research ethics committees approved the research. However, the 
third hospital’s committee procrastinated, and no final approval was forthcoming. 
Some of those who participated in Phase Three had experience working there. They 
confirmed that the practices reported in Phases One and Two reflect practices in the 
third hospital. 
6.2.1 Demography 
All observations took place in two different institutes, both of which have 
active, busy research departments and multiple genetic studies involving 
international collaborators. 
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TABLE 6-1: THE TWO RESEARCH SITES  
 
First hospital  Second hospital  
Specialty Ophthalmic – specialised  General – specialised  
Reference  Ministry of Health  Military hospital 6 
Capacity  400 beds  600 beds 
Branches in other cities  No  Yes 
Researchers’ education Weekly grand rounds  Many education programs  
MGE specialised 
laboratory  
Yes   Yes 
MGE research 
international 
collaboration  
Yes Yes 
Strict patient eligibility 
system  
Yes  Yes  
 
6.2.2 Observations 
In the Saudi culture, as explained in Chapter One, people usually attend their 
clinic appointments as families. Therefore, it was part of the natural sequence of 
events that the research teams held these interviews with families rather than with 
individuals. In the methodology subsection, I proposed that my involvement at this 
stage was very passive, meaning that I did not interfere with the natural sequence of 
events. When the research teams called for the patient, I followed the family but 
waited outside while the research team made sure that the patient had seen the poster 
and that he or she did not mind my presence, as noted previously as part of the verbal 
consent of Phase One.  
                                                        
6 This hospital treats not only personnel and their families but also other Saudi and 
non-Saudi nationals, based on specific eligibility criteria. 
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The research teams from the two hospitals requested verbal consent for me to 
observe the process of donating blood for MGE research. Of the total of eleven 
patients/families, only six agreed to be observed for this study.  Of the five who 
refused to be observed; only two families eventually donated blood.  
Six families were invited to participate in the first hospital, and four accepted. 
All four agreed to donate blood, to two different MGE projects. These research 
projects were managed by two different PIs with two different Western international 
collaborators. Of the two families who did not agree to be observed, one family 
eventually donated blood, and the other refused because they needed to catch a plane 
back to their village. As I explained, I was not in the room with the research team 
during the process of gaining verbal agreement to have the consent interviews 
observed. However, I saw the families being greeted in the corridors before they 
went inside the rooms. The appearance of the families who refused to participate in 
my research suggested that they were relatively affluent. For example, they wore 
expensive, clean clothes, and the expensive and strong Arabic oil perfume called 
Oadh. Both families spoke with the nurses in very clear English with American 
accents. 
In the second hospital, five families were approached regarding observation, 
and only two accepted; both donated blood for two different MGE research projects. 
Only one of the two observed donations went toward a project that had a PI with a 
Western international collaborator. Of the three families who did not agree to be 
observed for this research, only one family eventually donated blood. Unlike the 
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other hospital, the three families did not look significantly different to the observed 
patients.  
6.2.3 Phase One findings 
6.2.3.1 Describing the recruiting procedure 
With minor exception, the recruiting procedures were the same in both 
institutions. 
In all the observations of this phase, I noticed that the PIs or the MGE research 
were the treating physicians. This means that technically each of the PIs managed 
both teams: the research team and the medical team. To avoid confusion in this 
section, I will refer to research team personnel as ‘research team representatives’ or 
‘researchers’. The researchers usually report to the PI, who assumed responsibility 
for conducting the research. The PI was usually patients’ first point of contact. 
 
FIGURE 6-1: THE PI ROLE IN BOTH TEAMS ................................................................................  
 
In all my encounters, research teams had access to the list of outpatient 
appointments and knew in advance which patients would be targeted for recruitment. 
Printouts of the appointment lists were typically prepared a day before each clinic.  It 
PI is the 
treating 
physician 
Research 
Team 
(RT)
Medical 
Team 
(MT)
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was also the usual practice that on the day of a clinic, research teams would make the 
medical teams aware of which patients were of particular value to them. At that 
stage, patients had not yet been contacted. The research teams also reminded treating 
physicians to expect patients of particular interest for research in that day’s clinics. In 
addition to that, the patients’ files were flagged to remind the treating teams (i.e., 
doctors and nurses) to confirm each patient’s presence to the research team, and 
serve also to remind treating physicians of the patient’s importance. 
The research teams then waited for the doctor’s signal that a patient is ready 
for recruitment. I noted a general assumption among the waiting research teams that 
the doctors had informed the patients about the research and invited them to 
participate in it. Subsequently, I have confirmed with the research teams that this was 
usually the case. When the doctors contacted the research teams with the patients’ 
agreement in principle to participate, the research teams went to the outpatient clinics 
with a prepared set of documents, mainly national and international bilingual consent 
forms. 
In all the observed interviews, after the treating doctor contacted the research 
teams, the researchers brought the patients and their medical charts from the clinic in 
which they were seen to a nearby clinic in the same facility. They then began by 
confirming the patient’s name and date of birth.  See figure 5-2. 
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FIGURE 6-2: SUMMARY OF THE RECRUITMENT PROCESS 
All patients were asked to sign consent forms during their interviews with the 
researchers. This fact makes it relevant to recall the consensus in the literature about 
the validity of informed consent. In very general terms, for informed consent to be 
ethically and legally valid, the person who gives it must meet three main conditions. 
He or she must be: 
One day before patient's 
arrival 
•RT anticipates patient by 
reviewing outpatient 
clinic's records
•RT accesses targeted 
patient's medical records 
and flags them with a 
note to the MT to 
contact the research 
centre when patient 
arrives
•RT contacts the PI with 
a list of the anticipated 
patients
During patient's clinic
•RT visits the clinic and 
makes sure that the PI 
and his MT are aware of 
which patients are 
expected
•Records of patients who 
arrive are immediately 
checked by the MT for a 
flag requiring RT 
contact upon their 
arrival 
•MT contacts RT letting 
it know that a targeted 
patient has arrived
•When the RT is 
contacted, it starts 
preparing the paperwork 
for the patient's 
enrolment 
•PI opens the donation 
subject and agreement in 
principle to donate blood
•The MT informs the RT 
that the patient is ready 
to be recruited 
After patient's clinic 
•RT rushes to the clinic 
with the consent form 
and enrolment papers 
•RT interviews the 
patient to confirm the 
patient's identity and that 
approval was given to 
the PI during the clinic
•RT finalises the 
informed consent 
process and arrranges 
for blood extraction
•RT updates its records 
and sends the collected 
blood to be processed
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- Capable: the consenting person should have legal capacity to decide for him- 
or herself, 
- Acting voluntarily: consenting persons should freely decide without coercion, 
and 
- Informed: consenting persons should be given sufficient relevant information.  
It is also important to mention, as I argued in the first Chapter, that those 
elements seem based on Western normative assumptions about autonomy, 
individualism, free choice, free will, and liberalism. In this phase, in the instances I 
observed, data emerged that seem to contradict each of these three elements of 
informed consent. These contradictions seem to stem from a difference in the 
overarching normative relevant assumptions due to cultural differences. 
 
FIGURE 6-3: SUMMARY OF THE THEMES ARISING FROM PHASE ONE 
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6.2.3.2 Coercive practices 
The main challenge in interpreting the concept of coercion in the context of 
this work was that the concept of coercion, as opposed to its application, is culturally 
bound. There may be a mismatch between what Saudi patients perceive as being 
coercive and what, for example, UK patients might perceive as being coercive (as in 
SA patients expect greater direction, and paternalism is not necessarily regarded as a 
bad thing (see Subsection 1.2 The Saudi Arabian Context.)) People from different 
cultural backgrounds might, therefore, understand the term to mean the same thing, 
but if asked whether or not it would be appropriate to apply the term to the same set 
of scenarios, they might not all apply it to the same scenarios, depending on their 
cultural background. Equally, they might understand the term to mean the same 
thing, but some people might say ‘Its coercion and that’s bad’, and others ‘Its 
coercion, but what’s wrong with that?’. So, the normative meaning of the term might 
also be culturally different. According to the Saudi guidelines, and therefore the law, 
the donation of blood for MGE research must be voluntary or else it is unethical 
and/or illegal. The challenge in the observed cases is in how our framing of the 
context affects what appears to be coercion and what does not. In philosophy, what 
constitutes coercion is not fully agreed upon (Hasken, 2007). Based on the 
philosophical literature, there seem to be two different means of coercion. The first 
has to do with the techniques that are used to coerce a person, and the second has to 
do with the reasons a person might feel coerced (Anderson, 2014). The coercion here 
was not coercion by physical force. Rather, it was through the use of techniques that 
could be described as actively deceptive and through tactics that would usually 
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coerce patients, like the choice of the people who asked for patients’ consent and the 
speed at which patients were required to make choices regarding consent. 
Some patients were not sure about giving blood. With these patients, 
researchers assumed a salesman-like attitude.  Although they always began by stating 
that the patient was not obliged to give blood, they usually coupled that statement 
with stronger statements in support of participation, such as ‘Doing this will be 
written to your name in the hereafter’. Patients were also told that they would be 
pleasing God with their donations. Researchers usually finished by giving 
confirmation that the patient would be the first to benefit if something positive came 
out of the research. On one occasion, a family member told the researcher, in a 
sarcastic tone, that it was obvious to him that the researcher was desperate to have 
the blood withdrawn. They both laughed and the researcher’s reply was to tell the 
patient that it was not up to him; it was the doctor who wanted it this way. Assuming 
a hard-sell attitude, the researchers often seemed to be eager to finalize donations. It 
was not acceptable in either hospital to pay patients to participate in the research. 
Thus, the researchers used non-monetary incentives as tools to persuade patients to 
donate. For instance, in every interview I observed, the research team used the 
patient’s faith or belief system to convince him or her to donate. For example, 
patients were told that their participation would please God. In the Saudi context, 
charity is a means for devoted Muslims to please God, or at least to help people look 
like devoted Muslims. Researchers used terminology such as ‘eternally running good 
deeds’, meaning good deeds that continue to reward the person even after his or her 
death. These types of deeds are some of the most respected and pursued good deeds 
amongst Muslims. Again, it could be the case that the researchers truly believed that 
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they were obliged to open the eyes of fellow Muslims to an opportunity to change 
their destinies in the hereafter, which is all that matters in the devoted Muslim’s life. 
However, there is a very thin line separating persuasion from using religion as 
coercion. Muslims believe that on occasions where the needed charity is going to 
have huge impact on someone’s life, the charitable action become an obligation and 
that if you do not do it, it is a sin. For example, if someone has plenty of food, if a 
starving person asked him personally for some food for his/her survival, it is not a 
charity any more. It becomes a sin if not done. I believe that researchers crossed that 
line when they allow the idea that donation would be charitable to escalate to the 
assumption that it would be sinful to not participate in the research as people are in 
grave need. 
(a) Deception 
There is not space in this thesis to provide a full exposition of the concept of 
deception. Instead, I will present what I take deception to mean and then apply this 
understanding to the data I gathered. Deception contributes to enforcing a false belief 
either by an active action (e.g. telling a lie) or a passive action (e.g. failing to correct 
an untrue belief). Some of the behaviours I observed were clear examples of lying: 
potential research participants were apparently deliberately misinformed. In other 
instances, information that may have affected their decision was withheld and/or 
false beliefs, that seemed to be inclining them towards donation, were not corrected. 
It is also important to state that I am aware that coercion and deception are two 
different concepts and the meaning and acceptability of both are contested. However, 
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in the context of this thesis, I noticed that deception was used as a tool to coerce 
people in to donating blood for MGE research. 
A part of this work’s overarching aim is to understand how Saudis perceive 
MGE research. This requires an understanding about what happens between 
researchers and research participants in MGE research in Saudi Arabia. People could 
donate blood for various reasons, but according to the Saudi national and analysed 
international regulations, there is an emphasis on the choice of research subjects to 
be free from undue influence and free from ethically problematic exploitation (see 
Subsection 2.3.1.3 Avoid Local Research Subject Exploitation). It could be 
suggested that the research participants were deceived in cases such as donating 
blood for MGE research based on misleading information, lying or the creation of a 
situation where patients felt that the only reasonable option was to donate. 
This theme provides a means of interpreting how certain actions might lead to 
coercion. The main concern was to analyse at a deeper level what was said, in 
context and what it might mean to the patient. The notion of deception has not gone 
uncontested (Mahon, 2015). Mahon suggests that ‘deceiving is necessarily 
intentional, requires that another person [i.e. the deceived person] acquires or 
continues to have a false belief, and must involve the agency of the deceived person; 
and the deceiver must know or truly believe that the false belief that the other person 
[i.e. the deceived person] acquires or continues to have is false’ (Mahon, 2007, 
p181). In the context of MGE research in Saudi Arabia, the above definition can be 
divided into two. The first part concerns the beliefs that the donor acquires about 
his/her donation. Based on the observed level of communication and whether the 
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donor was informed about the research, the voluntariness of the participation, the 
risks of MGE research and how privacy would be protected, it can be claimed that 
evidence gathered during the observed recruiting interviews fulfilled the first part of 
the deception definition as per Mahon (2007). 
The second part of Mahon’s (2015) definition speaks of the motives and 
actions of the research teams and whether they intentionally reinforced the donor’s 
false beliefs or provided misleading information about the donations. This part is not 
easy to categorise because in some cases it is intention-based. For example, if A 
allows B to believe that certain action (or lack of action) would bring about a specific 
unwanted outcome, and A genuinely believes that his claim is true, it could be highly 
contested to rate A’s action as deceptive if A’s claim is mistaken. However, I will 
assume that the research teams have been trained to know that informed consent to 
participate in research is an essential pre-requisite to their involvement in research. 
In general, the challenge in looking at the account of deception is that it indicates an 
intention to mislead, which is problematic. I am unable to comment on the 
researchers’ intentions because I do not have data that enables me to make such 
comments. However, some of the observed cases gave a reasonable indication of 
deception, as I will evidence in this subsection. 
It is important to differentiate between two levels of persuasion; the first could 
be regarded as legitimate persuasion arising from the recruitment activity and with 
stress upon legitimate reasons for encouraging participation. Assuming that there is 
ethical approval, which was the case in all the observed sessions, legitimate reasons 
are the ones used to justify the research in the ethically approved research protocol. 
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The other type is what I inferred to be problematic persuasion, which is making the 
decision for the research subject, as opposed to allowing the subject to decide for 
himself, and then to say and do only whatever makes the research participant give 
the blood.  
I felt that some of the techniques research teams used to convince patients to 
donate observed during this phase could be categorised as coercion by deception, as I 
think patients were led to believe that they had to donate. Taking that limitation into 
consideration, I tried to use my judgment about where the research teams seemed to 
cross the line between legitimate persuasion and coercion. I used that information as 
a starting point to think about what would seem like coercion by deception (i.e., 
omitting information or giving wrong information) if it took place in UK. For 
example, where there are different levels of education, different levels of stress on 
the clinic waiting lists, and a normative presumption of informed consent based on 
free will. I will further differentiate between those whom I think were misinformed 
and those who were not informed at all. 
1) Misinformation 
On one occasion, a patient told the researchers that the PI had told her that her 
participation was for her own sake and would improve understanding of her own 
medical condition. The research team member conducting the consent interview 
agreed with this assertion. He added that informed consent was needed because of 
the extra work required for the sample and added that it was not a big deal. In that 
encounter, nothing was said about research, which, I believe, made the patient think 
that the blood was for clinical use, not research. The researcher in this encounter 
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failed to correct a false believe as well as providing false information. Both are 
problematic. The deception in this case occurred in two ways, and both of them can 
lead to the conclusion that patient’s consent was not voluntarily given 
Furthermore, no patients in the interviews I observed were given verbal 
information about the risks of participation. Instead, because the word ‘risk’ was 
included in the consent form, the researchers suggested that the risks referred to were 
those involved in extracting blood. This initiated a discussion about venepuncture. 
The researchers assured patients that they ‘will be taken care of’, and they ‘have 
nothing to fear’, as the technicians were very well trained in blood extraction. There 
was no mention of other risks that ought to be considered in the Saudi context such 
as stigmatisation. If the researcher genuinely believed that the only risks were in 
venepuncture, perhaps because the risk of stigmatisation had not occurred to them, 
then their practices fail to meet the second part of Mahon’s definition of deception, 
namely that “the deceiver must know or truly believe that the false belief that the 
deceived person acquires or continues to have is false” (Mahon, 2015, p181).  
Another example of misinformation occurred in the observations of over-
promising the benefits of the research. In the interviews I witnessed, all patients were 
promised that they would be the first to benefit from research in which they 
participated. The main problem with that claim is that, for most of the MGE research 
that I witnessed, there would be no tangible, foreseeable benefit other than increasing 
scientific knowledge about mutations. Thus, the promise of a tangible benefit might 
give the patient the false hope that something would be specifically tailored to his or 
her needs. On the other hand, the idea that we might benefit from some particular 
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research is a widely acceptable motivation for participating in it, both in Eastern and 
Western contexts (TallBear, 2013). In the context of the observed recruiting sessions, 
over-promising can be rated as misinforming. 
2) Not informed 
The other side the deception theme that emerged from Phase One was that of 
lack of information. The difference between this theme and the previous one is that 
this one highlights a paucity of information and the previous one pointed to 
misinformation. 
The Saudi guidelines spell out the general areas about which information 
should be provided. This includes information about risk, yet as we have already 
seen patients were not informed about all the risks. 
Withholding information may influence a patient’s decision to donate. The 
observed sessions lasted between 8 and 17 minutes. In the shortest interview, the 
time was spent signing the paperwork, verifying the patient’s personal details and 
extracting the blood. The interview started and ended without mentioning any details 
about the research apart from confirming that the patient was there to donate as per 
the doctor’s request (i.e., the PI’s request). The exact words used by the patient were 
‘The doctor told me that I have to do it, so I am doing it’. The researcher and his 
assistant seemed relieved, and they made no effort to provide any further 
information. In contrast, the maximum time spent with a patient was 17 minutes. 
This was, however, because the researchers wanted to have some more clinical 
information and to trace aspects of the patient’s family’s medical history before 
drawing blood. 
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Though patients were donating blood for genetics research, I did not see or 
hear anything about genetics research in the course of my observations. This limited 
the range of possible interpretations available to me. One option is that patients did 
not need any additional information about genetics research. This seems unlikely 
because of the apparently low level of education among these patients. For example, 
one of them was not able to read the Arabic word ‘genetics’ correctly on the consent 
form. He was given the informed consent document after the researcher attempt to 
summarise it in few words with the attitude that ‘this is just the normal paperwork 
procedure’. To the best of my understanding, according to how the patient behaved 
(i.e. looking at the paper, misreading most of the words, and not helped even in the 
form of correcting how some of the words should be read), he was not sure what he 
was actually signing. After the patient signed, he was asked to come with the 
researcher to the lab for the blood extraction, but he seemed not sure why, telling the 
researcher he just gave blood a few weeks ago for his routine six month follow up. 
The other possible interpretation is that the information imparted was insufficient to 
prompt even basic inquiries. This, too, would have led to silence on the topic of 
genetics in the discussions between researchers and donors. 
Under Saudi guidelines, researchers should provide patients with the informed 
consent form (which includes the needed information) with sufficient time to digest 
the information before the form is to be signed, and patients should receive a copy of 
the signed informed consent form afterwards. The use of separate information sheet 
is not common in Saudi Arabia, as it in the UK. The Saudi regulations stipulate that 
the informed consent document should contain all the necessary information in 
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detailed and precise elements described in details in the NCBE guidelines. The 
assumption is that providing the documents in advance will ensure that patients have 
time to read and understand the information provided. In the sessions I observed, 
patients were not provided with the informed consent sheet in advance, nor given a 
copy of the consent form to keep, bearing in mind that the information sheet and 
informed consent were produced as one document in all of the observed sessions. As 
a result, those patients were more susceptible to being deceived as they would have 
no means of checking what they were told against the ‘formal’ information they 
should have been provided with. 
Given that fewer than ten minutes were allotted to patients for their clinical 
appointment, during which time it appears they were also asked to donate blood for 
research, it may be reasonably inferred that most treating physicians were merely 
asking their patients to provide a blood sample, without further elaboration. The 
researchers were the patients’ other source of information. In the interviews 
observed, commonly a few minutes of general information about the importance of 
research was provided that was not related to the patient’s participation On one 
occasion I observed, the patient was visually impaired. The researcher guided his 
hand to the place where the signature was needed on the consent form. The patient 
was not able to read, and the informed consent form was not read to him. In that 
encounter, it seemed that having the patient’s signature was all that mattered. It is 
difficult to regard this person as having been informed. According to Mahon’s 
definition, this can be seen as deception because, I think, the deceiver knew or truly 
believed “that the false belief that the deceived person acquires or continues to have 
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is false” (Mahon, 2015, p181). In fact it is a deception on two different fronts: a) 
deceiving the patient when he was prompted to sign a document whose contents he 
could not possibly know, and b) deceiving the hospital’s efforts at quality assurance 
by auditing the consent forms, where the hospital would assume that the patient had 
at least an acceptable minimum of information about what he had signed. 
(b) Who asked 
I observed that the treating physicians seemed to be actively participating in 
the process of obtaining consent. I did not observe the initial contact between the 
patient and the physician-PI (this was the patient’s clinical consultation). In all of my 
observations, however, treating doctors had already made an initial request to 
patients that they donate blood. In five observations, patients said that the treating 
physician asked them to donate to research projects in which the treating physician 
was part of the research team. This practice contravenes the Saudi guidelines; if the 
treating physician is a researcher on the team, he or she should not ask patients to 
participate in that research. Moreover, the patients I observed were asked to donate 
during long-awaited medical follow-up appointments. In one observation, the 
treating physician appears to have told the patient to give blood for extra testing, 
rather than informing him that it would be used for research. 
(c) Rushing 
All of the consent interviews I observed seemed to me to be rushed. For 
example, researchers talked quickly, using jargon without explaining things, and 
some of them started the interview by saying that this should only take 10 minutes. 
As reported above, the interviews were indeed fairly brief (8 – 17 minutes, mean = 
  
 
 
 
165 
11). In 11 minutes on average, patients were greeted, introduced to the research 
team, had their identity confirmed, it was confirmed that they knew about the blood 
extraction, the consent document was signed, and they were escorted to a lab the 
blood extraction took place. From what I observed, it seemed to me that the 
researchers were rushing the informed consent procedure to the extent that it affected 
the quality of the informed consent taken.  
In general, time is needed to give the research participant the opportunity to 
think calmly. This suggests that insufficient time to decide was given to the 
participants, which may have resulted in the patients feeling coerced by the stress of 
rushing the decision to donate. The length of time of the interviews might not 
indicate deliberate coercion because it could be that the researchers were working on 
a tight schedule to provide the most efficient and pragmatic service possible. It is 
also important to say that even if rushing the recruiting session wasn’t deliberate, it 
might still have had a coercive effect. Based on that, given that the limited timeline 
for patient’s interaction with researchers or the PI, it raises questions about coercion, 
in the sense that there was no room for the participant to reflect upon their decision. 
6.2.3.3 Obstacles, challenges  
Another important theme that can be traced through my observations relates to 
difficulties encountered in the recruiting process. I noticed that patients mostly came 
from remote areas and expressed concerns about the follow-up appointment, which 
reflects the general characterises I explained in the chapter about the Saudi context 
(see Chapter Four.) Patients were eager to secure follow-up appointments. Lack of 
organisational support (i.e. no specific clinics was dedicated to research recruiting 
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and researchers had to recruit during the clinic time) seemed to emerge as a theme 
mainly as a function of being poorly organised. It also seems that there were no 
specific, institutional guidelines for the venues in which clinical research can take 
place. For example, five of the six observed interviews took place in very small 
clinic rooms. The clinic rooms were originally designed to accommodate a maximum 
of three people. However, on one occasion, a room was crowded with seven people, 
including the researcher, a technician to take the research participants to the lab for 
blood extraction, the patient, the patient’s relative, two children and me as the 
observer. 
Another challenge was in the design of the rooms where consent interviews 
took place. These were designed as large, open spaces (about 10m by 10m) but were 
subdivided into smaller rooms with very thin wooden walls and no individual 
ceilings. This means that any discussion in neighbouring rooms could be clearly 
over-heard. Three of the observed interviews were conducted while other patients 
were in the next room.  I suspect they could overhear us for two reasons. First 
because I could clearly hear everything said in the other room, so presumably people 
in that room could hear us equally well. Secondly, on the occasions where the 
participants refused to let me attend the informed consent session, I had the 
opportunity to hear the discussion if I wanted to but I decided to leave the clinic and 
return back to the office fearing that I might hear something that would influence my 
interpretations in a way that it should not. It was the case to the extent that one of the 
researchers was saying, as a joke, that I do not really have to be inside the room to 
record the conversation. 
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It could be the case that this was the best that could be provided by the hospital 
due to the lack of available resources. These were the clinic rooms, therefore 
presumably clinical contact also took place in this environment so it wasn't that 
lesser standards were in operation for research but rather the standard in general fell 
short of that necessary to protect confidentiality. A lack of resources is a general 
problem in Saudi Arabian clinical environment, and, accordingly, research funders 
might also suffer from a lack of resources. However, it is important to consider how 
best to distinguish between pragmatic solutions that are appropriate responses to 
current challenges, and responses that might affect the quality of the recruiting 
process. Large numbers of people in small places can affect research participants. It 
is difficult for people to make a decision that is entirely their own in front of an 
‘audience’. Privacy not only ensures confidentiality, it also enables potential 
participants to decide without the sense of being judged by others or acting on 
perceive peer-pressure.  
6.2.3.4 Patient vulnerability 
(a) Vulnerability 
In this work, the definition of vulnerability as per the Saudi NCBE regulations 
will be used, which is “individuals in need of additional protection for being minors, 
legally incompetent, or deprived of freedom of choice” (NCBE, 2010, p7.) This 
definition seems too pragmatic insofar as it is concerned mostly with who can be 
described as vulnerable as opposed to what is vulnerability. In order to understand 
more about vulnerability, I will use the definition used by CIOMS, as follows: 
“‘Vulnerability’ refers to a substantial incapacity to protect one's own interests owing 
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to such impediments as lack of capability to give informed consent” (CIOMS, 2008, 
p4.) This definition was chosen to complement the NCBE one because CIOMS 
(2008) was one of the main documents that inspired the Saudi regulations, as 
explained in Chapter Two of this thesis.  
Patients seemed very submissive during the six interviews. They were very 
quiet and apparently had no problem accepting both to donate and the premise that 
informed consent is just ‘paperwork’, as the researchers kept assuring them in most 
of the interviewed sessions.  
All the interviews started with the research team either escorting patients from 
the waiting area after calling for them or entering the room where patients was 
already waiting for them. In each of the interviews, a researcher arrived holding the 
patient’s medical charts and confirmed the name of the patient, exactly as a treating 
physician would do. This seems to have created the impression that the researchers 
were part of the clinical treatment team. In four out of the six interviews, patients 
complained to the researcher about different symptoms and expected the researcher 
to have answers for them. In those encounters, the researchers referred the patients 
back to the treating physician, but only after they had taken blood. 
(b) Sense of power 
Although some of the Saudi patients I observed manifested behaviour that I 
interpreted as suggesting that they were largely ignorant and helpless, this was not 
always the case. Some patients refused to participate, which suggests they at least 
knew that they were not obliged to consent. Some of them were sufficiently 
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confident not to allow me to attend as an observer. Among the group I observed, 
however, the only time a prospective participant showed signs of understanding, was 
when a relative said to one of the members of the research team who were pressuring 
the patient to donate, sarcastically, that it was obvious to the patient that the 
researcher is determined to get the blood. The tone and the look of the patient 
suggested what he thought was going on and the realization that he had something 
valuable to the researchers. It is difficult to generalise this observation, but it also 
might suggest that some patients did not feel disempowered. 
6.3 Phase Two: In-depth interviews with MGE research participants 
The observations in Phase One set the scene for Phase Two by providing 
expectations for what data might be collected. They also informed the topic guide 
that was used in the in-depth interviews during Phase Two. As a result of the interim 
analysis of results from Phase One, questions were redesigned to permit me to probe 
for richer data in the areas of revealed by those observations. It was also important to 
discover what the patients’ overall perceptions were and what they recalled from the 
recruiting interviews. The original plan was to interview 20 patients or to interview 
patients until saturation was reached. Most of the interviewees expressed concern 
about the speedy and superficial nature of the encounter, and demonstrated an 
apparent lack of understanding considering the fact that they had consented to 
participation in the MGE research. This was itself an important finding. Saturation 
was reached after 10 interviews. 
Several themes emerged from the interviews based on my interpretation of the 
data. The experiences of Phase One contributed to my interpretation.  
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6.3.1 Interviewee characteristics 
The patients I interviewed ranged in age between 34 and 72 years. In the case 
of the two oldest patients, who were 72 and 68, the patients’ oldest son and daughter 
respectively also attended the interview and participated in answering the questions. 
The education level of the interviewees varied between highly educated and 
illiterate (Table (5-2)).  In keeping with the Saudi culture, when a female donor did 
not want to be interviewed alone by a male researcher, I conducted the interview in 
the presence of a relative with whom she felt comfortable. Therefore, on two 
occasions the interview included the family member (Table (5-2)). In both cases, 
blood was taken from more than one family member with each individual’s consent. 
These cases were coded with an F for family rather than a P for person. Where I use 
quotations from these interviews I indicate the speaker as either the patient (P), who 
was the participant, or the family member, who was the accompanying person (F).  
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TABLE 6-2: CHARACTERISTICS OF THE INTERVIEWEES IN PHASE TWO 
 
6.3.2 Interview lengths 
The lengths of the interviews varied between 6 minutes and 17 minutes (mean 
= 10.5). Although the original proposal was to spend at least an hour with each blood 
donor, the interviewees did not have sufficient information to share about their 
experiences to make interviews of this length useful. Some of the interviewees were 
not sure why the blood had been taken. They also expressed what seemed to be 
confusion between my research (i.e., the interviews) and the research for which they 
had donated blood. Despite efforts to eliminate that confusion—which included 
providing an information sheet beforehand, making sure that patients understood the 
information, an introduction to the current research at the beginning of the interview, 
Code Age 
(years) 
Gender Occupation  Education  Interview 
Length 
(minutes) 
Institute  
F1 72 F&M Housewife Illiterate  17 1st Institute  
P2 68 M Farmer Illiterate  10 2nd Institute  
P3 64 M Government 
clerk  
High school  8 1st  Institute  
P4 54 M Military  High school  7 1st  Institute  
F5 60 F&F Housewife  Basic 
education  
9 1st  Institute  
P6 58 F Teacher  University  10 2nd Institute  
P7 34 F Registered 
nurse  
University  15 2nd Institute  
P8 41 F Private 
businesswoman 
University  8 2nd Institute  
P9 36 F Housewife High school  11 2nd Institute  
P10 56 M Military  High school  9 1st  Institute  
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and the process of building rapport—some interviewees still thought that I had 
something to do with their medical care. 
6.3.3 Phase Two findings 
In general, the data that emerged from the Phase Two interviews seemed to 
complement what I observed earlier. The experiences patients shared matched what I 
previously characterized as coercion either through deception, the choice of who 
asked for a donation or rushing the process. The researchers who had asked them to 
participate had clearly influenced their decisions to donate blood for the intended 
research. In addition, some of the patients seemed to understand the importance of 
the donation, to the point that they had attempted to bargain with the researchers. For 
example, they said they would agree to give blood only if the researcher agreed to do 
something in return, such as helping them to bypass the long queue at the pharmacy. 
My analysis is based on my own interpretation of what the interviewees said. 
To understand exactly what the patients were trying to say, I tried to put their 
statements in context using my knowledge and experience in the field of recruiting 
patients for research in Saudi Arabia. It is also important to note that I did not 
observe my interviewees providing consent.  
The themes that emerged from Phase Two are summarised in figure 6-4. 
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FIGURE 6-4: SUMMARY OF THE THEMES OBSERVED IN PHASE TWO 
 
6.3.3.1 Coercive practices 
Interviewees did not use the word coercion. However, they described practices 
that can be identified as at least potentially coercive. It is not common for Saudis to 
give negative, or what can be regarded as negative comments about their physician 
(Abolfotouh & Adlan, 2011; Adlan. 2013). This cultural consideration influenced my 
interpretation as to whether or not coercion was being suggested in the data. The 
difference between persuasion and coercion is blurred. In Subsection 6.2.3.2a 
Deception I differentiate between what I called legitimate persuasions and 
problematic persuasions. Therefore, I tried to analyse not only the words said by the 
interviewee but also its deeper meaning in the Saudi context. It is questionable 
whether the participants’ consent process followed the recommendations that ensures 
the three conditions of capacity, voluntariness, and information are met  
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Among the most important aspects of informed consent is that patient should 
make his or her decision freely and without coercion or undue pressure after given 
the needed relative information. The condition of being informed requires some level 
of two-way communication. Despite the fact that each culture has its own 
communication norms, there is limited tolerance for variation in the literature 
regarding how communication should be carried out in the context of providing 
information about research participation. Such limited tolerance in the literature, as 
well as in the analysed international regulations (see Subsection 2.3.1.2 Respecting 
other cultural norms), reflected strong commitment to liberal individual autonomy as 
opposed to other cultural values such as the values of community and family; such a 
strong commitment was perceived to be moral imperialism or neo-colonialism 
(Newton, 1990; Tan-Alora & Lumitao, 2001; Widdows, 2007). This could be one 
explanation for most of what has here been themed as coercion—coercion was 
initially defined within other cultural contexts (i.e., non-Saudi contexts) see 
Subsection 6.2.3.2 Coercive Practice.  
Patients’ perceptions of what was going on accorded with the notion of 
deception resulting from misinforming or lack of information. Two of the 
interviewed patients were among the six observed recruiting sessions in Phase One. 
In these specific two cases, as well as others, the theme of coercion by appealing to 
religion (i.e. they were lead to believe that blood donation is Godly rewarded) was 
reported. Those patients, however, did not say anything that implied coercion. This 
could be because they did not necessarily feel coerced because they might not have 
realized that they had been misinformed. In these specific cases, it could also be 
suggested that coercion was practiced subtly by the research team.  
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(a) Deception 
During the interviews, several patients made comments about the way the 
informed consent sessions were conducted. These comments can be interpreted in 
terms similar to those that emerged from Phase One. In Phase One, the concept of 
deception was introduced based on what was observed and how I understood it (see 
6.2.3.2 a. Deception). In this phase, the patients’ narratives of what they thought 
happened during the recruiting process were carefully assessed. It is difficult to make 
accurate claims about the intentions of the research teams; therefore, what will be 
suggested as deception was based on my own perception, based on patients’ reported 
perceptions. 
1) Misinformed 
Some of the interviewed patients seemed to be confused about the distinction 
between research and clinical interventions. However, the interpretation of deception 
emerges from their understanding of what they were told. This interaction with P8 
illustrates the confusion between his participation in research and the clinical 
examinations he needed as part of his regular appointment: 
Res: Do you have any idea about the differences between your appointments 
with your doctor and this research? 
P8: I feel that both are related, meaning they research to cure me and other 
patients. 
This person appeared to demonstrate a substantial lack of understanding as to 
the reasons for extracting the blood. Given his answer, as well as my own experience 
of observing a similar patient been consented by the same team that consented this 
patient, I am in a position to infer that the person was, even after the donation, 
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misinformed that the donation had nothing to do with her illness, diagnosis or 
treatment. In this particular case, the interviewee was a middle-aged businesswoman 
with a degree. My interview with her took place just one day after she had donated 
blood and signed the donation consent form, which means that memory fade may not 
be a factor in her ability to recall events.  The patient’s failure to differentiate 
between her donation for research and her clinical intervention suggests that she was 
misinformed. In response to follow up questioning, the patient did not seem able to 
give a clear account: 
Res: How did you hear about this research? 
P8: I came to the clinic first. A woman came, greeted me and introduced herself 
saying that she was from the research department and asked me a number of 
questions, and I answered her, and then we went down to the lab and they took a 
blood sample, and she said it is for a study or a test or something… 
Compared to the level of information and understanding suggested by the 
guidelines, this particular patient did not appear to have been sufficiently informed to 
provide an informed consent. This was the case with most of the patients I 
interviewed, regardless of educational background. 
There is literature about how education levels might influence the informed 
consent process; literacy increases understanding of informed consent (Cassileth, 
1980; Abolfotouh & Adlan, 2011; Adlan, 2013; Khedhiri, 2013). However, among 
the people I interviewed was a registered nurse, and I assumed that, through her basic 
nursing education; her general knowledge of genetics and of the research should 
have made her more informed. She, too, expressed the belief that her participation in 
the study was related to her treatment.  
‘No, in my case it was a therapeutic intervention.’ (P7) 
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However, all of the interviewed participants were selected based on the fact 
that they had recently donated blood for genetics research and not therapeutic 
intervention. The time gap between the interview and the donation is less likely to 
suggest that such an important detail could be forgotten. Adding this to what I 
witnessed some researchers say in recruiting for MGE research in Phase One, it 
could be suggested that in this specific context there was an element of deception 
through misinformation. 
Informed consent is highly dependent on what the patient understood, not only 
on what the researcher said. However, in some cases the use of language can be 
ambiguous. For instance, the Arabic word ‘tabarou’ means donation in general, 
which could include money donations or any other charitable work. When the word 
is used with blood, it usually indicates a blood donation for therapeutic use in other 
patients. Another word is usually used when blood is donated for research, 
‘musharakah’, which literally means participation. So if the research team used the 
word ‘tabarou’, it created the impression that the blood would be donated to other 
patients as a charitable act. This confusion was apparent in some interviews, where 
patients thought that they were doing ‘tabarou’ rather than research ‘musharakah’. 
For example, P8 in response to my question about her willingness to suggest 
participation in MGE research for which blood would be withdrawn to a friend or 
relative replied: 
‘Of course I will tell him to do ‘tabarou’ [donate blood], because ‘tabarou’ 
[blood donations] do not harm; my husband give ‘tabarou’ [donates blood] here 
in the hospital every six months, and that is a habit of ten years.’ (P8) 
Another participant mentioned that he would donate blood every month if his 
health would permit him to do so. According to the collected data, it appears that 
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some of the research participants were confused about the nature of the donation. 
This could be attributed to many factors, such as patients forgetting some of the 
given information to them, or being misled into thinking that they were doing 
tabarou as oppose to musharakah.  However, it is also plausible – based on my 
observations for Phase One – that the researchers (also) bear some responsibility. My 
impressions based on those observations to seem to have been borne out in the 
interviews for Phase Two. 
1) Not informed 
The second way in which patients may have been deceived is by omitting to 
tell them key information. As I am drawing the picture based on what the patients 
remembered, I tried to explore their understanding about their donations. The data 
collected in Phase Two suggests a noticeable level of ignorance within the group I 
interviewed. Arguably, the level of ignorance was too high to have satisfied the 
Saudi bioethics guidelines or the international guidelines in relation to consent to 
participation in research being properly informed.  
Among the most common forms of deception that I witnessed in the previous 
phase, was the lack of information provided to the participants, neither a copy of 
Participant Information Sheet (PIS) nor a copy of the consent form were given to any 
of the observed participants in Phase One. In SA the practice is to include the 
information on the consent form (as opposed to the UK where there is a separate PIS 
and consent form). In this phase some of the patients remembered that they had only 
signed a one-page consent form with no information sheet. They also claimed that 
they had not received a copy of the signed papers. 
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Res: All right, the papers that you have signed, do you remember how many 
pages?  
P10: One page? 
Res: OK, one page. Did they give you a copy? 
P10: No. 
Given the amount information provided verbally (based on what was observed 
in Phase One), given that the process did not permit prior reading/time for 
consideration of the written information that was provided (albeit it only one page), 
and given that participants did not get a copy of the information to read later, there 
are reasons to doubt the extent to which they could have been informed. Therefore, it 
can be suggested that genuinely informed consent in those specific cases was not 
obtained.  
Usually when someone goes to the treating physician in a regular follow-up 
clinic, he or she assumes that, unless stated otherwise, everything that happens in the 
clinic will be geared toward clinical investigation, treatment, and/or their care. In 
some cases in this study, however, patients were not just asked to donate blood but 
seemed to have been allowed to think that the blood collection was necessary for 
their treatment. Most of the interviewees confirmed that they were not informed. In 
the case below, the treating physician, who was expected to introduce the study and 
get the patient’s preliminary consent, did not tell the person anything. The patient 
was basically ignorant about the whole process of donating blood: 
Res: How did you know that there was research…? 
P3: He [the doctor] did not tell me anything. 
Res: So, the doctor did not say that there is research or blood withdrawal or—. 
P3: Wallahi [By Allah], he told me nothing about research. 
Eventually the patient gave blood to the research team, but he claimed that he 
was not informed about the nature of his donation. In this specific interview, I 
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wanted to tease out what the donor’s decision might have been if he had been given 
more information. In the following exchange, I was interested in exploring what his 
reaction might have been had he known that the benefits of this research would likely 
not accrue to him. 
Res: If they had told you that this research is for a lot of people and you won’t 
benefit from it personally, will you agree to donate? Or will you say let me think 
about it? 
P3: Wallahi, I do not know, but I might say ‘let me think about it’. 
It is reasonable to assume that one of the principal pieces of information that 
research participants need to understand is what risks participation might entail. In 
the Saudi culture, there are specific adverse consequences for individual and families 
arising from the stigmatisation surrounding some genetic conditions. The potential 
impact – if this had been explained – is not something individuals are likely to have 
forgotten about in the few days between their donation experience and interview for 
this study. This is especially the case if they would themselves be stigmatised for 
taking part, or face stigma as a result of the findings of that specific MGE research 
project.  I, therefore, tended to assume that if the interviewees did not mention that 
stigma was a risk when they were asked about the risks of their participation, the 
most likely explanation for this is that it was not brought to their attention during the 
informed consent process. Other suggestion could be that due to the nature of the 
stigma, participant may not have mentioned it for the fear that it would stigmatise 
them in my eyes. If this was the case, the nature of the answer would reflect that the 
participant was hiding something, or at least some of them. To the contrary, the 
response I had, was a very assuring, affirmative tone which, at least to my 
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interpretation and given my understanding of the Saudi culture and what I had 
learned from Phase One, did not indicate that they were hiding something.  
Res: All right, have you been told about any specific risks and the measures they 
have to deal with those risks? 
P7: No. 
Res: In general, do you know about any risks related to your donating to MGE 
research? 
P7: Never… They assured me, and I do not have any fears, I mean regarding 
blood donation for genetic research. They asked me and immediately I agreed. 
This participant was confident that no more information was needed before 
deciding to donate. Some patients only wanted to be assured that the blood was taken 
into the custody of the hospital. They seem to trust that the hospital would not do 
anything wrong and that anything done would be in their benefit. This is definitely a 
point of difference between the usual assumptions of what patients should be told 
while in this context. The patients did not care because they trusted the hospital. 
Res: Do you know where the blood [you gave] went? 
P8: No. 
Res: She did not tell you where? 
P8: No. 
Res: Do you want to know? 
P8: … This is a hospital. Of course it will be used for something to benefit me 
and not harm me, for sure. 
Some of the interviewees said things that could be attributed to some level of 
uncertainty about the research activity in which they participated. I considered such 
uncertainty problematic for two reasons: 1) the information (e.g. where the blood is 
going to be used) I was looking for was not provided to them in the recruiting 
session, and 2) their responses would have been more focused on their knowledge 
about the donation if they had been given the proper information. As per the Saudi 
research ethics regulations as well as the international guidelines that were used as 
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references for the Saudi regulations, information about blood donation should have 
been given to participants before they decided to participate. Many participants 
seemed unaware of things as simple as the difference between his or her research 
participation and the clinical care that he or she came to receive.  
Res: All right, do you have any idea about the difference between your regular 
medical intervention and your research contribution? Do you know the 
difference? 
P10: No, I do not know. 
 
Similarly, the participants did not have a clear idea of what genetics research is, even 
at a very basic level. This could be found in the majority of the interviews. 
 
Res: Good! Do you know that it is a genetic study?  
P2: What? 
Res: A genetic study?  
P2: [Hesitant and muttering.] 
Res: Do you know what a genetic study means? Did your doctor tell you what it 
is? 
P2: No. 
 ‘There is no awareness... We are a developing country, we are still developing, 
and we might know about these things [research] but… the majority of people 
do not have an idea or they do not understand… I mean most of them do not 
know what is needed, exactly, from them or why it is needed…’ (P7) 
In conclusion, one of the most important themes to emerge was the amount of 
ignorance around the topic of donating blood for research in general, and for MGE 
research specifically. This theme supports the observation results in Phase One. It is 
reasonable to assume that the participants did not have information to share because 
they had not been introduced to it during the recruiting process. This form of 
information deception varied between not telling a patient that he or she was going to 
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donate to research, to not giving information about the real risks of participation in 
MGE research. 
(b) Who asked   
Many of the participants suggested that the treating physicians asked them to 
donate blood for MGE research. 
‘We went to the doctor during our clinic appointment, and she said that they will 
take blood samples, and we said, “No problem.”’ (F5/S) 
The treating doctor seems to have provided sufficient information to one 
participant. She initially refused to participate, but she came back after one week and 
signed the informed consent form. She was the only one who reported this way of 
consenting. She was a registered nurse and worked in the same hospital in which she 
participated in the research. 
‘And the doctor gave me the informed consent form and told me to read it and 
come back again after one week, so after one week I can be back to do it.’ (P7) 
In conclusion, all of the participants were asked by their treating physicians to 
donate blood during their regular follow-up clinics. The physician-patient influence 
could be suggested by the sound of helplessness in the voices of the interviewed 
patients. Another factor that seemed to play a role in the interviewees in research was 
that the treating physicians had asked them to donate in the follow-up clinics. The 
context was that the patients had waited a long time for their appointments; they 
were desperate to be seen. They also were eager for subsequent follow-up 
appointments to be scheduled within a reasonable amount of time. In my own 
experience working with similar environments, if the physician asked the 
appointment clerk to give a patient an appointment at a specific time, it would be 
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done. However, if the patient was transferred to the appointment desk in the regular 
way, he or she would re-join a long waiting list with a minimum expectation of 
waiting from six months to more than a year. The desire for a quicker appointment 
may incline patients not to refuse any request the physician made. In the research at 
hand, I cannot confirm that this was the case because the arrangement of 
appointments was not included in the topic guide. The interviews uncovered one 
occasion in which a physician appeared to do everything correctly: he saw the donor 
in his clinic but gave her information and the option to think and come back later. 
This specific incident could be attributed to the fact that the donor was a registered 
nurse who worked at the hospital in which she had the follow-up appointment. 
(a) Rushing 
Most of the participants were ill and needed medical attention. However, the 
time allocated for them in their long-awaited appointments seemed to be insufficient 
even for their medical needs let alone for introducing the concept of MGE research 
blood donation.   
Res: The period between the times they called you in until they took the blood 
sample: do you remember how long it was? Five, ten, fifteen minutes, an hour, 
in that range? 
P9: Nothing more than half an hour. 
 The lack of time could be interpreted in two different ways: either this patient 
did not need more time to decide, or they were encouraged to decide more quickly 
than they wanted to. Although this particular patient did not use the word ‘rush’, the 
way “nothing more than…” was said reflected a level of dissatisfaction. Other 
patients were more frustrated and actually explained how they felt. 
… we wished if she talked a little longer, to educate us ... she just quickly 
checked … and did not chat much, we came from a long far away distance, she 
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did not even ask about the medication follow up. She quickly chatted; checked 
and sent us out … Honestly she only said quick things. She was in a hurry and 
about to leave.’ (F5) 
Due to the rushed nature of informed consent that was reported, it could be 
argued the participant did not consent in the way they should have (i.e. the patient 
should be given time to think with no stress or sense of time constraints). This added 
to my impressions based on the data from Phase One, that those research participants 
did not freely choose to participate. 
6.3.3.2 Patient vulnerability 
In the interviews, some participants made statements that suggested feelings of 
vulnerability. Others seem to have felt sufficiently empowered to bargain with the 
research team for their participation in the research, and they asked the research team 
to do something for them in exchange for their participation. 
a. Vulnerability of patients recruited by their treating physicians 
Vulnerability in the context of blood donation could take many forms. An 
example of this can be seen from F1, who suggested an invitation to participate via a 
poster would be more appropriate than a personal request from the treating 
physician. 
To put a poster giving short details about the research like that “If you want 
information about [the research], you can refer to [the clinic].” Then the patient 
will have the advantage of participation and will receive better care. It will be 
better for the patient to go personally, and he or she will be the priority for 
medical care. (F1) 
In the Saudi culture, there is a tendency for patients to not want to disappoint 
their physicians, and the above quote can be taken as the patient’s polite way of 
asking to avoid confrontation with the research team. The importance of this quote 
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comes from the fact that the son seemed to want to regain the power to make 
decisions about donating without the influence of the research team. Though in 
general there were many signs of frustration that could be attributed to many factors, 
without trying to overanalyse this quote it seems these family members were not 
happy with the way they were recruited. It is also important to mention here that I 
used a poster to announce our research in the recruiting process for these interviews, 
and we displayed it where patients could see it and decide if they would like to 
contact us. As this was the first time a poster advertising research was used in either 
of the two institutes, it could be the case that the patient was influenced by the way 
he was recruited to this research when he made this suggestion. 
 ‘Whenever I ask for a report or a request for air tickets [under the hospital 
policy], or a sitter, he always cooperates with me fully, whenever I request 
something.’ (P9) 
In some cases, though, patients understood that what was asked of them was 
something extra, but they felt indebted to the kind, helpful behaviour of the treating 
physician, and therefore assumed the favour should be reciprocated by donating 
blood if the physician asked. It appears that this patient felt that he did not have any 
choice but to accept, based on the Saudi culture characteristics, as explained earlier 
in Section 1.  
b. Vulnerability of patients asking if they would lose treatment 
privileges 
Another suggestion of vulnerability emerged from the interviews in many 
places in the form of participants’ inquires if they would be losing treatment 
privileges and being concerned that their rights would be compromised if they 
  
 
 
 
187 
expressed their opinions. This was the question most commonly asked by 
participants during the rapport building and before the voice recording permission 
and the informed consent signing. Based on my assurances of privacy protection, the 
patient signed an informed consent and voice recording started.  
F1: Will our opinion and comments affect our ability to receive medical care? 
The importance of this question stemmed from the context of how Saudis 
express fear. Saudis usually like to be seen as proud and fearless, even if they are not 
(See Subsection 1.2 The Saudi Arabian Context). None of the interviewees said 
anything harsh or made serious complaints about the hospitals or the treating teams. 
In the above case, the person expressed, in an extremely polite way, his frustration 
with the service he received which he expressed in the interview (quoted in 
Subsection d- Vulnerability counterargument), the fact he was not treated in the way 
he expected as a donor, and the general lack of organisation at the hospital. Yet, he 
was not comfortable enough to complain. One way of interpreting F1’s question is 
that in context, it reflected implicit feelings of fear that he might lose his treatment 
privilege, although this fear was not expressed explicitly.  
c. Vulnerability of Saudis wishing to appear to be devoted Muslims 
Patients were also vulnerable to the use of religion and suggestions that God 
rewards people who donate for altruistic reasons. Donation was presented as a 
charitable act: 
Res: Why didn’t you want your name mentioned in the blood donation informed 
consent? 
F5 I just want the Godly reward. 
Res: OK. 
F5: If my name is known, my Godly reward is gone. 
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Res: How can the Godly reward go? What is the relationship between the name 
and the reward? 
F5: Because it is charity and charity has to be secret. 
Res: OK. 
F5: It is then between you and your God only. 
 It is beyond the scope of this work to analyse the merits of charitable acts and 
their basis in religious belief. However, in the context of this research, it could be the 
case that religion and the notion of pleasing God rendered patients vulnerable in the 
sense that they felt unable to protect their interests because they would be unable to 
say even if they wished to, without risking be perceived as being impious. I believe 
the idea of charity was a result of how the researchers convince the patients to donate 
for two main reasons: 
- In Phase One, I observed the research team using religious innuendos to 
make the connection between donation and ‘Sadaqah Jariah’. This Islamic 
concept signifies the highest level of charitable acts—continuously rewarding 
charity that will continue to reward a person even after his or her death. 
- Once a suggestion is made that ‘donating blood for research is a virtue’, 
Saudis are less likely to refuse to do it. Saudis like to be perceived as religious 
people for cultural reasons, and the failure to perform a charitable act would be 
regarded as at worst a sin and at best the loss of the opportunity to portray 
oneself as a devoted Muslim. To engage the concept can therefore be to 
manipulate someone’s behaviour in the direction of the designated charitable 
act. 
It is fair to say that this point can be interpreted in a different way. For 
instance, it could be the case that what I witnessed in Phase One was not the norm. It 
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could be that patients in Phase Two were more oriented toward charitable actions 
and did not need the researchers to nudge them to donate. 
d. Vulnerability counterargument 
The argument for vulnerability was supported by many themes that emerged 
from the data. However, it is true that everyone is vulnerable to misinformation and 
deceit, but this produces a very wide and arguably meaningless understanding of 
vulnerability for it essentially means that everyone is vulnerable and that there is not 
special category of vulnerable person (Mackenzie et al, 2014). In this section I 
provide data to illustrate the point that despite the policy assumptions, patients are 
still vulnerable. This interpretation is viable if patients were unable to make adequate 
donation decisions for themselves. Some of the interviewed patients showed a degree 
of understanding and might have made their decisions based on anticipating the 
benefits of participation, which contradicting the claim of total vulnerability. 
Some participants demonstrated very clearly that they had expected something 
more in exchange for their agreement to donate. This suggests that some patients did 
know about the value of their contributions, expected the research team to pay them 
back in some way and felt able to assert themselves in this respect.  
‘Then the patient will have the advantage of participation and will receive better 
care. It will be better for the patient to go personally, and he or she will be the 
priority for medical care.’ (F1) 
This suggests that the person had some sort of expectation based on the 
assumption that he would be privileged as a patient gain advantages greater than 
patients who did not donate blood. In this particular case, the person wanted to get 
priority medical treatment. 
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The theme of vulnerability was not straightforward and easy to draw 
conclusions from because some patients seemed helpless. Based on previous 
suggestion in Chapter One, one might ask whether any typical patient in the 
Kingdom feels empowered when it comes to making medical decisions given that 
they as accustomed not to questioning their doctors, which seemed to be 
underestimated by the policy. On the other hand, there were other contexts in which 
patients had an agenda regarding benefits (e.g., gift reciprocation or being the first to 
benefit from the research outcomes). Given the context of the Saudi culture and 
health care system, it seems that patients were vulnerable insofar as they did not have 
the opportunity to refuse fearlessly. On the other hand, even those who were afraid to 
refuse to participate did have some level of hope or assumed some sort of payback, 
whether religious benefits from pleasing God or some more tangible benefits. 
6.3.4 Summary 
To conclude this subsection, the Phase Two interviews were very important for 
giving an insight into the perspectives of the interviewed patients. Without the 
observation data from Phase One, it would have been very difficult to understand 
why patients seemed to have little to share in these interviews. The researcher teams 
in Phase One seemed to assume, according to the policies, that Saudi patients cannot 
decide individually in an autonomy-based based manner. It seems that two sets of 
values were playing against each other in the field of donating blood for genetics 
research in Saudi Arabia. . The researchers’ world, as seen in Phase One, seemed to 
uphold research governance that assumes the values of autonomy, liberalism and 
principlism. On the other hand, the interviewed patients seemed to lean more toward 
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the values of trust, hope, piety, and, on some occasions, fear. The contrast of the two 
worlds seemed to encourage researchers to work pragmatically to satisfy both 
research governance by providing auditable documents, and the patients’ culture by 
providing assurances and promises. This claim will be discussed in the next chapter. 
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6.4 Phase Three: Focus groups 
Two focus groups were convened. The first group consisted of the researchers, 
research assistants, technicians and research nurses who actually collected blood 
from patients, either for their own research or on behalf of senior researchers who 
employed them. The second focus group comprised the policy-makers, ethics 
committee members and chairmen, national committee members and senior 
researchers. 
6.4.1 Participant Characteristics 
The characteristics of the participants in the first focus group are described in 
Table 6-3. Although the amount of recruitment experience they had varied, all held 
fairly junior posts. 
TABLE 6-3: CHARACTERISTICS OF FIRST FOCUS GROUP PARTICIPANTS* 
Code Gender Number of patients recruited** 
FG1/1 M More than 50  
FG1/2 M More than 500 
FG1/3 M More than 80 
FG1/4 F More than 500 
FG1/5 M More than 500 
FG1/6 F More than 500 
FG1/7 F More than 100 
*Occupation and years of experience are not presented to protect participants’ identity. 
**In this column, every participant who claimed to have recruited less than 500 was asked to estimate 
the number of recruited patients. 
 
There were eight participants in the second focus group; only one of them was 
female. The original distribution of the invitations had sought a gender balance. 
Women are under-represented in higher position in Saudi Arabia, so the time of the 
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meeting was fixed mainly based on the availability of the women who accepted the 
invitation, only one of those who confirmed eventually attended.  
TABLE 6-4: CHARACTERISTICS OF SECOND FOCUS GROUP PARTICIPANTS* 
Code Gender Expertise 
FG2/01  M Bioethics  
FG2/02  M Genetics 
FG2/03  M Bioethics  
FG2/04  M Genetics  
FG2/05  M Bioethics 
FG2/06  M Senior genetics researcher  
FG2/07 F Bioethics 
FG2/08 M Bioethics  
  * The occupation and level of seniority are not reported to protect participant identities. 
6.4.2 Results of the first focus group 
In general, the findings from this phase (asking people general questions in the 
beginning and then asking them to reflect on the data from Phases One and Two 
complement those of the previous phases, and they provide further explanations for 
some of the behaviours noticed earlier. When the participants were asked to reflect 
on the Phases One and Two data their general response was to accept the results, and 
many actually expressed shame. No one seemed to question the findings. On the 
contrary, they shared more stories that matched the findings. 
The group had a very thorough discussion about rushing patients’ decisions 
and why some of the attendees did think it was the best course of action under the 
circumstances. There was a consensus about the lack of organisational support, and 
participants offered some suggestions for how to overcome that challenge. In 
addition, the researchers revealed their opinions about patients’ vulnerability in light 
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of evidence about both patients who were totally ignorant and patients who had some 
knowledge and had tried to bargain with the research teams about giving blood. 
6.4.2.1 Coercive practices 
Coercion was a major theme that emerged from the data the participants 
provided. Several different strands could be found within this theme, including 
deception. Many participants agreed about the challenges that arose around 
organisational support. However, some of the participants felt strongly that current 
practices were the most pragmatic means of addressing the shortcomings of the 
health services in their hospitals. 
(c) Deception 
Some participants shared stories about researchers whom they thought knew 
the policies and how they had, according to the participants, deceived patient’s by 
taking blood without consent. 
FG1/6: They were drawing people’s blood without even consent. Sometimes 
patients were in the ICU. 
FG1/4: Or maybe because he was unconscious.  
The participants thought that the deceptive nature of the actions (in this case, 
extracting blood for research and telling the patient’s guardian that the extracted 
blood is for routine tests) deceiving the unconscious patient’s guardian about the 
nature of blood extraction) was due not to ignorance about those guidelines but to the 
senior researchers’ conflicts of interest, which motivated behaviour most of the 
group agreed was unethical and illegal.  
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In the participants’ experience, deception was not limited to patients. Some of 
them witnessed researchers trying to deceive ethics committees into retroactively 
approving research by claiming they got their results accidentally. 
FG1/2: They may say, ‘We found this in our way [by coincidence]…’ 
FG1/6: Exactly. 
FG1/2: Have they done a special test? ...  
FG1/6: I think what they did is unethical.  For me,[in my opinion] I do not 
know, but this is unethical. Inshallah [God’s will] it will never happen to me, 
but I know what I will do… 
FG1/2: This is just an example for the point raised—. 
FG1/1: For me,[in my opinion] this is because informed consent is to protect 
organisations, not those 5,000 patients. 
From the data provided in the group discussions, deception as a theme was 
further divided into several strands, including deception through misinforming and 
deception through not informing.  
1) Misinformed 
I was more able to discuss interim findings and explore the focus group 
participants’ understanding, explanations and justifications in some cases for most of 
the actions. From my analysis of data, deception through misinformation emerged as 
a subtheme of these discussions. 
The collected data reveals that there was a general consensus among the group 
that researchers might provide inaccurate information for two main reasons: 
- Lack of information: some of the participants seemed to think that there was 
a significant level of ignorance even among senior researchers themselves. The 
example they used to illustrate this point was the risks. Patients were not told 
about the risks of genetics research because, the group thought, the researchers 
themselves were not fully aware of them. Even if this could be true, 
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information about risk is not all that is being withheld, as presented in the 
previous phases.  
- Some of the participants seemed to believe that a strong sense of authority 
existed among the physicians. These participants tried to portray the sense that 
it was not physicians’ ignorance but their feelings of power or superiority that 
were significant—the physicians thought they knew better than the patients and 
everyone else including the research team members.  
 One participant related the following experience: 
Well that time I was not the assistant of that researcher, but I said, “Do you 
know that you need a consent to take this blood?” He said, “No, I do not need 
consent. We draw blood from those patients every day for various reasons.” I 
replied, “Yeah but… this patient or his relatives… they need to know that you 
are not taking it for regular blood work.” Not to know that was, you know, 
Creatinine or whatever. He [the doctor] is doing it for a certain study. He 
eventually said, “No, no, no! … We do not need that [informed consent]!” 
(FG1/6) 
Another line of discussion in which the participants were in agreement was that 
prospective donors were told that they were going to receive the genetics test results 
as soon as they were ready. It was likely that researchers did not believe this was 
true. 
I received a call earlier today. The blood was taken one year ago. The patient 
asked, “What happened to my blood? I keep calling you and you keep referring 
me to the doctor and to everywhere else. You keep saying call next week or next 
month. Now… tell me. Do you have any results for me?” So I had to refer him 
once again to my colleague who would have a better answer for him. (FG1/2) 
2) Not informed 
The focus group participants agreed that patients were given highly selective 
information, or, as they said, patients were only told about ‘the white part of the 
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project’. By ‘the white part’, participants meant that the researchers provided only 
the positive information and deliberately omitted the information that might 
negatively affect donors’ decisions or what they called it the ‘black side’ or ‘black 
part’ of the research. 
But… doctors… or what happens now under research projects [is that] they are 
trying to get [to present], as [FG1/3] said, the white parts of the project. But they 
did not try to mention the other part… 
He doesn’t know the consequences. If he is giving his blood, what is the black 
part of it? He knows the white part of it but what’s the black part he [does] not 
know, and we do not mention that to him. (PG1/01) 
From the context, it seems that what this participant meant by the ‘black part’ 
is the information that might incline the donor against participation in the research. It 
is interesting that this participant referred to the omitted information as a ‘black part’. 
From the context, what seems intended is that patients were given the versions of the 
story that would make them favourably disposed toward donating without letting 
them know about anything that might disincline participation. 
There are many commentators in the literature who have questioned the level 
to which physicians should be truthful to patients and who note that full truthfulness 
in the field of providing medical services can sometimes be harmful to patients’ 
interests (Blackhall et al, 1995; Higgs, 2007; Adlan & ten Have, 2012; Adlan, 2013). 
Even the Hippocratic Oath urges doctors to say only what patients can take, which 
might not be the full truth. “Perform [your duties] calmly and adroitly, concealing 
most things from the patient while you are attending to him … turning his attention 
away from what is being done to him; …revealing nothing to the patient’s future or 
consent conditions”, Hippocratic Oath as cited by Jackson (2013) p166. 
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In the context of this work, it seems that some of the researchers transferred the 
authoritative view from the field of medical practice to the field of medical research. 
It seems that the participants had witnessed enough from the physicians’ and senior 
researchers’ behaviours to agree with each other that most of those senior researchers 
patronised their patients, giving them minimal information in order to facilitate 
gaining their signatures. 
Many physicians do not believe in the consent process for a surgical procedure. 
The same goes for how they think of research. Some even think that it is just a 
routine practice: “I do not even need to tell the patient.” So… “I am the 
physician, and I know better than them. Why do I need them to sign this 
consent?” On the other side, still, there are some researchers who believe in 
patients’ rights. (FG1/05) 
The main difference was that in the case of recruiting for research, there were 
conflicts of interest between the physicians as treating doctors and their eagerness to 
research. The participants collectively believed that education was the best way to 
ensure patients were equipped to protect their interests. However, there was no 
specific reference to what they meant by education. The best explanation is that they 
were talking about improving patients’ general education levels, since there were no 
discussions of out-of-curriculum education like conferences or media. 
OK, they do not ask about the black part, but if he is educated he asks [about the 
black part]. Meaning if it [the research] doesn't have a direct benefit to me or if 
the effect is not OK, sometimes they refuse to participate if they are educated 
because he [the patients] talks about the other part. I agree with it—70% of 
subjects who are not educated would agree to participate without question. 
(FG1/3) 
It was agreed that when it came to recruiting patients, because they belonged to 
the same culture, they knew what made people participate and what scared them 
away. Such knowledge was a double-edged sword, as it could have been used to help 
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patients make decisions with help from people who understood their fears and hopes. 
On the other hand, it could have been used as a recruiting tactic where the aim was to 
get the patients’ blood regardless of other considerations. The participants seemed to 
agree that the latter was more widely practiced based on what they had seen in the 
field. The test case was using the word ‘research’ when inviting patients to donate 
blood, as the word has connotations that made patients afraid. Researchers knew, the 
participants suggested, that if the word was used, patients would lose interest in 
participating. 
Because he will not come to the clinic with the name “research” on it. It you ask 
him to a clinic without the word “research”, he will come. (FG1/3) 
(d) Who asked 
As in the previous subsections, another potential source of coercion was the 
effect physicians had on patients. This was the case when there was a power 
deferential between the doctor as a PI and his or her patient. Such a power 
differential may lead to patients being less likely to refuse what their physicians 
asked of them. It would appear that there was group consensus about the fact that 
coercion of this type existed. 
Many scholars have written about the patient–physician relationship and how 
the dynamic could easily be dictated by the hope factor in the sense that patient 
needs to be reassured by the treating physician (Williams, 2002; Higgs, 2007). As 
discussed in Chapter Two, most Saudis look at physicians as healers. Such an image 
appeals to patients’ hopes of being healed under the guidance of their physicians. So 
when a physician asks for something, it is likely to be perceived as an order even if 
the physician does not intend it to be—the kind of order that will upset the healer or 
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prevent the patient from being healed if it is not followed. This sense of the 
relationship was confirmed by the participants: 
Actually, they listen to us or to the doctor, and they feel it’s part of the treatment 
even [if] it is for just a study. And they will not say “No”. Even the feeling from 
the doctor when he asks them—[they think] that [this] means he will find for us 
a cure or treatment. There is another problem: if we explained anything to the 
patient, he might say “No”, but if the doctor said anything, the patient would say 
“Yes”.  (FG1/3) 
 
The data also seem to suggest that some of the participants felt they could not 
refuse the treating doctor’s request. The participants also reported, however, that 
whilst they thought that patients appeared to agree with their clinician, they also felt 
that this may not reflect their actual feelings. They noted from their own experience 
that some patients, as soon as they were out of the examination rooms, changed their 
minds. For them this is a source of frustration as it puts them in unwanted 
confrontations with the physicians/PIs. 
Some of the patients, they are first introduced to the study by my PI and they 
agree. Once we are shifted to another room, they disagree. Why did you agree in 
the first place? All of the sudden, they are busy… they have pharmacy… they 
have I don’t know what. (FG1/4) 
Some participants felt that the physicians they work with knowing they had 
influence over their patients, used it to persuade patients to reconsider their decisions 
not to participate, either by sweet-talking them or by overbearing questioning: 
Sometimes they [the patients] say no to me, [but] the doctor really wants the 
patient. He asks me, the doctor, to follow it up, I said “No”. He comes [to the 
patient] and said, “Why you do not want to participate?” He [the patient] says, 
“No… no, I will… I will [participate], no problems”. (FG1/2) 
When the doctor wants them to sign, he usually talks to them friendly to get 
them to sign. (FG1/3) 
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In contrast, it seems that participants were aware of the potential coercion and 
tried to resist it. The participants shared many examples in which they tried to 
educate patients and told them it was their right not to participate, and in some of 
those cases patients changed their minds about participating. This would be evidence 
of practice that does conform to the guidelines; however, they also suggested that 
this is not the usual practice. In addition to the above quote from (FG1/2), 
demonstrating how some doctors used their authority to change patients’ minds 
about participating in research, another story that was shared indicates that patients 
changed their minds about participating after being told that they really did not have 
to participate. 
It was also the consensus that this kind of power was not only in the hands of 
the treating physicians. The participants thought that the same effect could to be 
replicated by others for instance by wearing a white coat or introducing him- or 
herself with the title ‘doctor’. 
Because he was approaching the patients with the words “I am doctor such and 
such [his name]”, they believed in him more, and they consented, or they agreed 
to participate in the study more than with her [a person who did not introduce 
herself as doctor], even though she has better communication skills than he. 
(FG1/5) 
FG1/3: … we tell the patient that he can refuse [to consent], but we know that he 
[the patient] will never say no to the doctor.  
FG1/1: Do you, usually, wear a lab coat when you approach patients? 
RG1/3: No we do not. 
FG1/1: May be this is [the] problem [i.e. the patients do not listen to you].  
Res: Why did you ask about the lab coat? 
FG1/1: Because, if the patients did not see a person wearing a lab coat, they 
would think that this person is not a physician. 
In the last quote, there was a consensus among the group that attire plays a 
major role in patient decision to participate in research. This is because the lab coat, 
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according to the participants’ consensus, makes the participant think that the person 
wearing it is a doctor.  
(e) Rushing 
The participants seemed to agree that rushing patients to consent is a strategy 
for securing participation. However, using rushing as a tool of coercion did not 
receive the same level of consensus as the other themes. Some of the participants 
seemed to argue that, in their experience, giving patients more time to think about 
things meant they would be less likely to come back and/or they would have more 
scope for questioning their participation. 
 If I allow them to go home, they will ask many questions when I call. If they are 
here, it is just a direct yes or no. (FG1/3) 
Other participants argued that getting the consent on the same day is a 
pragmatic solution to the logistical problems that would inevitably accompany 
patients having to return to the clinic to participate. They thought that things like the 
lack of ready car parking and the absence of reliable public transportation in Saudi 
Arabia could work as deterrents to participation in research. This judgment chimes 
with the experience of one of the interviewees in Phase Two, who reported that she 
came from a very remote place and that her journey to the clinic took ten hours. For 
these kinds of reasons, the focus group participants thought it would not be right to 
call such patients back to the clinic to participate in research. 
It is difficult to come back… parking is a disaster. (FG1/4) 
 Some patients… it is difficult for them to come to two appointments in one 
year. (FG1/3) 
  
 
 
 
203 
So whilst the focus group participants seemed to agree that patients were 
rushed to decide, they disagreed about whether rushing should be regarded as a 
coercive strategy. Some of the participants did argue that it was a coercive, while 
others tended to draw on the distinction between working under the pressure of time 
and rushing as a coercive practice. The latter thought that rushing in that context was 
a pragmatic measure to prevent people from suffering the hardship of visiting the 
hospital on additional occasions. However, regardless of the motive for the rushing, 
the Saudi regulations on research ethics stress the importance of giving patients 
enough time to think about their decisions. The definition of ‘enough time’ would 
raise the question of where the line should be drawn between rushing as a coercive 
tool and rushing as a necessity dictated by a pragmatic approach to conducting 
research. In the next chapter, I will discuss further whether such rushing may have 
contributed to the severe lack of comprehension that I witnessed in Phases One and 
Two. 
6.4.2.2 Obstacles, challenges and responses 
Members of the group were very clear about the challenges they had faced and 
the obstacles they had experienced recruiting research participants. They also 
suggested a few measures that would help them to be more efficient and recruit in 
the most sensible and ethical way. 
(a) Lack of support 
Organisational support seemed to be perceived as lacking in light of the 
participants’ statements. The participants thought it was their job to recruit patients 
in the way that made sure patients gave blood, as opposed to recruiting patients in 
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way that give them the opportunity to say no, as they had to please the PIs. Some of 
them seemed sympathetic to the pressure doctors were under in terms of the number 
of patients that they had to see in each clinic in addition to their research patients. 
FG1/1: Also, we have to speed up the recruiting. 
FG1/6: Yes… if the researcher wants that, then yes. I mean, if you have a PI 
who has 35 patients in his clinic. 
FG1/4: This is only during the morning. 
Such agreement from the participants that researchers’ actions were excusable 
because of the amount of stress they were under suggests the question: ‘Why didn’t 
the institutions step in to help improve the quality of recruiting?’ A possible 
explanation is that the health system as a whole is under the stress of huge waiting 
lists. Some might argue that such stress makes the research activity seem like an 
expensive luxury that can be supported but will not be prioritised. 
There were other areas where participants reported a lack of support. Some 
participants acknowledged that their accommodation was inadequate and did not 
facilitate the protection of participant privacy during their recruiting sessions. 
Moreover, the clinical PIs were unwilling to help by offering one of their allocated 
clinic rooms when recruiting for their own research. 
FG1/2: We do not have special rooms for research…  
FG1/4: [Agreeing strongly] Once I asked a patient to consent in the corridor. 
So when I start to take the pedigree, the physician asks to leave the room. He 
thinks it’s OK because he has many patients. (FG1/2) 
The lack of support was not limited to the availability and quality of the rooms. 
There were also no specific ancillary services or personnel devoted to the research, 
which meant that the research patients had to suffer the experience of sharing the 
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out- or in-patient clinics with other patients. This created extra stress for the FG 
participants.  
Even when I start to use the conference room, we receive a complaint from the 
charge nurse. “This room is not for you or the patients,” she says. We also are 
asked to leave the room for a physician, or for whatever… I don't know what 
reason. It is a conference room! (FG1/4) 
…if I have a patient who needs examinations, ultrasound, blood for genetics, 
there is no support from other department and there is no support if he has 
research questions. (FG1/2) 
This suggested to me that it is not that the participants were not aware of how 
they ought to conduct recruitment but rather that they lacked the infrastructure and 
support to accord to the guidelines. 
(b) Distance, return trips and funding 
Among the challenges that researchers faced in the Saudi hospitals were that 
patients had to travel long distances, and the research centres did not have the 
financial means to reimburse their travel fees or even to provide logistical support 
like allocating parking spots for research participants. Three different issues within 
this theme were noted from the group discussions: 
i. Seizing the opportunity for patient follow-up clinics 
Patients who were needed for research often either came from remote places or 
were busy people. The fact that they were going to be in the hospital anyway seemed 
to encourage group discussions in favour of seizing the opportunity and inviting 
them for research. 
We cannot do it that way. Some patients don’t live in Riyadh. Even if they are in 
Riyadh, they won’t be free [from other commitments]. For some research, they 
need to be seen before and examined. How we can bring them in again? My 
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opinion: take time now and read it. If you like it, then that is it. Why do I have to 
send him home? (FG1/2) 
ii. Asking patients to return at their own expense 
Several participants reported that patients were asked to come from remote 
places to participant in research without reimbursement for travel expenses.  
FG1/2: We have a project, and we need to call patients to come to our hospitals. 
We bring them from remote places like Jizan [remote and to the south] or 
Tabouk [remote and to the north]. They paid for the tickets.    
Res: Who paid for the tickets? 
FG1/2: The patients did... We do not pay them any travel money 
reimbursements, but they are happy to come. Wallahi, they are very poor, yes… 
[It is true that] we have something; we call it a travel order for the patient, but 
we need the [whole] family, not just the one eligible patient. 
… 
FG1/1: We are [the researchers] abusing them [the patients]. 
This admission was strongly condemned by the group. Even the person who 
shared the story was not proud of what he thought he had to do. 
FG1/2: Yes I call it abuse... we do not care… Even as a coordinator I am not 
comfortable with it. 
iii. A potential conflict between what is regarded as the ideal situation and the 
reality 
The following lines discuss what could be interpreted as articulating a conflict 
between the ideal situation that is regulated by the NCBE and the reality, given the 
context of those two organisations and their geographical location. 
FG1/6: When I started to work as a CRC [clinical research coordinator], even 
before I attended the course, I was trained that every single patient has the right 
to take the consent and read it at home. 
FG1/2: In our area it is very difficult. I cannot just tell the patient to go and then 
come back in 24 hours. 
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This exchange illustrates a very central point in this research about the 
difference between what ought to happen in an abstract domain as per the bioethics 
guidelines (in this particular case, the ICH-GCP) and the concrete reality, with its 
difficulties and obstacles. This suggests a bigger question about what trade-offs 
between the two norms should be appropriate—i.e., the international norms seem to 
be written for a context in which services are closer to patients and there are public 
means for reaching them, while local reality admit that it is unreasonable to ask 
someone to return to a hospital that is hundreds of miles away. 
6.4.2.3 Patient vulnerability 
In agreement with what was noticed and reported in the previous two phases, 
the next theme to emerge from the data was that of patient vulnerability. The 
participants came to agreement through discussion and shared different scenarios in 
which patients, according to their experience, could have been taken advantage of, 
although some patients showed some signs of understanding the process. 
The participants seemed to believe that there was a level of vulnerability 
among patients, as they were eager to be seen and could not say no to their doctors. 
The participants suggested that patients were helpless in front of their treating 
physicians. They were very keen to be seen. Some of them had been waiting for 
appointments for a long time, so it is expected that, given the context of their 
opportunity to come to the hospital, they would not refuse. This finding overlaps 
with the view that research participants are confused about the difference between 
treatment and research. However, the argument for employing the concept of 
vulnerability here is supported by what the participants thought was a sense of 
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desperation that forced patients to participate in research in hopes that they would be 
seen. 
This one of the difficult things I did. I explained that, OK… yes we [will] 
examine you, but you will be [in] the research. And as a patient who doesn’t 
have [an] appointment for 6, 8 months, [he] just wanted to come. Especially with 
glaucoma, they want to see the [eye] pressure, they want to get the medication. 
(FG1/2) 
She said that “on a monthly basis at my work”—she works in a private lab—
“they take our blood for a study.” She even showed me the process and said, “I 
have a phobia now, and still I cannot say no.” (FG1/4) 
(a) Patient vulnerability counterargument 
The main assumption underlining the idea of vulnerability is that patients are 
helpless and feel pressured to participate or sometimes participate just to gain 
medical attention that they would normally have access to if it were not for the lack 
of health services. This assumption seemed to be undermined when some patients 
bargained to donate for MGE research, which suggested a sense of power rather than 
powerlessness. Members of the group tended to agree that from their experiences 
they had seen patients asking for favours in return for their participation in research. 
Other patients seemed to have information about the risk of stigmatization from 
MGE research, and the participants thought that they would tend to refuse to 
participate on the basis of that concern. 
I once had a patient who said that he won’t sign unless I go and get his medicine 
from the pharmacy. Because for me, I will stand in the queue of the employees 
and I might know one of the staff who might make it easier [laughs]… and we 
did bring him the medication. So I said, well, it is fair, I need something from 
you and you need something from me. (FG1/4) 
Some of the patients afraid of stigmatise [are afraid of being stigmatised] with 
specific genetic disorders or diseases. (FG1/6) 
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6.4.2.4 Responses to the presented data 
The themes reported to this point arose spontaneously from the conversation 
with minimal interaction from me as the focus group moderator. This following 
subsection is about how the focus group reacted to the summarised interim results of 
Phases One and Two.  In general, the substance of the discussions they engaged in 
might imply that what was presented was not far from what was really going on. The 
group’s first reaction when I had finished the presentation was one of long and total 
silence, and then participants started talking and discussing the issues raised. They 
seemed uncomfortable with the results, but they did not deny them, either. They 
admitted that they had personal experience of most of the themes. 
(a) Oversight regarding policies 
From the very beginning, participants were in agreement that what was 
reported was not the proper way to recruit patients for any kind of research, let alone 
MGE research. They attributed most of what they thought of as wrongdoing to the 
lack of authoritative, thorough inspection or oversight (they called it ‘upper hand’). 
They saw the lack of oversight as the main problem to be dealt with. 
The upper hand for imposing [enforcing] those guidelines and its rule is not fully 
activated. So, let’s take the American example, they have the FDA. … But here! 
We do not have that yet. We are not afraid that the Saudi FDA will come and 
inspect us. … So until now, we do not have an upper hand in the country. Once 
we have that, I would say that following or adherence to the regulation will be 
much better. (FG1/5) 
 They also seemed to believe that there were differences in how strict each 
institution was when it came to compliance with guidelines. 
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I do not know, but I noticed that doctors prefer to establish their genetics 
research in our hospital rather than other hospitals. I do not know, but maybe the 
restrictions in our hospital are less than those for clinical research. (FG1/1) 
Another point of agreement among the group was that they believed that there 
was a notable lack in adherence to guidelines. 
Are we following them [the international guidelines]? This is the question? Are 
we following these guidelines 100%? (FG1/6) 
Different speakers like FG1/5 and FG1/1 repeated the same question, ‘What 
are these international guidelines?’ which suggests in its face value that researchers 
do not know if there is an international code for MGE research or not. 
(b) The need to educate donors 
Educating donors about their rights emerged as a solution to most of the 
challenges that were mentioned.  
I think it has to do with educating the community, let them know that you are 
trying to do genetics research... or study, you know, Saudi Arabians in some sort 
of a family or group. (FG1/6) 
 This call for patient education was supported by others in the focus group. 
However, the term ‘patient education’ was not fully explained—i.e., it was not clear 
what they actually meant by patient education. Patient education can range from the 
basic education provided through the education system to very specialised efforts for 
specific educations, such as those targeting vulnerable groups with specifically-
tailored education activities (Branch et al., 2000). It could also take the form of 
conferences and meetings that provide educational materials (Marks, 2009). In the 
case of these participants, I think they meant about specifically educating patients 
about their potential participation even before the informed consent process was to 
take place. 
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We also need an education media to talk about research and what are patients’ 
rights if someone becomes a subject of research. Even inside the hospital and the 
committee, to approve at least a brochure or any education for patients. (FG1/3) 
FG1/5: I think this is lack of knowledge and lack of education. 
Res: Which part? 
FG1/5: It is the patient part. 
(c) The need to educate the doctors 
 On the other hand, the participants also suggested that it was just as important 
to educate the doctors. They compared RCTs regulation in GCP which is 
comprehensive and clear to MGE regulation. They thought that apart from a few 
lines in the national guidelines, there was nothing to it. 
OK! Let us all agree then that the most important thing is to educate the 
researcher himself, the... the... principle investigator. (FG1/4) 
Yes, what are the international regulations, if any? When it comes to clinical 
research I know the GCP. When it comes to genetics research, all what I know is 
few guidelines according to the NCBM. But strong, officially-imposed 
standards, I am not aware of them. (FG1/5) 
Because there are new people in the research. Maybe he is a consultant in his 
specialty, but in research he is a beginner. He needs also education in there. 
They need at least three months of coursework, at least. (FG1/7) 
It seems that there was unreserved agreement about the need to educate the 
researchers. 
6.4.2.5 Genetic material: Its importance in Saudi Arabia 
‘Genetic material’ seemed to mean any tissue that could have genetic material, 
or readily extracted genetic material. In very general terms, the presence of genetics 
research did not feature strongly in the discussion; most of what was said could be 
easily applied to any other kind of research, such as epidemiology, or even clinical 
 
 
 
 
 
212 
research. I tried to tease out what the group thought of genetic material in general, as 
an introduction to getting them talking about the genetics research specifically. 
The participants seemed to have a strong feeling about the Saudi genetic 
material, as they believed it had strategic value. They thought it could be used as 
biological weapon against Saudis. One of them actually tried to imply that Corona 
virus seems very specific in attacking only Arabs of a certain age. In a similar 
explanation, it could be the case that the group shared the belief that Saudi genetic 
material, if it fell into the wrong hands, could be used to develop biological weapons 
(e.g. viruses) specifically designed for Saudis, which could be seen as a matter of 
national security. 
…It may end up creating a biological weapon actually for a particular country or 
particular race inside that country. (FG1/5) 
Just by agreeing to send blood abroad, you are risking the society, not only the 
individual. (FG1/1) 
There is no specific touchable [concrete] reason right now, but you can see 
around us now that the Corona disease is now in the Eastern province.  I do not 
know, but the disease attacks specific people. All of them are Arab, and all of 
them are either under or over a specific age, and… (FG1/1) 
6.4.2.6 Summary 
In conclusion, the focus group was in harmony with my interpretation of the 
data from the previous phases and gave narratives to support the findings. It also 
confirmed that the focus group had experienced what can be themed as coercive 
practices in the form of giving misleading information and omitting important 
information. Also, there was enough to suggest that participants also had witnessed 
similar patterns of what I have interpreted as rushing patients into making quick 
decisions. This was for many reasons, some of them to coerce the patients, but some 
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of them were due to the lack of organisational support. However, the experiences 
participants related suggest that some patients knew what they were giving and 
began bargaining with the research team as a result. In addition, it appears that the 
group believed that Saudi genetic material needed to be protected, as it was 
considered to have strategic value. The genetic material was considered to be a direct 
threat to national security because it could be taken as the basis for race-specific 
virus or biological weapon of mass destruction, as well as raising concerns for the 
privacy of the donors who had given those materials. 
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6.4.3 Results of the second focus group 
The second focus group was run in the same way as the first: the first part was 
general discussion managed with the minimum intervention from my side around 
questions following the common topic guide. The second part asked for reactions 
and reflection on my interim findings from Phases One and Two. The general 
findings of this part of Phase Three were in agreement with all previous findings. 
This focus group consisted of policymakers some of whom had signed the actual 
Saudi National Bioethics guidance document before the King signed it as an 
indication of enforcement and political support. They also tried to defend some of the 
observed practices, as I will try to illustrate, but, in general, they tried to suggest 
corrective measures. Another important finding was that they all agreed that the topic 
was very difficult to tackle in Saudi Arabia for many reasons, including the lack of 
education. 
Among the differences I noticed between focus group 2 and the focus group 1 
was that the former assumed corrective action was needed. They tended perceive the 
data as highlighting problems that needed to be solved, including by revisiting the 
current regulations. The latter, in contrast, accepted the findings as the best that could 
be done given the context. 
6.4.3.1 Coercive Practices 
Members of the group seemed to agree that Saudi donors experienced some 
level of coercion from physicians. FG2/5 shared a very interesting story from his 
experience, as follows:  
I always quote a story about one of my patients. He has thrombosis… That 
patient happens to be a legal advisor, a legal consultant. So they were running 
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the genetics study for [advanced MGE research]. Of course they asked the IRB 
for approval and there was an eight page information sheet and informed 
consent. So the nurse… everybody who comes in they ask him to sign that and 
give his blood for the study. So the legal advisor looked at those eight pages and 
said, “Look, I will take it home, I will read it and then sign it, the proper way of 
doing it.” So the nurse went to the physician who is running the research and he 
came very upset, he torn up the pages… [Shouting] “You do not want to 
participate?!’, and he scared him. (FG2/5) 
This story was told by one of the leading bioethics experts in Saudi Arabia. 
This suggests that even among such high level bioethics authorities in the country, 
there is knowledge of a history of coercive practice. 
(a) Deception 
The composition of the group - senior, authoritative figures - had an effect on 
how the questions were addressed. They seemed more oriented toward finding 
problems, blaming them on something or someone and then trying to take measures 
to solve them. This attitude seemed to influence some of the discussions. For 
instance, they did not spend much time discussing the theme of deception. Instead, 
they agreed that it was a problem and then tried to pinpoint who was responsible, as 
the first step toward rectifying the problem. FG2/6 thought that it was usually the 
senior researchers/PIs (i.e., the people at the top of the research-authority pyramid) 
who were to be blamed, because the research teams usually aspired to satisfy them. 
Thus, research teams would pay more attention to what the PI and the research 
funding body wanted rather than to the correct way of collecting blood. 
The research centre administration or the PI are to blame in this because the 
coordinator or the research assistant want to satisfy the PI or researcher... 
(FG2/6) 
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It seems that, from the discussion, the participants assumed a power differential 
between the physician/PI and the research team. This differential influences the 
research team to defer to the physician/PI. This is in agreement with the themes that 
emerged from analysing data from the first focus group. 
(b) Who asked 
As in the previous subsection, it appeared that this group also accepted the 
premise that physicians have some kind of power over patients. The consensus 
among the participants was that they thought that the treating physicians were 
authority figures for their patients. The nature and the limits of this power or 
authority were not fully agreed upon, as there were some voices that suggested that 
they were not ultimate authorities while others suggested they were, insofar as 
patients interpreted physicians’ requests as orders. It seems that regardless of the 
limits of this power, the participants were not in favour of physicians recruiting for 
their own research. 
So it is sort of a power gradient. It is not absolute power; it is a power gradient. 
The patient is usually vulnerable and tries to be nice to whoever is taking care of 
him in terms of health care. This creates a power gradient they [physicians] can 
easily just say any words to them and they can get what they want. (FG2/01) 
 It is always known that the treating physician has some authority over the 
patient. (FG2/5) 
This also is in agreement with what was reported in Phases Two and Three in 
relation to patients giving more weight to requests from treating physicians than 
anyone else.  
The significance of their agreement that physicians had this kind of authority 
over patients is that the participants were senior researchers and decision-makers. 
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Participants in this focus group claimed to disapprove of doctors who exercised this 
kind of authority over patients.  
(c) Rushing 
This theme was not a prominent in the data from these participants. They 
seemed to take for granted as a prima facie principle that patients should be given 
time to comprehend the information and then decide. They did not think the time 
allocated to patient/doctor encounter could be stretched to include research recruiting 
as well. The group seemed to agree that rushing was a symptom of a more serious 
phenomenon: the overcrowding at clinics. 
… and to give the participant enough time to study it and ask questions. Your 8 
minutes or 10 minutes does not do it right.  (FG/5) 
6.4.3.2 Obstacles, challenges and responses 
(a) Lack of support 
The lack of organisational support was a very prominent theme in the 
discussion. The participants seemed to explain it as a function of the lack of 
manpower. A lack of manpower in the health care field meant that the few experts’ 
clinics and services were overcrowded with researchers having the same problems as 
clinicians.  
You know… one thing, Saraha [truly] it is difficult here in the clinics, the 
genetics clinics. Or the practices of our physicians here, they are overcrowded. 
(FG2/4) 
The word education was mentioned again in the context of lack of manpower. 
There was a consensus about the need to educate patients, but the main problem as 
the participants saw it was a lack of counsellors and people with the right 
backgrounds to carry out that kind of education. It seems that by education they 
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meant short, public programs that target specific groups like adult education. They 
thought many of the research ethics challenges in Saudi Arabia would be resolved if 
more people were available to facilitate this education. 
We do not have enough, let’s say, genetics counsellors—I mean the hospital has 
only two to educate people or participants. There [are] no workshops in the 
community. (FG2/2) 
6.4.3.3 Patient vulnerability 
- Suggestions of vulnerability 
At the outset of the focus group meeting, and before giving any data, it was 
clear that the issues of patient vulnerability and ignorance about the genetics research 
challenges were familiar to the members. Many voices shared the same concern that 
the nature of the Saudi people and their general level of education might prevent 
them from comprehending what their donations for research entailed. 
I’ve had that for a long time… haunting me… our... people in our country, in 
our society might not realize the actual dimensions of donating blood, as to what 
the consequences might be or what the future might reveal or what information 
could be taken out of the sample they delivered. (FG2/01) 
Participants suggested that the complex nature of MGE research did not lend 
itself to simplification for the average person and some level of a technical 
terminology may be necessary. The topic itself is new to the average person. Among 
the things that are not mentioned even in the education programs is the fact of our 
genetically homogenous society, wherein blood from one family or group of families 
can give information about a whole tribe. Thus, it seems that educating members of 
the public sensibly about MGE research, without scaring them, is not an easy task. 
This might be seen as an area in which patients are vulnerable because they are 
ignorant or perceived to be ignorant by PIs. This may undermine consent because 
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patients do not comprehend what they need to before making decisions about 
participation. 
I do not think that they are not aware only about the consequences, but also they 
are not aware about the genetics research itself. They cannot understand… most 
of the people, see… with the education standards… even people who [have] 
university degrees, they cannot understand well what genetics research is. 
(FG2/08) 
It seems also that there was agreement about the vulnerability of women to 
stigmatisation. As I tried to explain in the second chapter about the context of the 
Saudi culture, a stigma is more serious if the stigmatised person is female. 
Regarding females… some of them feel [the discrimination], and if they became 
stigmatised they will become more discriminated [against]. (FG2/7) 
- Patient vulnerability counterargument 
In the previous subsection, a few researchers shared stories about patients who 
had bargained with them over participating. The theme was not as prominent in this 
group as in the previous group. However, a few voices shared stories that counter-
balance evidence that patients are vulnerable. Some participants shared stories about 
patients who seemed knowledgeable. For instance, some patients refused to 
participate in MGE research because they feared stigmatisation. There was a sense 
that some of patients felt that participating in MGE research was some kind of a 
sacrifice that they are not willing to make for society. 
[They would say], Why should I go to participate? Why? Do we want to put 
ourselves at risk to be stigmatised… in the future… just to benefit the society? 
(FG2/7) 
 This was rated as a counterargument as it exhibits the ability to question and 
reason with the physician. 
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- Suggestion of the presence of some knowledge 
It was in this group of participants that data emerged to suggest that they 
thought that some patients do know about the potentially stigmatising effects of the 
results of MGE research. It was interesting to hear that, in their opinion, patients had 
appeared to act on this fear and refused to participate because of the stigma that 
might come with it. The experiences members shared about Saudi patients who had 
not wanted to know about their results may also reflect a similar fear, or so the 
participants seemed to think.  
But you know, at the tribe level, we know [a] certain disease [is] common in this 
tribe. They would say, “Why do you say [that] about this tribe, why do you 
mention this tribe?” [It is] always like that. So it is difficult, really, to deal… or 
convince, you know, people to donate or go on this. It’s fact of our society, 
[they] do not want to know about their results. They enjoy the veil of 
ignorance… (FG2/4) 
We have a [disease] carrier test that was conducted a few years back, and we 
noticed the pilot study taken from hospital staff, doctors, paramedics and 
pharmacists. And the majority of them, when we informed them that “You are a 
carrier,” [and that] “We should screen your husband or your wife if you are 
planning future for marriage.” They ignore it… they ignore it… they do not 
want to know the answer… Sometimes people do not want to know the future. 
[They say,] “Just let me live with peace of mind and when it happens, it 
happens.” (FG2/2) 
At the same time, the participants shared experiences that they understood to 
indicate that knowledge was not always a deterrent to participation. The participants 
shared examples of patients who were fairly educated about the risks, including the 
stigma and how the tests give information about more than just the individuals who 
donate, but elected to donate anyway. The consensus within the group was that the 
main reason patients donated in these cases was that they had altruistic motives.  
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Some people, of course, they may have some sort of altruistic attitude that they 
want to benefit the society with this research. That one thing: they know what 
they are getting into; the stigmatisation was mentioned, and so on. (FG2/5) 
The participants had an interesting round of discussion when they started to 
reflect on and beyond the scope of genetics data in controlled health domains. 
Providing information resulting from genetic testing on uncontrolled websites that 
had started to be available to people outside the scope of health care—for example, 
websites with family tree information and family genealogies—was condemned by 
all the participants. The problem, as the participants saw it, was that Saudis started to 
use those uncontrolled websites to prove blood purity and in some cases to gain some 
kind of tribal nobility, as explained in Chapter Two. With the focus group’s 
awareness about this sort of challenge, participants shared stories about lay people 
trying to use genetics technology available through these sites to prove nobility. This 
discussion suggests that there is not total ignorance about genetics in the Saudi 
population. On some public websites, there are very sophisticated discussions 
amongst the visitors to those websites about how to make sense of the genetics 
results these sites provide. One of the policy makers made a joking remark about one 
of his own relatives who suggested sending a buckle cell to the website so that they 
could try to confirm a higher social status, following the leads of another family of 
remote relatives who are now claiming that they have scientific proof that they are 
related to the purest blood of all, Al Ashraf.  This kind of action is unregulated, and, 
according to this group, regulating it would not be an easy task. 
I have been approached many times by groups of people or individuals from my 
family. They want to send a sample to the United States or Germany to find the 
DNA tree. I mean, to confirm [that they are] from this family or this tribe. They 
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are sending it without any controls! They just take a blood spot, and they send it. 
(FG2/2) 
We can tell you that… not only Onaizy or Harbi, no, we can tell that you [are 
from a specific] Harbi family… I had a guest, last week, from our village. He 
said, “Do you know x family from the other village?” I said “No,” he said, “Now 
they have become Ashraf [descended from the Prophet Mohammad’s blood].” 
(FG2/5) 
6.4.3.4 Responses to the interim analysis 
- Overview of policies 
There were a few voices suggesting enforced anonymisation as a solution to 
the stigmatisation risk. Those who suggested anonymisation thought that it would 
address the stigmatisation risks as well as most of the problems related to donor 
identity, like the promise of giving results (if the patient’s identity is anonymous, 
then the results cannot be promised by the PI or expected by the patient). 
Can we avoid all of that by completely anonymising all the samples that we are 
taking, so there is no stigma related to an individual? (PG2/7) 
Anonymisation might be able to deal with some of the risks around MGE 
research. In the literature it has been suggested that genetic material is not fully 
anonymizable (Gitschier, 2009; Boddington, 2012). The policy makers did not 
appear to have taken this aspect into account when proposing anonymity as a 
solution.  
The discussion took an interesting turn when I asked about how the group felt 
about using religious terminology in the recruitment process. Participants started 
talking about the larger role of religion in the Saudi Arabian bioethics guidelines. 
Religion, they felt, can inform the guidelines by providing a framework or 
principles for ethical research conduct. They seemed to believe that even the four 
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bioethics principles of Beauchamp and Childress (2009) and the CIOMS guidelines 
were compatible with Islamic teachings. 
An Islamic scholar in an Islamic organisation of medical science … studied 
these guidelines … and they found it is compatible completely. (FG2/08) 
They also thought that religion could improve both researchers’ adherence to 
guidelines and patient participation rates:  
Probably [religion] leads the way to better understanding and better cooperation 
by people if such factors could be involved or incorporated, somehow, into the 
regulation. (FG2/1) 
They suggested that religion might also be important in any sort of decision 
including medical ones. 
 I think religion plays a major role in major decision[s] in life, especially [in] our 
country. (FG2/02) 
 If… if… I speak to someone as a physiologist or atheist, they would say… 
“OK… the Shaik Aish yeqool [what does the religion say]?” Even if somebody 
is a physician that would speak volumes, but then they will wait and in the end 
ask, “Is it acceptable, is it permissible?” It will be taken as a fact if, only if, it is 
permissible by the religion. (FG2/01) 
Who should control or benefit from the genetic material and data formed part 
of the discussion. Participants explored ownership in Islam and applied this to 
genetics data. As per some Islamic secular understandings of ownership, both the 
genetics data and the genetic material can be seen as areas to be controlled, they 
thought. In the beginning, some members of the group thought that what mattered 
was the information that could be taken from the material, not the material itself. 
Eventually, there was an agreement within the group that both the material and the 
data can be controlled under Sharei’ law.  
 
 
 
 
 
224 
 It’s not the material itself. It’s not the sequence… it’s not the material itself, it’s 
the sequence, maybe, or the mutation therein, and how you can benefit from 
that. It’s… it’s a matter of knowledge rather than the material. (FG2/01) 
[Genetic] material is sitting there, it doesn’t have any benefit unless the 
researcher has invested time and effort and generated information. The 
information that is generated from that is… what is of a sellable value. (FG2/5) 
So it could be worthy [of benefit] also to generate that material again. So I think 
both sides. (FG2/4) 
- The need for education 
The very first response to the interim data was a long pose followed by 
conversations among the group that they are disappointed.  
This [The lack of adherence] is shocking… because these are procedures. Those 
procedures should have been carried out very easily without any detour to that 
what been emphasized in the regulations… so we are shocked that there is still 
been clumsily executed. (FG2/1) 
Based on that, education to both researchers and patient was suggested as a 
way to overcome the failure in adherence to the Saudi regulations. 
Unless you concentrate on [educating] people as much as you can… and on 
increasing the awareness through the… umm, ya’ni [I mean] media [or] things 
like that… I think people will accept things like that. (FG2/4) 
There [are] no workshops… for the community, I mean, like… some 
advertisements. For example, King Saud University, they have a community 
service department. They announce if there are workshops in computer skills… 
in writing skills. There are no workshops or even sessions regarding research or 
regarding genetics. (FG2/04) 
It is not clear from the discussion what sort of education they were suggesting. 
The closest attempt to giving an idea of what education was needed was the idea that 
it should be an official governmental effort supported by universities in the form of 
short courses or conferences and given to those selected to donate blood for MGE 
research. 
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Some voices agreed that educating patients is not an easy task, but suggested 
the alternative would be stopping the MGE research altogether, which was not 
considered a realistic solution.  
It is a far-fetched target, if you want to increase their awareness in the 
population, if you want to be certain that you are avoiding those aspects, the 
ones you’ve raised. Probably the easiest thing is to say, “Do not start any 
genetics research until you are certain that no ethics is involved with that 
subject,” but that is not realistic. Genetic research has to start at a certain point, 
but you have to minimize the impact of the negative aspects that you just 
mentioned. (FG2/01) 
6.4.3.5 The importance of DNA 
The group express their opinions on whether genetics research could pose a 
challenging ethical question due to the country’s tribal culture and its peoples’ shared 
DNA mutations. They were also in agreement that tribal stigmatisation is one of the 
main concerns, as the group discussed earlier. This was mainly because of the 
possibility of gaining too much information about large groups from blood taken 
from a few families. They added also that it could reveal unwanted information, like 
that patients are at risk of some serious diseases. 
Some, they know, just to know from which area they come… and… in some 
areas in Saudi Arabia there is nasopharyngeal carcinoma… It is very common… 
They know in certain areas there that if people are coming from there, they have 
it… It is not an individual stigma; this is a group or tribal or societal stigma. 
(FG2/2) 
It could also be looked at in a reverse way. If you’ve got a mutation, then you 
can tell which tribe that is. So, this is also sort of a sensitive issue that needs to 
be considered in the regulations. (FG2/01) 
In the first focus group, there was virtual consensus that the Saudi genetic 
material has some tacit strategic value and ought to be protected from being sent 
abroad for research without very thorough regulations or active monitoring. This 
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group shared these concerns. It appeared that there was unanimous agreement that 
Saudi genetic material should be protected for national security reasons. 
So this something that is very, very strongly at the heart of Al Amn Al Qaumi 
[national security]. There will be a time, I do not know when, but a time will 
come when people could decide that because of our genetic makeup they could 
send drugs that either could affect us positively or negatively. (FG2/01) 
Some of the participants seemed concerned that this genetic material was 
already used by other organisations without official Saudi permission.  
We had a visiting professor three months [ago]. She was giving us the 
opportunity to take quantities of genome results and to share it with us to have a 
legal umbrella…She said that “the problem is that I already collected some, but I 
need more.” Then I consulted [the research director]. He said it is not allowed 
according to the [Saudi] guidelines. (FG2/4) 
It also very important to note that the participants suggested that there are fluid 
boundaries between diagnostic work and research in the genetics field. This meant, 
according to them, that if we accept the premise that DNA has strategic value, even 
the diagnostic work should be looked at critically. The discussion went on to reflect 
on the fact that sometimes physicians are confronted with difficult cases that they 
cannot diagnose; they may then ask an international laboratory for full exon analysis 
(i.e. similar to individual gene mapping). As a result, those international laboratories 
seem to ask for full rights over the given material. The data that will be gathered 
from such laboratory work will be similar to the data gathered by MGE researchers. 
They then started to express concerns that the material and the information will be 
retained by the international organisations with consent to do anything they want 
with it. 
I mean, you send, for example, for the whole genome sequencing, for exon 
sequencing because you do not know what the patient [has]… Like you are 
fishing [laughter]. (FG2/2) 
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6.4.4 Conclusion 
Taking the data from all three phases into account the overarching finding is 
that there appears to be a difference between the aspiration for practice found in the 
written regulations and actual practice. 
6.4.5 Section Two Summary: 
So far, in the first section, I provided a normative analysis of the international 
guidelines that were used to inform the Saudi NCBE regulations. I also assessed in 
Section One the tensions between the NCBE regulations and Saudi culture and 
values. 
This second section was dedicated to answering the research questions 
concerning the extent to which the analysed guidelines in Section One are followed 
in practice. Also, I assessed what seemed to be the challenges of collecting blood 
from Saudi donors for MGE research, as perceived by the stakeholders. Then, I 
assessed the feedback of those charged with generating the Saudi guidelines and 
norms for research to the results of the investigation into current practice in relation 
to blood collected for genetics research.  
I am now in position to bring the findings from this section to bear on the 
issues and ideas discussed in Section One.  
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Section Three: Discussion and recommendation  
7 Chapter Seven: Discussion 
7.1 Overview 
In this chapter, I will argue that, due to the absence of specific oriented MGE 
research ethical guidance that is written with the Saudi culture in mind, MGE 
research should be seen as posing many challenges to the current NCBE regulations 
and that we need to move to more culturally-appropriate guidelines. In order to argue 
for this conclusion I will consider two pieces of evidence. First will be how blood is 
considered in the Saudi context. This will be explored in light of the findings 
outlined in the previous section and additional further evidence from Saudi culture, 
along with my personal reflections.  
Second will be an argument as to why some elements of the autonomy-based 
bioethics (i.e. specifically the part that suggests individual informed consent should 
be at the heart of research) is not the best framework to adopt when considering 
using donated blood for MGE research in Saudi Arabia. This will be in two parts; the 
first will establish the presence of the influence from western assumptions about 
ethics. This will be done by discussing the concept of consent as well as vulnerability 
and paternalism. The second will outline why an autonomy-based ethics approach, as 
understood by the Saudi policy makers, would be problematic in the context of MGE 
research in Saudi Arabia. According to the arguments presented in Section One and 
the data presented in Section Two, some elements of the autonomy-based ethics can 
be seen to be in conflict with what was presented as Saudi cultural characteristics. In 
this chapter trust-based ethics will be investigated more closely as one of the possible 
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alternatives to the autonomy-based ethics in the analysed context of Saudi Arabia. In 
addition to that, I recognise the potential to commit the is/ought fallacy (see 
Subsection 1.4.2 The is/ought fallacy) and to appear to take a particular side in the 
wider debate around cultural relativism. Therefore, I will start this section with an 
argument as to why this work should not be regarded as appealing to moral 
relativism.  
Having provided the overall outline of this chapter, I will now discuss the 
issues in detail. 
7.2 What the findings can be taken to imply 
In this subsection I will introduce the dilemma of how to understand the 
collected data. One interpretation of my results is that they point to a total failure to 
comply with the regulations for research in Saudi Arabia and that this is a major 
problem that needs to be corrected. Such a discourse of failure would call for 
stronger, and much firmer, guidelines in terms of education, encouragement and 
policing. Another interpretation is that the lack of adherence to the guidelines 
suggests that the guidelines themselves are not followed because they do not reflect 
important normative beliefs in Saudi culture, and this suggests that it is the guidance 
that needs to change and not the practice. Local guidelines, from this point of view, 
should reflect local cultural norms, rather than adopting wholesale the normative 
assumptions that drive the international guidelines. 
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7.2.1 The discourse of failure 
In Chapter Four, I introduced the notion of an autonomy-based approach to 
bioethics that is prominent in research guidelines and appears to have been the 
strongest influence on the Saudi guidelines (see Subsection 4.2 Autonomy-Based 
Bioethics). The findings presented in the previous section suggest that some 
researchers seem only to be complying with the formal requirements of gaining an 
informed consent: i.e. ensuring that there is a document called an ‘informed consent’ 
that has been signed by each participant recruited. The actual presence of what is 
called an ‘informed consent’ with a signature on it should not eclipse what informed 
consent is meant to represent (i.e. competence and voluntariness, and also an 
information element (see 1.1.1 Informed consent.) Themes from the collected data in 
Section Two of this thesis suggests that in some cases informed consent was not 
recorded in the way it was intended by the NCBE (See Subsection 3.2.4 Informed 
consent.) For example, in Phase One, the theme of deception could imply that some 
Saudi researchers are not complying with the enforced Saudi research guidelines. In 
Phase Three, the Saudi policymakers seem to respond to that implication with 
‘shock’, suggesting that at least some of them accept the narrative of failure to 
comply with the NCBE regulations. Therefore, corrective action (i.e. more 
education, and then discipline) is needed. 
Empirically, the discourse of failure could be regarded as a convenient 
narrative because it apparently captures the first reaction of many of the Saudi 
policymakers to the data presented in this thesis. However, such an interpretation 
suggests that the international guidelines capture the relevant universally accepted 
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norms (e.g. individual liberty) and should be adhered to by the Saudis when it comes 
to MGE research in Saudi Arabia. From this point of view, it seems that we have 
strong indications that most of those who participated in the empirical part of this 
thesis treated their research subjects in an unethical manner by focusing on gaining a 
signature in the document as if were all that is required for an ‘informed consent’. 
However, such a view suggests that the international regulations must be adhered to, 
with no excuses or exceptions. It assumes that such guidelines capture what is 
universally important and ought to be applied universally. However, it could be 
argued that such an approach misses the importance of the observed cultural reality 
and this is something that must be taken into account when we think about how to 
make our moral judgments (Dawson, 2013). Accepting the discourse of failure 
would, therefore, run “the risk of over-generalizing moral discussion by appealing to 
abstract and absolutist moral formulations” rather than responding to the particular 
case before us (Dawson, 2013 p.2). 
A clear example as to why local context matters to our ethical evaluation can 
be seen when we consider the meaning of blood in a tribal culture such as Saudi 
Arabia (see Subsection 7.3 The importance of Blood in Saudi Arabia). Giving an 
ultimate right to individuals to share or not share their genomic material for research, 
as the international guidelines do, ignores the fact that any results may potentially 
cause harm to a whole tribe due to the genetically homogenous nature of the Saudi 
tribes (see Subsection 1.3 Challenges of MGE research in Saudi Arabia). The same 
can be said if the state believes that the blood of its citizens ought to be protected for 
 
 
 
 
 
232 
national security reasons; autonomy-based bioethics would also be problematic and 
more difficult to justify. 
It is equally important, also, to note that the notion of blood purity and its link 
to identity is so central to Saudis that, by insisting on a set of guidelines that do not 
take those issues into account, we may threaten or potentially damage identity issues 
and community issues that are really important in that culture. Imposing autonomy-
based guidelines and their concentration on individual informed consent, at the 
expense of potentially damaging what is important to a local culture, can be seen to 
be ethically problematic. So, one might consider that it is for the concerned tribal 
community to decide whether or not certain kinds of outcomes that are promised by a 
specific piece of research are worth having, given the risks to the individual and the 
collective. Even if individuals are asked to consent to participate, and sufficient 
individuals agree to do so, and we assume that they understand what they are 
agreeing to, it does not mean that the tribe or community as a whole has been asked 
to consider whether, on balance, it believes that the research is worth doing and/or 
meets its needs. Of course, just because a community, on balance, agrees that a 
specific MGE research might be useful does not therefore imply, necessarily, consent 
for each individual in that population to participate has thereby been gained.  
Even if we choose to reject the discourse of failure, and accept the need to be 
sensitive to local context, it is important to see that this does not necessarily mean 
adopting moral relativism.  
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7.2.2 The discourse of moral relativism  
The discourse of moral relativism would suggest that the Western-ethics 
dominated international guidelines have shaped Saudi policy and that this is 
inappropriate. It is important to see that an acceptance of the importance of social 
context does not necessarily mean accepting moral relativism. Critiquing moral 
relativism would require a thesis in its own right, and space is limited. Nonetheless, 
it is important to recognise, at least schematically, its potential strengths and 
weaknesses.  
Moral relativism, as described by Sheehan (2007, p93), is the view that any 
moral judgment must be made from within, or relative to, a culture or society. Thus, 
according to Sheehan (2007) there is an absence of universal moral truth that holds 
across all cultures and contexts. Thus, different cultures may have different answers, 
and each may be regarded as correct within a specific cultural context.  
It could be attractive, in the context of this thesis, to adopt a position of moral 
relativism and argue that different ethical norms can reasonably be applied in the 
context of research ethics within Saudi culture as opposed to Western culture. Such a 
stand would call for totally rejecting the current Saudi research guidelines, given 
their Western origins, and the production of a new set of guidelines based on an 
informed and rigorous understanding of what is culturally acceptable to the Saudi 
population. 
The main challenge of moral relativism is that it tends to state that there is no 
universal moral truth. In a way, this could lead to more tolerance towards other 
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cultures, but it also means that practices, such as female genital mutilation (FGM) in 
Africa (Macklin, 1999), should be accepted by those outside of Africa (at least 
within Africa) because it is acceptable to those who share this cultural practice. In 
the west, FGM is condemned ethically and legally, and rated as a human rights abuse 
(Cook et al, 2002). Similar kinds of cultural behaviours would be difficult to defend 
as morally acceptable practices unless moral relativism is embraced.  
Some anthropologists/sociologists see the acceptance of such cultural 
behaviour as being a way to show tolerance to others and avoid imposing their 
(Western) cultural norms about what is right and what is wrong on other cultures 
(Macklin, 1999; Dawson, 2013).  However, one potential challenge to moral 
relativism in this context is that the appeal to the value of tolerance itself seems 
inconsistent with the idea that values are only culturally-specific. One way out of this 
position is to see that moral relativists might be forced to accept that there is at least 
one universal value, namely, tolerance. The coherence of such a position can be 
challenged because, for example, if society A is intolerant of society B, then society 
B ought to accept this fact if they accept relativism, because A’s societal views 
govern A’s behaviour even if this is a problem for B. In the context of MGE 
research, if society A does not believe in the importance of informed consent by 
individuals, they can basically collect blood from anyone using any means. If 
relativism is embraced, society B should not reject research collaboration with 
society A on the grounds that they do not share similar consent processes and norms, 
even if society B detests the action of conducting research without what they 
consider to be the proper informed consent procedures.  
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As mentioned earlier, in the context of this thesis, it could be an attractive 
position to appeal to moral relativism in order to respect Saudi cultural diversity. 
According to such a position it could be argued that individual autonomy is not 
something that is appreciated in Saudi in the same way as in the West, Therefore, as 
a gesture of tolerance, we ought to accept that it is acceptable to receive donated 
blood for MGE research in Saudi Arabia without consent. However, the problem 
with this approach is that “such practices are [only] to be understood, but are not 
legitimately open to debate, not to be labelled as wrong, and presumably not to be 
the focus for change” (Dawson, 2013, p2.) If moral relativism is embraced in order 
to understand the presented data, then we cannot label moral claims as right or wrong 
(Macklin, 1999; Dawson, 2013). This is attractive because it does not require any 
effort to change the status quo. Any judgment about any ‘wrongdoing’ can be 
attributed to cross-cultural differences. However, it is problematic because even 
inside the same culture, smaller groups could have different way of doing things. For 
example, I reported in an earlier publication a case where a huge family (more than 
40 persons) came in at the same time, driving from a remote place to a Saudi hospital 
to donate blood to a particular MGE research. The case was unusual and when 
investigated the research team found that the family elder (i.e. the one decide for the 
family) had been convinced by the physician/researcher that donating blood for this 
MGE research was a charitable act that would be rewarded generously in the 
hereafter (Adlan, 2013). In the data collected for this thesis a similar attitude towards 
recruitment was visible, namely convincing donors that donation was a charitable 
action and showed piety. Such action could be deemed as acceptable if we want to be 
consistent with the account of moral relativism, but in the view I am defending it can 
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be seen to be disturbing and could result in more difficult or rather impossible to 
justify actions. So, criticising autonomy-based guidelines in the context of Saudi 
Arabia does not mean accepting using genetic material without consent.  
Now, having argued against both the narrative of failure and the narrative of 
relativism, I will discuss how I suggest the data should be considered.    
7.2.3 Embracing the importance of social reality  
As I argued before, both the narratives of failure and of relativism are not the 
best way to look at the data in hand. The characteristics of an alternative plausible 
approach, I argue, must be both modest epistemically and modest ethically (Dawson, 
2013):  
 Epistemic modesty can be seen as a non-ideological pragmatism, as 
“accepting that we can be in error, proposing interpretations and 
proposals cautiously, open to discussion and the need for revisions in 
our view” (Dawson, 2013, p3). It reflects the importance of the 
empirical data and how they can be essential to understand the culture 
and its social context in order to provide the best ethics advice. This, 
however, should not be seen as moral relativism. In addition, such a 
view can be seen to assert the importance of the normative within 
bioethics. Epistemic modesty allows us to look at empirical data 
critically, allowing them be fully understood and analysed. Based on 
that, a normative moral judgment will be produced and we should not 
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be afraid to say that any practice is wrong if we believe it is so, and 
then use this judgment to produce further argument or policies.  
 Commitment to epistemic modesty implies being modest ethically 
insofar as “our moral judgments must also be open to reflection, 
discussion and the capacity for change.” (Dawson, 2013, p3.) 
To provide ethical answers within this understanding fits directly with the idea 
of encountering the Saudi MGE research experience that was explained earlier in 
justifying the choice of methodology (see Subsection 1.4 The Need for Empirical 
Data). Ives (2008) describes an encounter with experience as ‘[b]ringing 
philosophical ethical analysis to the ground, and rooting it in real people and in real 
problems’ (Ives, 2008). In the first section of this thesis I produced an understanding 
of the international guidance and used philosophy to determine and justify what 
reasonable guidelines should seek to achieve. I then attempted to find out what Saudi 
stakeholders, in the context of MGE research, thought. It is important to let the first 
section encounter the second and use reflective balancing to produce a ‘theory’ as to 
how the guidelines and future practice should look that both reflects the philosophy 
and the experience.  
After deciding how we ought to look at the data in hand, we are in a position 
now to introduce the argument that the current regulations are not an appropriate way 
to regulate MGE research in a social context like the Saudi one. In order to do so I 
will introduce how blood is regarded in Saudi culture.  
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7.3 What is blood in the Saudi context? 
In the previous section, I reported how confusion may occur generated by 
using the words for ‘donation’ and ‘participation’ interchangeably, and how this 
confusion had normative overlay related to the way in which charity is perceived as a 
religious duty in Saudi Arabia. If MGE research in Saudi Arabia is to be regulated 
appropriately, this regulation will need to acknowledge and accommodate the 
cultural significance of ‘blood’ in Saudi Arabia, and how this might differ according 
to context.  
7.3.1 Blood in the Islamic literature: 
As I explained in the introduction, Islamic values are central to Saudi culture 
(see Subsection 1.2.1 The Social Context in Saudi Arabia). Religious commitment is 
taken as a given, and for this reason social guidance often comes from religious 
sources. For example, insulin dependent patients are advised strongly not to fast 
during the Holy month of Ramadan because it could lead to serious hypoglycaemia 
and risk death of the patient. When it became clear that some diabetic patients were 
not heeding this advice, the MOH appealed to the Saudi religious leaders to issue a 
Fatwa forbidding such people from fasting (Adlan, 2013). Therefore, understanding 
how Islam thinks about blood is essential to understanding blood donation for 
research in a Saudi context.     
Blood is a frequent topic of discussion in Arabic and Islamic literature and is 
used in many ways with different meanings being attributed to it. One example of the 
word in Islamic literature equates it with life. In the Quran, many verses feature the 
word ‘blood’ with reference to ‘life’ in the sense that shedding blood means killing a 
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person: ‘And when we made a covenant with you: You shall not shed your blood…’ 
(Al Baqarah: versus 84). A similar notion is expressed in the Hadeeth (the prophet’s 
words), as narrated by Al Tirmidhi: ‘Everything belonging to a Muslim is inviolable 
for a Muslim; his honour, his blood and property. Piety is here (and he pointed to his 
chest thrice)’ (Hadeeth 234 An-Nawawi, 2014). These metaphors were common to 
ancient Arabic societies, where blood was a signifier of connection, life and honour.  
7.3.2 Blood in the Saudi context: 
In the Saudi context, there are generally three different perceptions with regard 
to donating blood. Firstly, it is seen as an opportunity to act altruistically with only 
godly rewards expected in return. There are many reasons why this notion seems to 
be rooted most in patients’ minds:  
1. The advertising campaigns in the media seeking blood donation for 
clinical blood banks. 
2. As a result of those companies the media seems to equate donating 
blood to saving lives. 
3. The act of saving a life is among the best rewarded actions in Islam; 
as the Quran says, ‘…and whoever keeps it [a man’s life], it is, as though he 
kept alive all mankind’. 
4. The other Islamic notion of eternal charity is also a factor, as 
explained earlier. 
5. For many years, the finalization of Saudi driver licence paperwork 
required the proof of a recent (less than two months old) blood donation. In 
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other words, a person needed to donate 500ml of his blood to a local blood 
bank and get a stamped and dated certificate to include it in the driver licence 
application. If someone was unable donate for a medical reason, a waver 
certified by their hospital had to be produced instead. The King Faisal 
Specialised Hospital and Research Centre blood bank mobile clinic used to 
be parked outside the driver licensing offices in the main cities to withdraw 
blood from those seeking a driver licence and then provide the required 
certificate. Currently, it is not clear whether this is still an active obligation. 
The official site of the ministry of the interior (MOI, 2014) does not mention 
this obligation while Okaz, a daily newspaper, reports that despite the fact 
that the MOI does not mention it on its official website, blood donation is still 
a requirement and driver licence applicants are expected to present that 
certificate in the main cities (Okaz, 2010). 
6. The governmental honor program known as the King Abdulaziz 
Medal is presented to those who donate blood more than 10 times. This 
incentive, someone might argue, undermines the notion of altruism insofar as 
people might donate blood for the medal and the opportunity to shake hands 
with the King or the King’s delegate. 
In the interviews, there were clear signs of confusion between three purposes 
for giving blood: donation to blood banks for use in the treatment of other patients, 
donating blood as part of a MGE research project, and providing a blood sample for 
clinical investigations as part of one’s own on-going clinical care. I noticed people 
speak with pride when they mentioned that they have donated blood. One of the 
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participants mentioned that he would donate blood every month if his health would 
permit him to do so when I asked him about his experience in donating blood for 
MGE. Confusion persisted in my own research existed me taking care not to use the 
world tabru which is linked to donation for people in clinical need (See Subsection 
6.4.3.2 C. Vulnerability of Saudis wishing to appear to be devoted Muslims).  
All of the above helped reinforce the notion of blood in Saudi Arabia as 
something valuable. It saves life; it gets you a highly ranked honour medal given by 
the King’s representatives; it is a pre-requisite for obtaining a driver's licence.  
The cultural and tribal norms of honour, linked to tribes’ generosity, represent 
an additional factor that endows blood donation with connotations of virtue. 
Consequently, abstaining from donating blood is given very negative connotations 
and is denounced and rejected by most Saudis. Indeed, refusing to donate blood for 
blood banks based on a hospital's request or the call of a friend requires strong 
justification. In fact, an act of bravery is required to challenge linking blood donation 
to godly rewards and tribal generosity (See Subsection 6.4.3.2 C. Vulnerability of 
Saudis wishing to appear to be devoted Muslims).  
The second widely held notion of blood’s status in the Saudi context concerns 
its value as a commodity, though not one with a literal monetary value. Some 
participants seem to describe donating blood for the purposes of research as a kind of 
transaction between the doctor and the patient. What they suggested was that patients 
offer blood and research teams offer in exchange a more compassionate service and, 
in some cases, special treatment. Hence there were reports of patients requesting 
specific favours in return for donating blood. This is exacerbated by the nature of 
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Saudi health care and the long waiting lists that sometimes deny patients care even 
when they need it urgently. Patients clearly feel that accommodating the research 
team will pay off for them in terms of accessing health care.  
7.3.3 Blood as identity tool  
In this subsection I will draw attention to how information derived from blood 
is currently used among Saudis, and some non-Saudis as a tool for political gains 
such as entitlement to Saudi Nationality. I build upon the evidence that other nations 
reinforce identity through the use of genetics. I will also reflect on what was 
presented in in Chapter Four (Subsection 4.6 Sending Saudi genetic materials outside 
Saudi Arabia) about how MGE research is being used as a tool to racially label Saudi 
tribes as either superior or inferior. This subsection draws attention to the serious 
repercussions of allowing MGE research to continue without specific regulation.  
In the Saudi political system, nationality is not a birth right in the sense that not 
every person born and raised in Saudi Arabia is entitled to be Saudi. This status is 
mainly determined by the father’s nationality, with some limited exceptions. For 
instance, offspring may obtain Saudi nationality if their mother belongs to the third 
generation of a Saudi family (i.e., if there is documentation proving that her paternal 
grandfather was originally Saudi).  
Furthermore the tribal borders are different from, and older than, the 
contemporary Saudi political borders. This means that, for example, tribal members 
who are inside the Saudi borders are distinguished from members of the same tribe 
outside Saudi borders. As a result, a system has been put in place so that tribal 
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members who are outside the boarders could be identified, so they can assert rights 
of reunion with their fellow tribe members inside the Saudi boarders. Previously, it 
was the responsibility of the tribal elder to write to the state, notifying them that a 
person was a blood relative and a tribal member. Based on the elder’s 
recommendation, a case would be opened and the state would study the case 
carefully prior to issuing a ruling on it.   
In recent years, people have been advertising in newspapers such as Al Sharq 
Al Awsat, AL Jazeerah, Al Watan and Okaz to request that the available genetics 
technology be used to provide evidence of entitlement to the Saudi nationality on the 
basis of a blood relation to a Saudi tribe member (AlRiyadh, 2012). A similar notion 
of biological citizenship was reported among the indigenous tribes in North America 
and the Native Americans, who sought entitlement to a list of benefits aimed at 
native Americans. In Vermont in the USA, for example, a bill was proposed in the 
General Assembly of the State of Vermont to establish standards and procedures for 
DNA testing in order to provide evidence of race identification (TallBear, 2013).  
For centuries, essential factors such as sharing blood, culture, geography, 
history, and loyalty, combined to determine Saudi tribal identities. Most people are 
proud to be linked by blood to their tribe, which gives them access to many 
privileges that would not otherwise be available to them. For example, marriage to a 
tribal woman is a guarantee of financial, legal, cultural and other types of support by 
the tribe’s political structures. Before ‘disembodied’ genetic information, tribal 
systems were like clubs with only a birth right membership entitlement. With the 
presence of DNA technology, people began to question each other’s blood purity and 
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in some cases, demanded that individuals ‘clear’ their names by volunteering to test 
their ancestry. A similar trend was reported by TallBear (2013) in her work on the 
genetic identity of Native American tribes; she thinks people seek these expensive 
tests for two main reasons: 1) to establish a lineage link in order to get access to 
benefits, and 2) for genetic anthropology reasons (TallBear, 2013). In contrast, while 
some scientific efforts in Saudi Arabia are dedicated to understanding Saudi genetic 
anthropology (Abu-Amero et al., 2009), the main consumer interests are to validate 
their claims to a certain status/membership.  
MGE research has the potential to promote blood purity by providing a new 
means of identity verification based on genetic traits. In the subsection on normative 
challenges, I described how blood purity could be seen as a racist tool with 
dangerous consequences (see Subsection 4.6 Sending Saudi Genetics Material 
Outside Saudi Arabia). Some tribes start to aspire to claim nobility based on genetic 
traits, and this notion becomes dangerous when groups use this to downgrade another 
tribe using genetic testing, claiming that members of that other tribe are not of pure 
blood.  
According to the website of the Texas-based genetic testing company 
www.FamilyTreeDNA.com their ‘…long term goal is to link written Arabian 
genealogies (tribal kinships) with DNA science in order to find genetic signatures of 
tribes, interrelationship between Arabian tribes and their common groups’. Arabs 
have one of the most detailed and intertwined subsection on their website. According 
to the members of both focus groups in my research, such genetic signatures are 
exactly what the Saudi policymakers and some of the senior researchers are trying to 
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protect society from with their activities in the field or when attempting to articulate 
related articles in the guidelines. The problem is that, the access to this service is not 
regulated.  
Websites such as www.familytree.com seem to introduce a new approach to 
social ranks among the Saudi tribes. The joking remarks from one of the focus group 
members about his cousin’s invitation to send blood to one of those website to prove 
noble blood, gave an indication that such websites and their use may be raising 
awareness of the potential problems of an emerging new genetic identity.    
Members of the second focus group were very sceptical about the service 
provided by those websites. They thought that such activity was gaining momentum 
among Saudis and should be looked at carefully. The main challenge is that the 
current policy fails to provide guidance about these website practices.   
7.3.4 DNA ownership 
In this subsection I will discuss ownership of DNA material as mentioned in 
the Saudi guidelines. The importance of this point stemmed from the fact that the 
NCBE regulations tried to solve the above mentioned challenges by asserting what 
the policymakers perceive as a strict level of control over the Saudi National genetic 
material. I will discuss in this subsection the importance of clarity and the 
importance of drawing a clear line between different actors like the donor, the 
researcher, the research centre and the NCBE.  
In Saudi Arabia, biomedical practice has not responded to the problematic 
business behaviours resulting from genetics research like monopoly ownership of 
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gene mutations, diagnostic tests and excessive patenting. However, it is not realistic 
to assume that the current policy is equipped to deal with those challenges without 
addressing those issues openly and firmly by the Saudi policymakers. In MGE 
research in Saudi Arabia, the stakes are potentially high in terms of what genetic 
information implies for the indigenous people of Saudi Arabia. The fact that the state 
represented by the NCBE has the right to control DNA material is interesting insofar 
as it may be seen as contradicting the more democratic values the Saudi bioethics 
guidelines appeared to be embracing, as discussed previously in Chapters Two and 
Three. If Saudi’s genetic material is owned by the state, theoretically the state can 
reverse someone’s decision to donate which appears to go against the autonomy-
based norms supported by the NCBE. In theory, the absence of clear boundaries 
between individual and state rights to genetic material risks a potential clash between 
different perceptions regarding how the rights over genetic material will be 
interpreted. The findings presented in Chapter Six suggest that some of the 
interviewed research participants tended not to care about who controlled their 
donations, albeit most of the interviewees lacked knowledge concerning their 
donation in general. If such lack of interest is present, it could be attributed to the 
many hypothetical reasons that actually were reported among some of the 
interviewees, like those listed below: 
1. They could be patronised by the treating doctor. 
2. They could be merely concerned with the notion of godly rewards. 
3. They could be interested, but only in the aspect of exchanging something for 
an immediate tangible benefit. 
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4. They trust the health care system to the extent that they entrust control of 
their health to it.  
5. They do not understand what they are doing in terms of donating or trading 
information. For example they know they have something the research 
wants but do not really know/understand what this is (and perhaps they 
do not care to know either?) 
I will discuss the trust factor in further detail later. The four remaining points 
assume some level of consciousness about control in the context of the ability to 
trade. The notion of having something to ‘trade’ whatever the context (e.g. favours 
from researchers or Godly rewards) has some elements of ownership.  However, 
generally in Saudi Arabia, absolute ownership of any kind of tissue (i.e. such as body 
organs or blood) does not have the same concept of absolute ownership in the sense 
of the private property rights (i.e. private property rights in the sense of absolute 
ownership in the sense of commodification of material (Jeremy, 2012)). This is 
mainly because in Islam people do not have the right of property over their bodies 
(Aramesh, 2009). The Saudi Guidelines clarified that the Islamic values ‘shall be 
observed’ (NCBE, 2010, p87). 
 In Phase Two, the question ‘who owns [controls] the donated genetic material 
right now’ was considered strange by the participants, who felt that either the 
material was no longer controlled by them, or that it was now for the doctor or the 
hospital to decide about those donated material. This was the case to the extent that 
the majority of them were not concerned about what happened to the blood; that is, 
whether it was analysed locally, sent to an international collaborator, or reused by the 
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research team or any other researcher without specific donor consent. Perhaps it is 
not a real problem to Saudis (specifically those interviewed in the context of this 
research) who donated blood for MGE research because they were concentrating on 
other more important issues like the concept of reciprocation in a gift-like transaction 
(see Subsection 6.3.3.2 a. Vulnerability counterargument.) This is one interpretation 
of the data gathered in my study, although this cannot be generalised due to the 
nature of the chosen design. 
The view that the state owns Saudi genetic material seems to be an over 
simplification, that might easily be challenged by the fact that there is no clear 
guideline regarding how and when the state should practise its right of ownership or 
even control against donors, against doctors and researchers, against Saudi research 
centres and against international research centre collaboration. Western ethics, 
however, might well emphasise individual control (even ownership) over genetic 
material. 
In Western legal literature, there is no consistent view on the specifics of who 
owns what, when and why when it comes to tissue ownership (Lipworth et al, 2011; 
Flaman, 2014). For example, the boundaries relating to biological matter when it is 
still inside the body and when it is outside the body and controlled by someone else 
are not clear (Boggio, 2013). Rao (2007) studied the legal trends in terms of how the 
body is perceived and as a result, provided three different paradigms for the body, 
body parts, blood and tissues. In his view, it is either protected by property, defined 
by a contract or under private protection (Rao, 2007; Allen et al, 2010; Boggio, 
2013). In the context of blood and tissues, it seems that these paradigms ‘exemplify 
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body as property’ (Rao, 2007, p376), which is problematic in the MGE research in 
the Saudi context for two main reasons: a) religious reasons as explained earlier, and 
b) the genetic nature of the Saudi tribes DNA, which indicates that all the tribe’s 
members, including those who have not yet been conceived, ought to be partners in 
this ownership model, or ought to protect their interests/have their interests 
protected.   
The main challenge of the Saudi NCBE guidelines is that they might not fit the 
reality of MGE research in Saudi Arabia for they lack the essential differentiation 
between biosamples and the data derived from them. Even if it is accepted that the 
biosamples are owned by the State, this fails to protect the State’s right over the data 
because the nature of data ownership is different from the nature of the genetic 
material, and therefore fails to protect research participants from potentially being 
harmed through the distribution of such data because non-maleficence should be 
articulated in this specific context to avoid ambiguity.  
The ownership issue was discussed between members of the second focus 
group when they were asked about ownership of the genetic material. They seemed 
to be in agreement that the donor and the researchers shared responsibility to control 
the genetic material based on the premise that they both needed each other to achieve 
the final results. However, there was extensive discussion about the actual value of 
the genetic material or the data harvested from it, and the response to this question 
will provide a better understanding of how ownership should be decided.  
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7.3.5 The absence of specific regulations for blood donation to MGE research 
in SA 
As I explained in Chapters Three & Four, there is no regulation in Saudi 
Arabia that is specifically oriented to regulate donating blood for MGE. The Saudi 
NCBE bylaws and their guidelines are the active tools currently regulating all kind of 
research using human participation, including MGE research (see Chapter Three).  
As analysed in Chapter Three, the Saudi NCBE regulations are general enough 
to cover some of the issues concerning donating blood for MGE research in the 
Saudi cultural context. There are articles therein which try to tackle some of the 
important issues such as controlling the Saudi National genetic material, and the call 
for establishing Saudi National biobanks. However, due to the specific way blood is 
conceived culturally and religiously, it can be fair to say that the current regulations 
are in tension with the local norms of the Saudi culture when it comes to activating 
those guidelines in practice for the following reasons: 
a) As I concluded earlier in Chapter Three, the national regulations were 
inspired by the western normative assumptions about ethics in the 
international regulations that were used as a reference for the Saudi ones.  
b) Some of the challenges concerning MGE research in Saudi culture are not 
specifically addressed in those guidelines (see Chapter Four).  
c) The weight that is given to informed consent in the regulations seemed to 
follow the western individualistic autonomy-based bioethics in prioritizing 
individual preferences above other values. 
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The above points, as well as the empirical data from this thesis, albeit that 
qualitative research is not meant to be generalizable, could be taken as an indication 
of tension between the Saudi NCBE regulations and the Saudi culture in the context 
of donating blood for MGE research.  
The end of this subsection concludes the first argument. Blood and its 
derivatives, specifically genetic material, are highly rated among Saudis for different 
reasons, such as it being equated with saving lives, or a means of presenting a new 
way of gaining racial superiority. An autonomy-based approach - in the sense that 
informed consent documentation should be prioritised - risks neglecting those 
challenges, which is ethically problematic. Therefore its utilisation in MGE research 
inside the health services providers (like a research centre) or outside them (like 
websites promising genetic linage detection) ought to be considered in a way that 
addresses these challenges. The lack of such regulations could be seen as the reasons 
for most of the noticed mismatch.  
7.4 Consent in the Saudi context  
In this subsection I will discuss my second argument in this thesis which 
concerns the Saudi trust culture that is manifested in the patient-physician 
relationships. I will take consent in the Saudi context for MGE research as an 
example to illustrate how a western understanding of consent in the domain of health 
related research is dominant. I will then contrast this with how more of a trust culture 
is prioritised in the lives of Saudis. 
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The reported data revealed more serious concerns about whether or not those 
participants in MGE research can be regarded as consenting, and whether or not 
informed consent was gained in the prescribed way; in other words was there any 
coercion, was he or she given enough information to decide for him/herself whether 
or not to participate, and to what extent vulnerability should be considered in MGE 
research in Saudi Arabia (See Subsection 6.5.3.3 Patient Vulnerability)? These 
questions will be addressed later in this chapter. Both international and Saudi 
guidelines emphasise participant consent in many ways, but a key issue is the process 
of informed consent. A powerful assumption can be seen in the emphasis given to 
the individualistic value of a person, whereby that person is best placed to decide 
what is best for him or her as a free-choice (Gillon, 2003, Beauchamp and Childress, 
2009). However, against this understanding the reported findings suggest some of the 
patients did not choose according to this understanding of free choice. According to 
the reported data, patients were asked to sign a document but told this document is 
nothing but ‘paper work’. Each patient did, however, sign what was called an 
‘informed consent’ document. This suggests that a request to sign the informed 
consent document may be something that is done to satisfy the regulations. So, in 
effect, this appears to be an interaction where the patient gives something, the 
researcher takes something and the interaction is underpinned by documentation that 
satisfies the regulations. This document does not, necessarily, reflect the true nature 
of the interaction; however, it has a legally authenticated signature. Because of the 
authenticated signature of the patient, it is very difficult to suggest that the process is 
illegal or unethical if an audit is carried out in the manner advocated by the ICH-
GCP. This suggests that the informed consent, in this specific context, was used to 
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justify the research or to tick a very essential box in the process required for 
conducting research. It is important to consider why Saudi researchers included in 
my study were inclined to manage that interaction the way they did. Understanding 
the reasons will help us explore the existent norms and values underpinning those 
transactions in the context of MGE research in Saudi Arabia. 
In general, the nature of this interaction gives rise to an even deeper question, 
regarding the place occupied by ‘consent’ itself in the Saudi context. According to 
Beauchamp and Childress (2009) consent can be implied (when patients hold out 
their arm willingly to have blood withdrawn) or explicit (when specific information 
is given to a patient who then decides between at least two options), in the context of 
medical ethics the latter is usually documented and is generally seen as a means of 
respecting autonomy. The Saudi regulations inherited the assumption of how we 
ought to regulate and document consent from the Western ones used as reference 
documents (See the 4.3 Informed consent in the Saudi context).  
In the Western context, consent is generally assumed to be more of an 
individual practice than a family decision (Tan-Alora and Lumitao, 2001; 
Beauchamp and Childress, 2009; Adlan, 2013) except in the case of genetics, where 
the notion of family consent is discussed and the weakness of an individualized way 
of looking at consent is more readily accepted/discussed (Tallbear, 2013; 
Boddington, 2012). In the Saudi context, on the other hand, the family has a more 
important role and a wider definition. As illustrated in Chapter Three, Saudi families 
are not just the next of kin but also include a much wider circle of relatives, and all 
family members come under the protection of the family as a whole. The oldest male 
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member of the family is of central significance to the extent that his opinions are 
regarded as orders rather than suggestions. This is reflected in the practice observed 
in Phase One of this study of approaches being made to families and not individuals. 
The consent given in cases like this is not necessarily for the good of the individual, 
but for the good of the wider family. In contrast, in Western literature relating to 
medical ethics, family consent is considered in a very limited context, for example, 
in the case of organ donation (Burroughs et al., 1998; Gortmaker et al., 1998; 
Siminoff et al., 2001) or critical care (Hackler and Hiller, 1990; Akabayashi et al., 
1999; McNamara and Monti, 1995). Even in those limited contexts, in critical care 
for example, the family is supposed to decide what is in the best interests of the 
individual patient, but if caregivers are not convinced that the right decision (the 
right decision here is referenced against their perception of the individual’s best 
interest) is being made, they have the right to intervene to reverse the next of kin’s 
decisions (Lindemann, 1995).  
7.4.1 Claim of ‘white coat’ effect 
The ‘white coat’ effect in English refers to the ways in which individual results 
can be affected by the fact that the patient is being tested – e.g. blood pressure and 
heart rate can be raised by the stress of being tested (Pickering et al., 1988). In this 
thesis, however, I propose to use it in different way to describe how patients may 
sometimes feel submissive towards a person wearing white coat on the assumption 
that anyone wearing a white coat is a medical doctor.  
The data collected for this thesis suggests that a patient’s decision, at least in 
the context of this work, does not seem to be an individual choice. It reflected the 
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idea that valid individual consent was undermined by lack of information and 
practices that might be coercive. It could be argued that the regulations seek to 
outline an ideal practice, but they may not seem to represent what is genuinely 
important to Saudis. In addition to this, the logistic support given to researchers does 
not help them to achieve what the regulations highlight as important (i.e. individual 
consent). For example, the consenting venue, such as the long-awaited regular clinic, 
and the person requesting the donation (often in my study the doctor himself was the 
first to get patient approval) all play a major role in convincing patients to donate. 
Members in the first focus group in particular seemed convinced that the most 
decisive factor influencing patients’ willingness to donate was that they trusted the 
doctor, more so than they trusted other caregivers or researchers. Moreover, 
participants in the focus group felt that patients assumed that anyone wearing a 
physician-style white coat was a doctor and in this sense it was the white coat that 
swayed their decision-making. Research led by Landry (Landry et al., 2013) reported 
that surveys at three locations in the Ochsner Health System (hospital clinic, satellite 
clinic, and inpatient ward), New Orleans in 2013 indicated a higher level of 
confidence in physicians who wore white coats, despite the patients’ knowledge of 
the theoretical risk of infection transmission from the physician’s attire. The reason 
for respecting the doctor’s attire may be different in the UK, since it seems that the 
white coat helps patients to identify physicians in busy clinics (Douse et al., 2004, 
Gooden et al., 2001, Landry et al., 2013). In addition, according to Goodern (2001), 
patients felt they could communicate better with physicians wearing white coats 
(Gooden et al., 2001). Whether patients regard white coats per se as a symbol 
deserving respect has not been studied in depth. However, it could relate to some 
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level of patient vulnerability or to being non-verbally influenced by the physician 
(Bommier et al., 2013). This is mainly for two reasons. The first is the assumption 
that anyone who wears a white coat is perceived to be a medical doctor. According to 
both focus groups, the members seemed to think confirmed that this assumption is 
made. The second point is that, to some extent, patients are influenced by this 
assumption in a way that renders them vulnerable. There was a consensus among the 
focus group members that the non-verbal influence was a real concern between the 
Saudi physicians and their patients. This is in agreement with earlier works that 
established the link between patients-physician and how it reflects on the quality of 
informed consent (Abolfotouh & Adlan, 2011; Adlan, 2013). Both of the above 
factors have emerged as themes among Saudi researchers and I have included them 
in this study with one major difference, namely, that I studied the context of Saudi 
MGE research participants and potential participants, while Douse et al., (2004), 
Gooden et al. (2001), Landry et al. (2013), and Bommier et al. (2013) studied 
patients in their regular clinics and not as research participants or prospective 
research participants.  
Patient vulnerability as a concept was present in all of the guidelines analysed, 
including the Saudi guidelines. However, with the exception of the Saudi national 
bioethics guidelines and the UNESCO principles, protecting vulnerability was a 
principle generally targeting special groups of people like children, pregnant women, 
prisoners and mental capacity impaired patients. Nevertheless, in 2013, the 
UNESCO report concerning the principle of protecting human vulnerability and 
personal integrity tried to explain its theory of the two types of human vulnerability 
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that could provide an explanation to how we might think of vulnerability in a Saudi 
context. The two types are specifically, ‘a) special (temporary or permanent) 
disabilities, disease and limitations imposed by the stages of human life; b) social, 
political and environmental determinants: for example culture, economy, relations of 
power, and natural disasters’ (UNESCO, 2013). Point b) requires further elaboration 
regarding patients in a clinical care context, where, for instance, patients’ pain or the 
higher status of knowledge represented by the treating physician give rise to some 
level of vulnerability between patient and physician (UNESCO, 2013). 
The Saudi National Bioethics Committee has a strict guideline stating that if 
the treating physician is a PI in a project, he or she should never ask the patient to 
participate. This is not related to the white coats issue per se; it more likely reflects 
the need to control, or eliminate, a perceived need to please the physician – which 
seems to be the underpinning reason why the white coat was highly regarded. The 
Saudi guideline was the only guideline - among the ones analysed in this thesis to 
take such a declaration. The ICH-GCP says “Neither the investigator, nor the trial 
staff, should coerce or unduly influence a subject to participate or to continue to 
participate in a trial.” (GCP, 1996, p15). This can be taken as a call for a neutral 
party to be the person who records consent, it does not specifically declare that a 
patient’s physician should not be involved in their recruitment to research. As 
explained in the Chapter Three, the NCBE guidelines seemed to anticipate the 
potentially coercive effect of the physician’s involvement, by preventing the treating 
physician from recruiting for his own research. This notion is problematic if 
autonomy-based bioethics is the choice for the Saudi NCBE, because the research 
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team (i.e. the one actually consenting for MGE research) is recruited by the 
physician PI. Thus, the barrier between the patient and his/her physician in terms of 
recruitment can be very fragile; perhaps not sufficiently robust to protect the 
potential participant from the kinds of undue influence the guidelines seek to 
prevent. The PI appraises the research team performance. The first focus group 
discussed the relationship between themselves and a treating physician who is also a 
PI, noting that: a) the physician expresses frustration when they sometimes allow the 
patient to express the right to say no, b) they felt that it is their job to satisfy the 
doctor by recruiting patients, c) in their experience it is sometimes the doctors 
themselves who are violating the recruiting rules and refuse to listen to them when 
they try to provide advice (Results Subsection 5.4.3.1: Deception). The regulations 
suggest that the research team should work independently of the physician. However, 
in reality, the physician has the full potential to exercise influence on the patient 
through the research team. 
The way I analysed the data does not lend itself to an exploration of the 
narrative of failure (see Subsection 7.2 What the finding can be taken to imply). 
Instead, I will look at the opportunity to learn from the context. It seems that there is 
enough evidence that, in this study, stakeholders believed that the physicians’ attire 
has an effect on the patients’ decision. They attributed that effect to a level of 
vulnerability. I, however, think that it is not the only reason. According to the Saudi 
cultural, religious and political contexts it would not be alien to attribute such an 
effect to the trust bestowed on the physicians as authoritative figures (see 1.2 The 
Saudi Arabian Context). I think that any effort aiming to regulate research ethics 
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cannot afford to ignore such a deep-rooted value. In such a culturally rich context 
both patient and physician have some cultural expectations that dictate the nature of 
the relationship. Therefore, and for similar reasons, informed consent process should 
not be taken as the only measure to justify research in such culturally rich contexts. 
This issue will be further discussed later in this section. 
The other possibility is the assumption that the Saudi physicians are always 
going to exercise their superior knowledge to act in the best interests/advantage of 
their patients, or at the very least not use it to harm them. From the data collected in 
this project, a similar theme emerged when some patients reported that they were 
told to donate without any explanation, in addition to stories told by both focus 
groups showing how the physician’s action could be seen as a restriction of the 
patients’ freedom. This could be construed as patient vulnerability towards the 
treating physician that undermines respect for a patient’s autonomy. The main 
challenge to this argument is that it assumes a tension between the patient and his 
physician. The connotation of the word ‘vulnerability’ suggests that an action to 
undo that vulnerability is needed. However, it is not necessarily the case that 
vulnerability is a negative property that needs to be addressed in all occurrences. 
Instead vulnerability could be seen as being value neutral. For instance in marriage, 
vulnerability is obvious as spouses make themselves vulnerable to each other’s love 
and needs in a mutually trusting and healthy environment. This way of looking at 
vulnerability could be relevant to the Saudi health domain, where vulnerability might 
arise from trust and evoke trustworthiness in return. Thus, understanding how trust 
works is far more effective than regulating for autonomy.  
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7.4.2 Trust in the organisation of health provision 
The two previous claims in the context of consent have paved the way to make 
the following argument about trust. According to the themes which emerged in my 
research, trust is central in the patient–physician relationship. Despite the risks of 
vulnerability, coercion or paternalism, trust can provide a contrasting explanation of 
the actors’ actions, which is no less credible than the other explanations. 
Trust as described by Clayton (2013) is bestowed on the trustworthy. In this 
definition there is an important difference between trust as an attitude or sometimes a 
choice, and the trustworthiness as a characteristic. My findings would suggest that 
the culture, religion, politics and tribal values have contributed to the patients’ 
attitude to trust that the physician will act according to the patients’ best interests. 
However, trustworthiness as a characteristic is more important in the context of 
Saudi Arabia because it, arguably, provides a more tangible and easy way to measure 
characteristics (e.g. knowledge and experience). I think that working with 
trustworthiness, in terms of providing clear measures for the laypersons to be able 
assess it, is a more sensible route in Saudi Arabia than fighting trust as a cultural 
value and asking patients to be sceptical and suspicious that physicians are serving 
an agenda that uses the patient rather than serving them. Therefore, trust, as 
suggested by Davies (1999), is more applicable to the Saudi policy making context. 
Davies (1999) indicates that trust reflects “expectations by the public that healthcare 
providers will demonstrate knowledge, skill and competence; further expectations 
too that they will behave as true agents (that is, in the patient’s best interest) and with 
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beneficence, fairness and integrity. It is these collective expectations that form the 
basis of trust” (cited by Canlan & Sanford, 2004, p7).  
My findings suggest that many participants have a genuine trust that the 
physician will only do what is appropriate. This could be explained by the 
physician’s social role as a person with knowledge (expert), as a healer, and as the 
one that will protect the patient’s best interests. In previous work, I documented my 
personal experience in a similar situation when my father was undergoing surgery. 
As the elder son, I was asked to make a decision during the operation. The physician 
indicated that “plan A” was not working, and they wanted me to choose between two 
alternatives. Despite all my education and what I stood for as a researcher, I 
genuinely wanted the physician to make the decision based on my father’s best 
interests. I thus asked the physician what he would choose for his own father in my 
place, and then just told him to do what he thought best (Adlan, 2013). At the time, 
informed consent in the contemporary sense of the term seemed to be unobtainable, 
as I was not equipped to take that decision with such grave consequences at stake. 
Although this experience relates to a treatment decision, it is likely that the same can 
be said about research in the health care setting. This experience is probably not 
unique. In general, the habitual trusting reference to doctors was such that people did 
not consider / develop the habit of questioning their judgments especially in Saudi 
culture (Abolfotouh & Adlan, 2011; Jamjoom et al, 2011; Al-Jumah and Abolfotouh, 
2011; Adlan, 2013; Khedhiri et al., 2013). This is in contrast to the Western 
countries, where trust in the health care providers seems to have declined because the 
main focus has shifted towards autonomy, and the patient must decide for him/her 
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self (Canlan & Sanford, 2004; O’Neil 2002). This, in fact, does not necessarily mean 
that European and North American patients distrust their physicians, it may rather 
mean that for the decision to be legally sound it should be taken based on 
enlightened decisions with explicit information in the way advised by autonomy-
based bioethics rather than by blind trust. 
My data suggest that among the sampled stakeholders there was awareness 
about the importance of trust as a value in the Saudi health context. Based on that, 
we can assume that the reason for the absence of the trust as a value in the Saudi 
research guidelines could be that it is not the most applauded value in the 
international regulations used as reference for the Saudi ones (O’Neill, 2002; 
Manson, 2007; Manson and O'Neill, 2007) This seems inconsistent with how people 
deal with trust in general even in the Western culture. For example, someone buying 
a brand new car would trust that the tyres would not be bald and cause a life-
threatening situation while driving. This of course may still be the case, but will not 
arise as a reasonable doubt if the car manufacturers and vendors are trusted for their 
professionalism. Trust-based bioethics does not necessarily mean giving in to 
paternalism and accepting any decision taken by the health care giver. On the 
contrary it could play a role in countering paternalism by suggesting when trust 
should be given and when it should be withheld. Trusting blindly might not be the 
wise thing to do. The appropriate call is to trust the trustworthy and not trust the 
untrustworthy. In this domain trust is an active decision rather that surrender to 
another’s will. The challenge is that it is not very well understood or discussed in 
western autonomy-based bioethics, which as I introduced, could be the reason why 
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trust is absent from the Saudi policies. The importance of such a suggestion is that it 
would be a starting point to address the issue of trust in the Saudi policies. The start 
could come through a critical analysis of the informed consent process and how the 
Saudi policy can use the applauded value of trust to improve the process of consent 
for MGE research. 
In this thesis I have presented some findings described as deceitful in the 
process of informed consent, which could instead be described differently through 
the trust narrative. It seemed to be the consensus in the focus groups that patients 
trust physicians when it comes to participation in health related research. The claim 
of deception in the findings was based on the failure to take essential steps such as 
providing information in the way specified in the regulations, and to let the patients 
decide freely after being thoroughly informed. It could be argued that some of those 
patients have given up their right to decide in preference to allowing the physician to 
make the right decision for them. This could mean that they trust the health service 
system to protect their best interests. In a way this could be an argument against 
deception, because we would not normally find those who set out to deceive us to be 
trustworthy. As I argued earlier, the informed consent doctrine has proved 
problematic in the context of Saudi Arabia for cultural, education, and logistical 
reasons. Trusting the treating physician, not only for health related issues but also in 
research participation, may be part of Saudi culture. The culture of trust would 
remedy the challenges of the contemporary understanding of consent in health care 
environments which is a claim that I will discuss further.  
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Adopting the international regulations committed the Saudi stakeholders to a 
specific way of how they ought to look at informed consent: that the patient should 
decide on his/her own interest based on an informed choice. To the contrary, my data 
would suggest the tendency to trust the physician. Thus, it is important to look for 
ways to use the value of trust and to translate it into a policy or part of a policy. It is 
not, however, in the interest of this thesis to go as far as suggesting a Saudi trust 
framework, but it is essential to indicate that the finding, if it would be shared by 
others, would act like a compass pointing towards the value of trust. It is also 
important to balance the call for introducing the value of trust between accepting it at 
face value in a moral relativist attitude -which I rejected in an earlier stage of this 
section- and totally ignoring the cultural reality by adopting the narrative of failure, 
which has also been rejected. This means that it is important to accept that even in 
the Saudi research context, it is important that people consent voluntarily to research. 
The call for introducing the value of trust should not mean that patient’s consent is 
not important any more. Trust, I think, should be used as a tool to enhance the 
culture of research participation as well as the consent process. Ignoring the value of 
trust, however, is as wrong as over applauding the value of individual autonomy.  
One way of looking at a trust-based bioethics is to start with Davies’s (1999) 
definition that cast light on the characteristics of trustworthiness. The stakeholders 
might be able to do that if they introduced to a transparent system to measure 
trustworthiness and if it was to be made available to the patient or the research 
subject. A system in which the accountability of researcher is announced and the 
choice is given to the patient or the research subject to trust that person would be of 
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help as an investment in the trust value and of use as a tool for the patient and 
research subject.  
As I argued earlier (see Subsection 4.2 Autonomy-Based bioethics), the level 
of information needed to fully inform the layperson is not realistic. “Trust-consent” 
may be a realistic additive to the fully informed consent. In the research domain, 
intelligent trust as advocated by Manson & O’Neill could be introduced as another 
element of professional ethics. Their argument is that to reach that level, it is 
important to shift the focus from patient consent to the patient–researcher 
relationship, and how the research organisation can introduce sufficient safeguards to 
prevent exploitation of the patient (Manson & O’Neill, 2007). The shift from 
consent-based participation to trust-based participation is not an easy one.  
With the discussion of the trust and its challenges in the context of health 
related research in Saudi Arabia it is important to say that when it comes to MGE 
research there are other challenges such as the genetically homogenous nature of the 
Saudi tribes. In addition to investing in the trust culture to protect the individual 
interest, another measure should be considered to protect the tribal interest. In the 
next subsection I will discuss how research committees can fill this vacuum.  
7.5 Ethics committees and protecting tribal interests: 
Almost two-thirds of the research ethics committee’s policy document is taken 
up by management regulations. The similarities between ICH-GCP and the Saudi 
bioethics research committee regulations are very noticeable, as explained in Chapter 
Two. In general, ICH-GCP looks at the role of an ethics committee as a review 
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board, with enough diversity to discuss if research proposals provide a justified 
balance between risks and benefits. However, risks in clinical research have a 
different meaning than risks in MGE research, as shown by two examples. Firstly, in 
the ICH-GCP, “risk” means any activity that subjects a person to more than regular 
day-to-day risk. This seems to have been the main reason that most of the 
stakeholders in this project reduced research risks to direct medical risks, such as the 
venepuncture in MGE research. Secondly, some might say that the use of identifiable 
genetic material in a proposal might be seen as a minimal risk to the donor. 
However, this disregards the wider understanding of risk in and around using 
identifiable material in MGE research in the Saudi context (see 2.3.3 Risk and 4.4 
Stigma in tribal context). 
It is fair to say that research committees are a very new phenomenon in Saudi 
Arabia. This is reflected by the amount of space dedicated to committee management 
in the Saudi guidelines. So there is little documentation to study the discrepancies 
between how the research committees actually operate versus how they are supposed 
to operate. The policy attempts to hold research committees liable for their decisions 
to approve research projects, and then to monitor them in the field in order to protect 
the research participants. In other words they are responsible both for assessing, and 
monitoring adherence to protocols.  
According to the focus groups, research recruitment had to take place during 
regular clinic times due to a lack of resources. If this is the case, it is difficult to see 
how the research committees can do what is expected of them, especially if it has to 
recruit an expert or non-medical representatives. In my own experience, current 
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practice is that research committee members are not paid for this extra work that is 
expected of them. Payment, however, is not the only challenge, as the level of 
knowledge of the research ethics committee members may not be specialised enough 
to tease out the actual risks of MGE and deal with them. On the other hand, the 
problematic assumption that a detailed explicit informed consent will be the solution 
to any problem could also be conceived as part of the problem. I do not have enough 
data to state with confidence which of these explanations is more likely to affect the 
overall productivity of the Saudi research committees, nor indeed whether both 
might be factors. 
In regard to MGE risks, as I argued earlier, there are three levels of genetic 
research awareness. Firstly, concerning patients: the majority of those who were seen 
or interviewed were not fully aware of the MGE risks, and the only risk they were 
able to recall being told about related to the venepuncture. Secondly, the awareness 
of the researchers is demonstrated by the first focus group. For the majority, if not 
all, of the participating research assistants, research nurses, and junior researchers, it 
took them a long time to reach the level of discussing serious risks like 
stigmatisation. They, initially, only discussed the venepuncture, which provides 
some explanation of the limited level of patient awareness. Thirdly, concerning the 
policymakers, it seems that they are aware of the many other risks in addition to the 
venepuncture, like the risk of stigmatisation and the risk around the notion of the 
national security aspect of genetics information. 
I think, these different levels of awareness are reflected in the work of the 
research committee. Not all of the committee members are senior researchers. It is 
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important to provide some understanding of what kind of education of research 
committees in Saudi Arabia is most likely to prepare them for reviewing MGE 
research. This will be discussed in the following section. 
7.5.1 The call for research committee education 
Another challenge is that, the education available to the human ethics 
committee members is based on what the national and international regulations say 
should happen in the operation of research. This is problematic for two reasons. The 
first is that these guidelines are very general and not equipped to deal with challenges 
concerning MGE research in Saudi Arabia. Second, there are no specific guidelines 
oriented to regulating MGE research. Therefore any education based on those 
guidelines will fall short of addressing the real problem of MGE research in Saudi. In 
order to protect participants they have to look at issues from the perspective of 
participants. The fact that the Saudi research committees have to approve MGE 
research in a genetically homogenous tribal context is making the committees’ job 
more challenging. Tribes have the right to be protected from the MGE risks such as 
stigmatisation. I believe that Saudi research committees are not very well equipped 
to deal with these issues. The policymakers in Saudi Arabia should look at this 
problem and provide prospective solutions and prevent harm, rather than wait until it 
is too late and then try to react afterwards. In theory, the person who should be 
educated enough to raise these issues should be the lay committee member (i.e. the 
non-affiliated member according to article 10.1 (NCBE, 2010 p32-33). However, this 
is practically problematic. This layperson will be from one tribe specifically and so 
may be, if he is educated enough, able to raise concerns regarding research either 
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within his geographical tribal frontiers or on diseases known to be common in his 
tribe. However, not all the Saudi tribes will have a voice on this specific committee, 
which could be problematic if we assume that representation from each tribe is 
necessary to protect the interests of all tribes. I do not think that this problem can be 
solved with the current authority bestowed on the local committee in terms of 
education and awareness of the problem that needs to be addressed. I think that such 
a task is better to be taken on at a higher and more serious level by the national 
committee. It could be suggested that the national committee invites representatives, 
highly educated in genetics, from all the tribes. These representatives should then be 
educated about those challenges, and then asked to give general guidelines that local 
committees can follow. The local committees could then forward research proposals 
to these representatives, if their input would be deemed important by the committees. 
This should go hand in hand with educating the research committees.  
In Saudi Arabia, as I explain earlier, we do not have philosophy education for 
committee members (see 1.4 The need for empirical data) and so they might lack the 
normative background that enables them to see and evaluate the differences in moral 
claims. This could be the reason for why the doctrine of informed consent is still 
highly regarded despite the complicated challenges around it. This is very troubling 
because in the NCBE regulations, as I explained in Chapter Three, the local ethics 
committees are legally responsible for the ethical conduct of the researchers in their 
organisations. To the best of my knowledge, there are no current assessments of the 
awareness of the risks of health related research in the Saudi context, among the 
members serving on research committees. Also, from personal experience, there is a 
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gap in the knowledge between what the research ethics members are expected to do 
and what they are currently doing. Therefore, it is crucial to work on an education 
program that is specifically tailored to research committee members in order to 
bridge the gap in the knowledge about the MGE research challenges in the Saudi 
context. There is also a crucial need to develop a specialised education in bioethics, 
including the moral theories to equip Saudi policymakers with better normative and 
analytic skills. 
7.6 Conclusion  
The two main lines of argument presented in this discussion were as follows: 
the fact that there are no specific regulations related to MGE research in a Saudi 
context, means that the existing regulations are in tension with Saudi culture. I also 
argued that trust is an important value to Saudi culture and it should be looked at 
more openly with reflection on the importance of having a transparent system to 
measure trustworthiness.  
Blood donation in the Saudi context is associated with positive values such as 
saving lives, generosity, and honour. In the Saudi tribal culture of consanguinity that 
has existed for hundreds of years information gained from genetic material can be 
very harmful to a larger population; the risks extend therefore beyond a consideration 
of the interests of the few who donate the blood that makes this research possible. 
The Saudi guidelines seem to anticipate the problems and the potential harm to 
patients that may arise from genetic information, including a threat to national 
security. One way that the NCBE tried to activate a system of protection for this 
  
 
 
 
271 
national security (i.e. genetic information) was to announce that the State owns the 
Saudi genetic material.  
The system by which genetic material is collected currently is based on 
autonomy-based bioethics, which posed many challenges as it assumed a specific 
level of education the absence of power differential between patient and physician. 
Physicians/researchers are also the ones who are expected to take measures to satisfy 
those guidelines that could be considered coercive or have a paternalistic nature. I 
have argued that introducing the value of trust could be the remedy to those 
challenges as it accords with the medical service in Saudi Arabia. 
Promoting trust-oriented bioethics is not an easy task. It requires work and 
dedication and whilst its success cannot be guaranteed, it provides the best platform 
for success in Saudi Arabia given the cultural challenges. 
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8 Chapter Eight: Recommendations  
8.1 Introduction  
In this final chapter, I will illustrate my thesis’ contribution to original 
research, limitations, and considerations for future work. Also, as this project used 
qualitative methods, it is important to be reflexive, which I will do towards the end 
of this section. 
The aim of this thesis was to explore the particular ethical challenges 
associated with using donated blood for MGE research in the context of Saudi 
Arabia, as a preliminary step to enabling policymakers to generate culturally 
sensitive bioethics guidelines for collecting and using blood for MGE research in 
Saudi Arabia. I decided that the best methodology to fulfil this aim successfully was 
to use normative policy- or practice-oriented bioethics (NPOB) (see General 
Introduction: Section One). To meet this aim through the chosen methodology, I 
normatively analysed the international guidelines that were used as reference 
documents for the Saudi National Bioethics Guidelines (NCBE) in order to 
investigate how those guidelines can regulate the collection and storage of blood 
samples taken from adults for research purposes (see Chapter One). Subsequently, I 
did the same with the NCBE guidelines with specific elaboration on the Saudi 
context (see Chapter Two), which paved the way for testing how those guidelines 
can be applied to the Saudi MGE research normative challenges (see Chapter Three). 
This work was then combined to produce a general picture as to what the dominant 
ethical expectations are, based on the analysed guidelines, and what could be the 
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challenges based upon reflection on how the Saudi context might pose a challenge to 
the requirements of these guidelines.    
The second stage was to see how the stakeholders of Saudi MGE research 
operate under the guidelines' assumptions and context outlined in the first section. 
The empirical project was completed in three phases. The first phase was an 
observation phase focussed on how Saudi MGE research is managed in current 
practice (Subsection: 4.2.1.1). The observation generated questions that I addressed 
by asking patients who had recently been offered the opportunity to participate as 
potential donors to reflect on this experience, which was done in Phase Two through 
in-depth semi-structured interviews (see Subsection 4.2.1.2). To close the circle, the 
experiences, perspectives and reflections on MGE research in Saudi Arabia of 
researchers and policymakers were gained in two separate focus groups. Participants 
were also asked to reflect on an interim analysis of the data collected in Phases One 
and Two (see Subsection 4.2.1.3.)  
The last stages of this thesis provided the opportunity to reflect on the 
normative assumptions shaping the regulations and compare them to practice, and 
then listen to what the policymakers made of that current practice (see Chapter 
Seven). In Chapter Seven I was able to provide a suggestion as to why there are 
challenges and I concluded: 
- Introducing the cultural value of trust may remedy the challenges which come 
with the autonomy-based bioethics. 
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- The current regulations do not deal with the issue of MGE research’s effect 
on the tribes and how it could introduce irreversible damages like stigma.  
- The crucial need for specialised education in bioethics, including the moral 
theories to equip Saudi policymakers with better normative and analytic skills.  
8.2 Research Gap and Contribution 
In the early stages of this study, it was clear that Saudi Arabia with a tribal 
context poses a challenge to the straightforward adoption of the internationally 
accepted research norms, particularly in relation to MGE research. Many researchers 
study the application of international guidelines in places different from where those 
regulations were initiated. However, no one has looked at MGE research in a context 
like the Saudi one. The importance of this investigation is that it provides a 
contrasting view to the context that generated the guidelines in question. Based on 
the fact that tribal cultures are not unique to SA, the findings of this study may be 
applicable to any culture that shares a similar tribal culture. 
The need for a specifically tailored education program for the research 
committee’s members was a very important finding in order to introduce the changes 
in Saudi bioethics practice by allowing normative analysis focused on moral and 
philosophical reasoning as a step to better bioethics practice. This was communicated 
to the funding body for this thesis and has already been adopted into two education 
activities:  the first was 5 days at the University of King Saud bin Abdulaziz for 
Health Science, King Abdullah International Medical Research Centre from 7th July 
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– 11th July 2013. The second one was 3 days at Kind Saud University, King Khaled 
Hospital from 10th Feb -12th Feb 2014 (Resalat Al Jameah, 2014) . 
The Saudi NCBE showed interest in this study's finding. This may lead them to 
apply some changes to the current regulations. It will also lead to engagement with 
King Abdullah International Medical Research Centre (the funding body) in 
education and consultation projects to study the suggested improvements to the 
regulations.  
I am, however, aware that my work did not give specific solutions to remedy 
the revealed challenges. It is, conversely, crucial to start with analysing the 
challenges in a rigorous way, as a first step towards dealing with them. One of the 
major findings is that I could not really interview participants because they knew so 
little – I wanted in depth interviews and barely managed to get people to speak for 
more than a few minutes. This actually calls for future work to understand this 
phenomenon and try to cast light on the actual reasons behind such lack of 
knowledge if we want to explore and expose hidden incompatibilities between the 
inherited assumptions of two studied contexts (the normative assumption about 
ethics in the regulations and the cultural values.)  
8.3 Study limitation 
Every research has its limitations, and this study was not an exception. I also 
faced some problems and dealt with them in the most professional way, given the 
available time and funds. It is important to acknowledge that this study did not aspire 
to give a specific set of solutions in a form of a checklist to be followed or avoided, 
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and it was not expected to provide one. It, rather, set out to question the status quo in 
the practice of MGE research regulations, and this it has achieved.  
The interviews were a total surprise insofar as they were much shorter than 
anticipated and were therefore not very informative. For example, one of the 
interviews was only 7 minutes, although it was expected to be 60 minutes. The lack 
of knowledge affected the way questions were asked. I had to use rather closed 
questions after the open-ended questions failed to get any responses. Even those 
closed questions were not understood, so I had to resort to more closed questions and 
the suggestion of possible options to get any responses at all. I concluded that this 
could be attributed to the fact that the participants had been given so little 
information by the researchers and apparently lacked much understanding as to what 
was going on in the research. On the other hand, the two focus groups were very 
successful and yielded rich data. It is unfortunate, however, that I had funds for only 
two focus groups. Perhaps in hindsight and with more money, more would have been 
better and it would also allow further follow up interviews to address the paucity of 
data. 
The translation issue was one of the problems that took a long time to solve 
due to a lack of qualitative research experience among the translators in Saudi 
Arabia. For the greater detail of how this was remedied, see subsection (5.2.3.4). I 
am satisfied that the final English translation was an accurate verbatim representation 
of the Arabic original texts. 
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8.4 Reflexivity  
It is important to see that this study used a qualitative method, and that as 
argued by Koch and Harrington (2002), it is essential for the researcher to engage in 
self-critique and self-appraisal, and to explain how his own experiences have, or 
have not, influenced the way he/she looks at the qualitative data. Reflexivity is 
regarded as a crucial contribution to the trustworthiness of any qualitative research, 
as it declares ‘up-front’ the values and processes that have guided the research 
stages. These include choosing the design, collecting the data, identifying the 
research informants, analysing the data, and writing the discussion (Lincoln and 
Guba, 1985; Sandelowski, 1986; Cutcliffe and McKenna, 1999; Meyer et al., 2001; 
Spencer et al., 2003). I will start with reflexivity to help the reader to understand my 
perspective.  
I am a middle-aged, middle-class, research bioethics advocate in the Kingdom 
of Saudi Arabia. I originally trained as biochemist and worked in molecular biology 
for a few years and then moved to health related research and became a certified 
clinical research professional. In my 15 years of experience in research, both genetic 
and clinical, I have been confronted with myriad bioethical dilemmas stemming from 
either the unsuitability of international research ethics guidelines to a country like 
Saudi Arabia, or the lack of understanding of, and adherence to, those guidelines. 
Early on I had conflicts with many stakeholders (including Western expatriates 
working in Saudi Arabia) who saw the Western ethical guidelines as a new 
imperialistic attempt to control research progress or a hurdle to complicate research 
rather than to help it, so they decided to ignore them. At one point I was in charge of 
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a clinical research unit that oversaw patient recruitment and I had to take decisions 
that, in some way, conflicted with those of my colleagues who did not see the 
importance of the bioethics guidelines. Sometimes those decisions put me in 
awkward situations and (with the help of supporters) forced me to question the status 
quo, in order to educate researchers to carry out more ethical research.  
The extent of how this could impact the process of the current research is 
uncertain, but it may have had an influence. I have no explicit agenda besides my 
declared aims and objectives. With this in mind, and with the support of my 
supervisors, I have maintained a high level of self-criticism and self-appraisal 
regarding the influence of my own preconceptions and beliefs on my research. This 
is a necessary step to minimise the impact of those perceptions and beliefs and allow 
my analysis to be driven by the data. 
8.5 Future work 
As I explained in this chapter I ended up with more questions than I started 
with. I rate this as a healthy outcome as it calls for more work, more understanding to 
provide the most accurate solutions or frameworks. Among the future work that can 
extend and continue the work of this thesis, is the need to understand what role 
Islamic bioethics might play in this field. 
Another area that has caught my interest as promising material for future work 
was the level of genetic information that patients need to have to empower him/her to 
decide for him/herself in the autonomy-based model of bioethics or to act as 
foundations for trust in the trust-based model of bioethics. 
  
 
 
 
279 
In the end, the research for this thesis was a learning process in which I came 
to understand how to think as a researcher in analysing and exploring my research 
questions, and ultimately provided the most suitable solution to the problems that can 
be solved, or accept it as limitation if it is cannot, in an academic open-minded 
spirit.    
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Appendix 1: Phase One, the observation phase, case 1 field note 
 
First Observation: 
The location is a very small screening room. Family of two females was interviewed. 
They refused to be separated for the consent process. Blood for MGE research was 
only requested of the mother, who is almost 70 years old, and she was the patient.  
The consent duration was 9 minutes from the time the coordinator started talking up 
to the signature.  
The coordinator was talking very quickly; he asked if the patient knows why she is 
here. ‘No, I do not know,’ the patient replied. He started asking what the doctor has 
told her, then she replied that the doctor “just asked her to give blood”. 
After that, the coordinator told the patient that this is research, and it is not a 
compulsory test; at this stage the patient started to be confused.  The patient wanted 
to know what is needed exactly. What is the needed sample? The coordinator 
explained to her that it is ‘only a blood test’ with no risk whatsoever.  
The coordinator told the patient that the research will be oriented towards the greater 
good and will help other patients, and if any good thing came out of the research that 
she will be given the priority to be treated with it. Also, the coordinator mentioned 
that consenting to give blood is something that she will be rewarded by God for.  
After that, the patient signed the informed consent, which is one page, without 
reading it. The blood extraction took place and patient was dismissed.  
 
Observations: 
 The location was very small for 5 people. The door was open, and the voices 
were very loud in a busy clinic.  
 The patient was not given a copy of the informed consent form  
 She was not given any time to think about it  
 The physician told her that it was just a blood test 
 The patient did not know what genetics research is  
 She signed without reading  
 The coordinator’s attitude was to get the blood 
 The only risk was discussed was the venepuncture risk  
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Appendix 2: Clinic Poster Phase One, for researchers 
 
Donating blood for Genetics Research in Saudi Arabia  
Are you expecting to recruit blood donors for genetics or molecular epidemiology 
research in the coming few weeks? If so, you may be able to help with our research. 
Abdallah Adlan is a PhD student in the University of Birmingham. The purpose of 
his research study is to help policy makers in Saudi Arabia provide culturally 
sensitive bioethics guidelines on donating blood for Saudi genetic and molecular 
epidemiology research. 
 
He would like to observe your consent interviews 
 
 This is not an assessment of your work. 
 You will not be identified in his results 
 You do not have to agree to let him observe you, but we would be grateful if you 
would. 
 
If you are willing to be observed: 
 Please make sure that your interviewees have seen our poster in the patients’ 
waiting area, understood it and does not object to the observer’s presence at the 
start of the interview. 
 You can request that the observer leaves the consent interview at any point. 
 
 Do not try to engage the observer in any way during the recruiting session  
 After the interview he will ask your participant if he or she is willing to be 
interviewed separately for a different phase of his research.  
 
This study has been approved by the University of Birmingham Science, 
Technology, Mathematics and Engineering Ethical Review Committee. (Reference 
ERN_12_1394 06/02/2013) and the local ethics Committee of KKESH: RP 1319-P, 
Date of Approval: 10/03/2013, and of NGHA: RC12/090/R, Date of Approval:  
26/03/2013. 
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 noisreV cibarA eht stneitap rof ,enO esahP retsoP cinilC :3 xidneppA
 
 
 إعلان للمشاركة ببحث
 
 الوراثية في المملكة العربية السعودية في دراسة للدكتوراه حول التبرع بالدم للبحوث
 
 
 
خلال الأسابيع  ANDهل متوقع آن تقوم بالاشتراك كمتبرع بالدم لبحث جيني أو متعلق بال 
 القادمة؟
 عاما؟ ٨١هل عمرك فوق ال 
 
 
 إذا أجبت بنعم، هذا الملصق موجه لك.
 
بالدم لبحوث علم عبدالله عدلان طالب دكتوراه في جامعة برمنغهام يدرس ظاهرة التبرع 
الأوبئة الوراثية والجزيئية   في المملكة العربية السعودية. والغرض من هذا البحث هو 
لنصح واضعي الأنظمة في المملكة العربية السعودية بمعرفة السمات الثقافية للمجتمع 
 السعودية. ANDبشأن أخلاقيات علم الأحياء لتبرع بالدم لبحوث ال
 
معك في الجلسة الأولي لتبرعك و توقيعك لوثيقة القبول يرغب الباحث بالحضور 
المتبصر. لك الحق بأن تقبل أو ترفض هذه الدعوة كما أن لك الحق في تغيير رأيك و 
 ذلك بأن تطلب من الباحث عبدالله عدلان مغادرة الإجتماع في لحظة دون إبداء الأسباب.
 
 
 
 
المراجعة الأخلاقية لكليات العلوم و وقد تمت الموافقة على هذه الدراسة من قبل لجنة 
 detad 4931-21-NREالتكنولوجيا و الهندسة و الرياضات بجامعة برمنجهام البريطانيه (
 PR) واللجنة المحلية الأخلاق لمستشفي العيون ومستشفى الحرس تباعا ً3102 beF 21 no
 3102/30/01، P-9131
  3102/30/62 ,R/090/21CR
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Appendix 4: Verbal Consent Confirmation - Phase One 
 
 
Donating Blood for Molecular and Genetics Epidemiology Research in Saudi Arabia 
 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisors: Professor Heather Draper and Professor Angus Dawson, University of 
Birmingham 
 
 
 
 
1. I confirm that I have seen the poster for staff about the above study and 
spoken to Dr Adlan about this research. I have had the opportunity ask 
questions and have had these answered satisfactorily. I have agreed to allow 
him to observe me gaining the consent of a patient to donate blood to 
research. I understand that my participation is voluntary and that I am free to 
withdraw at any time up to 48 hours after the consent interview has taken 
place without giving any reason by ringing Dr Adlan on the number on the 
poster. 
 
 
2. I confirm that I have spoken to my patient, that my patient has either read (or 
had explained to him/ her) the patient poster about this research and that s/he 
understands and agrees that his/her consent interview will be observed as part 
of Dr Adlan’s research. S/he knows that Dr Adlan can be asked to leave at 
any point by either of us.  
 
 
 
 
Name of researcher-
participant...........................................................................................................
.......... 
 
Signature: .................................................  Date: 
....................................................... 
 
 
Name of patient whose consent will be observed: ...................................... 
 
 
  
Please 
initial box 
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 إعلان للمشاركة ببحث
 
 للبحوث الوراثية في المملكة العربية السعوديةفي دراسة للدكتوراه حول التبرع بالدم 
 
 
 
خلال  ANDبالاشتراك كمتبرع بالدم لبحث جيني أو متعلق بال تم توجيه الدعوة لك هل 
 الأسابيع القادمة؟
 عاما؟ ٨١هل عمرك فوق ال 
 
 
 إذا أجبت بنعم، هذا الملصق موجه لك.
 
هرة التبرع بالدم لبحوث علم عبدالله عدلان طالب دكتوراه في جامعة برمنغهام يدرس ظا
الأوبئة الوراثية والجزيئية   في المملكة العربية السعودية. والغرض من هذا البحث هو 
لنصح واضعي الأنظمة في المملكة العربية السعودية بمعرفة السمات الثقافية للمجتمع 
 السعودية. ANDبشأن أخلاقيات علم الأحياء لتبرع بالدم لبحوث ال
 
لك الحق بأن تقبل أو  بتوجيه بعض الإستفسارات عن تلك تجربتك.يرغب الباحث 
ترفض هذه الدعوة كما أن لك الحق في تغيير رأيك و ذلك بأن تطلب من الباحث عبدالله 
 عدلان مغادرة الإجتماع في لحظة دون إبداء الأسباب.
 
 
 
 
الأخلاقية لكليات العلوم و وقد تمت الموافقة على هذه الدراسة من قبل لجنة المراجعة 
 detad 4931-21-NREالتكنولوجيا و الهندسة و الرياضات بجامعة برمنجهام البريطانيه (
 PR) واللجنة المحلية الأخلاق لمستشفي العيون ومستشفى الحرس تباعا ً3102 beF 21 no
 3102/30/01، P-9131
  3102/30/62  ,R/090/21CR
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Appendix 6: Information sheet (Phase Two) the English version 
 
Donating Blood for Molecular and Genetics Epidemiology Research in Saudi Arabia 
 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisors: Professor Heather Draper.  Professor Angus Dawson 
 
Participant Information Sheet 
 
Invitation to participate 
Thank you for thinking about taking part in my research project.  Please read the 
following information. It explains the purpose of this research and what taking part 
will involve. You can discuss this information with others if you wish.  If you would 
like further information, please contact me.  I will be in touch with you in a couple of 
days to see whether you are still interested in taking part, and if you are, we agree a 
date and time for your interview. 
Purpose of the research 
This research will try to help the policy makers in Saudi Arabia to improve the 
policies that rules donating blood for genetics research. To do that, I will analyse 
both the current Saudi and international policies that rules donating blood for 
genetics research. This will make me able to compare between those guidelines and 
the actual practices like the one you attended.   
I would like to interview you about your recent experience of consenting to give 
blood for research.   
Why have I been selected? 
You have been selected because you have recently agreed to donate blood for 
research. 
Do I have to participate? 
No, it is up to you to decide whether or not you want to take part.  If you do decide to 
take part and then change your mind, that’s fine. Just let me know. You can also stop 
the interview at any point. If you change your mind after the interview, you will need 
to tell me within 48 hours. You can do this by ringing me on . If this 
email is being read to you, the researcher will give you this number on a piece of 
paper so you can keep it safe in case you want to withdraw. After this time the 
information you have given me will be combined with the information from other 
people, and because this is done without names, I will not know what information is 
yours to take it out again. 
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What will happen to me if I participate? 
If you decide to participate, I will arrange a convenient time and place to interview 
you. The interview is expected to last for approximately one hour. During the 
interview I will ask you about your experience of donating blood for research. This 
interview will be audio-recorded. Your contact details will be destroyed once the 
interview has taken place, unless you want to receive a copy of the research 
summary. In this case once I have sent you the summary I will destroy your contact 
information.  
What are the possible benefits of taking part? 
There is no direct benefit to you.  
We hope that the development of better guidelines for donating blood for research 
will benefit everyone in Saudi Arabia.  
What will happen to the results of the research? 
We will write a report of the results of all of the interviews. These will be part of my 
PhD thesis. We also hope to publish the result in academic journals. I quote some of 
the things that you said in your interview in these results. I will not use your name 
and I will be careful not to identify you in others ways.   
Are there any risks involved? 
You will not be placed at risk in this study. 
Will my participation be confidential? 
Yes. All your personal information will be securely stored. Your name off will not be 
used and nor will that of anyone you talk about. After the audio- recording has been 
typed up word for word, only my academic supervisors and I will have access to 
anything with your name on it. The people doing the typing will have signed a 
confidentiality contract.  
We have to keep the audio-recordings for ten years to prove our research was real. 
This will be the responsibility of my supervisor Professor Heather Draper, who will 
ensure that they are kept safely and destroyed after ten years. 
How is this research organised, approved and funded? 
This research is a part my doctoral research at the University of Birmingham, where 
my supervisors are based. It is funded by a scholarship from the National Guard 
Health affair, Riyadh, Saudi Arabia  
The research has been favourably reviewed by the University of Birmingham 
Science, Technology, Mathematics and Engineering Ethical Review Committee, 
ERN_12-1394, Date of Approval: 06/02/2013,and by and the local ethics Committee 
of KKESH: RP 1319-P, Date of Approval: 10/03/2013, and of NGHA: RC12/090/R, 
Date of Approval:  26/03/2013 in Saudi Arabia. 
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My Contact details 
If you want more information, please contact me: 
 
If you wish to make a complaint you can contact: (if this sheet is being read to you, 
you will be given this information on a piece of paper to keep safe in case you need 
to complain) 
 
 
Thank you for taking the time to read this information. 
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  دعوة للمشاركة
 
في . لك أن تناقش مع من شئت. المفترض أن توضح لك الغرض من هذه الدراسة و ماذا يتوقع من المشارك 
خلال الأيام القادمة للتحقق من سأعاود الاتصال بك . حالة رغبت بالمزيد من المعلومات تستطيع الاتصال بي
 . رغبتك بالمشاركة و تحديد التاريخ و الوقت المناسب لك لكي تتم المقابلة
 
 :الغرض من هذه الدراسة
لنصح لواضعي الأنظمة في المملكة العربية السعودية بمعرفة السمات هذا البحث يهدف لتقديم ا
للقيام بذلك . السعودية ANDلبحوث ال الثقافية للمجتمع بشأن نظام أخلاقيات التبرع بالدم
سأحاول تحليل و دراسة الأنظمة السعودية و العالميه المتعلقة بالتبرع بالدم للبحوث 
الوراثية مما يمكنني من المقارنة بين تلك الأنظمة و الممارسة الفعليه لها في الواقع 
 . بحضور الجلسات مثل تلك التي حضرتها
 
 لماذا تم إختياري؟
 .اختيارك لأنك مؤخرا قبلت التبرع بالدم لبحوث جينية وراثية لقد تم
 
 هل يجب علي المشاركة بهذه الدراسة؟
لك أن تشارك أو ترفض المشاركة كما يحق لك تغيير رأيك في أي وقت تشاء أثناء  
ساعة من انهاء المقابلة بمجرد الاتصال علي علي الرقم  ٨٤المقابلة أو خلال 
ساعة المشار إليها  ٨٤بعد ال. طاء الرقم لك لذلك الغرضسيتم اع- ١٩٧٨١٢٥٠٥٠
بسبب أن المعلومات من هذه المقابلة سيتم دمجها مع المقابلات الأخري بصورة يصعب 
 . معهاالتعرف علي المصادر
 
 مالذي سيحدث لو قررت المشاركة؟
ة لو قررت المشاركة سأنسق الوقت و المكان المناسب لكي أجلس معك في مقابلة لمد
سيتم تسجيل هذه . أثناء هذه المقابلة سنتحدث عن مشاركتك و تبرعك بالدم. حوالي الساعة
المقابلة صوتيا كما سيتم طمس جميع معلوماتك مباشرة بعد الانتهاء من المقابلة مالم 
في هذه الحالة سيتم تأجيل طمس . تطلب مننا الحصول علي نسخة من النتائج النهائية
 .ال المعلومات لك بحسب طلبكالمعلومات لحين ارس
 
 ماذا سأستفيد من مشاركتي؟
 لا نعد بفائدة شخصية مباشرة 
غير أننا نأمل بتطوير الأنظمة الخاصة بالتبرع بالدم للبحِوث الجينيه و الوراثية مما يعود 
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 .بنفعه للمجتمع بصورة عامة
 
 كيف سيتم التعامل مع نتائج هذا البحث؟
ص بتحليل المعلومات التي حصلنا عليه من المقابلات الشخصية سنقوم بكتابة التقرير الخا
كما سنتطمح بنشر النتائج للمهتمين في الدوريات . كجزء من بحث الدكتوراه الخاص بي
بحسب طبيعة هذه الأبحاث قد يحتوي التقرير علي مقتطعات من . العلميه الأكادميه
 . ي صورة من الصورالمقابلة دون الإشارة ابأي حال من الأحوال لشخصك بأ
 
 هل توجد أية مخاطر مترتبة علي مشاركتي؟ 
 .لن يتم تعريضك لأي نوع من أنواع المخاطر في هذه الدراسة
 
 هل سوف تكون معلوماتي الشخصية سرية في هذه المشاركة؟
. هجميع معلوماتك الشخصية سيتم التعامل معها بحرص و لن يتم ذكر اسمك أو اسم اي شخص ستتحدث عن. نعم
في حالة . بعد أن يتم تفريغ محتوي المقابلة الصوتي لن يطلع أحد علي التسجيلات سوى المشرف الأكاديمي
 . الرستعانه بأي شخص خارجي لعمليه الطباعة سيتم توقيعه علي تعهد بالسرية
ستكون هذه بحسب الأنظمة سنحتاج للاحتفاظ بالتسجيلات لمدة عشر سنوات لكي نبرهن علي حدوث المقابلة و 
من مهام البرفسورة المشرفة هيذر درابر و التي تتأكد شخصيا من الحفاظ علي مستوي عالي من السرية و 
 . اعدام التسجيلات حين ينتهي الغرض منها
 
 كيف تتم ادارة هذا البحث وممن تمت الموافقة عليه و دعمه؟
وهي دراسة تم . جامعه برمنجهام البريطانيههذا البحث هو جزء من بحث الدكتوراه الخاص بي و المسجلة في 
 . دعمها من قبل إدارة الابتعاث بالشئون الصحية للحرس الوطني، الرياض
 
وقد تمت الموافقة على هذه الدراسة من قبل لجنة المراجعة الأخلاقية لكليات العلوم و التكنولوجيا و الهندسة و 
واللجنة المحلية ) 3102 beF 21 no detad 4931-21-NRE(الرياضات بجامعة برمنجهام البريطانيه 
  ,R/090/21CR و 3102/30/01 ،P-9131 PRالأخلاق لمستشفي العيون ومستشفى الحرس تباعاً 
  3102/30/62
 
 
 :معلومات الاتصال الخاصة بي
 عبدالله عدلان . د
 ١٩٧٨١٢٥٠٥٠
 ٧٨٧٧١صندوق بريد 
 ٤٩٤١١الرياض 
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اذا تمت قرآدت هذه الورقة سيتم اعطائك هذه العناوين (إذا رغبت بالتقدم بالشكوي يمكنك الاتصال علي 
 ):مكتوبه
 
 بروفسور هذر درابر 
 ١٤٩٦٤١٤١٢١٤٤+تلفون 
  
  
 شكرا لقرائتك هذه المعلومات
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Appendix 8: English Informed consent Phase Two 
Donating Blood for Molecular and Genetics Epidemiology Research in Saudi Arabia 
 
 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisors: Professor Heather Draper and Professor Angus Dawson, University of 
Birmingham 
 
1. I confirm that I have read and understand the information sheet dated 21 1 
2013 (version 1.1) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time up to 48 hours after the interview has taken place without giving 
any reason using the Dr Adlan’s contact details on the information sheet. 
 
3. I understand that my interview will be audio recorded. 
 
 
4. I would like to receive a summary of the results of this research.  
(Please initial one box only) 
 
 
 
5. I give permission for the research team to contact me asking for feedback 
regarding the research summary. 
 
 
6. I agree to take part in the above study. 
 
 
Name of participant: 
............................................................................................. 
 
Signature: ..............................................  Date: 
.................................................... 
 
 
Name of person taking consent: ....................................................................... 
 
Signature: ...................................  Date: 
.................................................... 
 
  
Please 
initial 
box 
By email By post I do not want 
a summary 
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 التبرع بالدم للأبحاث الجينية في المملكة العربية السعوديةبحث 
 
 عبدالله عدلان، طالب بجامعة برمنجهام .د: الباحث
 هيذر درابر و بروفسر آنجوس داوسن جامعة برمنجهام . بروفسور: المشرف
 
 آمل التأشير
 في المربع 
 
ميلادي و  ٣١٠٢-١-١٢المؤرخة بتاريخ بهذا أؤكد بأني قد قرأت أو قُرأت لي صحيفة معلومات الدراسة . ١
و المتعلق بالدراسة المعنونه بعاليه و انه قد اتيحت لي الفرصة لفهم المحتوي و توجيه  ١-١الإصدار رقم 
 .الأسئلة التي تمت الاجابة عنها بصورة مرضية
 ☐
د أثناد المقابلة أو أعلم بأن مشاركتي في البحث تطوعيه كما يمكنني الانسحاب من الدراسة في آي وقت أشا -٢
عدلان في رقمه الموضح . ساعة من المقابلة دون ابداء اي أسباب و ذلك عن طريق الاتصال بال د ٨٤خلال 
 .في صحيفة المعلومات
 ☐
 . أعلم بأن المقابلة سيتم تسجيلها صوتيا.٣
 ☐
 :آمل الحصول علي ملخص النتائج عن طريق الاتصال ب.٤
أشر على 
  رغبتك
 لا أرغب بالملخص بالبريد الالكتروني  بالبريد 
   
 
 لا أمانع من اتصال فريق البحث بي اذا رغبوا بأخذ رأيي في نتائج البحث . ٥
 ☐
 أوافق علي المشاركة في البحث الموضح أسمه عاليه .٦
 ☐
 :...............................................................اسم المشارك
 :.........................................................................التوقيع
 :..........................................................................التاريخ
 
 :...........................................................................اسم آخذ الموافقة
 :.........................................................................قيعالتو
 :..........................................................................التاريخ
  
  
 
 
 
293 
Appendix 10: Focus Groups –Phase Three - Power Point Slides 
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Appendix 11: Focus Group – Phase Three - Topic guide 
For researcher and policy makers: 
 How do you think the regulation of bioethics in the field of genetics is 
appropriate to Saudis? 
 What are the challenges in recruiting for MGE research in Saudi Arabia 
 How do stigma play rule in disseminating the research results 
 How can you protect your patients  
 What did you wish to see in the Saudi research guidelines and you did 
not find it?  
 How do you compare the SA research guidelines with the international 
ones? 
 How do you see the future of the new Saudi research guidelines? 
 Can you recall any case where the research ethics guidelines were 
hindering your ability to do research? 
 How do you recruit patients for your research? 
 What are the first things that happen when you see an interesting case for 
your research? 
 Can you walk me through the recruiting steps in details so I can imagine 
the process with you? 
 Why do think Saudi patients donate blood for research? 
 Who do you think own the donated material? Why? 
 Can you recall a patient discussing any sensitive issues like privacy, 
stigmatization, share patents rights, or any other concerns?  
 If your team was successful in patent a test based on donated material, 
what do you think should happen?   
 Have you been asked by a patient to withdraw the researched material? If 
the answer is   “yes”, then what did you do? Otherwise, how to deal 
with such request? 
 Have you been asked by a patient to withdraw the collected data? If the 
answer is “yes”, then what did you do? Otherwise, how to deal with 
such request? 
 What are the patients’ main fears? And how do you deal with them? 
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Appendix 12: Information sheet Phase Three –The first Group  
 
Donating Blood for Molecular and Genetics Epidemiology Research in Saudi Arabia 
 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisor: Professor Heather Draper & Professor Angus Dawson, University of 
Birmingham 
 
Participant Information Sheet 
Thank you for being willing to consider taking part in my doctoral research.  The 
following will give you more information about the research and what taking part 
will involve.  If you would like further information, please contact me.  I will be in 
touch with you in a couple of days to see whether you are still interested in taking 
part, and if you are, begin the process of setting a date for the focus group. 
Purpose of the research 
The aim of this research is to help policy makers in Saudi Arabia develop culturally 
sensitive bioethics guidelines for donating blood for molecular and genetics 
epidemiology (MGE) research in Saudi Arabia. It will analyse the current Saudi 
policies for MGE research and all the international policies that were used as 
reference points for these. I will then compare and contrast existing policies with 
current practice to assess how they address the emerging ethical issues. The results 
will be discussed in two focus groups, one with leading thinkers in Saudi bioethics 
and the other with more junior researchers.  I will facilitate these focus groups.   
Why have I been selected? 
You have been selected because you one of the leading thinkers in the field of 
bioethics in the kingdom of Saudi Arabia. 
Do I have to participate? 
No, it is up to you to decide whether or not you want to take part.  If you decide to 
participate in the focus group and then change your mind, please let me know. Once 
the focus group has started you can leave at any point without giving a reason. It will 
not, however, be possible to withdraw from the research anything you have said up 
to this point as the focus group is interactive and depends upon the input of all 
concerned, so it would be impossible to withdraw your data without impacting on the 
participation of others. 
What will happen to me if I participate? 
You will take part in a focus group that will discuss the results of my research to 
date. The discussion will audio-recorded. There are no follow-up meetings. Your 
contact details will be destroyed once the meeting has taken place, unless you elected 
to receive a copy of the research summary. In this case once I have sent you the 
summary I will destroy your contact information.  
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What are the possible benefits of taking part? 
There is no direct benefit to you of taking part.  
We hope that the development of revised guidelines for donating blood for research 
will benefit everyone in Saudi Arabia.  
What will happen to the results of the research study? 
The results will form part of my PhD thesis. We also hope to publish the results in 
academic journals. I may quote some of the things that you said in the focus group. I 
will not use your name and I will be careful not to identify you in others ways. It is 
possible, however, that those who know your views well may recognise you if you 
are quoted.   
Are there any risks involved? 
This is a low risk study. 
As there are a limited number of leading Saudi bioethics thinkers and their opinions 
are likely to be recognisable to other colleagues. To mitigate this risk, we will not be 
specific about your background (e.g. lawyer, religious scholar, researcher) when 
quoting you. 
We will also ask all of those attending the group not to discuss with others anything 
that was said during the meeting. 
Will my participation be confidential? 
All personal data will be securely stored and will only be available to me and my 
academic supervisors.  
Any identifying information will be removed during transcription and I will ensure this has been 
done properly when checking the accuracy of the transcriptions.  The audio recording will be 
downloaded at the earliest available opportunity to local computer and the file will 
be backed-up on a firewall-protected University of Birmingham server. The 
recordings will then be deleted from the audio recorder device. 
Contact details will be destroyed after the meeting. Audio recordings, transcripts and 
consent forms will be kept for ten years before being destroyed, in line with 
University of Birmingham research policy. Professor Heather Draper will serve as 
data custodian. 
Research organisation, funding and ethics approvals 
This research is a part my doctoral research at the University of Birmingham, where 
my supervisors are based. It is funded by a scholarship from the National Guard 
Health affair, Riyadh, Saudi Arabia  
The research has been favourably reviewed by the University of Birmingham 
Science, Technology, Mathematics and Engineering Ethical Review Committee, 
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ERN_12-1394, Date of Approval: 06/02/2013,and by and the local ethics Committee 
of KKESH: RP 1319-P, Date of Approval: 10/03/2013, and of NGHA: RC12/090/R, 
Date of Approval:  26/03/2013 in Saudi Arabia. 
Contact for further information 
Should you need more information you can contact me: 
 
If you wish to make a complaint, please contact: 
 
Thank you for taking the time to read this information. 
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Appendix 13: Invitation Email - Phase Three - The Second Group  
 
Dear ____________, 
 
Re Donating Blood for Molecular and Genetics Epidemiology Research in Saudi 
Arabia 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisors: Professor Heather Draper and Professor Angus Dawson, University of 
Birmingham 
 
Thank you for expressing on interest in my doctoral research. 
As we discussed earlier, I am inviting you to participate in a focus group meeting 
that will consist of six to nine policy makers in the field of bioethics in Saudi Arabia.  
Attached you will find an information sheet with more information about the project, 
the focus groups and what will be requested of you if you agree to participate..  
Yours faithfully 
 
Abdallah A. Adlan  
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Appendix 14: Information sheet Phase Three –The Second Group  
Donating Blood for Molecular and Genetics Epidemiology Research in Saudi Arabia 
 
Researcher: Abdallah Adlan, PhD student, University of Birmingham 
Supervisors: Professor Heather Draper & Professor Angus Dawson, University of 
Birmingham 
 
Participant Information Sheet 
Thank you for being willing to consider taking part in my doctoral research.  The 
following will give you more information about the research and what taking part 
will involve.  If you would like further information, please contact me.  I will be in 
touch with you in a couple of days to see whether you are still interested in taking 
part, and if you are, begin the process of setting a date for the focus group. 
Purpose of the research 
The aim of this research is to help policy makers in Saudi Arabia develop culturally 
sensitive bioethics guidelines for donating blood for molecular and genetics 
epidemiology (MGE) research in Saudi Arabia. It will analyse the current Saudi 
policies for MGE research and all the international policies that were used as 
reference points for these. I will then compare and contrast existing policies with 
current practice to assess how they address the emerging ethical issues. The results 
will be discussed in two focus groups, one with leading thinkers in Saudi bioethics 
and the other with more junior researchers.  I will facilitate these focus groups.   
Why have I been selected? 
You have been selected because you are a more junior researcher who has recruited 
blood donors for MGE research in Saudi Arabia. 
Do I have to participate? 
No, it is up to you to decide whether or not you want to take part.  If you decide to 
participate in the focus group and then change your mind, please let me know. Once 
the focus group has started you can leave at any point without giving a reason. It will 
not, however, be possible to withdraw from the research anything you have said up 
to this point as the focus group is interactive and depends upon the input of all 
concerned, so it would be impossible to withdraw your data without impacting on the 
participation of others. 
What will happen to me if I participate? 
You will take part in a focus group that will discuss the results of my research to 
date. The discussion will be audio-recorded. There are no follow-up meetings. Your 
contact details will be destroyed once the meeting has taken place, unless you elected 
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to receive a copy of the research summary. In this case once I have sent you the 
summary I will destroy your contact information.  
What are the possible benefits of taking part? 
There is no direct benefit to you of taking.  
We hope that the development of revised guidelines for donating blood for research 
will benefit everyone in Saudi Arabia  
What will happen to the results of the research study? 
The results will form part of my PhD thesis. We also hope to publish the results in 
academic journals. I may quote some of the things that you said in the focus group. I 
will not use your name and I will be careful not to identify you in others ways. 
Are there any risks involved? 
This is a low risk study. 
Will my participation be confidential? 
Due to the nature of focus group (participants deliberating face to face in a meeting), 
it is difficult to promise full confidentiality. We will ask all of those attending the 
group not to discuss with others anything that was said during the meeting. 
Any identifying information will be removed during transcription and I will ensure 
this has been done properly when checking the accuracy of the transcriptions.  The 
audio recording will be downloaded at the earliest available opportunity to local 
computer and the file will be backed-up on a firewall-protected University of 
Birmingham server. The recordings will then be deleted from the audio recorder 
device. 
Contact details will be destroyed after the meeting. Audio recordings, transcripts and 
consent forms will be kept for ten years before being destroyed, in line with 
University of Birmingham research policy. Professor Heather Draper will serve as 
data custodian. 
Research organisation, funding and ethics approvals 
This research is a part my doctoral research at the University of Birmingham, where 
my supervisors are based. It is funded by a scholarship from the National Guard 
Health affair, Riyadh, Saudi Arabia  
The research has been favourably reviewed by the University of Birmingham 
Science, Technology, Mathematics and Engineering Ethical Review Committee, 
ERN_12-1394, Date of Approval: 06/02/2013,and by and the local ethics Committee 
of KKESH: RP 1319-P, Date of Approval: 10/03/2013, and of NGHA: RC12/090/R, 
Date of Approval:  26/03/2013 in Saudi Arabia. 
Contact for further information 
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Should you need more information you can contact me: 
 
Thank you for taking the time to read this information. 
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